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1. Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
In therapeutic research, the knowledge of the molecular basis of a given pathology allows to 
reveal the role of one or more proteins as molecular effectors in a disease process (Wermuth 
2008). The protein class of G Protein-Coupled Receptors (GPCRs) plays a major role in 
diverse  signaling  pathways.  Enabling  most  physiological  processes,  GPCRs  are  suitable 
biological  targets  for  a  wide  range  of  therapeutic  approaches  (Conn  et  al.  2009). 
Approximately 25% of marketed drugs act by modulation, activation or inhibition of GPCRs 
(Overington et al. 2006, Jacoby et al. 2006). Especially important in the treatment of human 
central nervous system (CNS) disorders is the possibility to modulate the intensity of neural 
signal transmission. Agonists, antagonist and allosteric modulators are therefore in the focus 
of pharmaceutical research. A further objective is the reduction of off-target effects, which 
makes receptor subtype selectivity a key issue in the development of GPCR-binding ligands 
(Wermuth 2008). The optimization of an active molecule is usually facilitated by knowledge 
of the structure of the target protein. Since the structures of only a few family A GPCR-
ligand-complexes has been determined so far, drug design approaches for this target class rely 
on  already  known  ligands  and  biochemical  studies.  Computational  methods  allow  for 
additional drug discovery strategies such as ligand-based virtual screening and, by prediction 
of structural models, provide additional insight into receptor-ligand interactions of GPCRs.1. Introduction 
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1.1 GPCRs 
1.1.1 GPCR families 
GPCRs are the largest family of cell-surface receptors involved in signal transmission. 
GPCRs recognize molecular signals, mediated by glycoproteins, photons, hormones, 
neurotransmitters, odorants and pheromones, thereby playing the major role in cell-cell 
communication (Pin et al. 2003, Reggio 2006, Conn et al. 2009). The evolution of 
GPCRs towards interaction with diverse activating molecules increases the variety of 
signals recognized by the cell and the range of signaling pathways that can be triggered. 
Based on sequence identity and bound ligands, six GPCR families (named A to F) can 
be distinguished (Bockaert and Pin 1999, Fredriksson et al. 2003); not all have been 
discovered in humans so far. GPCRs can be classified in (Reggio 2006): 
 
•  Family A: rhodopsin-like receptors, 
•  Family B: protein binding receptors, 
•  Family C: charged neurotransmitter binding receptors, 
•  Family D: fungal pheromone binding receptors, 
•  Family E: cyclic adenosine monophosphate receptors, 
•  Family F: “frizzled and smoothened” receptors. 
 
The number of human GPCRs is estimated to be 720 to 800, which accounts for about 
2% of the human genome, and includes ≈380 unique functional non-olfactory GPCR 
sequences (Jacoby et al. 2006). Of 367 human GPCRs, 284 belong to class A, 50 to 
class B, 17 to class C and 11 to the “frizzled and smoothened” family (Jacoby et al. 
2006).  
 
1.1.2 Family C GPCRs 
The  third  GPCR  family  was  named  after  the  metabotropic  glutamate  receptors 
(mGluRs). They were identified in the mid 1980s as the first members of family C 
GPCRs  (Sladeczek  et  al.  1985,  Sugiyama  et  al.  1987).  Metabotropic  means  being 
involved in metabolic processes and leading to the activation of a “second messenger”. 
Family C is characterized by coupling to phospholipase C (Nicoletti et al. 1986) and 
includes  the  Ca
2+-sensing  receptors  (CaSR),  the  γ-aminobutyric  acid  (GABA)B 1. Introduction 
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receptors,  bride  of  sevenless  proteins  (BOSS),  orphan  GPCR5  and  GPCR6,  the 
pheromone and the taste receptors (Pin et al. 2003, GPCRDB June 2006 Horn et al. 
2003). Eight metabotropic glutamate receptors were discovered and sub-classified into 
three  groups based on sequence similarity, common pharmacology  and transduction 
mechanism  (Pin  &  Acher  2002).  Group-I  mGluRs  comprise  the  subtypes  1  and  5, 
Group-II mGluR2 and 3 and Group-III mGluR4, 6, 7 and 8. Family members of mGluR 
are  supposed  to  exert  their  modulatory  role  by  influencing  neuronal  excitability, 
synaptic transmission and plasticity (Pin & Acher 2002). Group-I receptors are typically 
localized at the postsynaptic membrane in somatodendritic domains, while Group-II and 
III are predominantly found presynaptically (Kew and Kemp 2005). The mGluR family 
has  been  implicated  in  the  pathology  of  major  neurological  disorders  such  as 
Alzheimer’s and Parkinson’s disease, as well as depression, schizophrenia, anxiety and 
pain (Pin et al. 2003, Conn et al. 2009). 
 
1.2 Structure and function of GPCRs 
In spite of their functional diversity, different GPCRs are supposed to have a common 
membrane spanning heptahelical domain. The transmembrane domain (TM) domain of 
GPCRs is the functional unit that is capable of activating G proteins. 
 
1.2.1 Structures of family A GPCRs 
Until recently, the three dimensional (3D) structures of only three functionally distinct 
GPCRs  were  known  (Protein  Data  Bank  [PDB],  Westbrook  et  al.  2002):  the  beta 
adrenergic receptor, the adenosine receptor and the rhodopsin subfamily, all of which 
are family A GPCRs. In the following, studies that contributed to the current knowledge 
of the structure and activation mechanism of GPCRs are reviewed.  
 
Bovine rhodopsin 
Rhodopsins are members of the largest GPCR family (A). Family A accounts for 77% 
of  all  human  GPCRs  (Jacoby  et  al.  2006).  Each  rhodopsin  protein  consists  of 
approximately 350 amino-acids. Rhodopsins are activated by five protons and trigger 
the signaling pathway that is responsible for optical vision (Palczewski et al. 2000). 11-
cis-retinal, a full inverse agonist that keeps rhodopsin in its ground inactive state can 
undergo  photoisomerization  to  an  all-trans-configuration  and  thereby  trigger  the 1. Introduction 
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formation of metarhodopsin. In 2000, Palczewski and co-workers published the first 
structure  of  ground  state  of  bovine  rhodopsin  (BR)  (Palczewski  et  al.  2000,  PDB 
identifier: 1F88, 2.8 Å) followed by metarhodopsin I (Ruprecht et al. 2004) and the 
metarhodopsin II structure in 2006 by Salom and colleagues (Salom et al. 2006, PDB 
identifier: 2I37, 4.15 Å), which is the photoactivated, deprotonated intermediate.  
 
β-Adrenergic receptors 
In 2007, a further breakthrough in structure elucidation of GPCRs was achieved with a 
2.4 Å crystal structure of the human β2-adrenergic receptor (β2AD) in complex with the 
partial inverse agonist carazolol (Cherezov et al. 2007, PDB identifier: 2RH1, 2.4 Å). 
A B A B
TM 1
TM 2
TM 3
TM 4
TM 5
TM 6
TM 7
EC 2
 
Figure 1: A) Structure of the human β2-adrenergic receptor (green) in complex with the partial inverse 
agonist carazolol (Cherezov et al. 2007). B) Structure of bovine rhodopsin (grey) in complex with retinal 
(Okada et al. 2004). Receptors are shown in cartoon, ligands in stick representation. 
 
In that study, an engineered protein was designed to reduce conformational flexibility. 
Furthermore,  an  extensive  optimization  of  crystallization  conditions  to  overcome 
drawbacks in GPCR structure determination has been performed. As carazolol is an 
inverse agonist, lowering its constitutive activity was crucial for the stabilization of the 
resolved conformation. Carazolol, being a diffusible ligand in contrast to the covalently 
binding retinal, provided new insights regarding receptor ligand interaction in GPCRs 
(Figure 1, A). Structural differences between the two receptors were striking in the 1. Introduction 
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extracellular loop two (EC2) that folds to a β-sheet and tightly occludes the retinal 
binding pocket, in contrast to the more exposed α-helical part that was observed for 
β2AD. Superposed receptor structures of BR and β2AD (Figure 1, B) show shifted or 
differently  kinked  helices  that  lead  to  adapted  binding  pockets  for  distinct  ligands, 
whereas structurally conserved helices remain the framework for functional properties. 
Despite the low sequence identity of only approximately 22% in TM regions, translated 
helices, different secondary structures, and constraints from disulfide bonds in loops, 
the  root-mean-square-deviation  (RMSD)  between  Cα-atoms  of  β2AD  receptor  (PDB 
identifier: 2RH1) and BR (PDB identifier: 1GZM) reaches 2.07 Å in the TM domain 
(Costanzi 2008). 
 
The  structure  of  the  β-adrenergic  receptor,  type  one,  was  solved  with  bound 
cyanopindolol (PDB identifier: 2VT4, 2.7 Å, Warne et al. 2008) and type two with 
cholesterol (PDB identifier: 3D4S, 2.8 Å, Hanson et al. 2008).  
 
A2A adenosine receptor 
In  2008,  the  structure  of  the  human  A2A  adenosine  receptor  in  complex  with  an 
antagonist has been determined, using stabilizing techniques that were developed for 
ß2AD. The A2A-complex structure included the antagonist ZM241385 (PDB identifier: 
3EML, 2.6 Å, Jaakola et al. 2008). In contrast to previous GPCR complexes, where the 
binding pocket of GPCRs is located parallel to the membrane plane, the A2A-ZM241385 
complex surprised by a different orientation and location of the bound ligand (Figure 2).  
 
The extended conformation of the ligand is arranged orthogonal to the membrane plane 
and forms interactions to TM7 and the EC3 loop (Figure 2, B). The EC2 loop has a 
coiled structure that is constrained by several disulfide bridges, two of which are unique 
for  the  A2A  adenosine  receptor.  Due  to  the  completely  different  interaction  of  the 
antagonist  to  A2A  adenosine  receptor  compared  to  ligand  binding  regions  in  other 
determined GPCR structures, the strict assumption regarding a common binding pocket 
of  GPCRs  will  have  to  be  revisited.  The  close  proximity  of  the  bound  ligand 
conformations to TM3, TM5, TM6, TM7 and the extracellular loops allow for a large 
variety of possible interactions. The numerous side chains forming these interactions 
might contribute to the high diversity of recognized molecules known to interact with 
GPCRs (Wermuth 2008, Conn et al. 2009). 1. Introduction 
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Figure 2: A) Structure of the human A2A adenosine receptor in complex with ZM241385 (grey) (Jaakola 
et  al.  2008)  and  ligand  conformations  of  retinal  (magenta,  Okada  et  al.  2004)  and  carazolol  (green, 
Cherezov et al. 2007). B) Enlarged section of A); all transmembrane (TM) helices besides TM7 and TM6 
are omitted for clarity. EC3 means extracellular loop 2. 
 
1.2.2 Activation of family A GPCRs 
GPCRs  are  considered  to  have  flexible  structures  that  can  change  upon  receptor 
activation and propagate a signal from the extracellular to the intracellular side. For 
rhodopsin,  details  on  structural  changes  could  be  elucidated  via  site-directed  spin 
labeling (SDSL) experiments (Farrens et al. 1996). These experiments involved cross-
linking  of  cysteine  residues  with  nitroxides,  followed  by  electron  paramagnetic 
resonance  (EPR)  spectroscopy  to  determine  interatomic  distances,  which  provided 
insight  in  structural  changes  that  occur  during  rhodopsin  photoactivation.  The  most 
pronounced movements in the transmembrane domain upon activation were observed 
for TM3 and TM6. A comprehensive discussion of observed movements is provided by 
Gouldson  (Gouldson  et  al.  2004),  who  incorporated  experimental  data  as  distance 
restraints in molecular dynamics studies that aimed to obtain the active and inactive 
states  of  rhodopsin  and  the  ß2AD  receptors.  Solid-state  nuclear  magnetic  resonance 
(NMR)  (Crocker  et  al.  2006)  and  double  electron-electron  resonance  (DEER) 
spectroscopy (Altenbach et al. 2008) revealed a separation of opposing residues in TM6 
and TM3 at the level of the chromophore by an outward rigid-body movement of TM6 1. Introduction 
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upon activation, starting from the proline bend region to the intracellular end of the 
helix. 
 
Similar  receptor  activation  was  proposed  for  all  GPCRs  because  of  the  conserved 
residues in the moving helices (“aromatic cluster”) as well as residues in G-protein 
interaction  (DRY-motif).  Sheerer  and  colleagues  were  able  to  provide  the  crystal 
structure of the active state of rhodopsin in its ligand free form (Figure 3), bound to an 
11 amino  acids  long  C-terminal  part  of  the  Gα-subunit  of  the  trimeric  G-Protein-
complex (Scheerer et al. 2008). In this conformation, guanosine diphosphate (GDP) is 
assumed to be released (Oldham et al. 2006). 
 
 
Figure  3:  From  Scheerer  et  al.  2008,  a  conceptual  model  of  the  crystal  structure  of  the  activated 
rhodopsin in its ligand-free conformation, bound to an 11 amino acids long C-terminal part of the Gα-
subunit  (synthetic  construct).  The  trimeric  G-protein  was  modeled  by  superposition  (PDB  identifier 
1GOT; grey) with the synthetic construct (red). GDP means guanosine diphosphate. 
 
In  the  activated  form  of  rhodopsin,  the  “ionic  lock”,  which  is  usually  established 
between Arg135 and Glu134 from the conserved E(D)RY motif in TM3 and the side 
chains of Glu247 and Thr251 in TM6, is broken. Since the G-protein domain occupies 
the space between TM3 and TM6, it triggers the outward movement of several helices 
(Figure  4).  The  authors  assume  that  local  effects  caused  by  G-protein  binding  also 
induce  long-range  stabilization  effects  that  are  propagated  up  to  the  ligand  binding 
pocket. 
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Figure  4:  Schematic  representation  of  changes  in  helical  positions  in  rhodopsin  (viewed  from  the 
intracellular side) between the conformation binding a G-protein to the intracellular part and the dark-
state rhodopsin (adapted from Scheerer et al. 2008). The activated conformation is indicated in grey and 
the  inactive  in  white.  The  area  for  the  C-terminus  of  the  transducin  Gαt  subunit  (GαCT)  binding  is 
indicated with a circle. Helix eight (H8) is a short α-helix localized orthogonal to the membrane plane and 
the seven TM helices. 
 
 
1.2.3 Domain architecture of family C GPCRs 
In  addition  to  the  TM  domain  that  is  common  to  GPCRs  (Figure  5,  A),  family  C 
receptors have a large extracellular N-terminal domain that resembles the Venus flytrap 
(VFT) in form and movement. Binding of an agonist triggers the closure of the bilobed 
structure, similar to the flower eponymous for the domain. The structure of the VFT 
domain has been solved for mGluR1 in presence and absence of its agonist L-glutamate 
and  the  antagonist  (S)-α-methyl-4-carboxyphenylglycine,  MCPG  (Kunishima  et  al. 
2000, Tsuchiya et al. 2002). Inside the VFT domain, endogenous ligands bind to the so-
called orthosteric binding pocket. One of them, L-glutamate, is the major excitatory 
neurotransmitter in the central nervous system and mediates its actions via activation of 
both ionotropic and metabotropic receptor families. The VFT is connected to the TM 
domain by the cysteine-rich domain (CRD) (Figure 5, B). 1. Introduction 
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Figure 5: Schematic representation of domains and binding sites of family A and a dimer of family C 
GPCRs. Crystal structures of the VFT (Kunishima et al. 2000) and TM domain (Okada et al. 2004) are 
shown in cartoon representation. The cell membrane is indicated by dashed blue lines. The CRD structure 
is  unknown  and  therefore  presented  schematically.  Ligand  binding  sites  are  indicated  by  ellipses. 
Depicted are in red the endogenous family A binding site, in yellow the orthosteric (endogenous) and in 
blue the allosteric sites of family C GPCRs. Molecule structures of the family A GPCR binding ligands 
retinal and carazolol, and the family  C GPCR binding ligands  glutamate and MPEP are linked  with 
arrows to their binding regions. Two family C GPCRs are assembled to a possible dimer (VFT dimer 
taken from crystal structure). 
In contrast to family A GPCRs the allosteric binding site of family C GPCRs is located 
inside the TM domain. Allosteric modulators which bind to the allosteric site are not 
competing with orthosteric ligands but can change the protein conformation resulting in 
changes of orthosteric ligands’ affinity or efficacy (Pin et al. 2004). 
 
1.3 Allosteric modulation of mGluRs 
Allosteric modulation of family C GPCRs is attractive for design of new drug molecules 
for various CNS diseases because allosteric binding sites are less conserved and thus 
allow for the development of subtype selective drug molecules. Although competitive 
agonists and antagonist that target the orthosteric binding site of mGluRs have been 
successfully designed (Schoepp et al. 1999), this remains a challenging task, because 
glutamate  binding  residues  are  conserved  across  the  metabotropic  family  and  most 
compounds  have  a  poor  bioavailability  and  CNS  penetration  (Kew  2004). 
Consequently, the allosteric binding site is considered to have a higher “druggability” 
than the orthosteric binding site (Kew 2004, Williams and Lindsley 2005, Malherbe et 1. Introduction 
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al. 2006). Further advantage of allosteric modulators is that they just “tune” the activity 
of  the  receptor,  because  they  do  not  activate  the  receptor  independent  from  the 
orthosteric agonist. Until today, several potent positive and negative non-competitive or 
allosteric modulators have been discovered for different family C GPCRs (for reviews 
see Kew 2004, Kew and Kemp 2005, Noeske et al. 2005, Williams and Lindsley 2005, 
Wang and Brownell 2007; and recent studies: Vanejevs et al. 2008, de Paulis et al. 
2006, Ceccarelli et al. 2007, Chen et al. 2008, Micheli et al. 2008).  
 
Allosteric  modulators  influence  the  physiologic  response  to  an  endogenous  agonist, 
exerting their effect when the latter is presented; they can be classified into negative 
(NAM)  and  positive  (PAM)  allosteric  modulators  and  inverse  agonists  (Kew  2004, 
Jacoby et al. 2006). The allosteric binding site of family C GPCRs is localized inside 
the TM region, analogous to family A GPCRs (Figure 5). NAMs reduce the potency or 
efficacy  by  an  orthosteric  agonist,  while  PAMs  enhance  it.  Under  experimental 
conditions, the identical concentration of the agonist leads to reduced (NAM) or higher 
(PAM) activation of the receptor in presence of allosteric modulators. Inverse agonists 
reduce the constitutive activity of a GPCR. One working hypothesis is that different 
modulators  stabilize  conformationally  distinct  forms  of  the  receptor  (Gether  and 
Kobilka 1998, Reggio 2006). Lu and colleagues proposed that ligand binding selectivity 
is determined not only by ligand binding residues, but also by the receptor conformation 
(Lu et al. 2007). They suggest that the intramolecular interaction network of GPCRs has 
evolved  by  mutations  in  order  to  support  the  recognition  and  selectivity  to  binding 
ligands. 
 
1.4 Activation and dimerization of family C GPCRs 
Dimeric structures of the VFT domains of mGluR1 bound to an antagonist, an agonist, 
and in the apo-form were resolved by X-ray crystallography (Figure 5, B) (Kunishima 
et  al.  2000;  Tsuchiya  et  al.  2002).  A  particular  change  in  the  arrangement  of  the 
domains due to the bound or non-bound ligand could be detected from these structures. 
The conformational change is proposed to be  propagated from the VFT to the TM 
domain and to stabilize a particular conformation, as it was reported for the tyrosine 
kinase receptors, the erythropoietin receptor (Livnah et al. 1999) or the atrial natriuretic 
peptide guanylate cyclase receptor (He et al. 2001).  1. Introduction 
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The VFT domains of mGluR1 and mGluR4 are known to be secreted as dimers (Selkirk 
et  al.  2002).  The  participation  of  the  C-terminus  of  mGluR1  splicing  type  b  was 
demonstrated to be essential for dimerization to splicing type a receptor by introduction 
of mutations to that part (Remelli et al. 2008). So far, only mGluR1 and CaSR have 
been reported to form heterodimers. For mGluR1 and mGluR5, no heterodimers could 
be detected when they were co-expressed in cells (Romano et al. 1996, Robbins et al. 
1999, Gama et al. 2001). Other family C members, GABAB and taste receptors, were 
thoroughly analyzed regarding heterodimerization and its implication on activation, as 
reviewed elsewhere (Pin et al. 2003).  
 
The TM domain of mGluR5 was analyzed independently to the VFT and was found to 
be sufficient for functional activation by modulators (Goudet et al. 2004). Furthermore, 
it  is  the  origin  for  constitutive  activity  for  mGluRs.  This  finding  strengthened  the 
relation of the TM domain of family C to family A GPCRs which bind endogenous 
ligands in the TM domain. The TM domain is essential for interaction with ligands and 
participation in dimerization and G-protein coupling through protein-protein interfaces. 
The presence of shared structural motives like the disulfide bond between the EC2 loop 
and  TM3,  the  amphipatic  TM8  and  conserved  helix  positions,  shows  similarities 
between  evolutionary  distinct  GPCR  families.  These  structural  relationships  imply 
evolutional neighborhood and are a preposition for structure modeling approaches of 
family C on the template of crystallized family A GPCR conformations, although the 
sequence identity is below 20%. 
 
1.5 Protein data - from sequence to structure to function  
Timely  analysis  of  the  high  sequence  output  generated  by  genomics  projects  is  a 
challenge for computational approaches in bioinformatics. The most recent release (v.98 
from  12  January  2009)  of  the  EMBL  Nucleotide  Sequence  Database  contains 
155,114,144  sequence  entries  that  comprise  265,307,725,081  nucleotides 
(www.ebi.ac.uk). Of these entries, 13,292,297 are of human origin; others belong to 
divisions  as  fungi,  invertebrates,  other  mammals,  mouse,  bacteriophages,  plants, 
prokaryotes, rodents and viruses.  
 1. Introduction 
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In  the  field  of  protein  sequence  assignment,  data  emerge  faster  than  for  protein 
structures  (Figure  6  and  Figure  7).  In  2009,  410,518  protein  sequences  and  51,535 
proteins  structures  were  registered  in  the  Swiss-Prot  (v. 56.8,  Bairoch  et  al.  2004) 
database and the PDB (v. Feb.2009, Westbrook et al. 2002), respectively. The number 
of Swiss-Prot entries with one or more pointers to the PDB is 13,713. In order to bridge 
this gap, computational biology is an area in great demand. 
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Figure 6: Number of PDB structures per year and those that were determined by X-ray or NMR, of all 
structures and protein structures only (v. Feb.2009, Westbrook et al. 2002). 
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Figure 7: Number of protein sequences registered per year in the Swiss-Prot sequence database (v. 56.8, 
Bairoch et al. 2004). Numbers are shown in thousands (k). 
 
Known protein structures have been assigned to fold- or domain-families based on their 
tertiary  structures.  Classification  results  are  stored  in  public  databases,  e.g.  CATH 
(v. 3.2.0,  Cuff  et  al.  2008),  which  contains  114215  assigned  domains,  or  SCOP 
(Andreeva et al. 2007) with 97178 domains. One of the objectives of the present study 1. Introduction 
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was  to  find  possibilities  to  interlink  data  on  function  and  structure  of  GPCR  TM 
domains  to  amino  acids  at  particular  positions,  using  homologous  proteins  and 
conservation analysis. 
 
Homology  between  protein  molecules  can  be  detected  by  similarities  reflected  in 
sequence, structure, or function (Schneider and Stephens 1990, Murzin 1998, Thornton 
et al. 1999). Prediction of structure and function is routinely supported by multiple 
sequence alignments as well as by phylogenetic tree reconstruction of protein families 
(Pei and Grishin 2001). Thus, significant sequence similarity can be expected to be 
reflected  in  local  structural  resemblance  in  regions  of  conserved  sequence  motifs 
(Grishin  2001).  These  structural  motifs  can  include  domain  arrangements  or  small 
molecule binding pockets, and determine the biological function of protein families. 
The  sequence-based  analysis  of  conserved  regions  was  particularly  focused  on 
throughout the study. 
 
1.6 Conservation analysis of GPCR families 
In  the  evolutionary  process,  structural  conservation  and  functional  divergence  are 
balanced. To date, 198 sequences of family C GPCRs have been determined in different 
species (GPCRDB, v. 10.0, Horn et al. 2003). In order to understand the information 
that is coded in amino acid sequences of GPCRs and to correlate it to structural and 
functional features, conservation analyses can be applied. In contrast to procedures that 
have been reported for family A GPCRs, and that are summarized in the following, the 
present study used conservation analysis for the characterization of ligand-binding and 
folding-determinant regions of family C GPCRs, referring to results of the family A 
studies for comparison. 
 
For 111 human family A GPCRs, Bondensgaard and colleagues found a correlation 
between  conservation  patterns  of  residues  in  the  ligand  binding  pocket  and  the 
privileged structure fragments in class A GPCR ligands (Bondensgaard et al. 2004). By 
docking of ligands with a so-called “privileged structure fragment”, they analyzed the 
common ligand binding pockets of class A receptors. Using entropy-based methods, 
variable  and  conserved  residues  could  be  distinguished.  The  variable  residues  are 
considered to be responsible for selectivity in ligand recognition, while the conserved 1. Introduction 
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residues,  typically  located  deeper  in  the  binding  pocket,  retain  a  predominantly 
hydrophobic and aromatic character, and are recognized by different ligand types. 
 
Universal properties of the conformation switch during activation that is present in all 
GPCRs were analyzed by the “Evolutionary Tracing” method (Madabushi et al. 2004). 
Based on mutagenesis data, residue clusters were defined that are important for ligand 
binding, G-protein recognition, and a linking core in between those regions. With the 
Evolutionary  Tracing  method,  sequence  position  variations  could  be  interpreted  by 
evolutionary  divergence.  This  led  to  definition  of  all  family  A  GPCR  common 
functional sites and ligand-specific functional sites, differentiating between the opsin 
subfamily and other family A members for the latter.  
 
Kratochwil published the so-called ligand binding pocket vector (LPV) that captures 
conserved patterns across the GPCR family and that was later translated to 3D receptor 
pharmacophore models, in which each amino acid is represented by the according single 
spherical pharmacophore feature (Kratochwil et al. 2005). The LPV was successfully 
applied for clustering functional subfamilies and facilitated the creation of a receptor 
pharmacophore in agreement with positions from mutation studies with MPEP, DFB 
and EM-TBPC experiments that have been conducted for the metabotropic glutamate 
receptors. The LPV was calculated using 1000 family A sequences and was used for 
sequence alignment to other GPCR families. 
 
Shannon entropy calculation is a widely used method to estimate the uncertainty of a 
variable or the order of a system (Shannon 1948). The Shannon entropy value can be 
interpreted as the certainty or variability of a position in multiple sequence alignments 
(Oliveira et al. 2002). The frequency of occurrence of an amino acid per position in the 
multiple  sequence  alignment  follows  the  rule  of  conservation  of  important  features 
(Mirzadegan et al. 2003). Pei and Grishin showed that by calculation of entropy-based 
conservation, determined from the amino acid frequency per position, the identification 
of conserved positions in multiple sequence alignments is feasible (Pei and Grishin 
2001). These conserved positions tend to be functionally or structurally relevant. Later, 
it was reported that five to nine groups of amino acids cover the largest variance and 
suffice  to  find  meaningful  statistical  patterns  when  applied  on  multiple  sequence 
alignments of homologous proteins (Wrabl and Grishin 2005). 1. Introduction 
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1.7 Prediction of GPCR 3D structures 
1.7.1 Structure modeling 
It  has  been  argued  that  the  structure  of  proteins  with  similar  sequences  to  already 
resolved proteins has a higher chance to be determined using similar crystallization 
conditions  (Jaroszewski  et  al.  2008).  As  a  result,  “difficult”  and  “easier”  families 
regarding  crystallization  have  been  described  by  the  authors.  The  four  functionally 
distinct GPCRs with known structure can only represent the beginning of understanding 
GPCR  structures,  considering  that  up  to  800  proposed  GPCRs  occur  in  the  human 
genome. Therefore, structure modeling of GPCRs is an essential approach to generate 
and  evaluate  hypotheses  on  ligand  binding  and  receptor  function,  and  also  for 
prospective virtual screening and flexibility studies by molecular dynamics simulations. 
 
It  has  been  demonstrated  that  the  native  tertiary  structure  of  a  given  protein  is 
determined  solely  by  the  protein’s  amino  acid  sequence  in  a  given  environment 
(Anfinsen  1973),  and  that  proteins  with  similar  sequences  adopt  similar  structures 
(Chothia and Lesk 1986). On the other hand, it has been demonstrated for conserved 
structural domains that they can originate from sequences with less than 12% sequence 
identity (Holm and Sander 1996, Hubbard et al. 1997, Rost 1999). All GPCRs possess 
the heptahelical domain, although sequences within each family share only around 20% 
sequence identity within TM regions, i.e., 20 to 30% for family A receptors to bovine 
rhodopsin (Jacoby et al. 2006). 
 
In absence of experimental structures for mGluR5 or other family C GPCRs, a receptor 
structure can be predicted in order to provide a context for correlation of conservation 
profiles and prediction of ligand binding modes. The approximate tertiary structure for a 
protein can be predicted based on the known 3D structure of a closely related protein 
family member; one possible approach is homology modeling. Homology modeling is a 
computational approach that performs the calculation of a protein model in four steps 
(Schwede et al. 2003):  
 
1.  Structural template selection (at least one protein with determined 3D structure) 
2.  Alignment of template and target sequences 1. Introduction 
16 
3.  Model building (protein backbone assignment, placing and energy minimization 
of side-chain conformations) 
4.  Model  evaluation  of  protein  geometry  with  respect  to  sterical  hindrance, 
potential  energy  (dihedral  angles,  angles,  bond-length  and  electrostatic 
interactions) 
In case where sequence identity is low or several templates are available, this procedure 
requires parameter optimization in the alignment and refinement steps.  
1.7.2 Modeling of the transmembrane domain of GPCRs 
Taking  advantage  of  sequence  identity  between  template  and  target  structures, 
homology modeling methods exploit the fact that evolutionary related proteins share a 
similar  structure.  The  question  of  whether  the  rhodopsin  structure  constitutes  an 
acceptable  template  for  comparative  modeling  of  other  family  A  GPCRs  has  been 
thoroughly investigated (Bissantz et al. 2003), concluding that rhodopsin is a suitable 
template,  at  least  for  antagonist  studies.  Numerous  studies  demonstrated  the 
applicability of comparatively modeled structures of GPCRs for rational drug design, 
among them α1AD, β2AD, β1AD, 5HT2c, dopamine D3, muscarinic M1, vasopressin 
V1a, tachykinin binding NK1, and cannabinoid CB1 receptors (Klabunde and Hessler 
2002, Evers and Klebe 2004, Bissantz et al. 2005, Evers and Klabunde 2005, Salo et al. 
2004). 
 
Recently, the accuracy of a GPCR structure that was predicted with homology modeling 
could be evaluated using the X-ray structure of β2AD as target and rhodopsin (PDB 
identifier:  1GZM)  as  template  (Costanzi  2008).  The  predicted  structure  reached  an 
RMSD of 2.04 Å for backbone atoms in TM regions. Furthermore, the author reported 
the high impact of the EC2 loop structure and the orientation of essential bulky side 
chains  in  the  binding  site  for  the  success  of  carazolol  docking  into  the  modeled 
structure. 
 
The quality of  a predicted structure depends on sequence similarity to the template 
structure. Close to optimal sequence alignments can only be obtained for closely related 
protein  sequences  with  identities  over  40%  (Sanchez  and  Šali  1997).  As  sequence 
similarity decreases, the alignment becomes more uncertain and is likely to contain an 
increasingly large number of gaps and alignment errors (Rost 1999, Marti-Renom et al. 
2000, Elofsson 2002). For distant homologues with a sequence identity below 30%, i.e., 1. Introduction 
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in the “twilight zone”, the resulting structure models cannot be expected to have a high 
precision in side chain orientations. The structure model accuracy that can be achieved 
is comparable to a structure resolution greater than 3.5 Å but is regarded sufficient for 
identification of conserved patches of surface residues (Marti-Renom et al. 2002). 
 
Further known problems in GPCR modeling arise from different helical structures of 
template and target helices defined by the composing residues, which can form π- and 
310-helical regions or introduce helix kinks (Yohannan et al. 2004). These kinks force a 
helix to bend at a specific position, which changes the helix flexibility (Altenbach et al. 
2008). When working with homology modeled structures, the introduced deviations in 
helical regions have to be considered (detailed discussion by Reggio 2006). Besides 
reasonable suspiciousness due to low accuracy and artifacts, modeled structures can be 
used for analysis of conserved chemical feature arrangement in a 3D context, providing 
a basis for comparison to known structures, as well as for understanding experimental 
findings. There are still a lot of open questions about GPCRs in respect of features that 
are essential for function, diversity and selective ligand interaction, thereby causing 
different modulations. 
  
1.8 Virtual screening 
High throughput screening is a common approach that allows to extract new active 
molecules out of a chemical library (Böhm and Schneider 2000, Bajorath 2002, Klebe 
2006). In order to reduce costs, which are increasing with the size of screening libraries, 
virtual screening can be carried out for selection of fewer molecules for experimental 
screening. Essential steps for a virtual screening approach consist of: 
 
1.  Library preparation and filtering 
2.  Encoding of the molecules with a descriptor 
3.  Application of an “in silico” model for molecule evaluation 
4.  Scoring the molecules in the chemical library 
5.  Selection of samples with a high model score 
 
The  preparation  step  commonly  includes  the  removal  of  molecules  with  undesired 
properties, the so-called “non-druglike” molecules (Sadowski and Kubinyi 1998) and 1. Introduction 
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“frequent hitters” (Schneider and Böhm 2002), as well as an application of absorption-
distribution-metabolism-excretion-toxicity (ADMET) filters (van de Waterbeemd and 
Gifford  2003).  “Drug-like”  molecules  are  supposed  to  fulfill  the  criteria  defined  in 
Lipinski’s “Rule of Five” (Lipinski et al. 1997). These rules are guidelines derived from 
the World Drug Index; they suggest that “drug-like” molecules have a molecular mass 
< 500  daltons,  a  calculated  octanol/water  partition  coefficient  <  five,  less  than  five 
hydrogen-bond  donors,  and  < 10  hydrogen-bond  acceptors.  “Frequent  hitters”  are 
molecules which bind unspecifically to different proteins or perturb the assay in another 
way.  By  ADMET  prediction,  the  behavior  of  molecules  in  aqueous  solutions, 
membrane permeation, metabolic clearance, reactivity and toxicity can be considered at 
an early step in the study (van de Waterbeemd and Gifford 2003). The more molecules 
can be excluded by these filters the more computationally demanding algorithms can be 
used for molecule evaluation afterwards.  
 
An evaluation model can be used for the prediction of structure activity relationships by 
classification,  probability  or  activity  estimation,  and  allows  for  a  ranking  of  data 
samples (molecules) according to their model score. Machine learning approaches can 
be used to develop structure-activity models for the molecule evaluation step. Among 
the  most  prominent  techniques  are  artificial  neural  networks  (Schneider  and  Wrede 
1998,  Noeske  et  al.  2006),  support  vector  machines  (Vapnik  1998,  Byvatov  and 
Schneider 2003) and evolutionary strategies (Rechenberg 1973, Schneider and Fechner 
2005).  These  techniques  establish  a  correlation  of  chemical  data  that  provides  a 
generalization or classification model. In the present study, supervised and unsupervised 
learning techniques,  represented by  Bayesian classifier (Duda et al. 2001) and self-
organizing maps (Kohonen 1982) were applied. These techniques depend on molecules 
with known activity to predict previously unknown activity for molecules in a chemical 
library. A general measure of success is the ability of a model to enrich the number of 
active molecules (“hits”) in a screening library.  
 
Computationally demanding methods like docking (Alonso et al. 2006, Yanamala et al. 
2008), free energy perturbation calculations (Kollmann 1993, Alonso et al. 2006), or 
application  of  other  3D  ligand-  and  receptor-structure-dependent  methodologies  that 
account for conformational flexibility can only be applied on a focused set of molecules 
(Carlson  and  McCammon  2000).  In  virtual  screening  campaigns,  several  molecule 1. Introduction 
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evaluation  procedures  can  be  carried  out  successively,  decreasing  the  number  of 
molecules in each run, up to a limit that is feasible for biochemical testing (Walter et al. 
1998). The combined application of similarity search and molecule docking and scoring 
have been reported as feasible for virtual screening for GPCR ligands (Schneider and 
Böhm 2002).  
 
1.9 Pharmacophores and molecular similarity 
The  concept  of  a  pharmacophore,  as  initially  formulated  by  Paul  Ehrlich  (Ehrlich 
1904),  defines  “a  composition  of  properties  that  make  a  molecule  a  drug“.  Its  first 
applications in molecular modeling approaches were reported by Monty Kier in a series 
of papers between 1967 and 1971 (Van Drie 2007). The IUPAC (International Union of 
Pure  and  Applied  Chemistry)  gives  a  more  precise  definition,  i.e.,  that  “a 
pharmacophore is the ensemble of steric and electronic features that is necessary to 
ensure the optimal supramolecular interactions with a specific biological target structure 
and to trigger (or to block) its biological response“. 
 
Methods  that  incorporate  small  molecules  and  define  receptor  interactions  from  the 
perspective of the ligand are referred to as ligand-based approaches. The missing 3D 
structures of macromolecules, especially GPCRs or ion channels, enforce the use of 
ligand-based  approaches,  including  pharmacophores,  for  rational  design  and 
optimization  of  novel  bioactive  molecules.  A  pharmacophore  model  derived  from 
known  ligands  can  guide  a  strategy  for  discovery  of  active  molecules.  However,  it 
should  be  emphasized  that  every  pharmacophore  model  always  defines  only  one 
specific binding mode. 
 
The  pharmacophore  concept  can  be  employed  in  pure  ligand-based  methods,  as 
3D quantitative  structure  activity  relationship  (3D-QSAR)  (Mason  et  al.  2001), 
pharmacophore-based search (Sheridan et al. 1989) and molecular descriptors (Böhm 
and  Schneider  2000),  but  also  combined  with  structure-based  design,  e.g.  pseudo-
receptor models (Tanrikulu and Schneider 2008). The advantage of 2D molecule graph-
based pharmacophore descriptors is that no 3D structure of the molecules is required 
and similarity calculations are alignment-free (pharmacophore encoding descriptors will 
be introduced in Chapter Molecular descriptors). The ligand-based  approach can be 1. Introduction 
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straightforward,  if  a  sufficient  number  of  active  analogues  have  already  been 
discovered. These active molecules allow for comparison to other molecules, using their 
pharmacophore points. Pharmacophore types include positively or negatively charged, 
hydrogen  bond  donor  or  acceptor,  hydrophobic,  aliphatic  and  aromatic  features. 
Pharmacophore points can be defined for atoms or chemical groups possibly involved in 
interactions with a receptor. They reference the entire set of atoms that can support the 
same type of interaction with the biological molecule. Since pharmacophores can be 
used to describe physicochemical properties of a molecule, they provide a possibility to 
compare molecules. 
 
In  computational  approaches,  various  chemical  structures  can  be  evaluated  in  an 
automated manner by similarity calculation to reference molecules. Similarity search is 
a virtual screening approach in which molecules with unknown activity are classified 
according to the level of their similarity to known active molecules (Willett 1998). In 
that way, molecular similarity allows for the selection of probably active molecules 
from a pool of molecules for further biochemical testing. This strategy of discovering 
novel active molecules by similarity search is based on the assumption that molecules 
with similar structure are more likely to have similar properties (Johnson and Maggiora 
1990, Brown and Martin 1997, Martin et al. 2002).  
 
The combination of similarity search with pharmacophore features directs the similarity 
criteria towards molecules with similar interaction properties. In addition, the search is 
not limited to molecules with identical molecular structure, allowing to find molecules 
with similar pharmacophore features but a different molecule scaffold. The discovery of 
alternative  scaffolds  by  scaffold-hopping  (Schneider  et  al.  1999)  provides  new  lead 
structures for further optimization (Renner et al. 2005).  
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1.10 Molecular descriptors 
Molecular descriptors are used to represent physicochemical properties and biological 
activities.  Numerical  molecular  descriptors  allow  for  the  generation  of  quantitative 
structure activity models. The calculation of molecular descriptors does not depend on 
empirically determined measurements and can therefore be performed sufficiently fast 
even for large molecule libraries. Examples of molecular properties that can be encoded 
in descriptors are the molecular mass, the polar surface area of the atoms’ 3D surface, 
the  2D  topology  of  the  molecule,  substructures  or  the  distribution  of  atom  types. 
Different molecular descriptors have been developed for virtual screening approaches 
(Todeschini and Consonni 2000).  
 
One way to calculate a numerical descriptor from the molecular structure is to use the 
molecular  graph.  The  molecular  graph  representation  reduces  a  molecule  to 
non-hydrogen atoms; atoms are represented by vertices and bonds are represented by 
edges (Balaban 1976). A molecular graph includes information about the number of 
bonds,  bond  types,  molecule  size  and  branching.  These  properties,  as  well  as 
physicochemical properties of atoms can be incorporated as counts, binary fingerprints 
or  combined  into  topological  feature  descriptors.  Similar  to  graph-theoretical 
approaches,  atoms  can  then  be  considered  as  starting  or  end  points  of  paths  in  a 
molecular graph. Atomic features can be integrated into topological description when 
considered as pairs of atom types, as it was introduced in the pharmacophore concept. A 
binning scheme allows for subdivision of such atom combinations into discrete groups, 
according to the path length between the atoms.  
 
The  present  study  focuses  on  the  application  of  topological  descriptors  in  virtual 
screening, especially on the Chemically Advanced Template Search (CATS) (Schneider 
et al. 1999). The CATS descriptor is a correlation-based descriptor that encodes the 
frequency of atom type pairs on the molecular graph. The concept of autocorrelation for 
topological structure was first introduced by Broto and colleagues (Broto et al. 1984).  
 
For  comparison  of  molecules  based  on  3D  descriptors,  a  3D  conformation  of  each 
molecule is required. 3D descriptors accounting for the molecular size and shape are 
calculated  directly  from  the  cartesian  coordinates  of  molecule  atoms  and  other 
quantities derived from the coordinates. Depending on the number of rotational bonds, 1. Introduction 
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several 3D conformations of one molecule are possible. While the binding conformation 
of a molecule has a defined 3D interaction to the receptor, which could contribute to the 
molecular  descriptor,  the  correct  prediction  of  this  conformation  would  require  the 
consideration of the native protein and its solution interactions, which influence the 
conformational freedom of the ligand. 
 
As  no  single  descriptor  encodes  all  relevant  information  for  the  establishment  of  a 
predictive model, it is beneficial to use different descriptors (Sheridan and Kearsley 
2002). 
 
1.11 Ligand binding mode prediction 
1.11.1 Ligand-receptor interaction 
The  first  concept  to  explain  drug  function  was  a  comparison  to  the  key-and-lock 
mechanism introduced by Emil Fischer (Fischer 1894). He proposed that a drug and its 
receptor (Fischer considered enzymes) sterically fit into each other and the drug has to 
be bound in order to influence the function of the protein. Linus Pauling deduced from 
enzymatic reactions that the flexibility of the ligand allows for an amplification of the 
binding during the reaction by flexible adaptation (Pauling 1946).  
 
A flexible adaptation of the ligand goes along with an optimization of ligand-receptor 
interaction in the binding pocket and influences the solvent. The binding site can be 
differently  buried  and  is  defined  by  amino  acids  and  their  chemical  properties. 
Depending on the type of amino acid, it can be involved in hydrogen bonds, ionic, 
hydrophobic or cation-π interactions with the ligand or stabilize a metal ion. Ligands 
complement some of the receptor’s interaction points and partially fill out the binding 
pocket. A binding mode is a particular set of interactions between defined atoms of 
ligand  and  receptor  side  chains.  Binding  affinity  arises  from  an  entropical  and  an 
enthalpical part, both of which can dominate receptor-ligand interactions. The Gibbs-
Helmholtz-Equation defines the change in the free energy (∆G) of a system at constant 
pressure (F I), depending on temperature. 
 
  S T H G ∆ ⋅ − ∆ = ∆ ,  F I 
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where ∆H is the change in enthalpy, ∆S the change in entropy and T the temperature. 
The  free  energy  is  positive  when  the  reaction  is  endothermic,  and  negative  in  the 
exothermic case. An increase in entropy lowers ∆G and increases the binding affinity. 
This  entropical  contribution  results  mainly  from  water  replacement  in  hydrophobic 
regions of the binding site and flexibility constraints of the ligand, and the enthalpic 
contribution from building of new interactions (Connelly et al. 1994). Therefore the 
binding affinity of a ligand corresponds to the changes in free energy upon binding.  
 
Beyond the flexible conformational adaptation of the ligand goes the induced fit theory 
proposed by Koshland, who states that the substrate is necessary to promote the proper 
orientation of catalytic groups (Koshland 1958). Most recent theory regarding the ligand 
binding process is influenced by increasing evidence that ligands can stabilize different 
active  receptor  conformations  (Cozzini  et  al.  2008),  referred  to  as  ligand-induced 
selective  signaling  (LISS,  by  Lu  et  al.  2007)  or  conformational  selection.  Lu  and 
colleagues suggested that receptor conformations play an important role in determining 
the binding selectivity of ligands in the human GnRH receptor (Lu et al. 2007).  
 
According  to  conformational  selection,  a  single  binding  site  can  exhibit  different 
binding  profiles  to  similarly  affine  ligands.  Additionally,  ligands  that  can  bind  in 
different binding modes were identified (McCammon 2005, Boström et al. 2006). The 
exploration of diverse protein-ligand-complexes and their ligand-free forms revealed 
that 75% of all intra-protein hydrogen bonds and 50 to 80% of all water-mediated intra-
protein hydrogen bonds in binding pockets are preserved upon ligand binding (Arora 
2005). These findings indicate that receptor flexibility and interactions with the solvent 
are factors that need to be accounted for in ligand binding prediction.  
 
1.11.2 Prediction of ligand binding modes 
A common computational approach to predict the binding conformation of a ligand to a 
receptor is the molecular docking procedure, as applied in the present study. In general, 
the  prediction  of  a  receptor  ligand  bound  conformation  includes  the  exploration  of 
ligand flexibility and optimization of the best fit into the binding pocket, evaluated with 
a scoring function. A wide variety of scoring methods as well as docking algorithms 
were evaluated for diverse protein-ligand-complexes (Wang et al. 2003, Warren et al. 
2006, Taylor et al. 2002, Leach et al. 2006). The results showed that docking methods 1. Introduction 
24 
are  able  to  identify  the  crystallographically  determined  conformation  and  recognize 
active molecules from a pool of decoys, but not for each of the tested receptor-ligand 
complexes.  From  the  scoring  performance  the  authors  concluded  that  the  available 
scoring  functions  cannot  estimate  ligands’  affinities.  In  addition,  insufficient  target 
structure resolution and difficulties in considering water-mediated interactions that have 
an impact on ∆G increases the complexity of the prediction of the native binding mode 
(Leach et al. 2006). 
 
For treatment of flexible receptors several approaches have been proposed. Common 
among them are molecular dynamics, flexible docking and the employment of rotamer 
libraries (Leach 1994) or protein ensemble grids (Knegtel et al. 1997). These methods 
allow for consideration of more than one possible conformation of the protein, thereby 
increasing the chance to find the binding conformation of the receptor. In addition, it 
avoids optimization of the flexible ligand towards a non-native binding mode for its 
respective class of ligands. 
 
1.11.3 Ligand binding modes for GPCRs 
Of particular interest for the present study was the ligand binding mode prediction for 
modeled  structures  of  GPCRs.  GPCRs  were  proposed  to  exist  as  a  conformation 
ensemble that is influenced by ligands, the membrane and interacting proteins (Fanelli 
and De Benedetti 2005, Lu et al. 2007). Since interaction of ligands with GPCRs is only 
known for few complexes resolved so far, the definition of possible binding modes of 
GPCR  ligands  depends  on  molecular  docking  using  modeled  receptor  structures. 
Costanzi  used  the  recently  resolved  ß2AD-receptor-ligand-complex  and  reported 
differences  in  side  chain  orientations  between  the  modeled  and  the  experimental 
receptor  conformation  (Costanzi  2008).  These  side  chain  conformations  have  high 
impact  on  reproducibility  of  the  ligand  conformation  using  docking.  Previously, 
different GPCR binding sites were explored with docking techniques for binding mode 
prediction for family A (Bissantz et al. 2003, Shacham et al. 2004, Evers and Klabunde 
2005, Costanzi 2008) and family C GPCRs (Malherbe et al. 2006, Vanejevs et al. 2008, 
Yanamala et al. 2008). However, no structural evidence of their correctness could be 
provided so far. The selection of binding poses has been based on possible interaction 
points defined by mutation studies, as well as enrichment rates for discrimination of 
active molecules from non-binding ones (Bissantz et al. 2003, Yanamala et al. 2008). 1. Introduction 
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The determined family A GPCR ligand complexes revealed differences between their 
binding sites due to extracellular loops which cover a large part of the binding site 
(Figure  1).  In  modeled  family  C  GPCR  receptor  structures  even  higher  structural 
uncertainties (only family A GPCRs are available as templates) can be expected than for 
models of family A receptors. This structure prediction problem is amplified by the 
possible flexibility according to a conformation ensemble of a GPCR. Ligand binding 
mode prediction for GPCRs has to deal with high degree of conformational freedom in 
the thermodynamic process of molecule interactions. Scope of the thesis 
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Scope of the thesis 
This  study  focuses  on  structural  features  of  a  particular  GPCR  type,  the  family  C 
GPCRs. Structure- and ligand-based approaches were adopted for prediction of novel 
mGluR5 binding ligand and their binding modes. 
The objectives of this study were: 
 
1.  An analysis of function and structural implication of amino acids in the TM 
region of family C GPCRs. 
2.  The prediction of the TM domain structure of mGluR5. 
3.  The discovery of novel selective allosteric modulators of mGluR5 by virtual 
screening. 
4.  The prediction of a ligand binding mode for the allosteric binding site in 
mGluR5. 
 
GPCRs are a super-family of structurally related proteins although their primary amino 
acid sequence can be diverse. Using sequence information a conservation analysis of 
family C GPCRs should be applied to reveal characteristic differences and similarities 
with  respect  function,  folding  and  ligand  binding.  Using  experimental  data  and 
conservation  analysis  the  allosteric  binding  site  of  mGluR5  should  be characterized 
regarding  NAM  and  PAM  and  selective  ligand  binding.  For  further  evaluation 
experimental  knowledge  about  family  A  GPCRs  as  well  as  conservation  between 
vertebrate rhodopsins was planned to be compared to results obtained  for family C 
GPCRs (Section 4.1 Conservation analysis of family C GPCRs). 
 
Since no receptor structure is available for any family C GPCR, discussion of conserved 
sequence positions between family A and C GPCRs requires the prediction of a receptor 
structure for mGluR5 using a family A receptor as template. In order to predict the 
mGluR5 structure a sequence alignment to a GPCR template protein will have to be 
proposed and GPCR specific features considered in structure calculation (Section 4.1.4 
Structure prediction of mGluR5). The obtained structure was intended to be involved 
in ligand binding mode prediction of newly discovered active molecules. 
 Scope of the thesis 
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For  discovery  of  novel  selective  mGluR  modulators  several  ligand-based  virtual 
screening protocols were adapted and evaluated. Prediction models were derived for 
selection  of  possibly  active  molecules  using  a  diverse  collection  of  known  mGluR 
binding ligands. For that purpose a data collection of known mGluR binding ligands 
should be established and this reference collection analyzed with respect to different 
ligand activity classes, NAM or PAM and selective modulators. The prediction of novel 
NAMs and PAMs using several combinations of 2D-, 3D-, pharmacophore or molecule 
shape encoding methods with machine learning techniques and similarity determining 
methods should be tested in a prospective manner (Section 4.2 Virtual screening for 
novel mGluR modulators). In collaboration with Merz Pharmaceuticals (Merz GmbH 
& Co. KGaA, Frankfurt am Main, Germany) the modulating effect of a few hundred 
molecules should be approved in a functional cell-based assay.  
 
With  the  objective  to  predict  a  binding  mode  of  the  discovered  active  molecules, 
molecule docking should be applied using the allosteric binding site of the modeled 
mGluR5  structure  (Section  4.2.4  Modeling  of  binding  modes).  Predicted  ligand 
binding modes are to be correlated to conservation profiles that had resulted from the 
sequence-based entropy analysis and information from mutation experiments, and shall 
be compared to known ligand binding poses from crystal structures of family A GPCRs. 2. Data 
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2. Data 
2.1 GPCR family C protein sequences 
Protein sequences of family C GPCRs were retrieved from the “information system for 
G  protein-coupled  receptors”  (GPCRDB  -  Release  10.0,  Horn  et  al.  2003).  160 
sequences  of  different  family  C  GPCRs  were  compiled:  53  metabotropic  glutamate 
(mGluR), 24 calcium-sensing like (CaSR), 30 GABA-B (GABR), 11 orphan GPRC5, 
nine orphan GPCR6, four bride of sevenless proteins (BOSS), 12 taste (TR) and 17 
putative pheromone receptors. Several filtering steps were carried out on the data set to 
remove inappropriate data; the remaining sequence numbers are given in Section 4.4.2, 
Table 2. Sequence filtering steps: 
 
1.  all  sequences  tagged  as  “variant”,  “hypothetical”,  “similar”,  “related”, 
“probable”, “splice” and “putative” were removed. 
2.  duplicate entries were removed 
 
2.2 Multiple sequence alignments from GPCRDB 
MSAs in the GPCRDB are automatically generated using an iterative profile alignment 
method  (Oliveira  et  al.  1993).  Two  multiple  sequence  alignments  (MSAs)  were 
retrieved from GPCRDB (GPCRDB - Release 10.0, Horn et al. 2003): 
 
1.  MSA of 96 family C GPCR sequences. 
2.  MSA  of  491  sequences  of  the  “vertebrate  rhodopsin  subfamily”  (family  A 
GPCRs).  
 
The same sequences as in Section 2.1 (these were not aligned) were retrieved as a MSA 
from GPCRDB. The MSA from GPCRDB should be compared to another MSA which 
is proposed in this study. 
2.3 Family C mutation data collection 
Available  information  on  mutations  in  family  C  GPCRs  from  published  scientific 
journal  articles  (Muehlemann  et  al.  2006,  Petrel  et  al.  2003,  Petrel  et  al.  2004, 
Schaffhauser et al. 2003, Xu et al. 2004, Hu et al. 2002, Knoflach et al. 2001, Hu et al. 2. Data 
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2005, Litching et al. 1999, Winning et al. 2005, Malherbe et al. 2003, Malherbe et al. 
2006, Jiang et al. 2004, Malherbe et al. 2003, Pagano et al. 2000, Miedlich et al. 2004) 
were collected and standardized to describe family C mutations in a comparable way. 
The accumulated data was structured as described below. 
 
Receptor:   receptor type 
Residue:  residue number 
BW_position:  sequence  position  according  to  the  Ballesteros-Weinstein 
numbering, numbering for all positions are based on the MSA, 
which was suggested in this study 
TM/Loop:  TM or loop number 
Modulator:  allosteric  modulator,  which  was  tested  for  affinity  or  effect 
changes using the mutated receptor 
Effect:  effect on affinity or modulation caused by the mutation 
Reference:  citation of the original publication 
 
The mutation data collection is applied throughout this study in discussion of positions 
or residues which were sensitive to a particular mutation. It is further used for binding 
site definition. All mutated positions are given in Appendix, Section 10.8 (Table A 3). 
 
2.4 Family C ligand data collection 
2.4.1 Literature ligand data 
A  data  set  was  compiled  based  on  ligands  published  in  literature,  including 
experimentally  determined  activity  values.  1240  mGluR  binding  molecules  were 
retrieved. For each ligand the biological effect as well as the receptor subtype tested in 
the experiments were noted. 490 of 1240 molecules were collected from literature and 
patent data bases by Dr. T. Noeske before.  
 
Properties included in the collection: 
molecule structure:   2D molecule structure 
molecule name:   molecule identifier, containing the authors name and ID used in 
the paper 
ligand type:  negative (NAM) or positive (PAM) allosteric modulator 2. Data 
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receptor_X:  receptor subtype definition, e.g. mGluR5 
binding_IC50_X:  activity value, IC50, from a binding assay given in nM, tested on 
the receptor subtype  
functional_IC50_X:  activity value, IC50, from a functional assay given in nM, tested 
on the receptor subtype receptor_X 
pIC50:  negative decadic logarithm (power 10) of IC50  
organism:  test organism or receptor type origin (mouse, rat or human) 
selectivity:  tag for indication if the ligand is subtype-selective 
reference:  citation of the original publication 
 
The placeholder X refers to the group of results associated to one of tested receptors 
subtypes. The collection contained an activity molecule pair for different combinations 
of the tested receptor, ligand and assay type. The complete ligand data collection can be 
found in Section 10.4 (Table A 1). 
 
2.4.2 Ligand data 
Additional ligand and activity data was provided by Merz Pharmaceuticals (Frankfurt 
am Main, Germany). Merz ‘in house’ mGluR binding compounds were selected and 
values  converted  to  the  literature  data  set  format.  Selectivity  was  calculated  from 
activity values determined in experimental mGluR1 and mGluR5 assays. A compound 
was considered as selective if the activity difference equaled factor 10. This guideline 
was  considered  to  be  sufficiently  high  to  discriminate  selective  from  nonselective 
molecules. Merz compounds were further used in virtual screening with shape similarity 
search (Section 3.11.1) and FCFP/PHRFP similarity calculations (Section 3.6.1); these 
applications were performed at Merz Pharmaceuticals.  
 
2.5 WOMBAT ligand data collection 
WOMBAT is a drug data collection distributed by Sunset Molecular Discovery (LLC 
Santa  Fe,  USA).  WOMBAT  2007.2  contains  203,924  entries  (178,210  unique 
SMILES), totaling 416,405 biological activities on 1,820 unique targets (Olah et al. 
2004). WOMBAT 2007.2 was compiled from 9,227 published papers from fourteen 
journals in the medicinal chemistry field between 1975 and 2007. 32% of WOMBAT 
ligands are GPCR binding molecules. In the present study the WOMBAT drug data 2. Data 
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collection (licensed by Merz, Frankfurt am Main, Germany) was used for selection of 
molecules binding to targets other than mGluR. 
 
2.6 Screening molecule libraries 
2.6.1 Data sets 
52 different vendor molecule data sets were used for virtual screening with machine 
learning and similarity search techniques. Table A 2 includes websites and versions for 
all applied vendor molecule collections, the collection in SD-format was provided by 
Merz  (Merz  Pharmaceuticals,  Frankfurt  am  Main,  Germany).  For  3D  similarity 
calculations the molecule conformation data bases were prepared with Phase (v.2.5, 
Schrödinger, LLC, New York, 2008) by Björn Krüger. The data set preparation steps 
for different virtual screening applications are described in detail in Section 2.6.2. The 
number of unique commercially available molecules was 5,124,879. 
 
2.6.2 Ligand data preparation 
Ligand data collections of various origins were used in virtual screening and molecular 
docking procedures. Two software packages, Pipeline Pilot (SciTegic, San Diego, USA) 
and Schrödinger (Schrödinger, LLC, New York, 2008), provide modules for molecule 
data  preparation.  Schrödinger  software  and  Pipeline  Pilot  were  licensed  by  and 
exclusively used at Merz Pharmaceuticals (Frankfurt am Main, Germany). In order to 
standardize the molecule atom types, all molecules involved in same procedure were 
prepared  the  same  protocol.  All  vendor  molecules  were  processed  through  a 
substructure filter which removed all molecules containing any of the chemical groups 
proposed by Hann (Hann et al. 1999). 
 
Ligand preparation for Pipeline Pilot 
Molecule standardization was employed using Pipeline Pilot procedures. The process 
comprised standardizing the stereo chemistry markings and formal charges and removal 
of all additional molecules from each entry besides the largest. All stereo centers were 
set  to  “unknown”  if  the  marking  was  absent  or  checked  for  validity  and  retained. 
Standard formal charges were applied to common functional groups (Figure 8). 2. Data 
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Figure 8: Functional groups with respective formal charges. R denotes the residual molecule part. 
Subsequently,  bases  were  deprotonated  and  acids  protonated,  setting  charges  of  the 
functional non-hydrogen atoms involved to zero. 
 
Ligprep module 
The ligand preparation procedure Ligprep (v2.0 distributed by Schrödiger, Mannheim, 
Germany)  was  used  to  generate  3D  molecule  structures,  including  stereo-  and 
protomers. The preparation includes the following actions: 
 
1.  Converting structures from 2D to 3D 
2.  Removing of counter ions and water molecules 
3.  molecule protonation at pH=5-9 
4.  Generation of stereoisomers 
5.  Performing of an energy minimization 
 
The energy minimization is performed using OPLS force-field (Jorgensen et al. 1996) 
with default settings: “rapid search”, “distance-dependent dielectric solvation model” 
and “no post-minimization iterations”. 
In the present study identical parameters were applied for all Ligprep calculations as 
follows: 
para_ligprep -epik -W e,-ph,7.0,-pht,2.0 -s 32 -r 1 -bff 14 -isd 
input.sdf –omae output.mae 
 
Phase module 
In order to perform similarity calculations for 3D structures, different conformers of 
each molecule were computed and stored in a data base (Phase v2.5, Schrödinger, LLC, 
New York, 2008). The preparation includes the following actions: 
 
1.  Generation of 3D conformations with Ligprep 
2.  Data base creation in Phase format 
3.  Multiple conformer calculation 2. Data 
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In step 3. ligand conformations were generated with torsional search. Therefore the 
molecule is divided into core and periphery. The peripheral groups are defined to have 
only one rotatable bond between the terminal groups and the rest of the molecule. All 
rotatable  bonds  besides  the  peripheral  are  assigned  to  the  core.  The  conformational 
search  procedure  generates  all  core  configurations  and  then  varies  the  peripheral 
configurations one-by-one. 
 
Parameter for data base creation: 
phasedb_manage -db db_name -new -mae input.mae -confs false -JOB 
conf_generate 
 
Parameter for calculation of multiple conformers per ligand: 
phasedb_confsites -confs all -JOB auto_confs -db db_name 
 3. Methods 
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3. Methods 
3.1 Multiple sequence alignment 
ClustalW (version as described in Fukami-Kobayashi and Saito 2002) was applied for 
the construction of MSA (Thompson et al. 1994). The algorithms works as follows: 
First, the complete distance matrix of all pair-wise sequence distances is calculated. 
Based on these distances a phylogenetic tree is generated by Neighbor-Joining (Saitou 
and  Nei  1987).  The  branch  lengths  include  information  about  the  assumed 
“evolutionary” distance of two sequences. The progressive alignment technique expands 
the  MSA  gradually  by  performing  pair-wise  alignment  of  groups  of  sequences 
according  to  the  branching  order  of  the  phylogenetic  tree.  Two  existing  MSAs  are 
aligned using profile alignment. ClustalW was applied with Blosum62 (Henikoff and 
Henikoff 1992) scoring matrix, gap open penalty = 7 and gap extension penalty = 1. 
Application details of ClustalW for a MSA of family C GPCRs is described in the next 
section. 
 
3.2 Multiple sequence alignment of family C GPCR protein sequences 
A MSA of 96 family C GPCR protein sequences was performed in several steps. First, 
all  subfamilies  (with  the  exception  of  putative  pheromone  receptors)  of  family  C 
receptors were aligned independently from each other; this was accomplished using 
ClustalW. Then manual changes in the alignment were performed using MOE Sequence 
Editor (MOE, 2006.08 release, Chemical Computing Group, Montreal, Canada). Some 
of  the  sequences  could  not  be  aligned  in  the  subfamily  alignment  without  gaps  in 
transmembrane regions and were therefore omitted. The remaining 96 sequences were 
included  in  the  family  C  multiple  sequence  alignment.  Sequence  numbers  and 
subfamilies are given in Section 4.1.2, Table 2. GPCR family C protein sequences and 
resulting alignment in Section 10.3, Figure A 1. 
 
MSAs  of  subfamily  sequences  were  aligned  to  each  other  keeping  the  original 
alignments fixed. Therefore the “partition” mode of MOE Align and Blosum45 (gap 
open=7,  gap  extension=1,  Kelly  1996)  were  used.  Published  alignments  were  also 
consulted in order to consider other possibilities (Jiang et al. 2005, Pagano et al. 2000, 
Pin et al. 2003, Malherbe et al. 2003, Kew et al. 2004, Xu et al. 2004, Surgand et al. 3. Methods 
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2006 and Petrel et al. 2003). The definition of TM boundaries is ambiguous, therefore 
they were chosen close to TM regions of BR, also considering structural properties of 
the residues (in TM, ionizable or charged amino acids are favored by the charged ends 
of phospholipids). On account of this the excised blocks start and end with amino acids, 
such as Asp, Glu, His, Lys, Asn, Gln and Arg, ensuring a capture of complete structural 
domains for further alignment. Each subfamily alignment was aligned to rhodopsin, in 
order to have a reference to excise the transmembrane regions at identical positions 
(TM1: 38-67, TM2: 72-101, TM3: 110-139, TM4: 141-171, TM5: 198-227, TM6: 249-
275,  TM7:  285-312,  BR  position  numbering).  After  the  seven  transmembrane  helix 
regions had been excised from subfamily alignments to rhodopsin, they were joined to 
form the family C MSA. The resulting alignment contained only TM helices, no loops, 
no extracellular domains and no non-TM spanning helix H8 or C-terminal domain. The 
entire family C GPCR sequence alignment is given in Figure A 1. 
3.4 Sequence identity 
Sequence  identity  was  calculated  for  subfamily  alignments  of  TM  helices  and  for 
identity of sequences to rhodopsin, respectively. Given a MSA two ways of sequence 
identity calculations were applied: 
 
1.  the number of positions in a MSA which are identical (F II). 
2.  average identity of the subfamily MSA to BR (F III).  
 
The two methods differ in a way that in the latter, the MSA is compared to an additional 
sequence, which is not part of the MSA. Then identity means the average identity of a 
subfamily  to  the  given  sequence.  Since  a  position  can  be  only  identical  (1)  or  not 
identical (0), each sequence of the MSA has to be compared separately to the given 
target sequence and the identities of all sequences in the MSA averaged afterwards. For 
the first method, all sequences at a  given position need to be identical, in order to 
consider this position to be identical (1). 
 
To 1.: The identity per position p is summed up for the entire MSA. A position is 
regarded as “identical”, if the same element (depending on the alphabet) is present in 
each of the sequences which are included in the MSA,  MSA seq∈ . 
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To  2.:  The  average  identity  of  a  MSA  to  BR  is  calculated  for  each MSA seq∈  
independently and averaged after summing up over all N sequences in the MSA (FIII). 
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3.5 Entropy conservation analysis 
The conservation of amino acids of different GPCR families was based on a multiple 
alignment  of  their  corresponding  sequences  and  evaluated  in  an  entropy  calculation 
approach.  For  each  position  of  the  MSA,  the  conservation  was  measured  applying 
Shannon Entropy (H, Section 3.5.3) on the frequency of occurrence for amino acids 
encoded  by  a  particular  scheme  (Section  3.5.2).  This  procedure  was  performed  to 
provide a description of the conservation for amino acids in TM regions of GPCRs. 
Each step of the procedure will be introduced in following. 
 
3.5.1 Sequence weighting 
Sequential data used for the MSA originated from different species and receptor types, 
leading to a biased representation in the data set. To account for this biased data bias a 
weighting scheme was applied (Sander and Schneider 1991). The weights are related to 
the density in sequence space covered by the different sequences. Therefore sequences 
from regions with higher local density were assigned lower weights and vice versa.  
 
The weight wa for sequence a reflects the similarity of a to other sequences (F IV), 
where  ab d is the distance (dissimilarity) between the sequences a und b. The distance 
between two sequences was calculated by counting the number of mismatches between 
sequences a and b: 
 
∑ =
N
b
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N
w
1
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with  ba ab d d =  and  0 = aa d . 
 
During calculation of frequencies for each amino acid type per position, each sequence 
contributing to the MSA has only an impact as strong as its weight, instead of equal 
contribution. 
 
3.5.2 Mapping amino acids to chemical property groups 
Instead  of  considering  amino  acids  independently,  they  were  treated  as  chemical 
property groups (Wrabl and Grishin 2005), such that matching property groups were 
regarded as matches in the MSA. This grouping allowed for monitoring of conservation 
of special chemical groups rather than on the level of individual amino acids. Residue 
types with similar interaction or volume properties can be substituted for each other. 
Some amino acids can have a particular impact on folding of a protein. Glycine and 
proline introduce kinks in helical structures, cysteine can participate in disulfide-bonds. 
The amino acid grouping (Table 1) was adapted from the structural grouping of MOE| 
Sequence Editor (2006.08 release, Montreal, Canada). 
 
Table 1: The definition of nine functional groups and amino acids belonging to these groups. Amino 
acids are given in standard three-letter code. 
   
functional groups  amino acids 
   
   
Aromatic  Trp, Phe, Tyr 
Aliphatic  Met, Leu, Ile 
Small  Ala, Thr, Ser 
Acidic  Asp, Glu 
Basic  His, Arg, Lys 
Neutral  Gln, Asn 
Cysteine  Cys 
Glycine  Gly 
Proline  Pro 
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3.5.3 Entropy based methods 
In the present study, Shannon entropy (H) was evaluated for its ability to point out 
special sequence positions of different receptor families in combination with amino acid 
grouping. Based on a multiple sequence alignment the conservation level was analyzed 
for each position. For each position in the alignment the frequency of each letter x from 
the alphabet X was counted. The alphabet was composed of the nine amino acid types, 
as introduced in the previous section (Table 1). 
 
Shannon entropy 
Shannon entropy is often referred to as a measure of the “uncertainty” of a variable 
(Shannon  1948).  Here,  uncertainty  is  interpreted  biologically  and  reflects  the 
conservation of a sequence position, or in structural context, a 3D feature involved in 
receptor function or tertiary structure formation. The calculation of H for a position Y in 
the MSA can be performed according (FV). 
 
 
∑
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where x is one amino acid type from the alphabet X of all considered amino acid types 
and p(x), the frequency. The lower the value, the more certain the random variable and 
the more conserved the position Y in the MSA. When the frequency of occurrence for 
all amino acid groups is equal, the entropy value is largest and can be interpreted as “not 
conserved”. Shannon entropy calculations were performed with a custom application 
implemented in programming language Java (Sun Microsystems, Inc. Santa Clara, CA 
95054 USA). 
 
3.5.4 Visualizing values on receptor structure 
In  order  to  analyze  the  calculated  H  values  in  a  structural  context,  a  visualization 
method was implemented. The H values for each position in the MSA were projected 
onto the modeled structure of one of the proteins used in the alignment. Therefore only 
positions  present  in  this  particular  receptor  structure  could  be  displayed.  In  the 
respective PDB file B-factor values were replaced by H values. The PyMOL (v.1.0, 
DeLano W.L. 2002) molecule viewer was used to create the graphical representation. 
Two different color schemes were used:  3. Methods 
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1. colors for representation of the most conserved amino acid type (courtesy of 
Benjamin Stauch) 
2. a colors gradient, representing the “conservation strength”. 
 
The color gradient was calculated with the color_b.py script (color_b.py v6.0 Copyright 
(c) 2004 Robert L. Campbell). 
 
3.6 Molecular descriptors 
3.6.1 Functional Class Extended-Connectivity Fingerprint 
The  functional  class  extended-connectivity  fingerprint  (FCFP)  is  a  circular, 
substructural, vectored, value-based descriptor (Rogers and Hahn 2005). It describes the 
2D  position  and  frequency  of  atomic  features  of  a  molecule  derived  from  the 
topological neighborhood in the molecular graph. 
 
The  generation  of  the  fingerprint  was  performed  in  several  steps  starting  with  the 
generation of initial atom codes. The FCFP includes a special atom typing for all the 
heavy  (non-hydrogen)  atoms  as  a  feature  for  functional  coding:  First,  atoms  are 
assigned abstracted interaction functions, i.e. hydrogen-bond acceptor, hydrogen-bond 
donor,  positively  ionized  or  positively  ionizable,  negatively  ionized  or  negatively 
ionizable, aromatic and halogen. This abstraction reduces the number of possible atom 
types. In the second step, a representation of each atom in larger structural environment 
is developed in an iterative way, similar to the Morgan algorithm (Morgan 1965). The 
maximal distance, defining the largest diameter of the generated features in number of 
bonds, is an additional fingerprint property and defines the considered substructure size, 
for example a distance of 6 is given in FCFP_6. Enlarging the neighborhood in each 
step of the iteration, atom codes of an atom are updated with the atom codes of the other 
atoms  in  range.  The  new  code  is  generated  using  a  hashing  scheme  and  is  always 
derived  from  the  last  iteration  not  the  initial  atom  codes.  The  type  of  the  bond 
connecting to the neighboring atoms as well as their atom codes are hashed to a new 
number, which is added to the present array containing the initial atom codes. This 
procedure is repeated until the target diameter is reached. The resulting FCFP contains a 
list of features present in the molecule, with duplicates removed. 
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Each feature corresponds to the presence of a structural unit. Structural units are not 
predefined so that virtually a high number of different features is possible depending on 
the molecules, while only a small set is present in one molecule. Here a difference was 
made  between  a  substructure  of  a  molecule  extended  in  any  possible  way  and  a 
substructure  included  entirely  without  other  extension  points  than  the  defined  ones. 
Figure 9 illustrates the difference to common substructure definitions. 
 
  A  B  C 
A
A           HO
OH
          HO
OH
 
   
Figure 9: A benzene ring with two attachment points (marked with an A) as presented in A is part of the 
structure C but not structure B according to the extended connectivity definition implemented in FCFP 
(SciTegic, San Diego, USA). 
 
Pipeline Pilot was used to calculate the FCFP_4 and FCFP_6 descriptors (SciTegic, 
Inc., 10188 Telesis Court, Suite 100, San Diego, CA 92121, USA). 
 
3.6.2 Chemically Advanced Template Search 
For  calculation  of  topological  descriptors  the  molecule  can  be  represented  by  a 
molecular graph. The molecular graph describes the molecular structure in 2D, where 
only bonds and atomic features define the molecule.  
 
In 1999, Schneider introduced a topological atom-pair descriptor (Chemically Advanced 
Template Search, CATS) which considers atom type pairs distributed over the molecule 
graph (Schneider et al. 1999). These atom types are defined as pharmacophoric features: 
hydrogen-bond donor, hydrogen-bond acceptor, positively charged, negatively charged, 
lipophilic.  Using  this  pharmacophoric  abstraction  molecular  interaction  patterns  are 
favored over chemical atom types by grouping many atoms similar in their interaction 
type to one pharmacophore type. For CATS descriptor generation all atom-pairs and the 
shortest paths connecting them are defined. In the next step for each distance in range 
from zero to nine bonds the number of different atom-pair occurrences is calculated. 
The resulting value vector contains 150 values resulting from 10 distance and 15 atom-
pair variation per distance. The values are further scaled by the number of all non-3. Methods 
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hydrogen atoms in the molecule. The software speedcats.com by Dr. U. Fechner was 
used  for  descriptor  calculation  (Fechner  et  al.  2003).  No  hydrogens  were  added  to 
molecules beforehand. 
 
A pharmacophore descriptor calculation variant as implemented in Pipeline Pilot, called 
pharmacophore  fingerprints  (PHRFP),  has  a  different  atom  typing  scheme  than  the 
CATS  descriptor.  The  PHRFP  discriminate  between  hydrogen  bond  acceptors  and 
donors,  positively  and  negatively  charged  and  ionizable  atoms  as  well  as  atoms  in 
hydrophobic or aromatic groups. Therefore out of 8 atom types 28 combinations can be 
achieved. In the present study atom pairs in distance of 2 to 15 bonds were considered. 
The PHRFP_2 contains number of bonds and number of rotatable bonds between the 
features additionally. 
 
The  concept  of  pharmacophoric  descriptors  allows  for  scaffold  hopping  in  virtual 
screening applications (Schneider et al. 1999, Fechner et al. 2003). As scaffold hopping 
is major goal in finding a new lead molecule and crucial for the present study, this 
molecule description was applied to similarity searching (Section 3.12) and molecule 
clustering with self-organizing maps (Section 3.13).  
 
The  two  different  implementations  of  the  pharmacophoric  fingerprint  concept  were 
applied  due  to  licensing  reasons,  CATS  (speedcats.com)  in  combination  with  in 
MOLMAP (by Prof. G. Schneider, Schneider and Wrede, 1998) at Johann Wolfgang 
Goethe-University and PHRFP in Pipeline Pilot (SciTegic, San Diego, USA) at Merz 
Pharmaceuticals (Merz, Frankfurt am Main, Germany). 
3.6.3 Shape descriptors 
Molecular  surfaces  define  shapes  of  molecules  as  3D  objects.  Based  on  3D  atom 
coordinates of  a molecule, the surface  can be  generated near to the van der Waals 
surface  or  the  solvent  accessible  surface  (Connolly  1983).  The  Gaussian  surface 
calculation  method  as  implemented  in  MOE  (Grant  et  al.  2001)  is  a  smooth 
approximation of the Connolly Surface (Connolly 1983) and is constructed from a sum-
of-Gaussians density derived from the atomic coordinates of the molecule. The surface 
is described by a density function v(x), with  i x  being the coordinate of the i-th atom and 
Ri its contact radius (FVI). 3. Methods 
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The Gaussian contact surface resembles the water accessible surface, when smoothing 
over cavities not large enough to contain a water molecule.  
 
Shape similarity of molecules can be calculated using shape descriptors. The spherical 
harmonics approach allows for rotation-invariant representations of geometric shapes 
(Zhan et al. 2006). The key feature of the spherical harmonics descriptor (SHD) is the 
alignment-free comparison of 3D molecular shapes. SHD is considered to be a global 
feature-based descriptor that is composed from spherical harmonics coefficients (Wang 
2008). 
 
To calculate the SHD of the 3D structure of a molecule, a shell model is applied. 3D 
coordinates can be given as Cartesian or spherical coordinates. The 3D surface point 
coordinates can be transformed into spherical coordinates. A 3D object can be described 
using points at concentric spheres around the centre of mass of the object. In order to 
express the point coordinates invariant to the radius, all coordinates are projected onto 
the  unit  sphere  or  -  in  other  words  -  for  each  sphere  with  a  different  radius  the 
coordinates are normalized resulting in the unit radius. Spherical coordinates define a 
point by two angles θ and φ, the radius is normalized by the unit sphere. 
 
The 3D shape of an object can be decomposed into a set of orthogonal basic functions, 
referred to as spherical harmonics (FVII). 
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The spherical harmonics function Y is defined by the two angles θ and φ for order l and 
degree m. The degree m is defined based on the l value,  { } l l l l m , 1 ,..., 0 ),..., 1 ( , − − − − ∈ . 
By choosing the order value, several spherical harmonics functions can be solved in the 
range of 1 to l. This set of orthogonal spherical harmonics functions defines a complete 3. Methods 
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3D description, and it is similar to unit basis vector descriptions. In this manner, any 
surface function r(θ,φ) can be decomposed into its spherical harmonics (FVIII). 
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The  coefficients  for  the  spherical  harmonics  decomposition  are  calculated  for  each 
combination of the order and the degree value defining unique properties of a 3D shape. 
The SHD used in the present work was defined as the norms of the decomposition 
coefficients of each degree component in every spherical harmonics order. 
 
For each molecule, the SHD is a vector of identical length. The length is defined by the 
order of spherical harmonics, according to 1 2
2 + + L L . Here, a 100 value descriptor was 
used, with L=9. In general, the shape becomes more detailed as the order parameter 
increases (Figure 10). 
 
Figure 10: Influence of the order parameter on accuracy of shape description. The original surface is 
represented as sets of spherical harmonics functions of order one, three, five and nine. Axes represent 
Cartesian coordinates. Adapted from (Wang 2008), with kind permission. 
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Gaussian  contact  surfaces  were  calculated  using  MOE|Compute|Surfaces  and  the 
Maps|Gaussian contact function (Grant et al. 2001). This function was applied to a 
MOE database containing the 3D structures of molecules that were extracted from the 
literature. The 3D molecule structures were calculated with Ligprep (v2.0, Schrödinger, 
LLC,  New  York,  2008),  as  described  in  Section  2.6.2.  For  the  Gaussian  surface 
calculation, all heavy atoms were considered and the clipping proximity was set to 5Å. 
The  maximum  memory  parameter  was  set  to  1MB,  defining  the  accuracy  of  the 
generated lattice. 
 
The SHD calculation was performed with MATLAB (MATLAB, Version 2006b, The 
Math-Works,  http://www.mathworks.com)  scripts  prepared  by  Quan  Wang  (Wang 
2008). 
 
3.7 Similarity measure 
Similarity between two molecules can be calculated using distance measures applied on 
a numerical molecule description. Common measures are for example the Tanimoto 
coefficient  (Tanimoto  1957,  Johnson  and  Maggioga  1990,  Willett  1998)  and  the 
Euclidian  distance  for  vectorial  molecular  descriptors  and  the  RMSD  for  atom 
coordinates.  A  detailed  discussion  of  similarity  measures  for  chemical  similarity, 
including Tanimoto and Euclidian measures, can be found elsewhere (Willett 1998).  
3.7.1 Tanimoto coefficient 
The Tanimoto coefficient (Tanimoto 1957) is defined by the sum of products of each 
descriptor position i for the reference R and the target T descriptor values, xRi and xTi 
(F IX). 
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The coefficient’s value range lies between 0 and 1. The higher the similarity, the closer 
is the coefficient value to 1. 
 
3.7.2 Euclidian distance 
The Euclidian distance between two vectors xR and xT was calculated according to F X. 
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with xRi and xTi the i-th vector element. 
 
3.7.3 Root mean square deviation 
The RMSD allows for the determination of structural similarity between two different 
three-dimensional structures of the same molecule. The RMSD between two structures 
is the square root of the average squared distances between equivalent atoms (F XI). 
One molecule conformation is regarded as the target conformation T and the other as the 
reference conformation R. The number of atoms is N. 
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3.8 Receiver-operating characteristic analysis 
The  Receiver-Operating  Characteristic  (ROC)  Analysis  can  be  applied  in  virtual 
screening to calculate the prediction accuracy of a binary decision model (Zou et al. 
2007, Fawcett 2006). The area under the curve (AUC) value describes the ability of a 
model to rank active molecules above decoys. The sensitivity (F XII) of the model is 
plotted  against  1 – specificity  (F XIII)  at  different  threshold  values  for  the  binary 
classification  (Figure  11).  The  specificity  and  sensitivity  are  calculated  using  the 
numbers  of  true  positives  (TP),  true  negatives  (TN),  false  positives  (FP)  and  false 
negatives (FN). 
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A ROC curve corresponding to random chance would connect the points (0,0) and (1,1). 
The AUC value summarizes the average diagnostic accuracy across the spectrum of 
threshold values. 
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Figure 11: Three hypothetical ROC curves representing the diagnostic accuracy (adapted from Zou et al. 
2007). Curve A (AUC equal to one) lies along the y-axis and corresponds to perfect accuracy, curve B 
lies between the cases A and C, the latter representing a random chance with AUC=0.5. The diagnostic 
accuracy improves the more a ROC curve moves towards curve A.  
 
In case of a Bayesian classifier (Section 3.11) the ROC curve represents the prediction 
rate at all possible threshold values for the probability value of the binary classification 
in “good” and “bad” samples. Here, the ROC plots and AUC values were generated 
with Pipeline Pilot (SciTegic, San Diego, USA) 
. 
3.9 Pareto-ranking 
In virtual screening as well as other applications where the result is a selection of data 
samples with several optimal properties, a ranking is required that favors more than one 
feature  for  optimization,  especially  in  cases  when  optimization  of  some  properties 
decreases the quality of others. In 1896, Pareto defined the Pareto-optimum concept 
(Pareto 1896). The goal of the optimization is to find a solution vector: 
[ ]
T
n x x x
* *
1
* , ,K =  that optimizes the function [ ]
T
I x f x f x f ) ( , ), ( ) ( 1 K = . 
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A solution is Pareto-optimal if there is no other solution that can have a function value 
closer to optimal without degrading another functional value. Given F as the set of all 
possible solution x, a solution is Pareto-optimal if the following holds for F x∈ ∀ : 
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I i
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An exemplary 2D situation is shown in Figure 12. 
 
 
Figure 12: The Pareto-ranking principle applied to eight solutions in a 2D space where both values f1 and 
f2 should be minimized. Filled points represent the Pareto front. The dashed lines going out from a point 
define the area that contains other points dominating the concerned point. If the area is not populated, this 
solution is not dominated by any other solution and belongs to the Pareto-front. Each rank X (given as 
number) includes all solutions that are dominated by X many other solution ranks, as demonstrated for 
solutions numbered one and two. 
 
In the present study, the Pareto-ranking was applied for a 2D optimization task, where 
the prediction score of two Bayesian classifiers focusing of different features were to be 
joined for hit list ranking (Section 3.11.2). A Pareto subset optimizer (by SciTegic, San 
Diego, USA) was applied. Parameters were chosen as follows: subset size: 100, number 
of  subsets:  10,  number  of  optimization  iterations:  10000,  first  property:  Bayesian 
“mGluR”-model  score,  second  property:  Bayesian  “selectivity”-model,  optimized 
property: a subset according to standard deviation, goal: score maximization. 
 
3.10 Diversity sampling 
Diversity sampling is a procedure for diverse subset selection of data samples. Essential 
for the sampling is the representation of data as a valued feature vector that allows for 
similarity  calculations  between  data  points.  The  goal  of  diversity  sampling  is  the 
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selection  of  samples  that  cover  different  areas  in  multidimensional  space.  The 
Maximum-Dissimilarity  algorithm  as  discussed  by  Snarey  is  a  common  method  for 
subset generation for model development applications (Snarey et al. 1997).  
 
The Maximum-Dissimilarity algorithm for selection of n out of m samples, with  m n ≤ : 
1.  Select randomly a data sample 
2.  Calculate dissimilarity to remaining data samples 
3.  Add the most dissimilar sample compared to the actual data sample to the result 
set 
4.  Return to step 2 with the last selected sample as actual sample, if the number of 
samples is less than n. 
 
In the present work, diversity sampling according to this algorithm was performed in 
order to split data into training and validation data for the Bayesian model development 
(Section 3.11). Molecules were compared and selected based on the FCFP_6 descriptor 
(Section 3.6.1) and their similarity was measured by the Tanimoto coefficient (Section 
3.7.1). 
 
3.11 Bayesian classifier 
3.11.1 Theory 
The Bayesian Classifier can be applied as method for binary categorization of data (Xia 
et  al.  2004).  A  prediction  model  can  be  trained  on  classified  patterns  and  then  be 
applied  for  probability  estimation  of  unclassified  data.  The  binary  classification  is 
performed with a Bayesian Estimator using a Laplacian correction, which can be used to 
calculate the likelihood of a pattern based on important features learned from training 
data. In the case of molecules, these features are presented as molecular descriptors for 
both training data of “good” (active) and “bad” (inactive) molecule classes. A trained 
Bayesian Classifier can give the likelihood of an unknown molecule to belong to the 
“good” class, based on presence and frequency of features coded with the descriptor. 
The  simple  naïve  Bayesian  classifier  is  supposed  to  perform  best  on  data  with 
independent attributes. However, empirical results showed that the performance is well 
even in cases where dependency is given (Bender et al. 2005) and that this is not the 3. Methods 
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only requirement for optimal prediction (Domingos and Pazzani 1997). Other prediction 
methods are not superior in equal situations. 
 
Given N samples available for training and M good samples being part of them, the 
probability of a “good” sample is P(good)=M/N. A further assumption is that feature F 
is present in A of B samples. It can be estimated that most features Fi are not important 
for discrimination, and therefore their probability equals the base probability P(good). If 
a feature is sampled K times, its probability is corrected to P(good)*K, (F XIV). This 
correction is necessary in cases when B tends to become very low and without the 
correction P(good|F)=A/B would give a value close to 1. The Bayesian estimator using 
a Laplacian correction is given in FXV. 
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with  ) ( / 1 good P K = . The relative estimation is further possible with 
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Most  features  that  are  not  important  for  classification  will  give  log  relative P ~ 0.  For 
features  more  frequently  present  in  “good”  samples  relative P > 0  and  less  frequent 
relative P < 0.  The  probability  function  (F XV)  is  calculated  for  each  feature  Fi.  The 
respective feature weights are summed up to provide a probability estimate for a new 
sample. 
 
3.11.2 Model training 
Two different Bayesian models were trained in order to be applied for virtual screening 
of selective mGluR5 binding ligands, the “mGluR”-model and the “selectivity”-model. 
Predictions from both models were joined by the Pareto-ranking method. 
 
mGluR-model 
An “mGluR”-model was trained using the FCFP_6 descriptor (Section 3.6.1). Three 
data sets were compiled from the literature data collection of family C ligands (Table A 3. Methods 
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1), the Merz “in house” screening collection (Section 2.4.2) and the WOMBAT data 
base (Section 2.5). Inactive molecules from the literature and Merz data sets were added 
to the “bad” data, since they are not presented in WOMBAT. 
 
“good” 
mGluR_1_5:   All  mGluR1  and/or  mGluR5  binding  ligands  from  the  Merz  and  the 
literature data collection with activity lower than 1000nM. Number of 
literature collection molecules: 870. 
“bad” 
not_mGluR:  Ligands (binding to other targets than mGluR) selected from WOMBAT 
using the diversity sampling (Section 3.10) method considering diversity 
based on the FCFP_6 descriptor. Number of molecules: 152269. 
bad_mGluR:   All  mGluR1  and/or  mGluR5  binding  ligands  from  the  Merz  and  the 
literature data collections with activity higher than 1000nM. Number of 
literature collection molecules: 117. 
 
Selectivity-model 
An  mGluR5  versus  mGluR1  “selectivity”-model  was  trained  using  the  FCFP_6 
descriptor. Three data sets were compiled from the literature data collection of family C 
ligands and the Merz “in house” screening collection. Ligands were assumed selective if 
their experimental activity data for both mGluR1 and mGluR5 differed about a factor of 
ten or higher. 
 
“good” 
selective_mGluR5:   All mGluR5 binding ligands that are selective for subtype five 
according to experimental tests. Number of literature collection 
molecules: 111. 
 
“bad” 
selective_mGluR1:   All mGluR1 binding ligands that are selective for subtype one 
according to experimental tests. Number of literature collection 
molecules: 57 
 3. Methods 
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not_selective:   All mGluR5 ligand that are comparably active at mGluR5 and 
mGluR1. Number of molecules: 115 
 
The “selectivity”-model focused on features discriminating selective mGluR5 molecules 
from non-selective molecules was established. The number of molecules was less than 
in the case of the mGluR-model, since information about activity values on different 
receptor subtypes was not available for all ligands. 
 
3.11.3 Retrospective validation 
In order to test the prediction accuracy of the method, the complete data set was split 
into training data for model development and validation data for quality assignment of 
the trained model. The data split was accomplished using a FCFP_6-defined diversity 
sampling (Section 3.10) method from Pipeline Pilot that chose 60% of the molecules 
from “good” and “bad” samples and 40% to be used as an external test set. In the 
retrospective validation, the predicted classification of molecules was compared to the 
known classification. The model score provided by the model is the sum of  relative P  
values of all features and is different to the normalized probability. Validation samples 
with probability to belong to the “good” molecules higher than 0.5 (threshold was not 
applied  in  prospective  screening),  were  considered  as  “good”  ones.  For  quality 
assignment, the number of true positive, true negative as well as false positive and false 
negative predictions was calculated.  
 
Prediction accuracy 
The accuracy of the model in predicting the likelihood of the validation data to be 
“good” samples was evaluated with the ROC plot and AUC value (Section 3.8). 
 
Classes’ separation 
The  ability  to  use  the  score  for  binary  classification  was  determined  as  follows. 
Prediction score of the Bayesian model were plotted against the frequency the score was 
assigned to molecules of the training and validation sets. This distribution histogram 
was analyzed in terms of the discrimination between “good” and “bad” samples by the 
model’s  prediction  score.  The  histogram  was  used  for  definition  of  the  score  value 
which defined the cut between molecules considered to be a “good” sample. 3. Methods 
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Protocol for combination of the “mGluR”- and the “selectivity”-model: 
 
1.  “mGluR”-probability prediction using the “mGluR”-model for all vendor 
molecules 
2.  Filtering of all molecules which have a model score below 24 (motivated by 
class separation) 
3.  Scoring the molecules with the “selectivity”-model  
4.  Definition of the Pareto front (Section 3.9) 
 
3.12 Similarity search 
3.12.1 Molecule shape similarity 
A 3D molecule structure defines the volume and interaction properties exhibited by 
chemical  groups  of  the  molecule.  These  features  can  be  used  for  comparison  and 
ranking of molecules by their similarity to a reference molecule. Conformers from a test 
molecule are aligned in various ways to the reference molecule and the similarity is 
computed  based  on  overlapping  hard-sphere  volumes.  Atom  typing  allows  for  the 
introduction of additional information into the similarity evaluation.  
 
A shape similarity search was performed using Phase (Phase v2.5, Schrödinger, LLC, 
New  York,  2008).  The  molecule  vendor  libraries  ASINEX  Platinum  Collection 
(vNov.2007, www.asinex.com) and SPECS (v2008.1, www.specs.net) were searched 
for molecules similar to the shape of MPEP. MacroModel atom types (MacroModel 
v9.6  Schrödinger,  LLC,  New  York,  2008)  were  applied  as  additional  molecule 
description.  For  shape  similarity,  the  calculation  of  the  3D  molecule  structure  was 
performed. The vendor libraries were prepared by Björn Krüger and used as a multi-
conformer database.  
 
Shape search with Phase (Phase v2.5, Schrödinger, LLC, New York, 2008): 
phase_shape -screen database –shape mpep.sdf -JOB job_name -CHECKPOINT 
directory -atomTypes mmod -sort 3. Methods 
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According to shape similarity to the reference  molecule vendor molecules could be 
ranked.  From  all  molecules  with  the  r_phase_Schape_sim-score  above  0.7 
molecules with diverse scaffolds were manually selected for testing. 
 
3.12.2 Descriptor-based similarity  
Molecular  descriptors  allow  for  a  quantitative  comparison  between  molecules.  The 
molecule structure is no longer the key description but the properties encoded by the 
coding scheme. Different descriptors can span different multidimensional spaces even 
for the same set of molecules and therefore define different neighborhood relations. 
 
In  the  present  study,  two  different  descriptors  were  applied  for  similarity  search, 
FCFP_4  (Section  3.6.1)  and  PHRFP  (Section  3.6.2).  The  similarity  search  was 
performed for both descriptor types using Pipeline Pilot (SciTegic, San Diego, USA) 
and the Tanimoto coefficient (Section 3.7.1) for similarity detection. The same search 
procedure and data sets were applied in both searches. Both searches were designed to 
select the most similar molecules to known selective NAMs binding to mGluR5. A total 
of 619 mGluR5 and 261 mGluR1 ligands were selected as reference molecules from the 
literature (Table A 1) and the Merz Pharmaceuticals ‘in house’ data collection (Section 
2.4.2). 
 
Search and ranking procedure: 
 
1.  Similarity calculation between screening molecules and known a) mGluR5 and b) 
mGluR1 binding NAMs with activity lower than 1000nM and filtering of those with 
similarity higher than a threshold value of 0.95. 
2.  Removal of all molecules that resulted from both steps 1b and 1a. 
3.  Ranking of remaining molecules according to Tanimoto similarity as calculated in 
step 1. 
 
Molecules with diverse scaffolds were manually selected from the ranked molecules list 
for experimental testing. 3. Methods 
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3.13 Self-organizing maps 
SOMs (or Kohonen maps) are an unsupervised machine learning technique that can be 
applied on various data presented as a numerical vector (Kohonen 1982). SOMs enable 
the  representation  of  multi-dimensional  data  and  preserve  distance  and  proximity 
relationships. These relationships between data clusters can be projected onto a 2D map. 
This map depicts neighborhood in multi-dimensional space. Not the entire network can 
be presented when projecting down to 2D. However, the projection helps to analyze the 
captured data relationships and data clusters. 
 
The number of neurons of a SOM has to be decided before the training; it should be 
close to the number of expected clusters. Data clustering is achieved by training of a 
neural net on data vectors. The aim of the training is the adaptation of the net to the data 
distribution in multi-dimensional space. During the training of a SOM, training data are 
“presented” to the net, a winner neuron is defined and the weight vectors of the winner 
neuron and its neighborhood are adapted according to the learning rate.  
 
Training algorithm: 
 
C = set of neurons, ξ = input pattern, w = weight vector, s = winner neuron, c = neuron, 
NS = neighborhood of neuron s, ε  = learning rate, t = number of learning patterns. 
 
Step 1:   Initialization of map A with N neurons i c : { } N c c c A ,..., , 2 1 = ; neuron weights 
n
c R w
i ∈  are generated by random sampling according to the distribution of 
the training data ( ) ξ p . Set the time parameter 0 = t . 
Step 2:  Choose a training pattern ξ  according to ( ) ξ p . 
Step 3:  Define the winner neuron with c w
C c
−
∈ ∀ ξ min . 
Step 4 :  Adapt neuron weights for neuron  r  with ( ) r rs r w h t w − = ∆ ξ ε ) ( . The inter-
neuron  distance  is  calculated  using  the  Hamming-distance H d ,  further  a 
Gaussian neighborhood function is applied for the winner neuron s.  
( )
 


 

 −
= 2
2
2
,
exp
σ
s r d
h
H
rs  
using the standard deviation according to 3. Methods 
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( )
max t
t
final
initial
initial t 







=
σ
σ
σ σ  
and a learning rate 
( )
max t
t
final
initial
initial t 







=
ε
ε
ε ε . 
Both parameters σ  and ε  undergo a time dependent adaptation based on an 
initial and a final value. 
Step 5:  1 + = t t . 
Step 6:  If  max t t < , then go to Step 2, else terminate. 
 
The mean quantization error (mqe)  can be  calculated from equation FXVI and is a 
measure for the dissimilarity of neuron members to the neuron. 
 
c R   =  Receptive field of neuron c. 
w  =  Weight vector centered on data of a neuron. 
 
∑∑
∈
− =
C R
c
c
w
N
mqe
ξ
ξ
2 1
 
F XVI 
 
In the present study, the Euclidian distance metric was used for similarity calculations 
(Section 2.7.2) using the implementation of the SOM-algorithm in MOLMAP (by Prof. 
G. Schneider, Schneider and Wrede 1998). Parameters such as the number of neurons, 
neuron  radius  and  the  number  of  training  cycles  were  defined  individually  and  are 
presented in detail in the following section. 
 
3.13.1 Self-organizing map based virtual screening 
The reference and screening data sets were encoded with CATS descriptors (Section 
3.6.2). The number of neurons was defined as 20×15, the neuron radius was set to 8 and 
the number of training cycles to 200,000. Different vendor molecule collections (Asinex 
Platinum Collection, Enamine, Specs, Ubichem and Maybridge, details on vendor data 
bases can be found in Section 10.5, Table A 2) were clustered separately with reference 
molecules and joined before step five of the protocol described below. 3. Methods 
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Protocol:  
1.  All molecules from the vendor data collection were encoded with CATS. 
2.  Reference molecules from the literature data collection (Section 2.4.1) were 
encoded similarly. 
3.  A SOM was trained using one vendor data base and reference molecules. 
4.  All vendor molecules from neurons containing selective reference ligands were 
selected. 
5.  For molecules selected in step 4, a prediction of mGluR probability with the 
“mGluR”-model Bayesian classifier (Section 3.11) was performed. 
6.  Molecules were ranked according to their “mGluR”-model score; those with 
scores below 20 were filtered out. 
7.  63 molecules were tested experimentally (13 from the Asinex, 27 from Specs, 3 
from Maybridge and 20 from Enamine pick collections). 
 
Since a single active molecule was discovered from the Asinex molecule collection, 
only neuron numbers that were selected in step four for that SOM are given here and 
will be discussed in Section 4.2.3 (0/1, 0/7, 0/14, 1/8, 12/9, 13/8, 13/10, 13/12, 14/10, 
14/11, 15/9, 15/10, 16/1, 16/9, 16/10, 17/0, 17/10, 17/11, 17/12, 17/14, 18/0, 18/11, 
18/13, 18/14, 19/7 19/9). 
 
3.13.2 Self-organizing map based clustering of the ligand data collection  
The literature ligand data collection (Section 2.4.1) of 1270 mGluR binding ligands was 
clustered based on two  different molecule descriptors, the SHD (Section 3.6.3) and 
CATS (Section 3.6.2). Diversity and neighborhood were analyzed using the projection 
of a trained SOM onto a 2D map (MOLMAP application by Prof. G. Schneider). The 
same generic molecule names were used in order to track the distribution of particular 
features of molecules, like size, target or functional effect. 
 
Ligand clustering using SHD and SOMs 
SHD  descriptors  with  100  dimensions  were  used  to  describe  the  molecules.  SOM 
training parameters were: the number of neurons 14×12, neuron radius 6 and number of 
training cycles 200,000.  
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1.  Calculation of the 3D structure for each molecule (Section 2.6.2). 
2.  Calculation of the molecular surface based on the 3D structure of the molecule 
(MOE Gaussian contact surface, v.2006.08, Montreal, Canada). 
3.  Calculation of the SHD (MATLAB v.2006b, scripts by Quan Wang). 
4.  Addition of a generic molecule names to enable class visualization. 
5.  SOM training based on SHD. 
6.  Projection of ligand classes onto the SOM using generic molecule names. 
 
Ligand clustering using CATS and SOMs  
SOM training parameters were identical to the SHD based SOM training. The CATS 
descriptor contained 150 dimensions in contrast to SHD with 100 dimensions. 
 
1.  All molecules from the vendor data collection were encoded with the CATS 
descriptor. 
2.  Addition of a generic name molecule name to enable class visualization. 
3.  SOM training. 
4.  Projection of ligand classes onto the SOM using generic molecule names. 
 
3.14 Experimental activity assay 
Virtual screening hits were tested for their modulatory effects in a functional cell-based 
assay. The mGluR is activated by an endogenous transmitter acting at the orthosteric 
binding  site  of  the  receptor.  Because  allosteric  modulators  do  not  compete  with 
endogenous agonist on the binding site, their effect can be measured by determination 
of increased or decreased response to the agonist. In the present study, ligand selectivity 
was the key issue. Therefore, computationally predicted active molecules were tested 
for  real  biological  activity  in  the  two  most  closely  related  metabotropic  glutamate 
receptors, mGluR1 and mGluR5. Both allosteric modulator types were determined, the 
positive (PAM) and the negative (NAM) ones. 
 
NAMs  are  defined  as  molecules  decreasing  the  activation  effect  of  the  orthosteric 
agonist. If the inhibition rate is measured at different concentrations, it can give a full 
dose response curve (DRC) for the ligand (Figure 13, A). The DRC allows to define the 3. Methods 
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IC50 value, which is the concentration of the NAM that reduces the activation by the 
agonist down to 50% of the maximal activation.  
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Figure 13: Schematic dose response curves of negative (NAM, A) and positive (PAM, B) allosteric 
modulators in a functional assay. The maximal signal is plotted versus the concentration of the allosteric 
modulator. The concentration to signal dependency is given as bold curve line. A) The IC50 indicates the 
concentration of a NAM which leads to 50% signal reduction. B) The endogenous agonist and by the 
dashed curve indicates the activation by the agonist after application of a PAM. The basal line indicates 
the regular receptor activity level, when no agonist is present. The potency of a PAM is expressed as left-
shift of the concentration response curve. 
 
PAMs enhance the activation of a mGluR by the orthosteric ligand. This can be detected 
as the maximal activation of the receptor at lower concentrations of the agonist than 
without the PAM (Figure 13, B). In the presence of a PAM the curve is shifted to left. 
 
Experimental  conditions  for  mGluR5  PAM  and  NAM  (Vanejevs  et  al.  2008)  and 
mGluR1 NAM (Renner et al. 2007) tests were published elsewhere and performed in 
the in vitro screening department at Merz Pharmaceuticals. For these experiments, the 
modulators were added to the test system prior to the agonist. The functional assay for 
mGluR5 depends on the calcium concentration increase, which is a downstream effect 
on mGluR5 activation. The increase of intracellular calcium after stimulation with the 
mGluR5 agonist was measured using a fluorometric imaging plate reader (FLIPR™) 
and  the  Ca-Kit  (both  Molecular  Devices,  CA,  USA).  Tested  molecules  were  pre-
incubated prior to the addition of the agonist. In case of the mGluR1 functional assay, 
the measured signal is the accumulation of [
3H]-Inositol Phosphates. All IC50-value of 
molecules discovered in this study were determined by measurement of the particular 
cell signal at five different concentrations of the allosteric modulator.  
 3. Methods 
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3.15 Docking 
3.15.1 Induced Fit Docking 
The prediction of protein-ligand complexes was performed with molecular docking. 
Using the “Induced Fit Docking” procedure as reported by Sherman (Sherman et al. 
2006) the receptor binding site was treated partially flexible. This approach combines in 
an  iterative  way  the  docking  of  ligands  in  rigid  proteins  implemented  in  Glide 
(Schrödinger,  LLC,  New  York,  2008)  and  the  modeling  of  receptor  conformational 
changes with Prime (Schrödinger, LLC, New York, 2008). The complete procedure is 
supposed to allow for the adaptation of the receptor structure to different ligands that 
otherwise would not necessarily fit into the original receptor binding pocket.  
 
IFD protocol: 
1.  Rigid receptor docking using softened-potential scoring. 
2.  Sampling of the protein for each ligand pose generated in the first step. 
3.  Re-docking  of  the  ligand  into  low  energy  induced-fit  structures  from  the 
previous step. 
4.  Scoring by accounting for the docking energy (GlideScore), and receptor strain 
and solvation terms (PrimeEnergy). 
 
The softened-potential was obtained by scaling the van der Waals radii of ligand and 
receptor  atoms  by  50%.  This  parameter  enables  to  find  ligand  poses  that  slightly 
penetrate the surface of the receptor. To remove larger sterical hindrances, particular 
residues can be allowed to mutate to alanine, thus enlarging the binding pocket. After 
the first docking, 20 poses were retained for further refinement. Having the mutated 
residues  restored,  the  complex  structure  was  minimized  by  sampling  the  residue 
conformations  within  5Å  of  the  ligand.  The  adapted  complexes  were  scored  with 
PrimeEnergy  terms  and  all  solutions  within  an  energy  threshold  above  the  lowest 
energy structure were retained. With the default docking, a re-docking was performed 
into the adapted receptors. The final scoring was performed by a combination of the 
Prime  energy  and  the  GlideScore.  GlideScore  is  focused  on  those  quantities  and  is 
softer regarding sterical clashes. The combined IFDScore (F XVIII) is composed as 
follows: 
 
  IFDScore = GlideScore + 0.05 x PrimeEnergy  F XVII 3. Methods 
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If the top ranked structures differed less than 0.2 in their IDFScore, the IFD protocol 
was repeated for the top ranked receptor structures using the results from the first round 
of  IFD  as  a  starting  point.  The  only  difference  was  made  for  the  default  docking 
parameters applied in that second round (1.0 and 0.8 for the van der Waals scaling for 
receptor and ligand atoms, respectively, and 0.0 for both the Coulomb-van der Waals 
and hydrogen bond energy cut-offs). 
 
3.15.2 Induced fit docking in mGluR5 
For  IFD, the receptor structure  was prepared using the Protein  Preparation  Wizard 
protocol (Schrödinger, LLC, New York, 2008). The preparation included the addition of 
hydrogens, the rotation of Asn, Gln and His residues by 180° when needed to maximize 
hydrogen bonding. A brief relaxation was performed on each starting structure with the 
“Refinement Only” option using the OPLS2001 force-field (Jorgensen et al. 1996). The 
minimization was terminated when an RMSD of 2.2 Å was reached.  
 
The  first  softened-potential  docking  was  defined  to  generate  20  initial  poses.  The 
hydrogen bond filter was set to 0 because some ligands possessed any hydrogen-bond 
donors or acceptors and the hydrogen bond filter would eliminate these. All docking 
calculations were run in the “Standard Precision” (SP) mode of Glide. 
 
The trim side and binding side definitions lacking known receptor-ligand complexes 
were defined manually. The trim side residues were selected to be mutated to alanine. 
The trim side included all EC2 loop residues facing the TM binding region (722, 726, 
732, 734, and 735). The binding side was the region where the back-bone atoms were 
treated flexibly. Therefore, all residues facing these regions were selected, as well as 
their next neighboring residues (mGluR5 residue numbers 624, 628, 629, 631, 632, 641, 
643, 644, 645, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 662, 
710, 713, 714, 716, 717, 718, 720, 722, 724, 730, 731, 732, 733, 734, 735, 736, 737, 
739, 740, 743, 744, 747, 748, 752, 777, 778, 781, 782, 784, 785, 787, 788, 789, 791, 
792, 808, 809, 811, 812, 813, 815, 816). 
 
All ligands were prepared with Ligprep (v.2.0, Section 2.6.2). The complete setup file 
for running the IFD is given in Section 10.1.  
 3. Methods 
      61 
3.16 Structure modeling 
Homology modeling is a methodology that allows to predict a 3D structure model of a 
protein using a related protein with known structure. Structure prediction for a given 
sequence via homology modeling consists of the following steps: 
 
1.  Identification of a homologue structure from the Protein Data Bank (Westbrook 
et al. 2002). 
2.  Sequence alignment of the template structure to the given sequence. 
3.  Generation of a model based on the sequence alignment. 
4.  Model refinement. 
 
In general, model quality follows the rule that models built based on close homologues 
with sequence identity higher than 40% will possess main-chain-atoms with an RMSD 
error of about 1Å (Sanchez and Šali 1997). 
 
3.16.1 MODELLER 
In  the  present  study,  the  software  Modeller  (9v1,  Eswar  et  al.  2007)  was  used  for 
structure prediction. The modeling method as implemented in Modeller considers a set 
of restraints derived from sequence alignment (Šali and Blundell 1993). During the 
process  of  structure  calculation,  the  violation  of  these  restraints  is  minimized,  a 
procedure called “modeling by satisfaction of spatial restraints”. The definition of an 
objective function, which is optimized during the search for the most probable model, is 
directed by: 
 
•  The calculation of distances and dihedral angle restraints derived empirically 
from a data base of protein structure alignments and expressed as conditional 
probability density functions. 
•  The  extension  by  CHARMM  (MacKerell  et  al.  1998)  force-field  terms 
enforcing proper stereochemistry. 
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3.16.2 Objective function 
Šali  and  Blundell  performed  a  systematic  and  quantitative  calculation  of  protein 
structure features and expressed them as probability density functions (pdfs) that can be 
applied as restraints for homology modeling (Sali and Blundell 1993). The basis for the 
calculation was provided by the database of known protein structures from the PDB and 
their  alignments  to  related  proteins.  Those  pdfs  took  in  account  the  main-chain 
conformation class (defined by six of the Ramachandran plot regions [Ramachandran et 
al. 1963]) of an equivalent residue, as well as the type of the modeled residue and the 
sequence similarity of the two equivalent local environments. The association of these 
residue  properties  of  two  related  proteins  is  a  major  issue  in  homology  modeling. 
Instead of using a value range distribution of distances between alpha-carbon atoms, 
residue  solvent  accessibilities  or  side-chain  torsion  angles  were  included.  Thus,  the 
back-bone  conformation  of  a  particular  residue  may  be  restrained  according  to  the 
residue type, the conformation of an equivalent residue in a related protein and the local 
sequence similarity between the two proteins.  
 
The objective function F is composed of dynamic and static restraint terms (F XVIII). 
The  dynamic  terms  are  updated  when  atoms  are  moved  in  order  to  minimize  the 
objective function violation. F is derived from different constraints including several 
features:  
 
 
∑ + = =
i
i i i symm k f c F R F F ) , ( ) (
,  F XVIII 
 
where Fsymm is an optional symmetry term, R are Cartesian coordinates of all atoms, c is 
a restraint (F XIX), f is a geometric feature of a molecule and k are parameters. The 
molecular pdf p can be defined by other pdfs that constrain individual distances and 
angles; the latter can also be defined by sums of pdfs obtained from the individual 
homologous proteins.  
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where wi is a weight constant.  3. Methods 
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3.16.3 Optimization of the objective function by MODELLER 
Modeller implements a Beale restart conjugate gradients algorithm (Shanno and Phua 
1980 and 1982) and the variable target function method (VTFM) (Braun and Gõ 1985) 
to the position of all non-hydrogen atoms. The restraints are sequentially introduced for 
optimization, resulting in a model that maximally fulfills all restraints. In a further step, 
the model can be energy-minimized by simulated annealing with molecular dynamics. 
The CHARMM function includes bond length, bond angle, dihedral angle, Lennard-
Jones  potential  and  electrostatic  terms.  The  calculation  of  the  restraints  from  the 
template  target  alignment  and  the  optimization  were  performed  automatically  as 
follows. 
 
Flowchart of comparative modeling by MODELLER 
 
1.  Read and check the alignment. 
2.  Generate atom coordinates, by transfer of equivalent atom coordinates from 
template and unknown coordinates using CHARMM topology library. 
3.  Calculate stereochemical, homology-derived and special restraints for the target 
from its alignment with the template. 
4.  Calculate a model that satisfies the restraints as well as possible.  
a.  Start with the initial model. 
b.  Partially optimize the model by applying the VTFM modifying the 
model by conjugate gradients. 
c.  Refine the model by simulated annealing with molecular dynamics. 
5.  Output of the refined structure and the calculated violation terms. 
 
3.16.4 Ballesteros and Weinstein numbering system for GPCRs 
Ballesteros and Weinstein used conserved residues across family A GPCRs in order to 
define a sequence independent numbering system (BW-numbering), which is applicable 
for all GPCRs (Ballesteros and Weinstein 1995). This system defines for each helix the 
highest conserved position as .50, by adding the helix number, for example 1 the BW-
numbering  results  in  1.5.  Downstream  sequence  positions  are  then  numbered 
increasingly from .50 and upstream positions decreasingly. These conserved positions 
in family A GPCRs are N1.5 in TM1, D2.5 in TM2, from the (D/E)RY-motif R3.5 in 3. Methods 
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TM3, P4.5 in TM4, P5.5 in TM5, W6.5 in TM6 and from the NPXXY-motif P7.5 in 
TM7. 
 
3.16.5 Homology modeling of mGluR 
 
Alignment 
The  amino  acid  sequence  of  mGluR5  was  retrieved  from  the  SwissProt  database 
(Bairoch et al. 2004), accession numbers P41594 and of bovine rhodopsin from the 
crystallographic structure with PDB ID 1U19 (Okada et al. 2004). Only the structure of 
the TM part of mGluR5 without the extracellular domain from sequence position 576 to 
865 was predicted. The TM helices were aligned in the same way as in the MSA of the 
mGluR subfamily to BR. For loops, the alignment was performed manually, because of 
high differences in length and sequence, optimizing a reasonable start conformation for 
further optimization. The resulting alignment can be found in Figure 16. 
 
Structure modeling 
Modeller can deal with several template structures. The structure of BR from PDB ID 
1U19  (resolution  2.2  Å,  Okada  et  al.  2004)  was  used  as  template  for  homology 
modeling. In two cases, the secondary structure of helices was enforced to exhibit α-
helical structure, because of missing indication of non-standard α-helical structure in 
mGluR5,  which  is  assumed  to  be  caused  by  prolines  in  BR.  These  prolines  are 
associated with the π-helix in TM5 and the 3
10-helix in TM7 in BR. Instead, modeled α-
helices, composed of amino acids of mGluR5 (prepared with MOE, Montreal, Canada), 
were used as templates. The α-helical TM5 and TM7 templates were superposed onto 
the  same  TM  helices  of  BR.  Special  constraints  (special_patches)  were  used  for 
modeling of the disulfide bridge between TM3 and the EC2 (Cys644 and Cys733). 
 
Initial models were constructed with Modeller 9v1 (Šali and Blundell 1993) automodel 
method and parameter slow for optimization with molecule dynamics. Modeller scripts 
for calculation of the homology models are available in Section 10.2.  
 4. Results and Discussion 
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4. Results and Discussion 
In the present study, aimed at characterization of structure and function of family C 
GPCRs,  different  strategies  were  applied  and  their  results  joined  in  a  combined 
discussion. These approaches included ligand, sequence and structure based methods 
which results will be introduced in the following.  
 
Family C GPCRs are a protein family of several receptors with different function. They 
can  be  activated  by  different  molecules  as  Ca
2+,  glutamate,  γ-aminobutyric  acid, 
sweeteners and pheromones, which are binding to the extracellular domain. The TM 
domain possesses a similar seven helical fold compared to family A GPCRs. Allosteric 
modulators bind in the TM of family C GPCRs analogous to agonist and antagonist of 
family A GPCRs 
 
Beginning with the conservation analysis of family C GPCRs, structural and functional 
properties of the TM domain will be discussed relative to their conservation (Section 
4.1). A literature survey of published mutagenesis experiments, conducted in the TM 
region of different receptors, will provide a detailed overview of experimental findings 
related to structure or function of this domain. Conservation values will be incorporated 
in structural context using a predicted protein structure of mGluR5 as representative for 
family  C  GPCRs.  The  structural  discussion  will  be  expanded  by  correlation  to 
properties of family A GPCRs and known 3D structures belonging to this family. 
 
In the second part, (Section 4.2) binding properties of allosteric modulators will be 
analyzed in a prospective virtual screening for novel mGluR5 ligands. The assembled 
ligand data  collection enabled to study properties of ligand binding in mGluR with 
ligand-based approaches. Active molecules, discovered with computational models, will 
be discussed in structural context using predicted ligand binding modes. The modeled 
receptor structure and ligand conformations will bridge to findings from the first part, 
providing insight into function and structure of family C GPCRs. 
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4.1 Conservation analysis of family C GPCRs 
The conservation analysis was applied in order to reveal conserved positions in the TM 
domain  of  family  C  GPCRs.  As  data  basis  for  the  analysis  a  multiple  sequence 
alignment of family C GPCR sequences was generated. Shannon entropy was calculated 
for  each  position  in  the  TM  domain  using  the  MSA.  The  function  associated  with 
conserved positions was defined using experimental data from studies performed on 
family A and family C GPCRs. The analysis was aimed at characterization of functional 
and structural features of family C GPCRs and the mGluR subfamily in particular. For 
mGluR  the  binding  site  was  defined  using  mutation  data  focusing  on  NAM/PAM 
binding regions and not conserved positions important for selectivity. In the following 
qualitative and quantitative results will be introduced starting with data. 
 
4.1.1 Mutation data collection 
Structural features exposed with mutation studies were collected from literature studies 
of  family  C  GPCRs  (references  on  17  publications  in  Section  2.3).  Mutation 
experiments elucidate the influence of particular amino acids on the activation of the 
receptor. In these studies functional implications of mutations were in each case tested 
in  combination  with  allosteric  modulators  of  different  types  (NAM/PAM/agonist), 
which allows for the definition and characterization of the binding pocket for different 
ligand types. Furthermore, the ligands can be compared due to different effects on their 
function, such as affinity changes, loss of modulation effect and activation levels of the 
receptor, which were caused by the respective mutation. These changes, which occur 
upon a mutation, can be detected by comparison to functional activity of the wild type 
receptor or using radioactively labeled ligands in order to track altered binding affinity. 
 
The number of mutations in the compiled mutation data collection summed up to 157 
and included four receptor types (mGluR1, mGluR5, CaSR and T1R3) of two different 
organisms,  rat  and  human.  Mutation  experiments  considering  eight  NAMs  and  five 
PAMs were included in the data collection, where in all cases ligand binding or efficacy 
has  been  altered  in  mutated  receptors  (Figure  14).  The  mutation  data  collection  is 
introduced here, since it is the basis for structural projections and discussions in all 
following sections. A PML-script visualizing the position of the mutations, which can 
be applied on a mGluR5 structure using PyMOL, is given in Appendix (Section 10.6). 4. Results and Discussion 
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NSP 2143
NAM hCaSR
IC50= 0.35mM
Calhex 231
NAM hCaSR
IC50 = 0.39mM
Fenobam
NAM rmGluR5
KD = 55.5nM
IC50 = 56nM
Lactisol
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IC50= 0.05mM
CPCCOEt
NAM rmGluR1
IC50 = 6.5mM
[3H]-EM-TBPC
NAM rmGluR1
KD = 6.6nM
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IC50= 35nM
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Figure 14: Ligands which were tested in mutation experiments with receptors of family C G Protein-
coupled receptors (Muehlemann et al. 2006, Petrel et al. 2003, Petrel et al. 2004, Schaffhauser et al. 
2003, Hu et al. 2002, Knoflach et al. 2001, Litching et al. 1999, Winning et al. 2005, Malherbe et al. 
2003, Malherbe et al. 2006, Jiang et al. 2004, Malherbe et al. 2003, Pagano et al. 2000, Miedlich et al. 
2004).  Modulators  of  calcium-sensing  receptors  (CaSR),  taste  (T1R3)  and  metabotropic  glutamate 
(mGluR)  receptors  are  classified  as  negative  (NAM)  and  positive  (PAM)  allosteric  modulators.  Test 
organisms are defined with leading letters h (human) and r (rat). 
 
All mutated positions were aligned according to the sequence alignment of family C 
GPCRs, which is discussed in the next Section, and could therefore be assigned position 
numbers according to Ballesteros-Weinstein numbering scheme useful for projection on 
any GPCR. 
 
4.1.2 Sequence alignment of family C GPCR 
This section will start with a description of numerical properties and preparation details 
of family C sequence data. In order to motivate the final preparation procedure of the 
MSA of family C GPCRs difficulties experienced in handling and automated processing 
and the adapted solutions will be discussed. It will include a comparison of the proposed 
family C MSA to an automatically calculated one available at GPCRDB (v.10.0, Horn 
et al. 2003). A complete MSA of 96 family C sequences is given in Appendix (Figure A 4. Results and Discussion 
68 
1). This MSA was essential for further conservation calculations of the TM region and 
the template target alignment used for homology modeling of the human mGluR5 on 
BR as template. 
 
A multiple sequence alignment (MSA) was performed based on 96 protein sequences 
selected from 160 family C sequences accessible from GPCRDB. The MSA consisted 
of TM helices, while all loop regions were omitted. In the following, a functional group 
of  receptors  with  a  similar  functional  profile  such  as  mGluRs  are  referred  to  as  a 
receptor subfamily and different receptors of such a subfamily as receptor subtypes, e.g. 
mGluR1, mGluR2. The collected sequences originated from different species and seven 
subfamilies defined by receptor function (Table 2). 
 
The approach for an alignment of family C sequences to BR was guided by matching of 
conserved family A sequence positions in TM regions to similar amino acids in the 
family C sequence (Kratochwil et al. 2005). In the present study a MSA of family C 
sequences facilitated the alignment to BR sequence. The procedure for construction of a 
family C-BR TM region alignment consisted of the following steps: 
 
1.  separate MSA of each of the family C subfamilies 
2.  alignment of each subfamily MSA to BR separately 
3.  extraction  of  the  TM  region  according  to  BR  helix  boundaries  for  each 
subfamily-BR-MSA 
4.  successive joining of subfamily-BR-MSAs by pair wise alignment according to 
BR sequence, which is included in each of the subfamily-BR-MSAs 
a.  if joining successful, meaning the subfamily is properly aligned to the 
family C MSA assembled so far, then proceed with 4 if any not-aligned 
subfamilies are left else finish. 
b.  if the new subfamily is shifted to the other subfamily MSA, than proceed 
with step 2 for alignment revision. 
 
MSA of family C subfamilies 
The mean identity value of family C subfamilies to BR was calculated to be 14%. The 
different subfamilies were unequally  conserved  within the subfamilies ranging  from 
88% (BOSS) to 11% (TASTE); therefore even functionally similar receptors are diverse 
in their protein sequences (Table 2). The high dissimilarities might have originated from 4. Results and Discussion 
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unequal distribution between species or receptors subtypes included due to data base 
composition.  From  evolutional  point  of  view,  the  diversity  between  receptors  with 
conserved function makes sense especially, if they are distributed to different tissues or 
participate in dimerization. Different receptor variants allow then a diverse but adopted 
controlled mechanism of response.  
Table 2: Sequence data statistics retrieved from GPCRDB (Horn et al. 2003). Sequence numbers are 
given for any of the different filtering steps. In all identity calculations only the transmembrane (TM) 
region  was  considered.  Family  C  subfamilies  are  metabotropic  glutamate  (mGluR),  calcium-sensing 
receptors (CaSR), γ-aminobutyric acid type B (GABA-B), taste (T1R3) and “bride of sevenless proteins” 
receptors (BOSS). The identity bovine rhodopsin (BR) is the mean identity of all subfamily sequences to 
BR.  
             
receptor subfamily  sequence  
number 
without variant, 
hypothetical, 
similar, related, 
probable, splice, 
putative 
unique 
successfully 
aligned 
 
identity in 
subfamily, 
TM only 
(%) 
identity to 
BR, TM 
only (%) 
             
             
mGluR  53  37  32  31  28  13 
CaSR  24  18  18  17  35  14 
GABA-B  30  24  23  20  12  11 
Orphan GPCR5  11  9  9  9  24  10 
Orphan GPCR6  9  8  4  4  49  13 
BOSS  4  4  4  4  88  11 
TR  12  12  11  11  11  13 
Putative pheromone 
receptors  17  4  4  -  -  - 
Human  22  22  20  20     
Total  160  116  105  96  -  14 
             
 
Successive MSA of family C sequences to BR 
Each family C subfamily MSA was aligned to BR and TM-MSAs were cut out close to 
rhodopsin helix boundaries according to their alignment to rhodopsin; BR positions - 
TM1: 38-67, TM2: 72-101, TM3: 110-139, TM4: 141-171, TM5: 198-227, TM6: 249-
275, TM7: 285-312. During the process of alignment of the excised MSA blocks, the 
prepared alignments to rhodopsin could be revisited, so that each subfamily was aligned 
to both - other subfamilies and to rhodopsin. Due to low sequence identity to BR (Table 
2), a particular amino acid in a single family C sequence often did not match a position 
in BR, but the most common amino acid or feature in the family C MSA more often did. 
This observation indicated that a single or few sequences can be aligned less reliably to 
a distantly related protein than a prealigned MSA of more closely related sequences, as 4. Results and Discussion 
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the family C subfamilies are. The resulting alignment contained TM helices exclusively, 
without  any  loops,  no  extracellular  domain  and  no  helix  eight  (H8)  or  C-terminal 
domains (Figure A 1). 
 
 The  decision  for  the  extraction  of  individual  TM  sequence  blocks  from  subfamily 
alignments  according  to  rhodopsin  TM  borders,  instead  of  finishing  the  family  C 
alignment and then align it to BR, was not only practically driven. The homology of 
each subfamily to BR could be tested when joining separate subfamily MSA aligned to 
BR, and additionally the whole family C MSA rechecked. The final alignment provided 
the basis for comparison of corresponding position of family C receptors to BR and 
through that to family A GPCRs in general. 
 
Trials of automated alignment of family C GPCRs 
In the beginning, the application of TMHMM2, a tool for TM region prediction (Krogh 
et al. 2001), failed for several sequences in finding of seven TM regions, therefore it 
could not be used for automated prediction and assignment of TM sequence parts for 
alignment. When applying TMHMM2 for the prediction of TM regions of mGluR5 only 
six TM regions were obtained: positions 582-604, 617-636, 692-714, 737-759, 774-796, 
803-825, while TM3 was missing. However, the TM assignments were helpful in many 
cases as a visual guiding tool for the first whole sequence alignments and the manual 
extraction of the TM regions. Another failed approach included the initial alignment of 
subfamilies using ClustalW (Thompson et al. 1994) followed by an alignment of the 
resulted subfamily MSAs to each other. Due to considerable differences in sequence 
length of receptors lacking the extracellular ligand binding domains and different loop 
lengths the alignment within subfamilies was always displaced. For this reason TM 
regions had to be excised, automatically aligned and then manually corrected.  
 
Evaluation of the proposed family C multiple sequence alignment 
All comparisons between family C alignments from GPCRDB and the MSA, proposed 
in this study, were performed considering the same sequences. Only regions present in 
both MSAs were compared, therefore both MSA versions were aligned to hmGluR5. 
The  conservation  calculations  with  Shannon  entropy  (H)  values  were  applied  for 
evaluation of the quality of the proposed and the GPCRDB supported family C MSA. 
The comparison showed, that the proposed alignment reached a considerably higher 4. Results and Discussion 
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conservation, by mapping more amino acids of the same type (sum of entropy values), 
than the automatically generated one (Figure 15). In particular TM3 and TM4 contained 
positions of higher conservation, while all other helices revealed different conserved 
positions compared to the GPCRDB alignment. 
 
Figure 15: Differences in Shannon entropy (H) values calculated for two family C multiple sequence 
alignments (MSAs) (1. from GPCRDB (v.10.0, Horn et al. 2003), 2. proposed in this study) using the 
nine functional groups. H values of both MSAs were subtracted from each other. Negative values indicate 
stronger conservation in the GPCRDB alignment and positive in the proposed alignment.  
 
The here proposed alignment of family C GPCRs was used for the conservation analysis 
instead  of  taking  the  automatically  generated  from  GPCRDB,  since  in  the  new 
alignment more conserved features matched, indicating a higher reliability (Figure 15). 
Compared  to  other  published  alignments  of  several  family  C  sequences  the  new 
alignment  was  constructed based on  a higher number of sequences  and therefore it 
should be more suitable for a conservation evaluation of the whole family C, since more 
sequence variability was captured. Besides conserved amino acids in family A GPCRs, 
as applied for the Ballesteros-Weinstein numbering which is supposed to facilitate the 
building of an alignment to family A sequences, several different alignments of family 
C sequences to BR were reported (Jiang et al. 2005, Pagano et al. 2000, Pin et al. 2003, 
Malherbe et al. 2003, Kew 2004, Xu et al. 2004, Surgand et al. 2006 and Petrel et al. 
2003). Prior to the new alignment, a comparison of the published alignments revealed 
major  differences  in  TM4,  TM5  and  TM7,  even  for  identical  sequence  pairs  thus 
indicating that despite conserved position different alignments could be proposed. 
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4.1.3 Entropy of conserved amino acid features 
The application of  entropy  calculations was aimed to define  conserved positions of 
amino acids within the TM domain and most conserved features at these locations. The 
nine  function  amino  acid  groups  allowed  for  fuzzy  sequence  descriptions,  where 
chemical or sterical features were used instead of single amino acids. A single amino 
acid is only described by one feature type, which leads to a considerable reduction of 
the applied chemical alphabet. Using these groups, the entropy calculation captures the 
conservation of the defined amino acid types. In case of H, low values indicate high 
conservation with respect to the amino acid typing scheme. 
 
The calculation of H revealed positions with low, medium and high conservation in 
family C GPCR TM regions (Table 3). Conserved positions indicated by low H were 
represented by amino acids: L, I, T, G, C, A, M, V, K and P. 
 
Table 3: Overview over the Shannon entropy (H) values calculated using the nine functional groups 
applied on the multiple sequence alignment of family C G protein-coupled receptor sequences. For the 
conserved  positions  the  amino  acids  of  metabotropic  glutamate  receptor  five  (mGluR5)  are  given  in 
parentheses using “single letter code”. 
   
Shannon 
Entropy  Sequence positions and amino acids in mGluR5 
   
   
H ≤ 0.6  (G)590, (T)594, (I)620, (L)622, (C)644, (L)662, (K)665, (T)666, (I)669, 
(I)703, (L)705, (L)750, (A)758, (I)774, (T)777, (M)778, (L)786, (V)806, 
(P)820, (I)825 
H > 0.6 & 
H ≤ 0.9 
587, 591, 602, 610, 613, 617, 647, 657, 660, 672, 696, 707, 711, 749, 770, 
783, 784, 787, 791, 814, 821 
H > 2.1  606, 616, 645, 689, 690, 691, 692, 734, 735, 737, 739, 747, 763, 773, 794 
   
 
The vertebrate rhodopsin (VR) subfamily (family A) MSA contained closely related 
sequences, therefore a higher number of absolutely conserved positions was identified 
with the H calculation (Table 4). The high conservation of VR subfamily members 
originated  from  similar  receptor  function,  which  was  not  the  case  considering  a 
collection of diverse family C GPCRs. The number of conserved positions was also 
influenced by loops, which could not be aligned in the family C MSA. Loop regions of 
the VR displayed lower H values, besides few positions like the disulfide bridge formed 
between TM3 (3.25) and EC2 (45.5) common for most GPCRs. 4. Results and Discussion 
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Table 4: Overview over the Shannon entropy (H) calculated using the nine functional groups using the 
multiple sequence alignment of the vertebrate rhodopsin family, given as sequence positions of bovine 
rhodopsin (BR). 
   
Shannon Entropy  Sequence positions for BR 
   
   
H = 0  23, 28, 31, 48, 55, 59, 63, 68, 72, 73, 75, 76, 79, 81, 105, 106, 112, 113, 
121, 126, 128, 130, 131, 133, 134, 137, 138, 139, 140, 146, 148, 161, 
171, 174, 176, 177, 179, 180, 182, 183, 187, 188, 189, 207, 222, 223, 
226, 240, 242, 243, 246, 249, 251, 252, 253, 255, 256, 257, 267, 268, 
290, 294, 296, 300, 302, 303, 305, 306, 309, 310, 345 
low, 
H ≤ 0.3 
9, 17, 23, 24, 28, 31, 43, 44, 47, 48, 55, 57, 59, 62, 63, 66, 67, 68, 68, 69, 
72, 72, 73, 73, 74, 75, 76, 76, 77, 78, 79, 80, 81, 105, 106, 110, 112, 113, 
118, 121, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 137, 138, 
139, 140, 141, 142, 146, 148, 148, 160, 161, 170, 171, 171, 174, 175, 
176, 177, 178, 179, 180, 180, 182, 182, 183, 183, 187, 188, 188, 189, 
190, 193, 207, 215, 219, 222, 223, 226, 230, 231, 237, 239, 240, 240, 
242, 243, 244, 245, 246, 246, 247, 248, 249, 250, 251, 252, 253, 255, 
255, 256, 256, 257, 258, 267, 268, 269, 272, 274, 290, 290, 291, 292, 
294, 294, 295, 296, 297, 298, 300, 300, 301, 302, 303, 303, 304, 305, 
306, 309, 310, 311, 312, 313, 316, 317, 338, 342, 345 
medium, H > 0.3 & 
H ≤ 0.5 
82, 103, 114, 115, 119, 130, 202, 216, 229, 234, 254, 263, 309, 314, 318, 
340, 343, 347, 348 
high, H > 2  1, 5, 7, 8, 16, 38, 111, 149, 194, 228, 273, 281, 282, 325, 326, 328 
   
 
Nevertheless,  since  all  GPCRs  possess  the  heptahelical  fold,  it  is  very  likely  that 
conserved structural motifs exist, i.e. a special residue arrangement necessary for the 
GPCR activation process. The conserved positions in the VR and the family C MSAs 
will  be  discussed  in  following  using  BR  and  the  homology  modeled  structure  of 
mGluR5.  
 
4.1.4 Structure prediction of mGluR5 
Based on sequence similarities it has been hypothesized that family C receptors may 
originate  from  a  fusion  of  a  heptahelical  domain  of  a  family  A  receptor  with  a 
periplasmatic  binding  protein  (Pin  et  al.  2003).  Therefore,  the  variety  of  signaling 
pathways  and  orthosteric  ligands  managed  by  GPCRs  could  be  enlarged  by  the 
extracellular ligand binding site. In the present study the focus lies on the TM domain 
being  the  binding  pocket  for  endogenous  family  A  ligands  and  allosteric  family  C 
ligands (Figure 5). In family C GPCRs the TM domain when expressed alone can be 
activated by allosteric modulators in a similar way as family A GPCRs (Goudet et al. 
2004).  4. Results and Discussion 
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This study particularly focuses on structural arrangements and sequential relationships 
between family A and C. Here, the BR X-ray structure (PDB identifier: 1U19, Okada et 
al. 2004) was applied for homology modeling of mGluR5 and projection of structural 
and functional features of family C onto the structure of mGluR5 and those of the VR 
family on BR. From the sequence alignment of mGluR5 to BR and to ß2AD, sequence 
identity  values  of  14%  and  13%  were  calculated  for  both  determined  structures 
respectively  using  only  on  the  TM  region  (Figure  16).  Therefore,  BR  was  used  as 
modeling template and β2AD, bound to carazolol, in the binding site analysis only.  
 
The loop regions were not modeled explicitly since all available templates differ in 
length and secondary structure, especially for EC2, the extracellular loop connecting 
TM4 and TM5 and covering the binding pocket of known GPCR structures. In BR the 
EC2 is folded into β-sheets, it has an α-helical structure in βAD receptors and a coiled 
structure stabilized by three disulfide bonds in A2A adenosine receptor. In the human 
A2A  adenosine  receptor  one  additional  disulfide-bond  constraints  EC3  exposing  the 
binding site to the solvent (Jaakola et al. 2008). 
 
                           1.4       1.5 
                            |         | 
2RH1.A      029 DEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQT 066 
MGR5_HUMAN  572 YLRWGDPEPIAAVVFACLGLLATLFVTVVFIIYRD--T 607 
MGR1_HUMAN  585 YLEWSNIESIIAIAFSCLGILVTLFVTLIFVLYRD--T 620 
1U19.A      033 EPWQFSMLAAYMFLLIMLGFPINFLTLYVTVQHKKLRT 070 
 
                            2.5       2.6 
                             |         | 
2RH1.A      067 -VTNYFITSLACADLVMGLAVVPFGAAHILMKMWT 100 
MGR5_HUMAN  608 PVVKSSSRELCYIILAGICLGYLCTFCLIAK---- 638 
MGR1_HUMAN  621 PVVKSSSRELCYIILAGIFLGYVCPFTLIAK---- 651 
1U19.A      071 -PLNYILLNLAVADLFMVFGGFTTTLYTSLHGYFV 104 
 
                         3.3       3.4       3.5 
                          |         |         | 
2RH1.A      101 FGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAIT 136 
MGR5_HUMAN  639 PKQIYCYLQRIGIGLSPAMSYSALVTKTNRIARILA 674 
MGR1_HUMAN  652 PTTTSCYLQRLLVGLSSAMCYSALVTKTNRIARILA 687 
1U19.A      105 FGPTGCNLEGFFATLGGEIALWSLVVLAIERYVVV- 139 
 
                                     4.4       4.5      
                                      |         | 
2RH1.A      137 ---------SP-FK-YQSLLTKNKARVIILMVWIVSGLTSFLPIQMH 174 
MGR5_HUMAN  675 GSKKKICTKKPRFMSACAQLVIAFILICIQLGIIVALFIMEPPDIMH 721 
MGR1_HUMAN  688 GSKKKICTRKPRFMSAWAQVIIASILISVQLTLVVTLIIMEPPMPIL 734 
1U19.A      140 ------C--KP--MS-NFRFGENHAIMGVAFTWVMALACAAPPLVG- 174 
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                                  45.5           
                                    | 
2RH1.A      175 WYRATHQEAINCYAEE--TCC--DFF-- 194 
MGR5_HUMAN  722 --DYP---SI----REVYLIC--N—-T- 735 
MGR1_HUMAN  735 --SYP---SI----KEVYLIC--N—-T- 748 
1U19.A      175 WSRY-----I-PEGMQ—-CSCGIDYYTP 194 
 
                         5.4       5.5       5.6 
                          |         |         | 
2RH1.A      195 ---T-NQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQL 230 
MGR5_HUMAN  736 ---T-N-LGVVTPLGYNGLLILSCTFYAFKTRNVP----- 765 
MGR1_HUMAN  749 ---S-N-LGVVAPLGYNGLLIMSCTYYAFKTRNVP----- 778 
1U19.A      195 HEETNNESFVIYMFVVHFIIPLIVIFFCYGQLVFTVKEA- 233 
 
                                      6.4       6.5 
                                       |         | 
2RH1.A      263 --------KFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD- 300 
MGR5_HUMAN  766 ------------ANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNY--- 797 
MGR1_HUMAN  779 ------------ANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNY--- 810 
1U19.A      234 AAQQQESATTQKAEKEVTRMVIIMVIAFLICWLPYAGVAFYIFTHQG 281 
 
                 7.3       7.4       7.5 
                  |         |         | 
2RH1.A      301 NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCL-- 342 
MGR5_HUMAN  798 KIITMCFSVSLSATVALGCMFVPKVYIILAKPERNVRSAFTTST 841 
MGR1_HUMAN  811 KIITTCFAVSLSVTVALGCMFTPKMYIIIAKPERNVRSAFTTSD 854 
1U19        282 SDFGPIFMTIPAFFAKTSAVYNPVIYIMMNKQFRNCMVTTLCCG 324 
 
Figure 16: Sequence alignment of ß2AD (chain A, PDB ID: 2RH1), the human mGluR5 (SwissProt-ID: 
P41594) and BR (chain A, PDB ID: 1U19). Identical residues for at least two sequences are highlighted 
in bold letters. Alpha-helical regions are given with grey background. Additional to sequence positions 
the  Ballesteros-Weinstein  notation  is  given  above  the  alignment.  The  conserved  disulfide-bond 
connecting EC2 and TM3 is highlighted in blue. Positions tested in mutagenesis studies on family C 
GPCRs affecting the binding of positive allosteric modulators are coloured green, of negative allosteric 
modulators in red and both types in yellow. Red letters indicate different amino acids between hmGluR1 
and hmGluR5. 
 
4.1.5 Projection of Shannon entropy values on a GPCR structure 
The  modeled  mGluR5  structure  provided  a  basis  for  conservation  analysis  in  3D 
context, therefore conserved features (Figure 18) and values (Figure 17) were projected 
onto receptor structure. Based on the sequence alignment used for homology modeling 
of mGluR5 on BR as template conservation of sequence positions between family A 
and family C was  compared. The mutation data collection (Table A 3), which was 
compiled  for  amino  acids  referenced  in  literature,  served  as  information  source  for 
binding site analysis, as discussed in Section 4.1.7. 4. Results and Discussion 
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TM 1
TM 2
TM 3
TM 4
TM 5
TM 6
TM 7
EC 2
H 8
conservation  
Figure 17: Projection of Shannon entropy values calculated using the nine functional groups. The colors 
define the level of conservation according to the color bar, from low (blue) to high (red) conservation. 
Grey regions were considered for calculation. The calculation was based on a family C G protein-coupled 
receptor alignment. The structure of the metabotropic glutamate receptor five was prepared by homology 
modeling using bovine rhodopsin as template.  
 
The projection of Shannon entropy values as a color scheme onto the structure of a 
GPCR allowed to detect the location of conserved position in three dimensional context 
(Figure 17). The comparison of family C to vertebrate rhodopsins (VR) revealed several 
similarly conserved and positioned types as prolines (TM4, TM6 and TM7) involved in 
helical kinks, as well as a basic cluster at the ends of TM3 and TM6. 
 
The most conserved features of the family C MSA were projected onto mGluR5 (Figure 
18, A) and the of the vertebrate rhodopsin family onto BR structure (Figure 18, B). 
Aromatic,  aliphatic,  neutral  and  small  amino  acids,  which  are  more  common  in 
membrane environment (Jones et al. 1994), were detected with Shannon entropy and 
nine functional groups as most frequently conserved types in the TM.  4. Results and Discussion 
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Figure 18: Most conserved features of A) family C MSA projected onto the modeled structure mGluR5 
and  B)  family  A/(Rhod)opsin/Vertebrate  rhodopsin  MSA  projected  onto  the  structure  of  BR.  Nine 
functional amino acid groups were used for sequence encoding. These groups are condensed to six color 
representations as described in the legend, the seventh color represents not quantified positions. 
 
For eight of nine amino acid types an equivalent most conserved type was discovered in 
both  MSAs,  family  C  and  VR  (Figure  19).  The  implication  of  these  positions  is 
discussed in the following sections. 4. Results and Discussion 
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Figure 19: Projection of the most conserved amino acid groups at corresponding positions identical in the 
transmembrane  region  (TM)  of  family  C  and  family  A  (VR)  G  protein-coupled  receptors.  Identical 
positions are  shown in colors representing the special amino acid types (eight types as given in the 
legend, “neutral” is missing, since identical positions were not observed for that type) and in light grey 
the not identical features. Not aligned positions are omitted.  
 
4.1.6 Conservation of structural and functional features 
Based on the idea that structural motifs are more conserved than sequences (Holm and 
Sander 1996, Hubbard et al. 1997, Rost 1999), GPCR common sites were evaluated 
with respect to conservation in family C. Several different structural and functional 
receptor  features,  helix-helix  contacts,  dimerization,  function,  motifs  and  the  ligand 
binding site, were analyzed and compared for the vertebrate rhodopsin and family C 
GPCRs. The mutation data collection (Table A 3) was applied for experimental details 
on family C, an equivalent collection published by Madabushi completed the data for 
family A GPCRs (Madabushi et al. 2004) as several studies focusing on a particular 
GPCR feature. 
 
Helix-helix Contacts 
In  the  homology  model  of  mGluR5  (Figure  20, A)  10  out  of  20  highly  (H ≤ 0.6) 
conserved family C positions were identified at helix-helix contact areas; two residues, 
3.25 and 7.36, are close to EC2 loop. These 10 residues with Shannon entropy values 
below 0.6 (Table 3) were G590 (1.46) and L622 (2.51) between TM1 and TM2, I620 
(2.49) from TM2 pointing towards TM3, also L662 (3.43), I669 (3.46) and K665 (3.5) 
in TM3 in contact to I774 (6.37) and M778 (6.41) in TM6 near the intracellular side and 
A758 (5.58) from TM5 facing T666 (3.47) in TM3. The disulfide-bridge to EC2 formed 
by residue C644 (3.25) in TM3 was also conserved.  4. Results and Discussion 
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A                    B 
Figure 20: Projection of Shannon entropy values (H) calculated with nine functional groups onto the 
transmembrane region (TM) of  mGluR5. Cα-atoms of residues are presented as spheres and colored 
according  to  H  conservation  values  for  the  family  C  G  protein-coupled  receptors  (GPCR)  multiple 
sequence alignment. A) Positions with H ≤ 0.6 (Table 3). B) H values of positions at family A GPCR 
helix-helix contacts (Palczewski et al. 2000, Teller et al. 2003). Positions are matched according to the 
bovine rhodopsin to family C GPCR alignment (Figure 16). 
 
A different picture emerged when helix-helix contacts from rhodopsin (Palczewski et al. 
2000,  Teller  et  al.  2003)  were  analyzed  on  the  mGluR5  structure  regarding  their 
conservation  in  family  C  GPCRs  (Figure  20, B).  Rhodopsin  contact  sites  did  not 
correspond to conserved family C positions. In the conformational state of the inactive 
rhodopsin, with retinal in the binding site, other residues form close contacts.  
 
Helical  packing  plays  a  crucial  role  in  the  folding  and  oligomerization  of  integral 
membrane  proteins  (Russ  and  Engelman  2000).  The  conserved  helix-helix  contacts 
define a mutual arrangement of helices in TM domains (Chugunov et al. 2007). The 
location of the most conserved positions in family C GPCRs lead to the conclusion that 
helix-helix-contacts are conserved regions facilitating the helical packing of the TM.  
 
Dimerization 
Prediction of dimerization sites for GPCRs is still a challenging task, as it can be seen 
from  modeling  and  experimental  studies  suggesting  different  possible  dimerization 
interfaces  for  rhodopsin  involving  helices  I/II/VII  or  IV/V/VI  (Filipek  et  al.  2004, 
Filipek 2005, Filizola and Weinstein 2005, Salom et al. 2006). Using Shannon entropy 4. Results and Discussion 
80 
conservation analysis for comparison of these proposed interfaces no preference of a 
more common interface could be observed (Table 5). 
Table 5: Shannon entropy (H) of residues proposed as important for receptor dimerization of rhodopsin, 
from  modeling studies ([1] Filipek et al. 2004, [2] Filipek 2005) and from experimental results ([3] 
Filizola and Weinstein 2005, [4] Salom et al. 2006). Positions are given for the metabotropic glutamate 
receptor five (mGluR5) and bovine rhodopsin (BR). The most conserved feature according to the nine 
functional groups is given for the family C GPCR and the vertebrate rhodopsins (VR). 
             
Position 
in 
mGluR5 
H for 
family C 
Most conserved 
group in family C 
Position 
in BR 
H for 
VR 
Most conserved 
group in VR 
Reference 
             
584  1.67  aliphatic  F45  1.35  aromatic  D (4) 
588  1.67  aliphatic  M49  1.23  aliphatic  D (4) 
591  0.79  aliphatic  F52  1.61  small  D (4) 
598  0.95  aliphatic  L59  0  aliphatic  D (3) 
634  1.98  aliphatic  Y96  1.88  aromatic  D (4) 
638  1.91  acidic  H100  1.88  aromatic  D (4) 
698  2.03  aliphatic  H152  1.24  basic  D (2) 
701  1.03  aliphatic  M155  1.31  aliphatic  D (2) 
704  1.18  neutral  A158  1.47  small  D (3) 
705  0.56  aliphatic  F159  1.13  aromatic  D (3) 
708  1.78  aliphatic  V162  0.95  aliphatic  D (2) 
712  1.14  aliphatic  A166  1.77  small  D (3) 
715  2.02  acidic  A169  1.35  small  D (3) 
717  1.68  proline  P171  0.02  proline  D (3) 
735  2.42  basic  D199  1.46  neutral  D (1) 
737  2.52  acidic  E201  1.32  acidic  D (2) 
738  1.36  aliphatic  S202  0.38  small  D (1) 
779  1.39  aromatic  I259  1.28  aliphatic  D (3) 
             
 
Filipek proposed that S202, D199 and E196 of two monomers are involved in receptor 
dimerization in rhodopsin (Filipek et al. 2004, Filipek 2005). According to the mGluR5 
model the end of EC2 connecting to TM5 contains three residues, N734, N737 and 
T742, which could be part of the proposed interface between TM5 and TM4. In case 
that TM5 is involved in dimerization, residues at TM4 pointing away from the receptor 
could be regarded as potential interacting points.  4. Results and Discussion 
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For family C receptors it is known (Pin et al. 2003) that dimers could be linked together 
by a disulfide bond through one or two cysteins located in the fifth loop of the VFT. 
Remelli  and  co-workers  showed  that  the  C-terminus  of  the  metabotropic  glutamate 
receptor  1b  regulates  the  dimerization  of  the  receptor  (Remelli  et  al.  2008).  Since 
neither the C-terminus nor the VFT were part of the conservation study, these findings 
could not be evaluated. With the exception of the reported heterodimerization of the 
mGluR1  and  calcium  sensing  receptor,  there  has  been  no  evidence  for  the 
heterodimerization  of  other  mGluRs,  in  fact  mGluR1  and  mGluR5  do  not  form 
heterodimers when co-expressed in cells (Romano et al. 1996, Robbins et al. 1999, 
Gama et al. 2001). 
 
Regarding family A GPCR dimerization, associations between TM1 and TM8 has been 
found  in  rhodopsin  crystal  structures,  the  physiological  relevance  of  this  contact 
remains unproven (Cherezov et al. 2007). For family A GPCRs, hypotheses involving 
TM6 in the ß2AD (Hebert et al. 1996) and TM4 in the D2 dopamine receptors (Guo et 
al. 2003) describe possible dimer interfaces, respectively. 
 
However no support for a conserved dimerization site based on the here proposed type 
of conservation analysis could be identified for any of the reported sites. Taking into 
account that residues in N- and C-terminal domains were experimentally tracked for 
involvement  in  receptor  dimerization  and  the  fact  that  functionally  distinct  GPCRs 
could  form  homo  as  well  as  heterodimers,  it  might  be  unreasonable  to  expect  one 
absolutely conserved dimerization region in the TM domain. 
 
Receptor activation 
Receptor activation data was correlated to H values calculated for VR subfamily as 
representatives of family A GPCRs. 16 mutations causing constitutive activity taken 
from  the  Madabushi  collection  (Madabushi  et  al.  2004)  of  family  A  GPCRs  were 
compared with conservation values calculated on the vertebrate rhodopsin subfamily 
(Table 6). Besides two moderately conserved residues (2.53 and 3.35) in the vertebrate 
rhodopsin family out of 16 considered, all other positions were  found  to be highly 
conserved (H ≤ 0.6) indicating that residues at these positions play an important role in 
receptor activation (Madabushi et al. 2004). These positions were further investigated in 
the MSA of family C GPCRs (Table 6).  4. Results and Discussion 
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Figure 21: Residues described by Madabushi and co-workers experimentally determined to be important 
for receptor activation (Madabushi et al. 2004). If mutated, the receptor turned out to be constitutively 
active. Structure of BR colored according to conservation calculated with H for the vertebrate rhodopsin 
subfamily MSA, Cα-atoms of concerned residues are shown in sphere representation. Residues are given 
in Table 6. 
 
In  family  C  GPCRs,  four  residues  (2.43,  2.45,  2.53,  3.35),  which  were  not  highly 
(H > 0.6) conserved, were exclusively located at contact regions of TM3 to TM2 and to 
TM4;  G120  is  also  low  conserved  (H = 1.35)  in  family  A  GPCRs.  Nine  of  the  16 
considered  positions  were  also  conserved  (H ≤ 0.6)  in  family  C  GPCRs,  especially 
seven (3.43, 3.46, 3.47, 3.50, 5.57, 6.37, 6.40) at the intracellular end of TM3, TM5 and 
TM6 in contact to each other, 1.5 at TM1 close to TM2 and 3.25 at TM3 in contact to 
EC2. 
 
From the positions described in Table 6 two have been proven so far to be important for 
function of family C GPCRs (Table A 3). The human response to lactisol could be 
introduced into the rat T1R3 by a mutation L740F (5.39) (Winning et al. 2005). S787F 
(6.5) is a naturally occurring mutation increasing calcium sensitivity for hCaSR (Hu et 
al. 2005). From the highly conserved (H ≤ 0.6) residues of family C GPCRs shown in 
Figure 20, other than these nine residues might be important for receptor function. 
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Table 6: Residues described by Madabushi and co-workers experimentally determined to be important 
for receptor activation (Madabushi et al. 2004). If mutated, the receptor displayed constitutive activity. 
HV stands for Shannon entropy value calculated using the nine functional groups for amino acids. For 
each position the most conserved feature is given. Positions highly (H ≤ 0.6) conserved in family C and in 
family A GPCRs are highlighted in bold. 
             
BW 
numbering 
Residue 
in 
mGluR5 
 
HV for 
family C 
Conserved group 
in family C 
Position in 
BR  HV for VR  Conserved  
feature in VR 
             
1.50  T594  0.6  small  N55  0  neutral 
2.43  S614  2.05  glycine  L76  0.02  aliphatic 
2.45  E616  2.45  acidic  N78  0.04  neutral 
2.53  G624  1.44  glycine  M86  1.42  aliphatic 
3.25  C644  0.54  cysteine  C110  0.04  cysteine 
3.35  S654  2  glycine  G120  1.35  glycine 
3.43  L662  0  aliphatic  L128  0  aliphatic 
3.46  K665  0.4  basic  L131  0  aliphatic 
3.47  T666  0.48  small  A132  0  small 
3.49  R668  1.87  basic  E134  0  acidic 
3.50  I669  0.09  aliphatic  R135  0.02  basic 
5.39  V740  0.92  aliphatic  V204  0.62  aliphatic 
5.57  A758  0.28  small  C222  0.9  cysteine 
6.37  I774  0  aliphatic  V254  0.52  aliphatic 
6.40  T777  0.59  small  M257  0  aliphatic 
6.50  A787  0.86  small  P267  0  proline 
             
 
G protein-coupling 
G protein-coupling is major part of the receptor activation, since it is responsible for 
signal  propagation  inside  the  cell.  Depending  on  the  G-proteins  different 
pharmacological processes can be activated, therefore special G-proteins and/or groups 
of  G-proteins  interact  with  particular  receptors  or  receptor  oligomers  (Jacoby  et  al. 
2006,  Kew  and  Kemp  2005).  For  selective  G-proteins  binding,  a  protein-protein 
interface  between  the  receptor  and  the  G-proteins  is  needed  (Scheerer  et  al.  2008). 
Several  positions  which  are  involved  in  G-protein  coupling  were  proposed  from 
modeling studies (Madabushi et al. 2004, Filipek et al. 2004) and some revealed by 
experimental tests (Palczewski et al. 2000, Acharya et al. 1997, Madabushi et al. 2004). 
 
According  to  our  conservation  calculations,  all  residues  summarized  in  Table  7  are 
highly conserved (H ≤ 0.6) in the vertebrate rhodopsin subfamily. Nevertheless, only 
few  correspond  to  similar  conserved  types  in  family  C,  which  could  be  due  to 
interactions with completely different G-proteins in comparison with family A GPCRs 
or uncertainties in intracellular site alignment and modeling. The opposite was observed 4. Results and Discussion 
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for the metabotropic glutamate receptor subfamily (mGluR), there 13 of 24 reported 
positions are absolutely conserved, with H values equal to zero.  
Table 7: Residues which were reported as important for G protein-coupling and the Shannon entropy (H) 
values  calculated  for  the  metabotropic  glutamate  receptor  (mGluR)  and  the  vertebrate  rhodopsin 
subfamilies ((1) Palczewski et al. 2000, (3) Madabushi et al. 2004, (4) Filipek et al. 2004, (8) Acharya et 
al. 1997). GP stands for proposed and G for experimentally validated changes on G protein-coupling.  
         
Ballesteros 
Weinstein 
numbering 
H for 
mGluR  H for family C  H for vertebrate 
rhodopsins  Reference 
         
         
1.63  0.97  2.23  0.04  GP (4) 
2.39  0  0.8  0.02  G (1, 3) 
2.40  0  1.04  0.02  G (3) 
2.45  0  2.45  0.04  G (3) 
3.49  0.48  1.87  0  G (3) 
3.5  0  0.09  0.02  G (3) 
3.51  1.23  2.09  0.02  G (8, 3) 
3.52  0  1.84  0.2  G (8) 
3.53  0  0.88  0  G (1, 3) 
3.54  0.75  1.3  0  G (8,1) 
IC2  0.41  2.06  0.02  GP (4) 
IC2  0.75  2.53  0.82  GP (4) 
4.36  0  1.63  1.02  GP (4) 
4.37  0  1.63  0.02  GP (4) 
5.58  0.96  1.42  0  G (3) 
5.61  0  0.95  0  G (1) 
6.32  0  1.04  0  G (8) 
6.33  0  0.89  0.02  G (8, 1) 
6.34  0  0.92  0  G (8) 
6.36  1.47  2.32  0  G (1) 
6.37  0  0  0.52  G (3) 
7.53  0.66  1.59  0  G (3) 
7.57  1.34  2.11  0  G (3) 
7.59  0.2  1.79  0.11  GP (4) 
         
 
The new structure of squid rhodopsin (2Z73, Murakami and Kouyama 2008) revealed 
great  differences  in  the  helix  lengths  compared  to  the  bovine  form,  which  were 
explained by the authors as essential for different light absorption capabilities of the to 
rhodopsin types. Therefore, it can be concluded that the G-protein coupling interface is 
optimized  in  distinct  signal  transduction  pathways  and  might  be  only  conserved 
between receptors binding to similar G-proteins. The correlation of G-protein interfaces 
to signaling molecules it outside the scope of present analysis. 
 
The intracellular side of the TM3 domain which interacts with the G protein contains 
the  “DRY”-motif  (Scheerer  et  al.  2008),  named  after  the  conserved  amino  acids  at 4. Results and Discussion 
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positions 3.49, 3.50 and 3.51. According to our alignment the DRY-motif seems to be 
not conserved in family C GPCRs. Instead, a BasicXXBasicXXBasic-motif was found 
conserved  at  positions  from  3.46  to  3.52  with  hydrophobic  or  neutral  residues  in-
between. Only the first basic position was preserved in family C receptors, both other 
basic  positions  were  acidic  for  taste  receptors.  The  mGluR  subfamily  showed  a 
conserved KXXRXXR amino acid cluster. The DRY-motif is part of the ionic lock 
proposed to stabilize the inactive conformation of BR (Scheerer et al. 2008). The ionic 
interaction  in  BR  is  established  between  Arg135  and  Glu134  from  the  conserved 
E(D)RY motif in TM3, and the side chains of Glu247 and Thr251 in TM6. According to 
the modeled structure of mGluR5, close contacts between residues in TM3 and TM6 
could be observed: Lys665, Arg668 in TM3 and Glu770, Tyr773 in TM6 (Figure 22). 
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Figure 22: Superposition of bovine rhodopsin (BR, grey) with the modeled structure of mGluR5 (blue) 
focusing on the ionic lock. All helices besides TM3 and TM6 all loops are omitted for clarity reasons. 
Hydrogen bonds are indicated with dashed lines in black for BR and blue for mGluR5. 
 
In  GPCRs,  where  constitutive  activity  could  be  observed  (Cherezov  et  al.  2007, 
Rasmussen et al. 2007), no ionic lock is proposed to stabilize the ground state. A2A 
adenosine and ßAD receptor structures revealed that the DRY-sequence participates in 
interactions to the IC2 loop. The IC2 loop is helically structured in A2A adenosine and 
ß1AD  receptors  and  the  presence  of  that  helix  correlates  with  constitutive  activity 
profiles (Jaakola et al. 2008). Therefore, the modeled structure might be biased towards 
interactions  insight  the  DRY-region  which  are  present  in  the  template  structure. 4. Results and Discussion 
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Nevertheless, charged side chains are in close proximity in the mGluR5 model and 
might be a comparable cluster which links TM3 and TM6 together, both helices are 
involved in receptor activation of GPCRs (Crocker et al. 2006, Altenbach et al. 2008). 
 
In general, TM3 revealed the most inconvenient amino acid types according to common 
amino acid distributions proposed by Jones for TM regions (Jones 1994). The reason for 
that is the localization of TM3 inside the helix bundle with limited contacts to the lipid 
bilayer. 
 
4.1.7 Conservation of the ligand binding site 
Ligand binding in the TM domain of family C GPCRs 
For the definition of the binding pocket information from mutation studies conducted in 
the  TM  of  family  C  GPCRs  was  used  (Table  A  3).  This  information  included  the 
particular mutation, the tested ligand type (NAM/PAM, Figure 14) and the impact of a 
mutation on ligand effect compared to the wild-type receptor. These positions were 
considered  important  for  ligand  binding  in  family  C  GPCRs  and  evaluated  with 
Shannon  entropy  values.  Additionally  a  comparison  was  made  to  known  family  A 
binding sites (Table 8). A position was considered to be important for ligand binding, if 
at least one ligand was affected in binding or effect by a mutation at this position. It 
should be noted that mutations at the same position have different effect on the tested 
ligands. A total of 36 different positions were considered for binding site analysis, they 
were composed from the mutation data collection and the binding site of carazolol. 
According  to  changes  tested  with  mutations  25  positions  are  involved  in  allosteric 
modulation and 12 are essential for functional activation by the agonist. 
 
Residues which were proposed to be involved in interaction with carazolol (Cherezov et 
al. 2008, supplementary material), a diffusible ligand, were analyzed with respect to 
conservation values of family C GPCRs and the mGluR subfamily and mutation data 
(Table 8). According to the conservation calculation for the mGluR subfamily out of 16 
highly conserved (H ≤ 0.6) positions in mGluR eight are also conserved (H = 0) in VR 
subfamily. 11 out of the same 16 positions could be proven my mutagenesis studies to 
be important for allosteric modulation by ligands for family C GPCRs. These results are 
in agreement to the fact of similar location for the allosteric binding sites of family C 
GPCRs and the endogenous binding pocket of family A GPCRs. 4. Results and Discussion 
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Table 8: Mutations tested on family C GPCRs with respect changes in ligand effect of different ligand 
types (PAM, NAM, agonist). All ligands used for these studies are presented in Figure 14. Conservation 
values calculated using Shannon entropy (H) using the nine functional groups (overall H ranges from 0 to 
2.55)  as  well  as  the  most  conserved  group  are  presented  for:  family  C,  the  metabotropic  glutamate 
receptor (mGluR) subfamily and the vertebrate rhodopsin (VR). Interacting residues of the ß2AD with 
carazolol (Cherezov et al. 2007), an inverse agonist, are included for comparison. 
               
BW 
numbering 
Bovine 
rhodopsin 
position 
H for 
VR 
Effected 
ligand type 
in family C 
Conserved group  
family C/ 
mGluR 
H for 
family C  
H for 
mGluR 
ß2AD 
interactions 
with 
carazolol 
               
2.64  T97  1.2  PAM, NAM  Aromatic/ 
Aliphatic  1.12  0.66   
3.27  L112  0.7  NAM  Aliphatic  1.42  1.14   
3.28  E113 
(retinal)  0  PAM  Basic  0.71  1.0  W109 
hydrophobic 
3.29  G114  0.55  NAM  Basic  2.11  0   
3.32  A117  1.41  NAM  Aliphatic  1.29  0.22  D113 h-bond 
3.33  T118  0.06  NAM  Glycine  1.54  0 
D114 
hydrophobic 
3.36  G121  0 
PAM, 
NAM, 
agonist 
Aromatic  1.2  1.81  V117 
hydrophobic 
3.37  E122  1.18  agonist  Small  1.05  0.64  T118 
hydrophobic 
3.39  A124  0.77  PAM, NAM  Cysteine/Small  1.82  1.54   
3.4  L125  0.78  NAM  Aromatic  0.91  0   
4.45  W161  0  PAM  Small  1.9  1.1   
4.46  V162  0.95  PAM  Aliphatic  0.5  0.35   
5.32  Y191  -        -  F193 
hydrophobic 
5.38  F203  0        1.14  Y199 
hydrophobic 
5.39  V204  0.62  agonist  Aliphatic  0.92  0.8   
5.42  M207  0  NAM  Aliphatic/Small  2.06  1.6  S203 h-bond 
5.43  F208  0.93  PAM, NAM  Aliphatic  1.52  1.01   
5.44  V209  1.28  PAM  Glycine  1.46  1.25   
5.46  H211  1.1  PAM, 
agonist  Small  2.43  1.84  S207 
hydrophobic 
6.44  F261  0  PAM, NAM  Small  1.84  0   
6.48  W265  0  PAM, NAM  Aromatic  1.14  0  W286 
6.49  L266  1.57  agonist  Aliphatic  0.53  0   
6.5  P267  0  agonist  Small  0.86  0   
6.51  Y268  0 
PAM, 
NAM, 
agonist 
Aromatic  1.24  0  F289 
6.52  A269  0.02  agonist  Aliphatic  1.18  0  F290 
hydrophobic 
6.53  G270  1.70  agonist  Proline  1.35  0   
6.54  V271  1.33  agonist  Aliphatic  0.88  0   
6.55  A272  0.2  NAM  Aromatic  1.66  0 
N293 
hydrophobic 
7.32  P285  1.70 
PAM, 
NAM, 
agonist 
Aliphatic  1.66  0.6   4. Results and Discussion 
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7.33  I286  1.42  PAM, NAM  Small  1.71  1.0   
7.35  M288  1.0  NAM  Small  1.28  0 
Y308 
hydrophobic 
7.36  T289  0  NAM  Aliphatic  0.52  0   
7.37  I290  0.1  PAM, NAM  Aliphatic/Small  1.45  0.4   
7.39  A292  0.02        0  N312 h-bond 
7.4  F293  0.90  NAM  Small  1.64  1.22   
7.43  K296 
(retinal)  0  agonist  Aliphatic/small  1.56  0  Y316 h-bond 
               
 
It is possible that different ligands bind within the TM region of family C GPCRs in 
different binding modes like in the case of family A GPCRs, the adenosine (Jaakola et 
al. 2008) and the ß2AD receptors (Cherezov et al. 2007). Chen discovered for mGluR 
group I that CPPHA does not interact with the receptor the same way as MPEP (Chen et 
al.  2008)  and  emphasized  even  the  hypothesis  that  different  binding  modes  might 
trigger  different  signal  transduction,  since  it  is  known  that  mGluR5  can  couple  to 
multiple G protein types (Pin et al. 2003). Depending on the mutation and the ligand, a 
single mutation could have different or even opposite effects on ligand binding for the 
same receptor, as it is the case for 3.36, 3.4, 6.51, 6.55, and 7.4. Amino acid positions in 
the  TM  crucial  for  interaction  with  allosteric  modulators  according  to  mutagenesis 
studies in mGluRs are highlighted in Figure 23.  
TM4
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TM7
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PAM
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7.35
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Figure 23: Mutated positions of mGluR receptors, which show impact on ligand binding or allosteric 
effect: NAM (12), green: PAM (12), yellow PAM and NAM (8). The homology modeled structure of 
mGluR5  with  view  from  the  extracellular  site  is  shown  in  cartoon  representation.  Overview  about 
mutated positions is given in Table 8. 4. Results and Discussion 
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The  importance  of  several  aromatic  residues  in  the  TM  cleft  was  discovered  with 
mutagenesis studies (Malherbe et al. 2003, Malherbe et al. 2006). There, it could be 
shown that the binding of fenobam, DFB and MPEP (mGluR5) as well as EM-TBPC 
(mGluR1) depend on these aromatic amino acids in TM6: 6.48, 6.51, 6.55 and TM3: 
3.4. Position 6.48 is essential for NAM binding (Figure 23). There a W784F mutation in 
mGluR5  reduces  and  W784A  abolishes  fenobam  binding  (Malherbe  et  al.  2006). 
Additionally, a mutation at that position (W784A or W784A in mGluR5) can increase 
PAM effect of DFB (Muehlemann et al. 2006). It seemed that the “aromatic cluster” in 
TM5 and TM6, F261 (6.44), W265 (6.48) and Y268 (6.51) might contribute less to the 
selectivity of ligand binding than to a general activation mechanism in mGluRs, since 
NAMs and PAMs equally depend on these positions and the position were conserved. 
 
The conservation analysis revealed that positions 3.4, 6.48, 6.51 and 6.55 are conserved 
(H=0) in the mGluR subfamily, but not conserved overall in family C. The GABA-B 
and the Taste subfamilies contain sequences, which have different amino acid types at 
these positions (Figure A 1). Here, the conservation analysis pointed out a difference 
between mGluR and the GABA-B and Taste subfamilies as part of family C GPCRs. 
 
Selective ligand binding 
Family  C  GPCRs  bind  their  endogenous  ligands  in  the  extracellular  VFT  and  no 
endogenous ligands are known for the TM region. Therefore, in contrast to family A 
GPCRs, one might assume that residues in the TM binding site are less conserved, as it 
would be in case of homologous receptors binding their endogenous ligands. Subtype 
selective ligand binding facilitates the reduction of side-effects in medical treatment. 
Not conserved positions which were discovered in mutation studies as contributing to 
ligand binding should be considered as promising sites for selective ligand binding. 
Changing  amino  acid  type  at  position  7.32  abolishes  ligand  binding  for  different 
receptors (rmGluR5a, hCaSR, hmGluR1b, rmGluR1a and hT1R3), having different non 
conserved amino acids with a special interaction for each receptor (Malherbe et al. 
2006, Muehlemann et al. 2006, Jiang et al. 2005, Hu et al. 2005). This position is not 
conserved in family C (H=1.66), which points out its importance in selective ligand 
recognition.  
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Conservation  calculation  for  the  metabotropic  glutamate  receptor  subfamily  (50%) 
revealed  higher  conservation  than  for  the  whole  family  C  (8%).  TM3  and  TM6 
undergoing conformational changes during activation (Altenbach et al. 2008) possess 
the  highest  number  of  conserved  positions.  All  mutations  from  the  mutation  data 
collection  which  has  been  tested  at  mGluR  are  facing  the  TM  binding  site  in  the 
modeled receptor structure of mGluR5 (Figure 24) but are not identically conserved, 
what might be essential for development of selective ligands. 
 
For  a subfamily like mGluRs conservation  and selectivity  can behave  a follows on 
examples of 3.39 (selective) and 3.4 (non-selective). The mutation Ser3.39 abolishes 
DFB,  fenobam  and  MPEP  binding  and  effect  in  mGluR5  (Mühlemann  et  al.  2006, 
Malherbe et al. 2006, Pagano et al. 2000), but is not conserved in family C (H=1.82) or 
mGluRs (H=1.54) either. Close to it, position 3.4 is conserved in mGluRs and involved 
in NAM binding of mGluR1 (Malherbe et al. 2003a) and mGluR5 (Malherbe et al. 
2006). 
conservation conservation
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Figure 24: predicted mGluR5 receptor structure colored according to H values of the mGluR subfamily. 
Loops besides short part of extracellular loop 2 are omitted. Colors are applied as a color gradient, from 
red over white to blue representing high, middle and low conservation. Residues of mGluR5 at positions 
tested in mutation studies with mGluRs as important for ligand binding (Table A 3) are shown in stick 
representation. 
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It is not known in detail how the activation takes place and how allosteric modulators 
could  influence  the  conformational  changes  during  this  event.  From  the  correlation 
experiment  using  mutation  data,  conservation  values  und  crystal  structures  of  a 
covalently bound and a diffusible ligand, similarities in the binding site of family C and 
A GPCRs could be defined. This discussion will be continued in Section 4.2.4 using 
predicted mGluR5 ligand binding modes. 
 
4.1.8 Conservation analysis - conclusions 
The GPCR protein family allows for signal trafficking through cell membranes using a 
mechanism of activation by the transmembrane domain (Farrens et al. 1996, Altenbach 
et al. 2008). The goal of the conservation analysis was the analysis of function and 
structural implication of amino acids in the TM region of family C GPCRs and their 
evaluation  in  structural  context.  The  performed  Entropy  calculations  allowed  the 
identification of features within the TM region of 96 diverse family C GPCRs with 
functional  importance.  These  features  were  compared  to  published  structurally 
important sites of family A GPCRs. As a proof of concept experimentally determined 
positions controlling receptor function were determined at low entropy values in either 
the mGluR as the vertebrate rhodopsin subfamily. All structural features and positions 
involved in helical packing and activation in family C receptors could be interpreted 
using the 3D receptor model of mGluR5. 
 
Entropy  calculations  in  ligand  binding  site  of  family  C  GPCRs  allowed  the 
discrimination of differently conserved positions in family C and the mGluR subfamily. 
These differences mark important positions in the binding site in several family C 
GPCRs: 
 
•  Exclusively subfamily conserved positions (H ≤ 0.3) might define particular 
receptor function or the ligand binding site, but not subtype selectivity (3.29, 
3.32, 3.33, 3.4, 6.44, 6.48, 6.55, 7.35, 7.36, 7.37, and 7.4).  
•  Not  conserved  position  neither  in  family  C  nor  mGluR  (H  >  0.3),  but 
experimentally determined as important for allosteric ligand binding but not 
agonist effect alone, might define receptor subtype selectivity (2.64, 3.27, 3.28, 
3.39, 5.42, 5.43, 5.44, 7.32, 7.33) 4. Results and Discussion 
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With  a  focus  on  structural  motifs  crucial  for  functional  activity  as  a)  helix-helix 
contacts, b) receptor dimerization interfaces, c) G protein interaction sites d) general 
structural motifs and e) ligand binding sites similarities between the two GPCR families 
could  be  evaluated.  Especially  in  case  of  helix-helix  contacts  several  conserved 
positions (1.46, 2.51, 2.49, 3.43, 3.46, 3.47, 3.5, 5.58 6.37 and 6.41) were identified, 
which were different to analogous helix-helix contacts in BR and might compose a 
conserved pattern coding for TM packing in family C GPCRs. A conserved sequence 
pattern around the DRY-motif (Scheerer et al. 2008), which is involved in G-protein 
coupling, was observed in mGluR5.  
 
The conserved helix-helix contacts, the location of the G-protein interface and positions 
involved in ligand binding in the predicted structure model of mGluR5 were evidence of 
appropriate  sequence  alignment  and  modeling  template  selection.  By  projection  of 
mutated positions onto the structure of mGluR5 the ligand binding site of family C 
could be visualized and an overlap with the one of family A GPCR detected based on 
known complex structures (Table 8). The location of NAM and PAM binding regions of 
family C GPCRs projected on mGluR5 revealed similarities to findings published by 
Bissantz for family A GPCRs (Figure 25, Bissantz et al. 2003). Bissantz proposed a 
smaller binding region for agonists which is completely included in the antagonists’ 
binding region (Figure 25, B). Here, in the mutation data collection for family C GPCRs 
both NAM and PAM regions overlapped and were located between TM2, TM3, TM5, 
TM6 and TM7 according to the predicted mGluR5 structure (Figure 25, A). The broad 
distribution of positions involved in ligand interaction (Figure 25) of family C GPCRs 
visualize the diversity of different ligand classes recognized by the subfamilies. 4. Results and Discussion 
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Figure 25: TM ligand binding region of GPCRs. A) mGluR5 model with residues from mutation studies, 
which influence the binding or effect of negative (NAM) and/or positive (PAM) allosteric modulators in 
family C GPCRs (Table 8). B) D3 antagonist model with agonist and antagonist binding regions for 
family A GPCRs (Bissantz et al. 2003).  
 
4.2 Virtual screening for novel mGluR modulators 
The discovery of mGluR5 selective modulators is important for antipsychotic treatment 
(Conn et al. 2009). The ability of virtual approaches to discriminate mGluR NAMs 
versus  PAMs  and  selective  molecules  from  non-selective  using  different  molecule 
encoding methods will be analyzed in the beginning of this section. The subsequent 
prospective virtual screening approaches which  were  applied here will be discussed 
with  respect  to  discovery  of  structurally  distinct  molecules  compared  to  reference 
molecules.  Which  structural  features  of  the  “hit”  molecules  were  important  for 
modulation and can bind to similar regions in the binding pocket will be emphasized 
using reference molecules and binding mode prediction in the modeled structure of 
mGluR5. 
4.2.1 Ligand data analysis 
Optimization of small molecules binding to mGluRs has been successfully carried out 
and described in literature and patents (Williams and Lindley 2005, Wang and Brownell 
2007, Conn et al. 2009). Published structural information about molecules and their 
activity values was used to compile a training data set for virtual screening purposes. 
1246 unique molecules were collected and categorized in functional classes, such as 4. Results and Discussion 
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NAM  or  PAM,  and  assigned  experimentally  determined  receptor  selectivity  for 
mGluR1, mGluR2 and mGluR5 and their activity range (Table 9). 
 
Table 9: Quantitative overview over the ligand data set of mGluR binding ligands and their activity. 
Negative  (NAM)  and  positive  (PAM)  allosteric  modulators  were  differentiated  regarding  the  target 
receptor and activity values.  
NAM & PAM 
Activity  ≤ 1000nM  X  inactive  X  X 
Receptor    mGluR1 & mGluR5  mGR5  mGR1 
Number  977  117  698  279 
NAM 
Activity ≤1000nM  X  X  X  X  X   
Receptor    mGR5  mGR1  mGR5  mGR1  mGR1/5 
Selective        yes  yes  no 
Number  870  615  255  111  57  15 
PAM 
Activity  ≤ 1000nM  X  X     
Receptor    mGR5  mGR1  mGluR 2/4/7 
Number  150  83  24  43 
 
The ligand data collection was primary used to set up training sets for virtual screening 
purposes and to classify/cluster ligands into different classes (Figure 26).  4. Results and Discussion 
      95 
NAM_bm_mGluR1; 
255; 20%
NAM_bm_mGluR5; 
615; 50%
PAM_mGluR5; 83; 
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other_mGluR; 152; 
12%
 
Figure 26: Composition of the data collection containing molecules, which were tested for activity on 
mGluR receptors. 1246 molecules are grouped according to their activity profile (NAM or PAM), activity 
range below 1 M (bm) and target molecule type. The number of ligands per class is given as number and 
percentage value. 
 
In  order  to  evaluate  the  diversity  of  the  compiled  data  collection  it  was  analyzed 
regarding the included  variety of structural fragments. Therefore most frequent ring 
assemblies and contiguous chains present were enumerated (Pipeline Pilot, SciTegic, 
San Diego, USA). The frequency of occurrence of the structural fragments represents 
the structure and scaffold diversity of the data set (Figure 27).  4. Results and Discussion 
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Figure  27:  Ring  assemblies  of  known  mGluR  binding  allosteric  modulators  in  the  literature  data 
collection sorted by decreasing frequency (as indicated by bold numbers). 
The frequency of substructures and atomic properties in the data set are relevant to 
determine their importance for machine learning techniques or encoding by molecular 
descriptor. Data set composition can bias the relevance of a feature by over- or under-
representation of this feature in the data set. Frequency detection for single rings, linker 
constructs and frequent substituents could give an indication which substructures are 
dominating  the  data  collection  and  would  be  expected  to  be  favored  in  screening 
applications featuring substructural similarity (Figure 28).  4. Results and Discussion 
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Figure 28: Frequencies of most frequent substructures counted in the literature data collection of known 
mGluR binding allosteric modulators. 
 
After the analysis of structural diversity the metabotropic data collection was utilized as 
data pool for selection of particular representative molecules for model training and 
similarity calculations. 
 
4.2.2 Clustering of mGluR ligands using Spherical Harmonics Descriptors 
The ligand data collection consisted of 1246 ligands binding to mGluR which were 
published in scientific journals or patents. The collection was analyzed with a SOM, a 
machine learning technique, based on two different descriptor types, the CATS and the 
SHD  descriptors.  The  CATS  descriptor  is  defined  on  the  topological  (2D) 
representation  of  a  molecule,  the  molecular  graph,  and  captures  pharmacophoric 
features  and  their  distribution  in  a  molecule.  In  contrast  the  SHD  relies  on  the  3D 
conformation of a molecule and includes information about size and 3D volume. Both 
methods where tested regarding their ability to be used for representation of functionally 
diverse clusters, these are mGluR1 and mGluR5 modulation or NAM and PAM effects. 
Considered functional clusters included different functional effect types such as NAM 
and PAM, different volumes and targeted receptors. A SOM was trained for each of the 4. Results and Discussion 
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descriptors and clusters defined using the 2D map projection of neighbourhood and 
neuron population. 
 
Both descriptor types were suitable for discrimination of NAM and PAM clusters but 
not  without  overlapping  neurons  (Figure  29  and  Figure  30  both  C/D).  PAMs  were 
clustered in regions of the map with high quantization error. Quantization errors are 
observed in neurons where the data samples clustered are less similar to each other. 
NAMs outnumbered the PAM samples and were clustered more accurately. The reason 
for the better representation was that during the training more neurons were adapted to 
NAMs and NAM samples were presented more frequently. 
B
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  min  max 
Figure 29: A self organizing map trained on 1246 mGluR ligands described with spherical harmonics 
descriptor. A) Overall frequency, B) quantization error. Neurons and frequencies of C) PAM and D) 
NAM ligands, exclusively. The color scale indicates the number of assigned patterns or the quantization 
error from minimal to maximal. Grey fields represent empty neurons where no samples of the projected 
type were assigned to. 4. Results and Discussion 
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Both  the  clustering  with  SHD  and  CATS  could  not  separate  the  classes  exactly. 
Evaluation  criterion  was  the  number  of  neurons  which  only  NAMs  or  PAMs  had 
exclusively been assigned to. Using SHD 19 out of 34 PAM (55%) neurons were also 
assigned at least one NAM. The CATS descriptor lead to 10 (41%) mixed neurons out 
of  24  PAM.  The  separation  of  PAM  and  NAM  was  more  accurate  with  the 
pharmacophore description of CATS than the shape description by SHD. Still, based on 
these descriptor types NAMs and PAMs were not classified accurately. 
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Figure 30: A self organizing map trained on 1246 mGluR ligands described with chemicals advanced 
template search (CATS) descriptors. Projection shows the A) Overall frequency, grey fields represent 
empty neurons, B) quantization error, including only C) PAM or D) NAM. The color scale indicates the 
number of assigned patterns or the quantization error from minimal to maximal. 
 
Clusters  for  large  (> 24  non-hydrogen  atoms),  medium  sized  (> 18  and  ≤ 24  non-
hydrogen atoms) and small (≤ 18 non-hydrogen atoms) ligand classes were observed 
indicating the diversity of molecules regarding that respective feature (Figure 31). 4. Results and Discussion 
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Figure  31:  Self-organizing  map  (SOM)  of  the  ligand  data  collection  using  spherical  harmonics 
descriptors for molecule representation. The trained SOM is the same as in Figure 29. Here, molecules 
with different atom numbers are projected A) 491 large (>24), B) 633 medium (>18 and <24) and C) 146 
small (<18). The color scale indicates the number of assigned patterns from minimal (blue) to maximal 
(red). 
 
The  SOM  trained  with  SHD  (Figure  29)  and  the  one  with  the  CATS  (Figure  30) 
descriptor were analyzed with respect to separation of target receptor clusters, mGluR1 
and mGluR5 (Figure 32). The distribution of clusters for receptor targets mGluR1 and 
mGluR5 revealed that using SHD in 61 of 85 (71%) mGluR1 neurons, mGluR5 samples 
were clustered as well. For the map trained with the CATS descriptor a lower overlap 
was detected, 34 of 71 (47%) neurons. Further, it was observed that neuron clusters 
frequently represented the scaffold series of the data set. Using these descriptors the 
neurons  were  adapted  to  dominating  similarities  insight  scaffold  clusters,  which 
included  selective  and  nonselective  molecules.  Therefore  the  SOMs  possessed  low 
discriminative power regarding mGluR1 and mGluR5 selectivity. 4. Results and Discussion 
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Figure  32:  Projection  of  ligands  binding  to  mGluR5  (left)  and  mGluR1  (right)  resulted  from  SOM 
trained on spherical harmonics descriptor (SHD, top) and chemically advanced template search (CATS, 
bottom) descriptors. A) mGluR5 with SHD, B) mGluR1 with SHD, C) mGluR5 with CATS and D) 
mGluR1 with CATS. The trained SOMs are given in Figure 29 and Figure 30. The color scale indicates 
the number of assigned samples from minimal to maximal. 
 
Taken together, SOM clustering revealed that the chosen shape and pharmacophoric 
molecule  description  is  insufficient  for  predicting  functional  differences  between 
molecules. Still, they allow to detect a trend in receptor selectivity, as observed for the 
CATS clustering. It was stated that the application of different descriptor types can be 
beneficial  for  capturing  more  relevant  molecule  properties  (Sheridan  and  Kearsley 
2002). Thus, the combination of molecular shape with atom typing as well as several 
pharmacophore  encoding  techniques  was  applied  for  virtual  screening  for  novel 
mGluR5 binding molecules.  
 
 4. Results and Discussion 
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4.2.3 Virtual screening 
Virtual screening allows for selection of molecules with a particular activity profile out 
of million of compounds. The discovery of novel selective allosteric modulators would 
be relevant for treatment of central nervous system disorders (Pin et al. 2003). In the 
present study several procedures were applied in order to detect active and selective 
allosteric modulators for mGluR subtypes 1 and 5 (Figure 33).  
 
25
18
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41
Bayesian models + FCFP_6
M3 similarity search + FCFP_6
FCFP_4 similarity search
PHRFP_2 similarity search
CATS SOM
Shape similarity search
 
Figure 33: 228 molecules selected with different virtual screening methods (given in the legend) for 
experimental testing of activity on mGluR5. 
 
Five combinations of molecule descriptors and prediction techniques were applied for 
prediction of mGluR binding molecules. Experimental verification was applied for 228 
virtually selected molecules. From each approach a number (Figure 33) of molecules 
was selected for in vitro testing: pharmacophore based descriptors CATS with SOMs 
(63 molecules), PHRFP_2 (56) and FCFP_6 (25) both in similarity searches, FCFP_6 
with a Bayesian model (25) and shape defined similarity (41). Each of the virtual hit 
molecules  was  tested  for  agonism  and  antagonism  in  a  Fluorescent  Imaging  Plate 
Reader (FLIPR
TM) functional screen (Vanejevs et al. 2008). The read out of the assay is 
Ca
2+-concentration and all values are IC50 values calculated from DRC. All molecules 
active on mGluR5 were tested for activity on mGluR1 in order to determine selectivity.  
 
The variety of techniques can be anticipated to cover diverse molecular features and 
possibilities to evaluate their similarity. In the following, results of different similarity 
calculation  approaches  using  known  active  molecules  are  described.  Further  on,  all 4. Results and Discussion 
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molecules verified experimentally for modulating function on mGluR1 or mGluR5 are 
discussed  regarding  their  novelty  compared  to  the  reference  data  collection  and 
dependency on the descriptors used or virtual selection method applied. 
 
Shape search 
Since shape restricts molecules to a particular volume and can define the 3D form of the 
binding pocket, this feature was applied for virtual screening of novel compounds. The 
conformationally  restricted  molecule  2-methyl-6-(phenylethynyl)pyridine  (MPEP, 
Gasparini  et  al.  1999),  a  selective  mGluR5  NAM,  which  possesses  an  accurately 
predictable planar geometry was used as 3D reference molecule. Shape similarity is a 
scalar  measure  between  1.0  (maximally  similar)  and  0.0  (minimal  similarity).  The 
similarity  is  weighted  using  chemical  atom  typing.  2399  out  of  382671  Specs 
(www.specs.net,  v2008.1)  molecules  had  a  calculated  shape  score  above  0.7 
representing 0.63% of all data base molecules. 41 molecules were selected based on 
shape  similarity  and  tested  in  vitro.  M1  (Figure  34)  revealed  functional  activity 
(IC50=2.2  M) and selectivity for mGluR5. The r_phase_Shape_Sim score for M1 
was calculated to be 0.7357, maximum similarity equals to 1.0. 
 
M1  possessed  moderate  activity  (IC50=2.2  M)  against  the  human  mGluR5  in 
comparison  to  the  applied  query  MPEP  (IC50=2 nM).  Structurally  similar  ligands 
(Figure 34) were already reported in similar activity range (Roppe et al. 2004, Iso et al. 
2006). 
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Figure  34:  Reference  and  virtual  “hit”  molecules  from  a  shape  similarity  search  (Phase  v.2.5, 
Schrödinger, LLC, New York, USA). Activity value for M 1 was defined in functional NAM assay on the 
human mGluR5. 
 
The  discovery  of  M1  proves  that  shape  similarity  was  a  detectable  and  traceable 
molecular  feature  (Figure  35).  In  case  of  mGluR  binding  ligands  it  allowed  the 
discovery of a moderately active molecule within the scope of the ligand class of small 
molecules  defined  by  MPEP  or  3-[(2-methyl-4-thiazolyl)ethynyl]pyridine  (MTEP) 
analogues, the heteroarylazole class. 
A  B  C  D 
 
Figure 35: The query 3-[(2-methyl-4-thiazolyl)ethynyl]pyridine (MPEP, A) and the “hit” molecule (M1, 
B) of a shape similarity search. M1 was discovered with a shape based molecule alignment (C) and 
additionally  scored  using  MacroModel  atom  types  (D).  The  representation  of  molecular  shapes  was 
calculated with Schrödinger software (Schrödinger, LLC, New York, 2008) and colored according to 
MacroModel atom types (A, B, C). Molecule alignment is given in wire frame representation (C, D). 
 
Shape similarity mainly depends on the 3D structure of query and screened molecules. 
Therefore, it can be inferred that different query molecules would support a broader 
coverage of chemical space. A low enrichment of other scaffolds or molecules with 4. Results and Discussion 
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larger  molecule  size  was  observed  when  MPEP  shape-based  similarity  ranking  was 
tested on known mGluR ligands (data not shown). 
 
Using molecular docking (IFD by Schrödinger, LLC, New York, 2008) several different 
docking conformations were observed for M1. Figure 36 shows one possible binding 
mode of M1, in which the molecule extends orthogonal to the membrane plane and 
might be involved in an interaction to Arg648 and Trp785. 
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Figure 36: Binding conformation of molecule M1 in the modeled structure of mGluR5, predicted with 
molecular docking (Schrödinger, LLC, New York, 2008). A) View from extracellular site B) view from 
the TM between TM5 and TM6. Residues in close contact to M1, Trp785 and Arg648 are highlighted in 
stick representation and hydrogen-bonds indicated with dashed lines. 
 
Bayesian classifier 
Bayesian classifiers were applied for probability estimation of molecules’ classification 
with respect to a classification scheme. The probability prediction was carried out with 
two  Bayesian  classifiers  aiming  at  selection  of  active  mGluR  binding  molecules 
(“mGluR”-model), which are selective for mGluR5 (“selectivity-model”) at the same 
time.  The  two  classifiers  were  combined  for  final  molecule  selection  (procedure 
explained in Section 3.11). The “mGluR”-exhibited a promising prediction accuracy for 
the  validation  data  set  (Figure  37).  The  AUC  value  reached  0.963,  which  was 
considered accurate. Therefore the classifier applied in more than one of the virtual 
screening approaches (in a combination with the “selectivity”-model and as ranking 
methods in CATS-based clustering using a SOM) as additional scoring method. 4. Results and Discussion 
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Figure  37:  Receiver-Operating  Characteristic  (ROC)  curve  of  the  Bayesian  classifier  used  for 
discrimination between  mGluR active  molecules and  molecules binding  to different target  molecules 
(“mGluR”-model) or being inactive in tests on mGluR1 or mGluR5. The True Positive Rate is plotted 
against the False Positive Rate, the area under curve (AUC) equals to 0.963. 
 
The number of ‘good’ and ‘bad’ samples was plotted versus the Bayesian classifier 
score  for  the  “mGluR”-  and  the  “selectivity”-models  in  a  histogram,  respectively 
(Figure 38). The histogram for the mGluR-classifier (Figure 38, A) revealed only the 
small  overlap  between  active  in  inactive  molecules  regarding  the  “mGluR”-model 
score. According to prediction performance on the validation data set, the “mGluR”-
model score was considered for molecule ranking. 
 
For  the  selectivity  classification  a  less  predictive  model  (“selectivity”-model)  was 
obtained  because  of  fewer  data  samples.  The  score  histogram  showed  a  good 
discrimination between a) selective mGluR5 and selective mGluR1 and b) not selective 
mGluR5 molecules (Figure 38, B), but the performance was influenced by scaffold 
clusters (as described in Figure 27) and was therefore considered less reliable. However, 
the  “selectivity”-model  was  subsequently  applied  after  scoring  with  the  “mGluR”-
classifier. A Pareto-front definition for the 2D optimization of both model scores was 
calculated and 25 diverse molecules were selected for experimental testing.  4. Results and Discussion 
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Figure 38: Histogram of Bayesian model scores (x-axis) versus frequency of samples with a particular 
model score (y-axis). Active (red) samples and inactive (blue) samples are indicated with colors. Training 
and test data are included. A) “mGluR”-model, active: mGluR1/5 IC50 ≤ 1000nM, inactive samples: 
Wombat data collection and  mGR1/5 IC50 > 1000nM B) “selectivity”-model active samples:  mGR5 
selective, inactive samples: mGluR1 selective and mGluR5 not selective. 
 
In functional tests on mGluR5 three molecules M2, M3 and M4 were discovered with 
with IC50=458nM (M2, Figure 39), IC50=1780nM (M3, Figure 41) and IC50=3890nM 
(M4,  Figure  44),  respectively.  M4  was  selective  for  mGluR5  (IC50=3890nM, 
IC50>10 M), but possessed a lower activity than the other two molecules, M2 and M3. 
M3 was twice as potent as M4 but not selective (M3: mGluR5 IC50=1780nM, mGluR1 
IC50=3100nM).  
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Figure 39: Molecule M 2 discovered with Bayesian classifier prediction. The black and the red box 
outline parts of M2 which are structurally similar to molecules included in the training data set such as 
present to the right of M2.  
 
The  molecule  structure  of  M2  contains  substructures  similar  to  MTEP  analogues 
(outlined in black in Figure 39, Cosford et al. 2003) as well as molecule series reported 
by Bonnefous (outlined in red, Bonnefous et al. 2005), both ligand series were included 
in the reference data set (Figure 39). It should be mentioned that a PAM series (Figure 4. Results and Discussion 
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39,  Williams  and  Lindsley  2005)  possess  a  similar  part  to  the  substructure  of  M2 
outlined in red. The PAM is enhanced at ortho-position in contrast to meta in M2 by the 
MTEP like substructure (outlined in black substructure in Figure 39). 
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Figure 40: Binding pose of molecule M2 in the modeled structure of mGluR5 predicted with molecular 
docking (IFD, Schrödinger, LLC, New York, 2008). A) View from extracellular site B) view between 
TM5 and TM6. 
 
The docking conformation predicted for M2 (Figure 40) revealed a parallel orientation 
of the acetylenic part (outlined in black, Figure 39) to Trp785 and the amid-linker was 
proposed to make a hydrogen bond interaction to Arg648. In the docked conformation 
(Figure 40) the acetylenic molecule part extends parallel to the helix bundle deep into 
the  TM  cleft.  The  non-acetylenic  molecule  part  (outlined  in  red,  Figure  39)  shows 
similarities  to  molecule  9  (Figure  39,  Bonnefous  et  al.  2005)  and  is  oriented 
orthogonally to the helix bundle and closely to TM3 (Figure 40). 
 
Wang et al. 2007 
mol 57 
IC50=9nM
Micheli et al. 2008
Mol 16
pIC50=7.8
Micheli et al. 2008
Mol 92
pIC50=7.9
Alagille et al. 2005
mol 9 
IC50=740nM
mGluR5 IC50=1780 nM
mGluR1 IC50=3100 nM
M3
Wang et al. 2007 
mol 57 
IC50=9nM
Micheli et al. 2008
Mol 16
pIC50=7.8
Micheli et al. 2008
Mol 92
pIC50=7.9
Alagille et al. 2005
mol 9 
IC50=740nM
mGluR5 IC50=1780 nM
mGluR1 IC50=3100 nM
Wang et al. 2007 
mol 57 
IC50=9nM
Micheli et al. 2008
Mol 16
pIC50=7.8
Micheli et al. 2008
Mol 92
pIC50=7.9
Alagille et al. 2005
mol 9 
IC50=740nM
mGluR5 IC50=1780 nM
mGluR1 IC50=3100 nM
M3
 
Figure 41: Molecule M3 discovered  with Bayesian classifier prediction. The black  and the red box 
highlight parts of M3 which are structurally similar to molecules included in the training data set such as 
presented to the right of M3. 
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Structurally similar molecules to M3 (Figure 41) were reported to exhibit a middle to 
low nanomolar affinity to mGluR5 (Micheli et al. 2008, Alagille et al. 2005 and Wang 
et  al.  2007).  The  acetylenic  MPEP  like  molecule  part  (outlined  in  red,  Figure  41) 
contains no pyridine as present in MPEP. The nitrogen in the pyridine ring might be 
relevant  for  selectivity  to  mGluR5,  since  M3  is  not  selective  and  MPEP  is.  The 
acetylenic linker region should overlap in the binding pocket with the selective MPEP 
and  MTEP  analogues  (Gasparini  et  al.  1999,  Cosford  et  al.  2003,  Alagille  et  al. 
2005a/b, Vanejevs et al. 2008). 
 
After the discovery of M3 a similarity search with FCFP_6 descriptor was performed 
and 18 of the best ranked (using Tanimoto similarity Section 3.12.2) neighbors were 
experimentally tested. All 18 molecules were tested with IC50>10 M. The reason for the 
activity  failure  of  these  molecules  was  analyzed.  A  flexible  alignment  (Phase  v2.5, 
Schrödinger, LLC, New York, 2008) of the molecules was performed (Figure 42) and 
revealed that the variability introduced at the acetylenic molecule part (outlined in red, 
Figure 41) lead activity loss at mGluR5. 
 
Figure 42: Flexible ligand alignment of M3 (stick representation, Phase v2.5, Schrödinger, LLC, New 
York,  2008)  and  18  structurally  similar  molecules  (line  representation),  with  pharmacophore  points 
defining  similar  regions.  All  18  molecules  are  functionally  inactive  on  mGluR5.  Pharmacophore 
definition: H1 (blue sphere) hydrogen bond donor, A2 (red sphere) hydrogen bond acceptor, H3 (green 
sphere) hydrophobic and R4-5 (yellow rings) aromatic. 
 
The multiple ligand alignment revealed high sterical difference in the non-acetylenic 
part of the ligands (Figure 42). The docking suggests that this part extends deeply into 
the TM cleft of mGluR5 (Figure 43). Bulky substituents would be hardly tolerated in 
the narrow space deeper in the TM cleft. The docking poses more over revealed that the 4. Results and Discussion 
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pyridine nitrogen of M3 might be involved as a donor in a hydrogen bond with Gln647, 
the carbonyl oxygen in another one to Arg648 (Figure 43). The distance between the 
non hydrogen atoms (ligand)N---O(Gln647) is 1.93Å and (ligand)=O---N(Arg648) is 
2.99Å. By rotation around torsional angles (χ3 and χ4) of Arg648 the construction of an 
ideal hydrogen bond to the carbonyl atom would be feasible, but was not observed in 
the docking. 
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Figure 43: Binding poses of molecule M3 in the modeled structure of mGluR5 predicted molecular 
docking (IFD, Schrödinger, LLC, New York, 2008). A) View from extracellular site B) view from the 
TM parallel site between TM5 and TM6. In both representations the EC2 loop is omitted.  
 
M4  is  a  selective  NAM  of  mGluR5  IC50=3890nM.  For  M4  the  highest  structural 
similarity to reference molecules was observed for a series developed by Astra Zeneca 
and Addex Pharmaceuticals SA (Figure 44). The oxadiazole and the triazole rings of 
M4 are also present in these reference structures. 
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Figure 44: Molecule M4 discovered with Bayesian classifier prediction. Structurally similar molecules 
included  in  the  training  data  set  are  presented  to  the  right  of  M4.  AZ=AstraZeneca,  AP  SA=Addex 
Pharmaceuticals SA. 
 
For  molecule  M4  no  hydrogen  bonding  was  predicted  using  IFD  and  the  modeled 
structure of mGluR5. Diverse binding modes resulted from IFD, therefore, the docking 
poses were not regarded highly reliable. 4. Results and Discussion 
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Figure 45: Binding poses of molecule M4 in the modeled structure of mGluR5 predicted with molecular 
docking (Schrödinger, LLC, New York, 2008). A) View from extracellular site B) View between TM5 
and TM6. 
 
The Bayesian approach lead to the discovery of three active NAMs down to nanomolar 
IC50 on mGluR5 but the “hit” molecules were structurally related to known molecules 
used in the reference data set. The reason for the high structural similarity to reference 
molecules  can  be  traced  back  to  the  fingerprint  calculation  which  focuses  on 
substructures.  The  Bayesian  probability  calculation  is  sensitive  to  the  number  of 
reference  features,  in  the  case  of  the  fingerprint  these  features  were  substructure 
frequencies. Dominating features in the reference set led to a higher scoring in classified 
molecules than less frequent substructures. 
 
FCFP_4 similarity search 
According  to  the  assumption  that  similar  molecules  might  exibit  similar  activity 
(Johnson and Maggiora 1990, Brown and Martin 1997, Martin et al. 2002), vendor 
molecules  were  compared  to  reference  molecules  measuring  similarity  in  the  space 
defined by a molecular descriptor. The similarity search using the FCFP_4 descriptor 
was performed with same reference data as the PHRFP_2 similarity search (details on 
procedure  in  Section  3.12.2)  but  a  different  molecular  encoding.  The  goal  was  the 
prediction of novel selective mGluR5 NAMs using 615 reference NAMs. Molecules for 
testing were picked manually from a list ranked according to similarity to the reference 
mGluR5  NAMs  with  nanomolar  activity.  The  selection  of  25  molecules  from  this 
ranked  list  was  done  manually  because  of  high  similarity  of  top  ranked  molecules. 
Diverse  molecule  scaffolds  with  Tanimoto  (Section  3.7.1)  similarity  above  0.75 
according  to  FCFP_4  were  considered  for  testing.  M5  (mGluR5  NAM)  and  M6 4. Results and Discussion 
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(mGluR5 PAM) exhibited activities of IC50=8120nM and EC50=288nM. The structure 
of M5 will not be shown here, because it was considered for patenting. The structurally 
most similar molecules to M6 which were part of the reference data set were previously 
described of having low nanomolar activities (Figure 46). 
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Figure  46:  Active  molecule  M6  discovered  with  a  FCFP_4-based  similarity  search  using  mGluR5 
binding NAMs with IC50 ≤ 1000nM. 
M6 is a PAM which has striking similarity to NAMs, especially to molecule 27 (Figure 
46) as published by Alagille and co-workers with EC50=235nM (Alagille et al. 2005). 
M6 resembles the structures shown in Figure 46, it contains the acetylene linker and the 
pyridine ring on the right side of the linker, but possesses no methyl group next to the 
heteroatom in the thienyl or left heterocycle. Similar slight structural changes using a 
methyl group were reported recently by Sharma and colleagues (Sharma et al. 2008). 
The authors changed the well known ligand MPEP which is a frequently analyzed NAM 
possessing a simple molecule structure and derived new PAMs (Figure 47). Molecule 
12a (12a-k is the original numbering from Sharma et al. 2008, Figure 47) shares the 
scaffold with PAMs, 12h to 12k, and differs from 12h only in the position of the methyl 
group.  
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Figure 47: PAMs reported by Sharma and colleagues in 2008 (numbering as in original publication). 
MPEP analogues,  which  were converted to positive allosteric  modulators of  mGluR5 (Sharma et al. 
2008). 4. Results and Discussion 
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The  discovery  of  M6  was  interesting  since  this  molecule  suggests  that  the  NAMs 
reported in literature can be converted to PAMs by addition of a single methyl group. 
This result is in line with studies performed by Sharma and strengthens the hypothesis 
that NAM and PAM can share the same binding region (Sharma et al. 2008). 
 
PHRFP_2 similarity search  
The pharmacophore fingerprint PHRFP_2 was applied in a similarity search (Section 
3.12.2)  for  new  selective  mGluR5  NAMs.  The  combination  of  calculations  for 
similarity of unknown molecules to mGluR5 NAMs separately from mGluR1 similarity 
calculations should avoid the selection of nonselective molecules and focus mainly on 
mGluR5 ligands. A single mGluR5 selective molecule with IC50 < 10 M was detected 
(M5, Figure 48). For this molecule M5 it was experimentally determined that it has low 
micromolar  activity  (IC50 = 1960nM)  while  being  inactive  on  mGluR1  and  thereby 
selective.  
A 
 
B 
 
Figure 48: Molecule M5 discovered with PHRFP_2-based similarity search from Enamine molecule 
collection. M5 is selective regarding mGluR5 (IC50=1960nM). A) Structurally similar molecules from the 
reference set. B) Structurally similar molecules described in literature, which were not included in the 
reference set. 
 
Known reference molecules with comparable substructures were used to explain the 
activity of the new active molecule (Figure 48). The molecule can be regarded as a 
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chimeric structure from different molecule series. The training data sample from patent, 
WO 03/093236,  has  been  reported  with  mGluR5  related  indications  as  Parkinson's 
disease, dementia, cognitive disorder, vomiting, depression, Huntington's chorea. 
 
Molecules from the training data set share one structurally similar part highlighted in 
black in Figure 48. The other molecule part (outlined in red) of M5 was unsuccessfully 
developed  for  mGluR5  PAMs  (Williams  and  Lindsley  2005)  and  independently 
discovered for NAMs by Renner in a virtual screening approach, but tested inactive for 
mGluR5 NAM activity (Renner et al. 2005). The combination of both substructures was 
combined in M5. 
 
Molecule  features  present  in  the  discovered  molecule  M5  were  analyzed  as 
pharmacophore point pairs encoded in PHRFP_2 (Figure 49). 
 
Figure  49:  PHRFP_2  pharmacophore  feature  pairs  present  in  the  virtual  hit  molecule M5.  H-bond 
acceptors (cyan), aromatic ring (yellow), positive ionizable (dark blue),  hydrophobic  (light  grey) are 
highlighted. Starting from the top molecule on the left side, the molecule atoms are typed according to 
pharmacophore features and paths of variable length connecting different feature pairs are enumerated. 
The PHRFP_2 description captures pairs from the whole molecule as well as parts of it. 
 
The predicted ligand binding conformation of M5 (Figure 50) revealed a comparable 
binding region to M3 (Figure 43) and a possible interaction to Arg648, however, no 
interaction was predicted to Gln647 as for M3. 4. Results and Discussion 
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Figure 50: A predicted binding mode in the modeled structure of mGluR5 of M5 discovered with a 
PHRFP_2-based  similarity  search.  Residues  in  close  proximity  to  the  ligand  are  highlighted  in  stick 
representation. 
 
CATS-based clustering using a self-organizing map 
The Asinex Platinum Collection (version Nov2007) and the mGluR literature data set 
were clustered using SOMs (MOLMAP by Prof. G. Schneider, Frankfurt, Germany). 
The reference (literature) data were clustered in a defined area of the SOM. Based on 
CATS  molecule  description  reference  molecules  possessed  higher  intra-class 
similarities  than  to  most  Asinex  samples,  which  is  a  realistic  relationship  for  an 
optimized ligand class (Figure 51). Nevertheless, 3728 of 130353 Asinex molecules 
which were assigned to these reference cluster neurons were scored with the Bayesian 
classifier  referred  to  as  the  “mGluR”-model  (Section  3.11.2).  The  “mGluR”-model 
determines if a molecule is more similar to active mGluR than WOMBAT molecules 
(other  non-mGluR  drugs).  All  molecules  with  “mGluR”-model  score  below  20 
(motivated by class separation performance Figure 38) were removed and the residual 
ranked and selected for testing (13 molecules). “Hit” molecule M8 (Asinex ID: ASN-
17326353) reached a Bayesian “mGluR”-model score of 38.18 and was discovered at 
rank 26 from all tested molecules with a slightly lower “mGluR”-score of 38.18 than the 
highest ranked molecule with 44.58 (lowest reached 20.03). In the SOM M8 possessed 
an Euclidean distance to the centre of neuron 15/10 of 0.771 and was discovered in a 
cluster with 269 molecules implying 86 reference compounds. The Euclidean distance 
of  the  closest  reference  molecule  to  the  cluster  centre  equaled  to  0.741  and  of  the 
farthest was 1.21.  
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Figure 51: Self-organizing map (SOM) representation in 2D, colored by frequency of molecule samples 
from minimal (blue) to maximal (red) number. Training data included the Asinex Platinum Collection 
(version Nov2007) and mGluR literature data collections and was encoded with the chemically advanced 
template search (CATS) descriptor. A) SOM colored according to frequency of training data B) Selection 
of neurons which included selective mGluR5 molecules. “Hit” molecule M8 (Figure 52) was discovered 
in neuron 15/10. 
 
Active and inactive mGluR ligands were included in the literature data set which was 
clustered with the Asinex molecules by the SOM (Figure 51). It was observed that in 
the CATS descriptor space differently active molecules were not separated into different 
clusters. 
 
A  comparison  of  M8  to  the  reference  ligand  collection  revealed  which  structurally 
related molecules are already known (Figure 52). These molecules possess high affinity 
as selective NAMs of mGluR5 (Figure 52).  
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Figure 52: Hit molecule M8, discovered in the Asinex Platinum collection using chemically advanced 
template search and a self-organizing maps and structurally similar reference molecules. The IC50-value 
of M8 was determined in functional mGluR FLIPR assay. All molecules are subtype selective. 4. Results and Discussion 
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The  discovered  molecule  M8  exhibited  activity  of  IC50=548nM  and  differed  from 
known ligands in the position of the substitution with the cyano group which lead to low 
nanomolar activity for acetylen linker including scaffold series (Alagille et al. 2005, Iso 
et al. 2006 and Micheli et al. 2008). A recent study by Vanejevs present a similar 
substitution like in M8 as starting point and lead to the discovery of potent mGluR 
NAMs for mGluR1 and mGluR5 as well as PAMs for mGluR5 (Figure 53, Vanejevs et 
al. 2008). 
A  B 
 
 
Figure 53: From Vanejevs et al. 2008. A) Molecule 10a (original publication number) resulted from B) a 
pharmacophore alignment of 10a with known active molecules. It shows a cyano group at a similar 
position on the pyridine cycle as M8. 
 
Here, the single “hit” molecule M8 was reported out of 63 molecules selected using 
CATS and a SOM. Besides the 13 Asinex molecules all other 50 molecules selected for 
experimental testing (27 Specs, 3 Maybridge and 20 Enamine pick collections), which 
were  selected  in  similar  manner  to  the  Asinex  molecules,  all  50  were  functionally 
inactive on mGluR1 or mGluR5. The reason might lie in the post filtering step with the 
Bayesian “mGluR”-model. It was applied since the SOM filtering resulted in too many 
molecules for experimental testing and did not allow for a linear ranking. In the present 
study the combination of pharmacophoric molecule ecoding with machine learning and 
subsequent ranking with Bayesian classifier lead to a “hit” rate of 2%. 
4.2.4 Modeling of binding modes 
The transmembrane ligand binding site of GPCRs was modeled and analyzed for a 
particular family C receptor, the human mGluR5. The binding conformations of several 
ligands  discovered  by  virtual  screening  methods  were  predicted  using  molecular 
docking.  Uncertainties  in  side  chain  orientations  of  the  modeled  structure  were 
accounted  for  by  optimization  of  receptor  and  ligand  flexibility  during  the  docking 
process.  Selected  docking  poses  were  correlated  to  experimental  data,  gained  from 4. Results and Discussion 
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mutations  studies  of  family  C  GPCRs  and  crystal  structures  available  from  known 
complexes of family A GPCRs. Even family A binding ligands might posses an entirely 
different interaction profile compared to family C GPCRs both TM binding pockets 
originated  from  an  ancestral  transmembrane  protein  and  both  TM  domains  have  a 
similar heptahelical arrangement (Pin et al. 2003). So far none endogenous ligands are 
known  which  bind  to  the  TM  domain  of  mGluRs  only  for  the  orthosteric  site  and 
therefore, it can not be expected that the binding pocket is as conserved as in family A 
GPCRs. The accuracy of a predicted family C GPCR structure using a family A GPCR 
as template remains unknown until experimental prove. Therefore the mGluR5 structure 
is treated in present study as hypothetical and applied for retrospective evaluation of 
experimental data. 
 
Docking poses  
Since for each of the mGluR5 ligands several diverse poses resulted from docking, they 
were evaluated manually. Selection criterion was: obligatory space occupation between 
TM3, TM5 and TM6 with interactions to side chains of residues facing the TM binding 
pocket  (focusing  on  data  from  mutation  studies  Table  A  3).  Similar  molecule 
substructures were expected to occupy similar parts of the binding pocket.  
Trp785
A B
Trp785
Gln647
Arg648
Gln647 Arg648
 
Figure 54: Docking conformation of 4 NAMs (M1, M2, M3 and M5) discovered in this study in the 
modeled structure of mGluR5. A) View from the extracellular site showing the TM binding region. B) 
Side view between TM5 and TM6, residues in close proximity are highlighted. 
 
The hypothetical binding region for  acetylenic  substructures was defined in parallel 
orientation to the membrane lipids and to Trp785 and located between TM3, TM5 and 
TM6. All MPEP- or MTEP-like ligands discovered with virtual screening as they are 
M1, M2, M3 and M5 were placed similarly by molecular docking with respect to the 4. Results and Discussion 
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acetylenic molecule part (Figure 54). Hydrogen bond interactions were mainly observed 
to Arg648 and Gln647, both located in TM3. For the small ligand M1 docking poses in 
parallel orientation to the helices as well as parallel to the membrane were predicted 
(data not shown). Larger ligands, M2, M3 and M5, occupied both oriented locations 
(Figure  54).  The  docking  pose  of  M1  (parallel  to  helix  orientation)  in  which  the 
acetylenic molecule part overlapped with the one in M2, M3 and M5 has been selected 
(Figure 54). 
 
Binding pocket of mGluR5 
Mutation studies revealed the location of the mGluR group I binding pocket between 
TM3, TM5, TM6 and TM7 (Litching et al. 1999, Pagano et al. 2000, Malherbe et al. 
2003, Muehlemann et al. 2006, Malherbe et al. 2006). The docked ligand poses were 
predominantly placed in the binding pocket defined by these mutated residues (Figure 
55).  
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Figure 55: Binding pocket of the modeled structure of mGluR5 containing docked conformations of M1, 
M2,  M3,  M4,  M5,  M6  and  M7.  Docking  poses  which  achieved  the  highest  score  according  to 
docking_score (IFD, Schrödinger LLC, New York, 2008). Residues involved in mGluR5 NAM binding 
known from mutagenesis studies are highlighted. All residues are in close distance to the ligands (< 4Å). 
 
Amino  acids  Met802  (Muehlemann  et  al.  2006),  Ser805  (Litching  et  al.  1999)  and 
Ala810 (Malherbe et al. 2006, Pagano et al. 2000) at TM7 could not be correlated to the 
binding poses because they were pointing away from TM3 and TM6 according to the 
proposed receptor model. The largest molecules (M2,  M3,  M4, M5 and M7)  were 
placed in the region close to Met802, Ser805 and Ala810 but no directed interactions 
with them are suggested by the proposed docking poses. 4. Results and Discussion 
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Figure 56: A modeled structure of mGluR5 with M3 (given in sphere representation, black transparent) 
in A side view and B top view from extracellular side. Residues discovered with mutation studies for 
ligand binding in family C GPCRs are given in stick representation. Structure is colored according to 
conservation (Shannon entropy values) of the mGluR subfamily. Colors are applied blue (low entropy, 
high conservation) to red (high entropy, low conservation). Extracellular loops are omitted for clarity 
reasons. 
 
The conservation level of residues involved in ligand binding of family C GPCRs was 
high (Figure 56 A-B, for further details see Section 4.1.7). The predicted conformation 
of the largest ligand, M3, occupied regions close to positions probed by mutations.  
 
The  selection  procedure  for  docking  poses  was  influenced  by  ligand  binding 
conformations known from crystal structures of BR and ßAD receptors. It should be 
mentioned that the result of the docking is dependent on the modeled structure which 
changes when a different sequence alignment or structural template is applied. Since the 
extracellular  loops  could  not  be  modeled  reliably  due  to  low  conservation  and  the 
conformation of the EC2 loop (covering up the binding pocket similar to the modeling 
template rhodopsin), docking results for the modeled mGluR5 structure might not have 
provided suitable interactions to any of the loops and are restricted to the binding pocket 
of retinal. 
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Ligand binding of GPCRs 
Several  crystal  structures  of  βAD  receptors  with  bound  inverse  agonists  (carazolol, 
cyanopindolol,  and  cholesterol),  the  BR  with  retinal  and  the  human  A2A  adenosine 
receptor with an antagonist have been solved so far. The bovine rhodopsin complex 
with  retinal  was  used  as  template  structure  for  mGluR5  modeling  and  belongs  to 
familyA  receptor  with  a  covalently  bound  ligand.  For  comparison  reasons  known 
crystal structures of GPCR complexes (PDB  IDs: 1U19, 2RH1, 2VT4, 3D4S) were 
superposed  with  the  modeled  mGluR5  structure,  resulting  in  superposition  of  their 
ligands with the docked conformation of M3 (Figure 58).  
 
The  superposition  of  the  adrenergic  and  rhodopsin  receptors  revealed  that  the 
transmembrane  binding  sites  occupied  by  their  ligands  carazolol,  cyanopindolol, 
cholesterol and retinal overlaps in general and with the one defined by docked poses of 
mGluR5  NAMs  (Figure  58  A  and  C).  All  three  inverse  agonist  carazolol, 
cyanopindolol,  cholesterol  are  located  in  the  upper  part  of  the  TM  cleft  and  bind 
through polar interactions to amino acids at TM3 (3.28 and 3.32), TM5 (5.42) and TM7 
(7.39 and 7.43) and hydrophobic contacts to aromatic amino acids 5.32, 5.34, 5.38, 
6.48, 6.52, 6.51 and 7.35 as shown for carazolol in Figure 57 (Cherezov et al. 2007, 
Hanson et al. 2008, Warne et al. 2008 and Okada et al. 2004).  
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Figure 57: The structure of ß2AD and carazolol (PDB ID: 2RH1, Cherezov et al. 2007). Residues in 
close proximity to carazolol are given in stick representation and contact indicated with dashed lines. 
Shannon entropy values for the β-adrenergic subfamily MSA (from GPCRDB, v.10.0, Horn et al. 2003) 
are  projected  onto  the  protein  structure.  Colors  are  applied  as  follows:  blue  (low  entropy,  high 
conservation) to red (high entropy, low conservation). EC2 is omitted for clarity. 
 
Retinal  extends  deeper  into  the  TM  cleft  as  it  has  been  observed  for  predicted 
conformations for NAMs of mGluR5 (Figure 58 B). The binding pocket extension in 
direction to TM2 and TM1 was similar for mGluR5 NAMs M1, M2, M3 and M5 and 
retinal. 4. Results and Discussion 
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Figure  58:  Superposition  of  crystal  structures  of  1U19,  2RH1,  2VT4,  3D4S  and  predicted  mGluR5 
structure with docked ligands (M1, M2, M3 and M5). The rhodopsin structure (1U19) is given in cartoon 
and  ligands  in  sphere  representation.  Ligand  colors  are  applied  as  follows:  βAD  ligands  (carazolol, 
cyanopindolol, cholesterol) in green, retinal in yellow and docked mGluR5 ligands (M1, M2, M3 and 
M5) in red. Different views on the same superposition are given A) view from the extracellular site on the 
TM. EC2 and part of the N-terminus are omitted for clarity. B) Side view, only retinal and mGluR5 
ligands present C) retinal, mGluR5 ligands and carazolol, cyanopindolol, cholesterol. 
 
The  allosteric  modulation  of  G  protein-coupling  through  NAMs  in  GPCRs  is  still 
current issue in GPCR function research. Scheerer stated that G protein-coupling at the 
intracellular part of the transmembrane  region  close to the DRY-motif common for 
most GPCR can induce long-range stabilization effects into the ligand binding pocket 
(Scheerer et al. 2008). In mGluR5 and 2RH1 (β2AD with carazolol, Cherezov et al. 4. Results and Discussion 
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2007) the ligand binding pocket is in a comparable distance of 20Å and 23Å to Arg668 
and Arg131. 
 
At the time the first and until now only human A2A adenosine receptor structure became 
available it has been suggested that no common conserved binding pocket is shared by 
all  GPCR  subfamilies  (Jaakola  et  al.  2008).  In  agreement  with  the  hypothesis  of 
conformational selection by the ligand (Cozzini et al. 2008), meaning that a ligand can 
stabilize a particular conformation of the receptor which is not the only one the receptor 
can adopt, different binding modes for NAMs can be expected. So far no proof was 
provided  for  different  agonist  or  antagonist  binding  sites.  Mutations,  which  were 
collected  from  literature  in  order  to  define  the  binding  pocket  of  agonists  and 
antagonists, indicated overlapping binding region, as discussed in Section 4.1.8. The 
present study revealed that a similar location can be accommodated by mGluR5 NAMs, 
discovered  with  virtual  screening  strategies.  Using  molecular  docking  a  common 
binding region for several NAM was defined which are in contact to amino acids and 
positions important for NAM affinity and effect. 
 
4.2.5 Virtual Screening - conclusions 
Based on the knowledge about diverse potent mGluR binding ligands several virtual 
screening procedures were applied in order to find novel mGluR5 selective allosteric 
modulators. Eight active molecules with functional activity below 10 M out of 228 
tested made a “hit” rate of 3.5%. The “hit” rate per strategy  was different because 
unequal  molecule  numbers  were  available  for  acquisition  and  further  experimental 
testing  and  because  the  individual  differences  between  the  approaches  applied;  the 
respective results are 12% (combined Bayesian model (“mGluR”- and “selectivity”-
model) with FCFP_6), 8% (FCFP_4-based similarity search), 2.4% (MPEP-based shape 
similarity), 1.8% (PHRFP _2-based similarity search) and 1.6% (CATS-based SOM 
clustering  with  subsequent  “mGluR”  Bayesian  model  ranking).  Similarity  search 
approaches discovered three of eight active molecules. By combination of two Bayesian 
models three additional molecules were retrieved. Shape-similarity search and SOM 
clustering  with  subsequent  Bayesian  model  scoring  lead  to  one  additional  active 
molecule  each.  The  most  potent  NAMs  (M8  and  M2)  yielded  IC50=548nM  and 
IC50=458nM and were discovered with the CATS-based clustering using SOMS and the 
Bayesian two-models approaches. 4. Results and Discussion 
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Three molecules (M2, M6 and M8) possessed activity in nanomolar and five (M1, M3, 
M4, M5 and M7) in low micromolar range. Seven of the molecules (all but M3) were 
selective  to  mGluR5.  The  single  nonselective  molecule  M3  (discovered  using  a 
Bayesian model with FCFP_6) contained an acetylene linker, which so far was only 
reported to be part of selective mGluR5 binding ligands. The structure of the single 
PAM M6 (discovered with FCFP-based similarity search) was an example similar to a 
recently reported series of known NAMs which were converted to PAMs by changing 
the position of a methyl group a pyridine ring (Sharma et al. 2008).  
 
The number of tested and active molecules did not allow for comparison of prediction 
accuracy  in  prospective  virtual  screening.  The  goal  to  find  novel  mGluR5  binding 
modulators was achieved, even for both modulator classes, the negative and positive 
allosteric modulators.  
 
For each of the “hit” molecules a binding mode was predicted using molecular docking 
with the modeled receptor structure of mGluR5. The binding area was predicted to 
overlap with the space occupied by ligands in several crystallized family A GPCRs. A 
hypothesis has been derived for molecules with differences in size regarding orientation 
in  the  TM  region.  From  the  predicted  binding  poses  it  was  suggested  that  small 
molecules could share the binding cleft between TM3, TM5 and TM7 perpendicular to 
the  membrane  plane,  the  occupation  of  this  TM  region  is  in  line  with  published 
mutation  experiments.  Large  molecules  were  predicted  to  bind  using  more  space 
parallel to the membrane plane, which is analogous to the retinal binding position. For 
four of the ligands (M2, M3, M5 and M7) it was predicted that Arg648 at TM3 might 
be involved in binding in mGluR5. Ligand M3 extended to a further polar interaction to 
Gln647. Published mutation studies define the same region as important for binding as 
it was occupied by the docking poses.  
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5. Outlook 
This study facilitates an improved understanding of the structure and function of family 
C  GPCRs.  The  binding  of  allosteric  modulators  of  mGluR5  were  analyzed  using 
sequence-, ligand- and structure based approaches. Future steps towards understanding 
of  the  family  C  GPCR  activation  process  can  be  expected  from  more  detailed 
experimental  results  regarding  structure  as  well  as  improvement  of  computational 
approaches which are used its prediction and evaluation. 
 
In  future  work  the  results  of  the  performed  conservation  analysis  could  be  used  as 
guidance for design of molecular biology experiments targeting particular conserved 
positions of family C GPCRs, at conserved positions as they were discovered at helix-
helix contacts. Mutation or labeling experiments at these positions could provide further 
insights  into  interaction  networks  between  amino  acids  in  the  TM  region  and  their 
contacts to loop regions. The GPCR structures known so far differ in bending of TM 
helices  and  possess  unique  stabilizing  contacts;  pairs  of  residues  involved  in  those 
contacts might build a set of exchangeable amino acid combinations and could be used 
for motivation of different amino acid grouping schemes than the scheme applied in this 
study. This would allow to track  additional features important for TM packing and 
might contribute to understanding of changes taking place during activation. 
 
Uncertainties  regarding  the  modeled  structure  of  mGluR5  could  be  evaluated  more 
thoroughly using all available family A GPCRs as templates, since each of them could 
provide  in  some  structural  parts  a  better  starting  point  for  structure  prediction. 
Conservation profiles of structural features might be applicable to local alignment of the 
target  sequence  to  several  structural  templates  in  order  to  reveal  a  closer  relation. 
Besides these computational efforts, the binding pocket definition for family C GPCRs 
will  benefit  most  from  additional  crystal  structures  of  more  closely  related  GPCRs 
especially those containing PAMs or agonists. 
 
So far dissimilarities between  family  A  GPCR complex structures were detected in 
interaction of ligands with the EC loops. This raised the attention to their relevance in 
correct  ligand  pose  prediction.  The  EC2  loop  has  been  crystallized  in  β-sheet 
(rhodopsin, 1U19), α-helix (β2AD receptor, 2RH1) and constrained coil conformations 5. Outlook 
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(A2A adenosine receptor, 3EML) for different receptor types. This points out that the 
loop regions adopt structured conformations which are important for function. Family C 
GPCRs possess a cysteine-rich domain, which connects the VFT to the TM and might 
be structured to exhibit contacts to EC loops. This is the most uncertain part in structure 
prediction of all GPCRs to date and remains essential for understanding of family C 
receptor activation. 
 
The preparation of docking protocols could benefit from predefined interactions and 
provide  easier  selection  procedures  for  probable  common  binding  poses  for  several 
diverse ligands. Different structural templates would further allow to define differently 
formed  binding  pockets.  Their  fold  cannot  be  adapted  with  docking  procedures 
considering  receptor  flexibility.  Several  residues  predicted  as  possible  partners  for 
interaction to the virtually discovered molecules could be tested in mutation analysis 
with artificial amino acids to prove the hypothetical binding mode. 
 
The discovery of novel mGluR binding ligands remains challenging since NAMs and 
PAM share the same molecular scaffolds (Sharma et al. 2008) and it seems more likely 
that substituents define receptor selectivity and modulation effects. The application of a 
variety of virtual screening approaches revealed several methods as capable of active 
molecule prediction. De novo design of molecules (Böhm 1992, Böhm and Schneider 
2000) might contribute new ideas for novel molecule frameworks which could replace 
known scaffolds while still presenting interacting groups in the required orientations.  
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6. Summary 
G protein-coupled receptors (GPCR) are the largest family of cell-membrane located 
receptors involved in various signaling pathways and for this reason a widely analyzed 
biological target molecule in the pharmaceutical research area. GPCR ligands modulate 
neuroleptic  communication.  Small  molecules  binding  to  GPCRs  are  aimed  to  cure 
different central neural system disorders as schizophrenia, Alzheimer’s and Parkinson’s 
diseases. Receptor based drug design is difficult in case of GPCRs due to the limited 
number  of  crystal  structures.  Throughout  evolution  the  function  of  GPCRs  were 
optimized  to  enable  the  recognition  of  diverse  types  of  transmitting  molecules. 
However,  the  fold  of  the  transmembrane  domain,  the  signaling  processes  using 
G proteins as well as the location of the transmembrane ligand binding side remained 
similar. Since this study focused on family C GPCRs and the only structurally resolved 
GPCRs belong to family A, the transmembrane domain conserved between both types 
was analyzed in comparative way. Aiming at understanding of functional and structural 
features  of  family  C  GPCRs  and  their  difference  to  family  A  GPCRs  experimental 
findings were correlated to patterns conserved in their sequences. To characterize the 
transmembrane  binding  site  of  family  C  ligands,  the  TM  domain’s  structure  was 
modeled derived from a family A GPCR as template. 
 
Representatives from two GPCR families, bovine rhodopsin (BR, family A) and the 
metabotropic glutamate receptor five (mGluR5, family C), were selected to investigate 
common  feature  conservation.  The  structure  of  mGluR5  was  predicted  choosing  a 
suitable template for homology modeling based on the level of sequence homology. For 
mGluR5 sequence identity in the TM region was optimized reaching 12% to the human 
β-adrenergic receptor type 2 and 13% to bovine rhodopsin, therefore BR was chosen as 
structural  template.  For  the  entire  family  C  and  the  vertebrate  rhodopsin  subfamily 
conservation profiles were calculated using Shannon entropy and projected onto the 
structure of mGluR5 and BR, respectively. 
 
The Shannon entropy analysis was applied for definition of conserved positions in the 
TM of family C GPCRs. This analysis was based on a multiple sequence alignment 
(MSA) of 96 functionally diverse sequences of family C GPCRs. The MSA proposed in 
this study was found to contain more conserved positions than the publicly available 6. Summary 
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alignment derived in a completely automated manner. Using a chemical amino acid 
typing  scheme,  the  family  C  MSA  was  analyzed  position-wise  regarding  the 
conservation of these groups. The correlation of available experimental data for family 
A and C GPCRs allowed to define functionally and structurally important positions as 
well  as  differences  for  both  families.  According  to  the  modeled  mGluR5  structure 
conserved positions were located at helix-helix contacts.  
 
Experimental  data  describing  functional  and  structural  effects  in  diverse  family  C 
GPCRs caused by mutations in TM region were collected from literature yielding 157 
mutations for 14 TM domain binding molecules. In this study the combination of site-
directed mutagenesis studies with the entropy conservation analysis method has proven 
valuable  in  testing  and  refining  hypotheses  for  ligand  binding  targeting  the  TM 
allosteric binding pocket of metabotropic glutamate receptors. 
 
In a virtual screening approach several techniques to describe molecules and to build a 
predictive model were evaluated. A ligand data base of 1240 diverse mGluR binding 
ligand  series  served  as  knowledge  base  to  establish  predictive  models  for  mGluR5 
active molecules. Previous selectivity assignments enabled the compilation of focused 
sets of reference molecules for model training. 2D and 3D molecule ecoding versions 
were applied in combination with machine learning and similarity-based techniques in 
order to predict potentially active molecules. Topological pharmacophore fingerprints 
and molecular shape similarities were employed in similarity searches with SOMs and 
Bayesian networks. Out of 228 molecules selected with different methods, 8 molecules 
exhibited  functional  activity  below  10 M  (experiments  provided  by  Merz 
Pharmaceuticals).  Seven  molecules  were  tested  as  negative  (NAM),  one  as  positive 
allosteric  modulator,  among  the  seven  NAMs  was  a  single  non-selective 
(mGluR1/mGluR5) NAM. Similarities to reference molecules could eventually explain 
the activity of the selected molecules. A possible binding orientation of the mGluR 
binding ligands was predicted for several of these virtually discovered molecules. 
 
Negative allosteric modulators were docked into the modeled binding pocket of the 
human mGluR5 using a procedure which accounts for receptor flexibility and therefore 
allows to conformationally adapt the interacting residues. Ligand conformations were 
analyzed based on the resulting docking poses resulting in a hypothesis where several 6. Summary 
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ligands overlap in their binding area. The volume of the binding pocket was compared 
to known complex structures of GPCRs. Retinal (BR) and the inverse agonists’ (ß2AD) 
binding conformations were compared to the suggested ligand poses of mGluR NAMs. 
An overlap of NAMs and the crystallized ligands was detected. For the β-adrenergic 
receptors (three experimental protein structures with diffusible ligands available so far) 
and the mGluR subfamilies the conservation analysis of the binding pocket revealed 
that residues in close proximity to ligands are conserved in functional families besides 
few residues, which might facilitate ligand selectivity among subtypes.  
 
Both the sequence and the ligand-based approaches revealed similarities and differences 
between functionally diverse GPCRs and provided a basis for modeling of family C 
binding modes using knowledge from family A receptors. The prepared data, consisting 
of sequences, mutations and ligands, in its combination supported the application and 
analysis of the employed methods.  
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7. Zusammenfassung 
Im  Rahmen  dieser  Arbeit  wurden  Konzepte  zur  Aufklärung  struktureller  und 
funktioneller  Eigenschaften  von  G-Protein  gekoppelten  Rezeptoren  (GPCR)  der 
Familie C  entwickelt  und  angewendet.  In  diesem  Zusammenhang  wurde  anhand 
verfügbarer  experimenteller  Daten  aus  Mutations-  und  Ligandenbindungsstudien  ein 
Vergleich  konservierter  Bereiche  der  Rezeptor-Familien  A  und  C  angefertigt. 
Anschließend an die retrospektive Analyse wurde eine prospektive virtuelle Vorhersage 
neuer  mGluR5  (metabotroper  Glutamatrezeptor  des  Typs  fünf)  bindender  Moleküle 
durchgeführt und das Ergebnis durch  Laborexperimente validiert.  Insgesamt wurden 
Sequenz-, Struktur- und Liganden-basierte Methoden angewendet und ihre Ergebnisse 
im einem strukturellen Kontext zusammengefasst und diskutiert. Dieser wurde durch 
die  vorhergesagte  dreidimensionale  Struktur  des  mGluR5  geschaffen.  Die  Struktur 
wurde  anhand  der  bekannten  Röntgenkristallstruktur  des  bovinen  Rhodopsins,  eines 
Familie  A  GPCRs,  modelliert  und  einer  Prüfung  bezüglich  der  Eignung  für 
Ligandenbindungsstudien unterzogen. 
 
GPCRs  zeichnen  sich  durch  strukturelle  und  funktionale  Gemeinsamkeit  in  der 
Transmembrandomäne  (TM)  aus.  Diese  durchspannt  mit  sieben  alpha-helikalen 
Bereichen die Zellmembran und ermöglicht die Weiterleitung extrazellulärer Signale in 
das Innere der Zelle. Auslöser solcher Signale können unterschiedlichen Strukturklassen 
zugeordnet  werden:  Peptide,  Ionen,  Neurotransmitter  und  andere  kleine  organische 
Moleküle. Die Erkennung der Signalmoleküle führt zu einer Konformationsänderung 
des  Rezeptors  und  wirkt  sich  dadurch  aktivierend  auf  G-Proteine  aus,  die  am 
intrazellulären Teil des GPCRs gebunden sind. G-Proteine lösen sich vom GPCR und 
leiten weitere biochemische Reaktionen innerhalb der Zelle ein. Unterschiede zwischen 
GPCR  ergeben  sich  durch  die  Bindung  verschiedener  Signalmoleküle  und  die 
nachgeschalteten G-Proteine. Somit kann beides zu einer Erhöhung der Variabilität von 
Singaltransduktionswegen  beitragen.  Im  humanen  Genom  werden  bis  zu  900 
verschiedener GPCRs vermutet. Die Implikation dieser Rezeptorklasse in die Kontrolle 
wichtiger Prozesse im menschlichen Körper macht ihre Erforschung aus kommerziellen 
Gründen besonders attraktiv; 40% der verkäuflichen Medikamente wechselwirken mit 
GPCRs. 
 7. Zusammenfassung 
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Aufgrund  von  Ähnlichkeiten  in  der  Proteinsequenz,  dem  pharmakologischen  Profil 
sowie  der  Art  der  gebundenen  Liganden  gilt  die  Klassifikation  der  GPCRs  in  fünf 
Familien. Die Familie A ist die größte und am meisten untersuchte und beinhaltet die 
zur  Zeit  einzigen  strukturell  aufgeklärten  GPCRs.  Strukturell  charakteristisch  für 
Familie C GPCRs ist die extrazelluläre Domäne (VFT, engl. venus fly trap benannt nach 
dem  Funktionsprinzip),  die  für  die  Bindung  des  körpereigenen  Neurotransmitters, 
Glutamat,  erforderlich  ist.  Glutamat  aktiviert  den  Rezeptor  über  die  orthosterische 
Bindestelle,  von  der  über  eine  Konformationsänderung  die  Aktivierung  auf  die  TM 
übertragen  wird.  Die  Sequenzähnlichkeit  der  VFT  zu  einem  bakteriellen  Protein 
ermöglichte  die  Hypothese  über  die  Fusion  dieser  extrazellulären  und  der 
transmembranen Domäne (Pin et al. 2003). 
 
 Die  am  längsten  bekannte  nicht  bakterielle  GPCR-Struktur  ist  die  des  bovinen 
Rhodopsins (BR, engl. bovine rhodopsin) im Komplex mit Retinal. Zur Vorhersage 
einer  Struktur  für  mGluR5  wurde  die  am  höchsten  aufgelöste  Struktur  von  BR  als 
Vorlage  verwendet.  Diese  Modellierung  erfolgte  mit  der  Methode  des  comparative 
modeling (auch als Homologiemodellierung bezeichnet), bei der das Proteinrückgrad 
der  strukturellen  Vorlage  als  Initialposition  zur  Platzierung  von  Aminosäuren  der 
Zielstruktur  verwendet  wird.  Die  Annahme,  nach  der  Sequenzidentität  zu  einer 
ähnlichen dreidimensionalen Faltung von Proteinen führt, stellt die Grundlage für die 
Vergleichbarkeit der Strukturen dar und entscheidet über die Qualität des Ergebnisses. 
Daher  werden  die  Proteinsequenzen  als  Grundlage  für  die  Überlagerung  im 
Modellierungsprozess  aligniert.  Im  Falle  von  mGluR5  wurde  das  Sequenzalignment 
manuell angefertigt, da die Sequenzidentität bei 13% lag und nur aufgrund konservierter 
Aminosäuren  in  den  einzelnen  TM  optimiert  werden  konnte.  Die  Verfeinerung  des 
mGluR5-Modells erfolgte mittels struktureller Optimierung des protonierten Rezeptors 
zum nächsten Energieminimum hin.  
 
Die strukturelle Verwandtschaft von GPCRs der Familien A und C sollte anhand von 
Proteinsequenzen  verglichen  werden.  Als  Grundlage  wurde  ein  multiples 
Sequenzalignment (MSA) von 96 Familie C GPCRs verschiedener Funktion erstellt. 
Das MSA wurde automatisiert für die unterschiedlichen Subfamilien generiert. Diese 
wurden anschließend manuell korrigiert, zusammengeführt und an BR aligniert. Die 
Diversität in Länge und Aminosäurekomposition machte ein verlässliches Alignment 7. Zusammenfassung 
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kompletter Sequenzen schwierig und die Reduktion des MSAs auf einzelne TM-Blöcke 
erforderlich. So entstanden sieben MSA-Blöcke, jeweils ein Block pro TM-Helix. Bei 
Familie C GPCRs sind die sieben TM-Helices an der Bindung allosterischer Liganden 
beteiligt.  Die  durchschnittliche  Identität  der  Aminosäuren  in  der  TM  wurde  für  die 
unterschiedlichen Subfamilien im Einzelnen sowie für das gesamte Familie C MSA 
evaluiert.  
 
Zur weiteren Konserviertheitsanalyse (KA) wurde eine Kodierung der Aminosäuretypen 
in  Gruppen  nach  ihren  chemischen  Eigenschaften  in  der  Entropieberechnung  nach 
Shannon  angewendet.  Diese  Gruppen  sollten  ähnliche  Aminosäuren  als  konserviert 
zusammenfassen,  so  dass  die  KA  insbesondere  Änderungen  zwischen  chemischen 
Klassen  erkennbar  machen  kann.  Die  abstrakte  Betrachtung  knüpfte  dabei  an  die 
unterschiedliche  Tolerierbarkeit  einer  Aminosäuresubstitution  an,  wie  sie  in 
Substitutionsmatrizen  für  Alignments  Verwendung  finden.  Insgesamt  wurden  neun 
Gruppen definiert und die Entropieberechnung auf diesem alternativen Alphabet auf das 
MSA angewendet.  
 
Entropie ist eine Eigenschaft, die in dem Bereich der Informationstheorie untersucht 
wurde,  um  den  Informationsgehalt  in  einem  weitergeleiteten  Signal  zu  bestimmen. 
Entropie wird auch als der Grad der Unordnung in einem System bezeichnet. Ein hoher 
Entropiewert wird deswegen als Unordnung oder Rauschen interpretiert, ein niedriger 
hingegen repräsentiert einen Zustand mit hohem Ordnungsgrad oder Eindeutigkeit. Im 
Zusammenhang mit einem MSA wurde dieses Verständnis auf die Konserviertheit einer 
Sequenzposition  in  der  GPCR  Familie  übertragen.  Für  jede  Position  wurde  die 
Konserviertheit anhand der Häufigkeit im Auftreten verschiedener Aminosäuregruppen 
festgestellt. Der Beitrag einer Sequenz richtete sich dabei nach der Diversität, die diese 
im Vergleich zu anderen Sequenzen beitrug. Diese Maßnahme soll verhindern, dass die 
ungleichen  Anzahlen  bekannter  Sequenzen  in  unterschiedlichen  Subfamilien 
mitbewertet werden. Das Ergebnis der KA enthielt sowohl die Entropiewerte als auch 
die  am  meisten  konservierte  Gruppe  einer  Sequenzposition.  Folgende 
Bewertungskriterien wurden zur Interpretation der Werte in Anspruch genommen: 1. 
experimentelle Befunde aus Mutationsstudien an Rezeptoren der Familie C, 2. KA der 
Rhodopsin Subfamilie der Vertebraten, 3. veröffentlichte KA Studien für Familie A 
GPCRs und 4. Kristallstrukturen von Familie A Rezeptor-Ligand-Komplexen. Aus den 7. Zusammenfassung 
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in der Literatur veröffentlichten Mutationsstudien wurde eine Mutationsdatensammlung 
erstellt, in der die Sequenzpositionen der mutierten Aminosäuren anhand des Familie C 
MSA auf entsprechende Positionen in der Sequenz von mGluR5 und BR übertragen 
werden konnten. Auf die gleiche Weise wurden bekannte Mutationen an Familie A 
GPCRs über das Alignment zu BR in Zusammenhang zur Familie C GPCRs gesetzt. Da 
BR als Grundlage für die Modellierung der mGluR5-Struktur genutzt wurde, wurde die 
KA auf die Subfamilie der Vertebraten-Rhodopsine angewendet. Das dazu verwendete 
MSA stammte aus einer öffentlichen Datenquelle und war aufgrund der Ähnlichkeit 
innerhalb dieser Funktionsklasse automatisiert erstellt worden. Konservierte Bereiche 
beider GPCR Familien wurden korreliert und einzelne Position, deren funktionale oder 
strukturelle Bedeutung durch Mutationsstudien bestätigt wurde, detailliert diskutiert. Zu 
diesen für GPCRs charakteristischen Region gehörten Helix-Kontaktstellen, funktionale 
Sequenzmotive,  G-Protein  koppelnde  Stellen,  Dimerisierungs-Kontakflächen  und  die 
TM-Bindetasche  für  Liganden.  Im  Bereich  der  Bindetasche  fanden  auch  bekannte 
GPCR-Komplexe ihre Anwendung und wurden vergleichend diskutiert. Für strukturelle 
Merkmale  sowie  Teile  der  Bindetasche  konnten  Ähnlichkeiten,  die  aus  der  KA 
resultierten,  bestätigt  werden,  im  Gegensatz  zu  hypothetischen  Dimerisierung-
Kontaktflächen. 
 
Über die TM-Bindetasche der mGlu-Rezeptoren ist bekannt, dass die Anregung des 
Rezeptors  von  einem  allosterischen  Modulator,  der  in  der  TM-Bindetasche  bindet, 
beeinflusst  werden  kann.  Dieser  regulierende  Effekt  ist  entscheidend  für  den 
medizinischen  Einsatz  von  allosterischen  Modulatoren.  Negative  allosterische 
Modulatoren (NAM) hemmen die Aktivierbarkeit des Rezeptors durch Glutamat und 
positive  allosterische  Modulatoren  (PAM)  erhöhen  diese,  ohne  dass  sie  um  die 
Bindetasche mit diesem konkurrieren.  
 
Mit dem Ziel, neue selektive allosterische Modulatoren für mGluR5 zu finden, wurden 
mehrere  Liganden-basierte  Ansätze  zur  virtuellen  Vorhersage  der  Aktivität  von 
Molekülen entwickelt und getestet. Die dabei angewendete Strategie basierte auf der 
Kenntnis  bereits  bekannter  Liganden,  deren  Strukturen  und  Aktivitätswerte  für  das 
Erstellen von Vorhersagemodelle genutzt werden konnten. Strukturen bekannter mGluR 
bindender  Moleküle  wurden  wissenschaftlichen  Veröffentlichungen  entnommen  und 
gemeinsam  mit  Eigenschaften,  die  sie  in  ihren  Effekt  beschreiben,  in  einer 7. Zusammenfassung 
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Datensammlung  festgehalten.  Die  Liganden-Datensammlung  diente  als  Referenz  für 
Struktur-Wirkungs-Beziehungen,  die  mit  Hilfe  von  computergestützten 
Vorhersagemethoden  untersucht  und  zur  prospektiven  Molekülbewertung  eingesetzt 
wurde. 
 
Für die virtuelle Handhabung wurden alle Moleküle mit Kodierungsverfahren in ein 
untereinander  vergleichbares  Format  überführt.  Ingesamt  wurden  Oberflächen, 
Substrukturen  und  Pharmakophor-Eigenschaften  beschreibende  Kodierungen 
angewendet. Die Spherical Harmonics Descriptors (SHD), die das Volumen und die 
dreidimensionale  Form  eines  Moleküls  wiedergeben,  und  die  Chemically  Advanced 
Template  Search  (CATS)  Deskriptoren,  die  die  Häufigkeiten  von 
Pharmakophorpunkten im Molekül kodieren, wurden zur retrospektiven Analyse der 
Referenzliganden  eingesetzt.  Dabei  konnte  festgestellt  werden,  dass  selektive  sowie 
unterschiedlich  stark  aktive  mGluR  Liganden  in  dem  von  den  Deskriptoren 
aufgespannten Raum nur schwer unterschieden werden können. Die Unterscheidbarkeit 
wurde anhand von Clustern in einer selbst-oganisierenden Karte (engl. self-organizing 
map, SOM) überprüft. Für NAMs und PAMs konnten einige separate Cluster definiert 
werden. Die Molekülkodierung mit CATS schnitt besser ab und wurde anschließend für 
die prospektiven Vorhersagen weiterverwendet.  
 
Die  prospektive  Vorhersage  stützte  sich  auf  unterschiedliche  Methoden  zur 
Ähnlichkeitsberechnung  und  Arten  der  Molekülkodierung.  Zwei  verschiedene 
Pharmakophortypen  beschreibende  Deskriptoren,  CATS    und  PHRFP,  sowie  die 
Functional  Class  Extended-connectivity  Fingerprints  (FCFP)  wurden  zur 
Ähnlichkeitssuche mit Tanimoto-Bewertung eingesetzt. Die Ähnlichkeit zu bekannten 
hochaktiven  Modulatoren  des  mGluR5,  die  nicht  an  mGluR1  bindenden,  sollte  zur 
Auffindung selektiver NAMs führen. Durchsucht wurden, abhängig von der Methode, 
bis zu 5 Millionen käuflich zugänglicher Moleküle. Zwei ergänzende Klassifikatoren 
nach Bayes wurden trainiert, um die Ähnlichkeit zu hochaktiven mGluR-Liganden und 
selektiven mGluR5-Liganden als Wahrscheinlichkeiten ausdrücken zu können. Beide 
Modelle wurden nach dem Dominanzprinzip von Pareto zur Selektion von potentiellen 
Liganden  kombiniert.  Die  mit  CATS  definierte  Ähnlichkeit  wurde  weiterhin  zum 
Clustern der Referenzmoleküle mit unbekannten Molekülen unter Verwendung einer 
SOM eingesetzt. Moleküle aus Neuronen, die selektive mGluR5 Liganden enthielten, 7. Zusammenfassung 
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wurden im zweiten Schritt durch die Bewertung mit dem Bayes’schen Klassifikator 
nachgefiltert und sortiert. Ebenfalls im Rahmen der Ähnlichkeitsbewertung wurde der 
NAM, MPEP, als Referenz zur Molekülform (engl. shape) basierten Suchen verwendet. 
Anhand  aller  sortierten  Moleküllisten,  die  als  Ergebnis  aus  unterschiedlichen 
Vorhersagen resultierten, wurden Moleküle zur experimentellen Testung ausgewählt. 
Die  Testung  der  Moleküle  wurde  von  Mitarbeitern  des  Unternehmens  Merz 
Pharmaceuticals durchgeführt. Die Moleküle wurden hinsichtlich ihrer modulatorischen 
Wirkung  am  mGluR5  gemessen,  wobei  negativer  oder  positiver  Effekt  festgestellt 
werden konnten. Die Art der Messung war funktional, da Änderungen des Ca
2+-Levels 
in  der  Zelle  nachgewiesen  wurden.  Für  NAMs  wurde  eine  Konzentrationsreihe 
gemessen,  welche  die  Berechnung  des  IC50  (Konzentration  des  NAMs,  bei  der  die 
Aktivität  des  Rezeptors  um  50%  reduziert  ist)  ermöglicht.  Bei  PAMs  wurde  die 
Erhöhung  der  Aktivierung  gemessen.  Nachgewiesene  Modulatoren  wurden  zur 
Selektivitätsbestimmung einer Testung am mGluR1 unterzogen. Insgesamt konnten 8 
von  228  getesteten  Molekülen  im  Aktivitätsbereich  unter  10 M  ermittelt  werden, 
darunter befand sich ein PAM. Von den restlichen sieben NAMs waren fünf selektiv für 
mGluR5. Der einzige nicht selektive Ligand enthielt einen Acetylenlinker, der bislang 
als  charakteristisch  für  mGluR5  selektive  Liganden  galt.  Jeder  Ligand  wurde  auf 
Ähnlichkeit zu Molekülen des Referenzdatensatzes untersucht und dessen Aktivität mit 
diesem verglichen. 
 
Alle  identifizierten  NAMs  wurden  hinsichtlich  möglicher  Interaktion  mit  mGluR5 
untersucht. Die Moleküle wurden in das zuvor erstellte Strukturmodel von mGluR5 mit 
Hilfe des molekularen Docking eingepasst. Docking ist ein Verfahren, das die Struktur 
des  Liganden  in  der  Bindetasche  des  Biomoleküls  platziert.  Da  es  sich  um  eine 
vorhergesagte  Struktur  handelte,  wurde  die  Ungenauigkeit  in  der 
Seitenkettenausrichtung durch flexible Anpassung beim Moleküldocking (engl. induced 
fit docking, IFD) berücksichtigt. Für eine Reihe der Seitenketten, die in Richtung der 
TM-Bindetasche orientiert werden könnten, wurde ein Protokoll angewendet, das diese 
optimiert, um die Interaktion mit dem Liganden zu verbessern. Das IFD behandelt den 
Liganden und den Rezeptor flexibel und ermöglicht durch schrittweise Evaluierung mit 
einer Bewertungsfunktion und Anpassung ein Ergebnis zu erzielen, das weniger von der 
Ausgangskonformation  abhängt  als  beim  Docken  mit  rigiden  Rezeptoren.  Die 
Ergebnisse des IFD wiesen ähnliche Bewertung für unterschiedliche Ligandenposen auf 7. Zusammenfassung 
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und wurden deswegen manuell selektiert. Diese Vorgehensweise sollte eine Hypothese 
ermöglichen,  wie  die  Liganden  in  der  Bindetasche  lokalisiert  werden  könnten.  In 
Abwesenheit  eindeutiger  Vorlagen  für  Familie  C  GPCRs  wurden  Komplexe  von 
Vertretern  der  Familie  A  zum  Vergleich  herangezogen.  Diese  definierten  den 
Bindetaschenbereich, der auch in Bezug auf die gefundenen Liganden von mGluR5 als 
hochwahrscheinlich angenommen wurde. Überlappende Bindeposen mit den Liganden 
des  BR  und  ß2AD  sowie  der  sieben  zu  dockenden  Liganden  wurden  bestimmt  und 
Seitenketten  im  engen  Kontakt  dazu  analysiert.  Zusätzlich  wurde  die 
Mutationssammlung zum Vergleich hinzugezogen, die den Bindebereich eingrenzt und 
mögliche  Interaktionspartner  beschreibt.  Die  Bindungshypothese  entsprach  einer 
Überlagerung der gefundenen Moleküle und ihrer möglicher Interaktionspunkte, konnte 
jedoch  ohne  weitere  strukturelle  Information  aus  Experimenten  nicht  ausreichend 
validiert werden. 
 
In  dieser  Studie  wurden  mit  unterschiedlichen  Methodiken  der  Bio-  und 
Chemieinformatik orientiert an experimentellen Ergebnissen, Fragestellungen bezüglich 
des Funktionsmechanismus von GPCRs untersucht. In ihrem Verlauf wurden diverse 
Daten  aus  experimentellen  Befunden  zusammengefasst  und  im  strukturellen 
Zusammenhang  korreliert.  Die  Untersuchung  der  Sequenzen  ermöglichte  neue 
Erkenntnisse  bezüglich  konservierter  Bereiche  zweier  GPCR  Familien.  Anhand  der 
Entdeckung  neuer  Liganden  mit  unterschiedlichen  computergestützten  Methoden 
konnten diese Suchverfahren evaluiert und ihre Schwächen und Stärken identifiziert 
werden.  Exemplarisch  am  mGluR5  konnte  die  Eignung  einer  modellierten  GPCR-
Struktur für eine Hypothesengenerierung bezüglich Ligandenbindung und struktureller 
Zusammenhänge untersucht werden.  
 8. References 
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9. Abbreviations 
2D and 3D  Two dimensional and three dimensional 
5HT2c  5-hydroxytryptamine (serotonin) receptor 2C 
Å  Ångström 
Ala, A  Alanine 
AP  Addex Pharmaceuticals 
Arg, R  Arginine 
ASN   Asinex serial number 
Asn, N  Asparagine 
Asp, D  Aspartic acid 
AUC  Area under curve 
AZ  Astra Zeneca 
ß2AD  Beta adrenergic receptor type two 
Blosum45  BLOcks SUbstitution Matrix 
BOSS  Bride of Sevenless Proteins 
BR  Bovine rhodopsin 
BW  Generic numbering according to Ballesteros and Weinstein 
(Ballesteros and Weinstein 1985) 
Ca
2+  Calcium 
Calhex231  4-Chloro-N-[2-(1-naphthalen-1-yl-ethylamino)-cyclohexyl]-
benzamide 
CaSR  Calcium sensing receptor 
CATS  Chemically Advanced Template Search 
CHARMM  Chemistry at HARvard Molecular Mechanics, a  
force-field and macromolecular simulations program 
ClustalW  General purpose multiple sequence alignment program for  
DNA or protein sequences 
CNS  Central nervous system 
CPCCOEt  2-Dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-
carboxylic Acid Ethyl Ester 
CRD  Cystein-rich domain 
Cys, C  Cystein 
D3  Dopamine receptor 3 
DEER  double electron-electron resonance 
DFB  N,N’-Bis-(3-fluoro-benzylidene)-hydrazine 
DMSO  Dimethylsulfoxid 
DRC  Dose response curve 
EC  Extracellular 
EC50  Effective Concentration, a doses which leads to 50% of 
measured effect 
EM-TBPC  (1-Ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-
benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile 9. Abbreviations 
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EPR  electron paramagnetic resonance 
HV  Entropy value 
FCFP  Functional class extended-connectivity fingerprint  
FLIPR  Fluorescent Imaging Plate Reader 
FN  False negatives 
FP  False positives 
GABA-B, GABR  Gamma-aminobutyric acid type B receptor 
GDP  guanosine diphosphate 
Gln, Q  Glutamine 
Glu, E  Glutamic acid 
Gly, G  Glycine 
GPCR  G-protein coupled receptor 
GPCR5  G-protein coupled receptor family C group 5 
GPCR6  G-protein coupled receptor family C group 6 
GPCRDB   GPCR data base, information system for G protein-coupled 
receptors 
G-Protein  Guanine nucleotide-binding proteins 
H  Helix 
HD  Heptahelical domain 
hCaSR  Human extracellular calcium-sensing receptor precursor 
(CaSR) 
His, H  Histidine 
hT1R3  Human taste receptor type 1 member 3 precursor (Sweet 
taste receptor T1R3) 
IC  Intracellular loop 
IC50  Inhibitory concentration, a measure of the effectiveness of a 
compound in inhibiting biological or biochemical function 
ID  Identification 
IFD  Induced fit docking 
Ile, I  Isoleucine 
IP  Inositol phosphate 
IUPAC  International Union of Pure and Applied Chemistry 
KA  Konserviertheitsanalyse 
Ki  The binding affinity of the ligand 
Leu, L  Leucine 
Ligprep  Ligand preparation module Schrödinger, LLC, New York, 
2008 
LISS  Ligand-induced selective signaling 
LPV  ligand binding pocket vector 
LY 487379  N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)-pyrid-3-yl-methylamine 
Lys, K  Lysine 9. Abbreviations 
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M  Molecule 
M1  Muscarinic receptor 1 
MATLAB  "Matrix laboratory", a numerical computing environment 
and programming language 
max  Maximum 
MCPG  (S)-α-methyl-4-carboxyphenylglycine 
Met, M  Methionine 
mGluR or mGR  Metabotropic glutamate receptor 
mGluR1, mGluR5  Metabotropic glutamate receptor subtype one, five 
min  Minimum 
M-MPEP  [3H]2-methyl-6-(3-methoxyphenyl) ethynyl pyridine 
MOE  Molecular Operating Environment 
MPEP  2-Methyl-6-(phenylethynyl)-pyridine 
MSA  Multiple sequence alignment 
MSF  Multiple sequence files 
MTEP  3-(2-Methyl-thiazol-4-ylethynyl)-pyridine 
NAM  Negative allosteric modulator 
nM  nanomol 
NMR  nuclear magnetic resonance 
NPS R-568  [3- (2-Chloro-phenyl)-propyl]-[1-(3-methoxy-phenyl)-ethyl]-
amine 
NPS2143  2-Chloro-6-[3-(1,1-dimethyl-2-naphthalen-2-yl-ethylamino)- 
2-hydroxy-propoxy]-benzonitrile 
NA  Nucleic Acids 
PAM  Positive allosteric modulator 
PDB  Protein data bank 
pdf  Probability density function 
pH  "Power of hydrogen", a measure of the acidity or basicity of 
a solution 
PHRFP   Chemically advanced Template search (CATS)  
pharmacophore fingerprints 
PML  PyMOL script 
Pro, P  Proline 
QSAR  Quantitative structure activity relationship 
RMSD  Root mean square deviation 
Ro 67-7476  2-(4-Fluoro-phenyl)-1-(toluene-4-sulfonyl)-pyrrolidine 
ROC  Receiver Operating Characteristic  
SDF  Structure-data file 
SDSL  site-directed spin labelling 
H  Shannon entropy 
Ser, S  Serine 
HV  Shannon entropy value 
SHD  Spherical harmonics descriptors  9. Abbreviations 
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SMILES  Simplified Molecular Input Line Entry Specification 
SOM  Self-organizing map 
SP   Standard precision 
SwissProt  Biological database of protein sequences 
Thr, T  Threonine 
TM  Transmembrane 
TMHMM  Transmembrane hidden Markov models 
TN  True negatives 
TP  True positives 
TR  Taste receptor 
Trp, W  Tryptophane 
Tyr, Y  Tyrosine 
Val,V  Vvaline 
V1A  Vasopressin receptor 
VR  Vertebrate rhodopsin 
VTFM  Variable target function method  
ZM241385  4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-yl)amino]ethyl}phenol  
 M   Micromol 
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10. Appendix 
10.1 Schroedinger IFD Protocol in .inp File Format 
mGluR5 
# Global Variables 
#  These variables affect the entire job, and must all appear 
#  before the first STAGE declaration.  Multiple INPUT_FILE 
#  entries are supported, as are files containing multiple 
#  receptor structures. 
# 
#  If beginning with an existing Pose Viewer file, simply specify 
#  it as the INPUT_FILE (making sure the name ends in "_pv.mae") 
#  and ensure that the first GLIDE_DOCKING stage is commented out. 
#  The ligand used in producing the Pose Viewer file must also be 
#  provided to the second GLIDE_DOCKING stage, using the LIGAND_FILE 
#  keyword. 
INPUT_FILE  mGluR5_rec.mae 
SUBJOB_HOST new.q 
NUM_PRIME_CPUS  1 
NUM_GLIDE_CPUS  1 
 
# Protein Preparation 
#  Run a simple constrained minimization of the receptor 
#  structure(s). 
STAGE PPREP 
  RMSD  2.2 
 
# Prime Loop Prediction 
#  Perform a loop prediction on the specified loop, including 
#  side chains within the given distance.  Only return 
#  structures within the specified energy range from the 
#  lowest energy prediction, up to the maximum number of 
#  conformations given. 
# 
#  Note: This stage is disabled by default.  Uncomment the 
#   lines below and edit the fields appropriately to enable it. 
#STAGE PRIME_LOOP 
#  START_RESIDUE A:11 
#  END_RESIDUE A:16 
#  DISTANCE_CUTOFF 5.0 
#  MAX_ENERGY_GAP 30.0 
#  MAX_STRUCTURES 5 
#  USE_MEMBRANE no 
 
# In order to temporarily remove the side chains of residues 
# (i.e., mutate to Ala) that are blocking the binding site, 
# uncomment the following STAGE line, and then specify the 
# sidechains to be removed using either one of the two Methods 
# described below. 
# 
STAGE TRIM_SIDECHAINS 
# 
# Method 1: Manual specification.  Uncomment the following 
# line and list the desired residues in the format indicated. 
# 
  RESIDUES  _:722,_:726,_:732,_:734,_:735 
# 
# Method 2: Automatic determination based on predicted 
# flexibility.  Uncomment the following lines, and specify 10. Appendix 
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# the residues, ligands or other species which define the 
# binding site.  All sidechains within DISTANCE_CUTOFF 
# of these species will be tested for flexibility and 
# trimmed if deemed necessary. 
# 
# RESIDUES  AUTO 
# BINDING_SITE   
# DISTANCE_CUTOFF 5.0 
 
# Glide Docking 
#  Perform the initial Glide docking, producing a 
#  ligand-receptor complex for each pose requested/found. 
#  If multiple receptor structures are used, the requested 
#  number of poses will be generated for each structure. 
STAGE GLIDE_DOCKING 
  RECEPTOR_CCUT  0.25 
  LIGAND_FILE  ligands.maegz 
  LIGANDS_TO_DOCK all 
  LIGAND_CCUT  0.15 
  CV_CUTOFF 100.0 
  HBOND_CUTOFF  -0.05 
  INNER_BOX 10.0 
  MINIMUM_POSES  1 
  BINDING_SITE  residues 
:624,:628,:629,:631,:632,:641,:643,:644,:645,:647,:648,:649,:650,:651,
:652,:653,:654,:655,:656,:657,:658,:659,:662,:710,:713,:714,:716,:717,
:718,:720,:722,:724,:730,:731,:732,:733,:734,:735,:736,:737,:739,:740,
:743,:744,:747,:748,:752,:777,:778,:781,:782,:784,:785,:787,:788,:789,
:791,:792,:808,:809,:811,:812,:813,:815,:816 
  OUTER_BOX auto 
  RECEPTOR_SCALE  0.70 
  LIGAND_SCALE  0.50 
  MAX_POSESPERLIG 10 
  PRECISION SP 
 
# Determine Residue to Refine 
#  Compile a list of all residues within the specified 
#  distance of any pose of the ligand. 
STAGE COMPILE_RESIDUE_LIST 
  DISTANCE_CUTOFF 5.0 
 
# Prime Refinement 
#  Optimize the side chains of the residue list compiled 
#  previously, then minimize them along with the ligand. 
STAGE PRIME_REFINEMENT 
  NUMBER_OF_PASSES  1 
  USE_MEMBRANE no 
 
# Sort and Filter 
#  Only retain poses with Prime Energies within the 
#  specified range from the lowest energy pose. 
STAGE SORT_AND_FILTER 
  POSE_FILTER  r_psp_Prime_Energy 
  POSE_KEEP 30.0 
 
# Sort and Filter 
#  Only retain the top number of poses specified. 
STAGE SORT_AND_FILTER 
  POSE_FILTER  r_psp_Prime_Energy 
  POSE_KEEP 20# 
 
# Glide Docking 
#  Redock the ligand back into the newly optimized receptor, 10. Appendix 
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#  using default Glide settings. 
STAGE GLIDE_DOCKING 
  BINDING_SITE  ligand Z:999 
  RECEPTOR_SCALE  1.00 
  RECEPTOR_CCUT  0.25 
  LIGAND_FILE  ligands.maegz 
  LIGANDS_TO_DOCK self 
  LIGAND_SCALE  0.80 
  LIGAND_CCUT  0.15 
  CV_CUTOFF 0.0 
  HBOND_CUTOFF  0.0 
  INNER_BOX 10.0 
  MAX_POSESPERLIG 1 
  OUTER_BOX auto 
  PRECISION SP 
 
# Scoring 
#  Compile the IFD Score, consisting of the GlideScore for 
#  the Glide Redocking plus 5% of the Prime Energy from the 
#  Prime Refinement. 
STAGE SCORING 
  SCORE_NAME  r_psp_IFDScore 
  TERM 1.0,r_i_glide_gscore,0 
  TERM 0.05,r_psp_Prime_Energy,1 
  REPORT_FILE report.csv 
 
10.2 Homology Modelling Data 
10.2.1 Alignment in PIR Format 
The following alignment is referred to as 'alignment.ali' in the Modeller script file. 
 
>P1;1U19 
structureX:1U19: : A: : A:::2.2:0.200 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
---------------------------------------MNGTEGPNF-----YVPFSNK 
TGVV-----RSP-F-EAP-QYYL-AE--PWQF----SMLAAYMFLLIMLGFPINFLTLYV 
TVQHKKLRTP-LNYILLNLAVADLFMVFGGFTTTLYTSLHGYFVFGPTGCNLEGFFATLG 
GEIALWSLVVLAIERYVVV-------C--KP--MS-NFRFGENHAIMGVAFTWVMALACA 
APPLVGWSRYIPEGMQ--CSCGIDYYTPHEETNNESFVIYMFVVHFIIPLIVIFFCYGQL 
VFTVKEAAAQQQESATTQKAEKEVTRMVIIMVIAFLICWLPYAGVAFYIFTHQGSDFGPI 
FMTIPAFFAKTSAVYNPVIYIMMNKQFRNCMVTTLCCG--KNPLGDDEASTTVSKTETSQ 
VAPA* 
>P1;H5_straight 
structureX:H5_straight:::::::: 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 10. Appendix 
      163 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
-----------------------------------LGVVTPLGYDGLLILSCTFYAFKTR 
N* 
>P1;H7_straight 
structureX:H7_straight:::::::: 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
------------------------------------------------------------ 
----------------------------------------------------------MC 
FSVSLSATVALGCMFVPKVYIIL* 
>P1;mGluR5 
sequence:mGluR:::::::: 
MVLLLILSVLLLKEDVRGSAQSSERRVVAHMPGDIIIGALFSVHHQPTVDKVHERKCGAV 
REQYGIQRVEAMLHTLERINSDPTLLPNITLGCEIRDSCWHSAVALEQSIEFIRDSLISS 
EEEEGLVRCVDGSSSSFRSKKPIVGVIGPGSSSVAIQVQNLLQLFNIPQIAYSATSMDLS 
DKTLFKYFMRVVPSDAQQARAMVDIVKRYNWTYVSAVHTEGNYGESGMEAFKDMSAKEGI 
CIAHSYKIYSNAGEQSFDKLLKKLTSHLPKARVVACFCEGMTVRGLLMAMRRLGLAGEFL 
LLGSDGWADRYDVTDGYQREAVGGITIKLQSPDVKWFDDYYLKLRPETNHRNPWFQEFWQ 
HRFQCRLEGFPQENSKYNKTCNSSLTLKTHHVQDSKMGFVINAIYSMAYGLHNMQMSLCP 
GYAGLCDAMKPIDGRKLLESLMKTNFTGVSGDTILFDENGDSPGRYEIMNFKEMGKDYFD 
YINVGSWDNGELKMDDDEVWSKKSNIIRSVCSEPCEKGQIKVIRKGEVSCCWTCTPCKEN 
EYVFDEYTCKACQLGSWPTDDLTGCDLIPVQYLRWGDPEPIAAVVFACLGLLATLFVTVV 
FIIYRD--TPVVKSSSRELCYIILAGICLGYLCTFCLIAK----PKQIYCYLQRIGIGLS 
PAMSYSALVTKTNRIARILAGSKKKICTKKPRFMSACAQLVIAFILICIQLGIIVALFIM 
EPPDIM--HDYPSIREVYLIC--N--T----T-N-LGVVTPLGYNGLLILSCTFYAFKTR 
NVP----------------ANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNY---KIITMC 
FSVSLSATVALGCMFVPKVYIILAKPERNVRSAFTTSTVVRMHVGDGKSSSAASRSSSLV 
NLWKRRGSSGETLRYKDRRLAQHKSEIECFTPKGSMGNGGRATMSSSNGKSVTWAQNEKS 
SRGQHLWQRLSIHINKKENPNQTAVIKPFPKSTESRGLGAGAGAGGSAGGVGATGGAGCA 
GAGPGGPESPDAGPKALYDVAEAEEHFPAPARPRSPSPISTLSHRAGSASRTDDDVPSLH 
SEPVARSSSSQGSLMEQISSVVTRFTANISELNSMMLSTAAPSPGVGAPLCSSYLIPKEI 
QLPTTMTTFAEIQPLPAIEVTGGAQPAAGAQAAGDAARESPAAGPEAAAAKPDLEELVAL 
TPPSPFRDSVDSGSTTPNSPVSESALCIPSSPKYDTLIIRDYTQSSSSL* 
 
10.2.2 Modeller script 
# Addition of restraints to the default ones 
from modeller import * 
from modeller.automodel import *    # Load the automodel class 
 
log.verbose() 
env = environ() 
 
# directories for input atom files 
env.io.atom_files_directory = './:../atom_files' 
# directories for input atom files 
env.io.atom_files_directory = 'directory' 
 
class mymodel(automodel): 
    def select_atoms(self): 
#    All residues from 1 to 5: 10. Appendix 
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        return selection(self.residue_range('577', '860')) 
#  def select_atoms(self): 
#       return selection(self) - selection(self.residue_range('1', 
'5')) 
    def special_restraints(self, aln): 
        rsr = self.restraints 
#       Add some restraints from a file: 
#       rsr.append(file='my_rsrs1.rsr') 
 
#       Residues 580-604 should be an alpha helix: 
        rsr.add(secondary_structure.alpha(self.residue_range('580', 
'604'))) 
#       Residues 608-638 should be an alpha helix: 
        rsr.add(secondary_structure.alpha(self.residue_range('608', 
'638'))) 
#       Residues 639-675 should be an alpha helix: 
        rsr.add(secondary_structure.alpha(self.residue_range('639', 
'675'))) 
#       Residues 685-718 should be an alpha helix: 
        rsr.add(secondary_structure.alpha(self.residue_range('685', 
'718'))) 
#       Residues 738-762 should be an alpha helix: 
        rsr.add(secondary_structure.alpha(self.residue_range('738', 
'762'))) 
#       Residues 766-797 should be an alpha helix: 
        rsr.add(secondary_structure.alpha(self.residue_range('766', 
'797'))) 
#       Residues 801-839 should be an alpha helix: 
        rsr.add(secondary_structure.alpha(self.residue_range('801', 
'839'))) 
 
    def special_patches(self, aln): 
        # A disulfide between residues 644 and 733: 
        self.patch(residue_type='DISU',residues=(self.residues['644'], 
                                                  
self.residues['733'])) 
 
a = automodel(env, 
              # file with template codes and target sequence 
              alnfile  = 'alignment.ali', 
              # PDB codes of the templates 
              knowns   = ('1U19', 'H5_straight', 'H7_straight'), 
              # code of the target 
              sequence = 'mGluR5') 
a.starting_model=1 
a.ending_model=5 
a.md_level = refine.slow 
a.make()                            # do homology modelling 
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10.3 Multiple Sequence Alignment 
TM1 
BW position        1.4        1.5       1.6 
           |         |         | 
1U19.A               SMLAAYMFLLIMLGFPINFLTLYVTVQHKK 
P22815|BOSS_DROME    DTWVATGLTAAILGLIATLAILVFIVVRIS 
Q24738|BOSS_DROVI    DTWVATGLTAAILGLIATLAILVFIVVRIS 
Q24265|Q24265_DROME  DTWVATGLTAAILGLIATLAILVFIVVRIS 
Q8MSJ2|Q8MSJ2_DROME  DTWVAAGLTAAILGLIATLAILVFIVVRIS 
Q90WL6|Q90WL6_SPAAU  EPFGIALAICAVLGVVLTAFVMGVFVRFRN 
Q8JI04|Q8JI04_SQUAC  EPFGIALTIFAVLGILITSFVLGVFIKFRN 
Q6XAF1|Q6XAF1_SALSA  EPFGIALALCSVLGVFLTAFVMGVFIKFRN 
Q6XAF2|Q6XAF2_SALSA  EPFGIALALCSVLGVFLTAFVMGVFIKFRN 
P41180|CASR_HUMAN    EPFGIALTLFAVLGIFLTAFVLGVFIKFRN 
Q80ZA8|Q80ZA8_RAT    EPFGIALTLFAVLGIFLTAFVLGVFIKFRN 
P48442|CASR_RAT      EPFGIALTLFAVLGIFLTAFVLGVFIKFRN 
P35384|CASR_BOVIN    EPFGIALTLFAVLGIFLTAFVLGVFIKFRN 
Q9QY96|CASR_MOUSE    EPFGIALTLFAVLGIFLTAFVLGVFIKFRN 
Q6XAF3|Q6XAF3_SALSA  EPFGIALALCSVLGVFLTAFVMGVFIKFRN 
Q5YEV6|Q5YEV6_OREMO  EPFGIALAICAVLGVVLTAFVIGVFVRFRN 
O73639|O73639_FUGRU  DTIGIALLVVSLIGSFLTCAVALVFFYHRT 
O73638|O73638_FUGRU  ETMGALLAAVSLFGAALTSLVFCVFFRFRH 
O73637|O73637_FUGRU  EPLGICLTAASLLGTVISVVVLGIFIHHRS 
O73636|O73636_FUGRU  EVLGIILAVFSVGGACLAVITAAVFFHHRT 
O73635|O73635_FUGRU  EPFGIALAICAVLGVLLTAFVMGVFVRFRN 
O75899|GABR2_HUMAN   LPLYSILSALTILGMIMASAFLFFNIKNRN 
O88871|GABR2_RAT     LPLYSILSALTILGMIMASAFLFFNIKNRN 
Q9BML6|Q9BML6_DROME  PTIYIVSASASVIGVIIATVFLAFNIKYRN 
Q9Y133|Q9Y133_DROME  PTIYIVSASASVIGVIIATVFLAFNIKYRN 
Q8IN24|Q8IN24_DROME  PTIYIVSASASVIGVIIATVFLAFNIKYRN 
Q5TRW6|Q5TRW6_ANOGA  ITIFVVLASTSCVGIIMATVFLAVNITFRN 
Q9V3Q9|Q9V3Q9_DROME  LPLFVCMCTISSCGIFVAFALIIFNIWNKH 
Q9BML7|Q9BML7_DROME  LPLFVCMCTISSCGIFVAFALIIFNIWNKH 
Q8NHA5|Q8NHA5_HUMAN  QKLFISVSVLSSLGIVLAVVCLSFNIYNSH 
Q8IW08|Q8IW08_HUMAN  QKLFISVSVLSSLGIVLAVVCLSFNIYNSH 
Q6PGJ2|Q6PGJ2_MOUSE  QKLFISVSVLSSLGIVLAVVCLSFNIYNSH 
Q9WV18|GABR1_MOUSE   QKLFISVSVLSSLGIVLAVVCLSFNIYNSH 
Q9UBS5|GABR1_HUMAN   QKLFISVSVLSSLGIVLAVVCLSFNIYNSH 
Q8K451|GP156_RAT     PALLGVIWTFLSCGLLLVLFFLAFTIRCRK 
Q8NFN8|GP156_HUMAN   PVLLGIVWTFLSCGLLLILFFLAFTIHCRK 
Q6PCP7|GP156_MOUSE   PALLGIMWTFLSCGLLLVLFFLAFTIRCRK 
Q9VPS7|Q9VPS7_DROME  PLAFYTIATLSSVGIALAIAFLAFNLHFRK 
Q8IPW4|Q8IPW4_DROME  PLAFYTIATLSSVGIALAIAFLAFNLHFRK 
Q8MSP9|Q8MSP9_DROME  PLAFYTIATLSSVGIALAIAFLAFNLHFRK 
O96954|O96954_GEOCY  VPLTVVYVALAVGGLVFAIVCVFFTVIFRK 
Q8BHL4|RAI3_MOUSE    EGWGIALETLAAVGAVATVACMFALVFLIC 
Q8NFJ5|RAI3_HUMAN    EAWGIVLETVATAGVVTSVAFMLTLPILVC 
Q9JIL6|GPC5D_MOUSE   GPWAIVLESLAVIGIVVTILLLLAFLFLMR 
Q9NZD1|GPC5D_HUMAN   GPWGIILESLAILGIVVTILLLLAFLFLMR 
Q8K3J9|GPC5C_MOUSE   GAWGIVSEAVAGAGIITTFVLTIILVASLP 
Q9NQ84|GPC5C_HUMAN   GAWGIVLEAVAGAGIVTTFVLTIILVASLP 
Q923Z0|GPC5B_MOUSE   AIWGIVVEAVAGAGALITLLLMLILLVRLP 
Q9NZH0|GPC5B_HUMAN   AIWGIVVEAVAGAGALITLLLMLILLVRLP 
Q6PA25|Q6PA25_XENLA  AAWGIVLETLAAAGIVFSIILILALLIMMP 
Q5T6X5|GPC6A_HUMAN   DSLAILLLILSLLGIIFVLVVGIIFTRNLN 
Q5U9X3|GPC6A_BRARE   SGFAIVLLILAALGVLLLFFMSALFFWQRH 
Q8K4Z6|GPC6A_MOUSE   DSLALLLIALSLLGIAFVLAIGIIFTRNLK 
Q9PW88|GPC6A_CARAU   SGFAIALLTLAALGILLLISMSALFFWQRN 
Q9Z0R8|TS1R1_RAT     EPISLVLIAANTLLLLLLVGTAGLFAWHFH 
Q99PG6|TS1R1_MOUSE   EPISLVLLAANTLLLLLLIGTAGLFAWRLH 
Q7RTX1|TS1R1_HUMAN   EHTSWVLLAANTLLLLLLLGTAGLFAWHLD 10. Appendix 
166 
Q9Z0R7|TS1R2_RAT     EVPTIVVAILAALGFFSTLAILFIFWRHFQ 
Q925I4|TS1R2_MOUSE   EVPTIVVTILAALGFISTLAILLIFWRHFQ 
Q8TE23|TS1R2_HUMAN   EAPTIAVALLAALGFLSTLAILVIFWRHFQ 
Q7RTX0|TS1R3_HUMAN   EPAVLLLLLLLSLALGLVLAALGLFVHHRD 
Q717C1|TS1R3_GORGO   EPAVLLLLLLLSLALGLVLAALGLFVHHRD 
Q717C2|TS1R3_PANTR   EPAVLLLLLLLSLALGLVLAALGLFIHHRD 
Q923K1|TS1R3_RAT     EPAVLSLLLLLCLVLGLTLAALGLFVHYWD 
Q925D8|TS1R3_MOUSE   EPVVLSLLLLLCLVLGLALAALGLSVHHWD 
P41594|MGR5_HUMAN    DPEPIAAVVFACLGLLATLFVTVVFIIYRD 
Q75QW7|Q75QW7_APIME  SAFAIAPAVISCLGIVATMAVACLLFHHRD 
P91685|MGR_DROME     SLFALIPMAIAIFGIALTSIVIVLFAKNHD 
Q8CFQ7|Q8CFQ7_MOUSE  SPWAALPLLLAVLGIMATTTIIATFMRHND 
Q863I4|MGR6_RABIT    SPWAAPPLLLAVLGIMATTTVVGTFVRHNN 
Q68ED2|MGR7_MOUSE    SPWAVIPVFLAMLGIIATIFVMATFIRYND 
P70579|MGR8_RAT      SPWAVVPVFIAILGIIATTFVIVTFVRYND 
P47743|MGR8_MOUSE    SPWAVVPVFIAILGIIATTFVIVTFVRYND 
O00222|MGR8_HUMAN    SPWAVVPVFVAILGIIATTFVIVTFVRYND 
P35400|MGR7_RAT      SPWAVIPVFLAMLGIIATIFVMATFIRYND 
Q14831|MGR7_HUMAN    SPWAVIPVFLAMLGIIATIFVMATFIRYND 
P35349|MGR6_RAT      SPWAALPLLLAVLGIMATTTIMATFMRHND 
O15303|MGR6_HUMAN    SPWAAPPLLLAVLGIVATTTVVATFVRYNN 
P31424|MGR5_RAT      DPEPIAAVVFACLGLLATLFVTVIFIIYRD 
P31423|MGR4_RAT      SPWAVLPLFLAVVGIAATLFVVVTFVRYND 
Q14833|MGR4_HUMAN    SPWAVLPLFLAVVGIAATLFVVITFVRYND 
P31422|MGR3_RAT      DAWAIGPVTIACLGFLCTCIVITVFIKHNN 
Q9QYS2|MGR3_MOUSE    DAWAIGPVTIACLGFMCTCIVITVFIKHNN 
Q14832|MGR3_HUMAN    DAWAIGPVTIACLGFMCTCMVVTVFIKHNN 
P31421|MGR2_RAT      DAWAVGPVTIACLGALATLFVLGVFVRHNA 
Q14416|MGR2_HUMAN    DAWAVGPVTIACLGALATLFVLGVFVRHNA 
P23385|MGR1_RAT      DIESIIAIAFSCLGILVTLFVTLIFVLYRD 
P97772|MGR1_MOUSE    DIESIIAIAFSCLGILVTLFVTLIFVLYRD 
Q13255|MGR1_HUMAN    NIESIIAIAFSCLGILVTLFVTLIFVLYRD 
Q90ZF3|Q90ZF3_ONCMA  NPESIVQVVFACLGILVTSFVTFIFVLYRD 
Q9V4U4|Q9V4U4_DROME  SAWAIGAMAFSATGILVTLFVMGVFVRHND 
Q9V4U3|Q9V4U3_DROME  SAWAIGAMAFSATGILVTLFVMGVFVRHND 
Q7KQS9|Q7KQS9_DROME  SAWAIGAMAFSATGILVTLFVMGVFVRHND 
Q75QW6|Q75QW6_APIME  SGWAIGAMSFSATGILITLFVCGVFLKHND 
Q70GQ8|Q70GQ8_DROME  SAWAIGAMAFSATGILVTLFVMGVFVRHND 
Q62916|Q62916_RAT    SPWAVLPLFLAVVGIAATLFVVVTFVRYND 
 
TM2 
BW position          2.40      2.5       2.6 
                      |         |         | 
1U19.A               LNYILLNLAVADLFMVFGGFTTTLYTSLHG 
P22815|BOSS_DROME    VFEGNPTTSILLLLSLILVFCSFVPYSIEY 
Q24738|BOSS_DROVI    VFEGNPVTSILLLLSLILVFCSFVPFSMEY 
Q24265|Q24265_DROME  VFEGNPTTSILLLLSLILVFCSFVPYSIEY 
Q8MSJ2|Q8MSJ2_DROME  VFEGNPTTSILLLLSLILVFCSFVPYSIEY 
Q90WL6|Q90WL6_SPAAU  VKATNRELSYVLLFSLICCFSSSLIFIGQP 
Q8JI04|Q8JI04_SQUAC  VKATNRELSYLLLFSLICCFSSSLIFIGEP 
Q6XAF1|Q6XAF1_SALSA  VKATNRELSYLLLFSLICCFSSSLIFIGEP 
Q6XAF2|Q6XAF2_SALSA  VKATNRELSYLLLFSLICCFSSSLIFIGEP 
P41180|CASR_HUMAN    VKATNRELSYLLLFSLLCCFSSSLFFIGEP 
Q80ZA8|Q80ZA8_RAT    VKATNRELSYLLLFSLLCCFSSSLFFIGEP 
P48442|CASR_RAT      VKATNRELSYLLLFSLLCCFSSSLFFIGEP 
P35384|CASR_BOVIN    VKATNRELSYLLLFSLLCCFSSSLFFIGEP 
Q9QY96|CASR_MOUSE    VKATNRELSYLLLFSLLCCFSSSLFFIGEP 
Q6XAF3|Q6XAF3_SALSA  VKATNRELSYLLLFSLICCFSSSLIFIGEP 
Q5YEV6|Q5YEV6_OREMO  VKATNRELSYVLLFSLICCFSSSLIFIGEP 
O73639|O73639_FUGRU  VRANNSDLSFLLLFSLTLCFLCSLTFISPP 
O73638|O73638_FUGRU  VKASNSELSFLLLFSLTLCFLCSLTFIGRP 
O73637|O73637_FUGRU  VRANNSELSFLLLVSLKLCFLCSLLFIGRP 10. Appendix 
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O73636|O73636_FUGRU  VRANNSELSFLLLFSLTLCFLCSLTFIGAP 
O73635|O73635_FUGRU  VKASNRELSYVLLLSLICCFSSSLIFIGEP 
O75899|GABR2_HUMAN   IKMSSPYMNNLIILGGMLSYASIFLFGLDG 
O88871|GABR2_RAT     IKMSSPYMNNLIILGGMLSYASIFLFGLDG 
Q9BML6|Q9BML6_DROME  IKMSSPHLNNLIIVGCMITYLSIIFLGLDT 
Q9Y133|Q9Y133_DROME  IKMSSPHLNNLIIVGCMMTYLSIIFLGLDT 
Q8IN24|Q8IN24_DROME  IKMSSPHLNNLIIVGCMMTYLSIIFLGLDT 
Q5TRW6|Q5TRW6_ANOGA  IKMSSPHLNNLIIIGCILTYLSVIFLGLDS 
Q9V3Q9|Q9V3Q9_DROME  IQSSHPVCNTIMLFGVIICLISVILLGIDG 
Q9BML7|Q9BML7_DROME  IQSSHPVCNTIMLFGVIICLISVILLGIDG 
Q8NHA5|Q8NHA5_HUMAN  IQNSQPNLNNLTAVGCSLALAAVFPLGLDG 
Q8IW08|Q8IW08_HUMAN  IQNSQPNLNNLTAVGCSLALAAVFPLGLDG 
Q6PGJ2|Q6PGJ2_MOUSE  IQNSQPNLNNLTAVGCSLALAAVFPLGLDG 
Q9WV18|GABR1_MOUSE   IQNSQPNLNNLTAVGCSLALAAVFPLGLDG 
Q9UBS5|GABR1_HUMAN   IQNSQPNLNNLTAVGCSLALAAVFPLGLDG 
Q8K451|GP156_RAT     VKMSSPNLNIVTLLGSCLTYSSAYLFGIQD 
Q8NFN8|GP156_HUMAN   VKMSSPNLNIVTLLGSCLTYSSAYLFGIQD 
Q6PCP7|GP156_MOUSE   VKMSSPNLNVVTLLGSCLTYISAYLFGIQD 
Q9VPS7|Q9VPS7_DROME  IKLSSPKLSNITAVGCIFVYATVILLGLDH 
Q8IPW4|Q8IPW4_DROME  IKLSSPKLSNITAVGCIFVYATVILLGLDH 
Q8MSP9|Q8MSP9_DROME  IKLSSPKLSNITAVGCIFVYATVILLGLDH 
O96954|O96954_GEOCY  IRLSSPNLNYLIGLGAIILYFNVITLVIPT 
Q8BHL4|RAI3_MOUSE    NKRKMLPAQFLFLLGVLGVFGLTFAFIIKL 
Q8NFJ5|RAI3_HUMAN    NRRKMLPTQFLFLLGVLGIFGLTFAFIIGL 
Q9JIL6|GPC5D_MOUSE   SQWNVLPTQFLFLLAVLGLFGLTFAFIIQL 
Q9NZD1|GPC5D_HUMAN   SQWNVLPTQLLFLLSVLGLFGLAFAFIIEL 
Q8K3J9|GPC5C_MOUSE   KKRSLLGTQVFFLLGTLGLFCLVFACVVKP 
Q9NQ84|GPC5C_HUMAN   KKRSLLGTQVFFLLGTLGLFCLVFACVVKP 
Q923Z0|GPC5B_MOUSE   ERKRPVCLHFLFLLGTLGLFGLTFAFIIQM 
Q9NZH0|GPC5B_HUMAN   EKKSPVGLHFLFLLGTLGLFGLTFAFIIQE 
Q6PA25|Q6PA25_XENLA  AKRAVSPVQLIFLIGTFGIFGLTFAFIVEL 
Q5T6X5|GPC6A_HUMAN   KSSGGLRVCYVILLCHFLNFASTSFFIGEP 
Q5U9X3|GPC6A_BRARE   VKAAGGPLCHLILVSLLGSFISVVFFVGEP 
Q8K4Z6|GPC6A_MOUSE   KSSGGLVVCYVMLICHALNFASTGFFIGEP 
Q9PW88|GPC6A_CARAU   VKAAGGPLCHLILFSLLGSFISVIFFVGEP 
Q9Z0R8|TS1R1_RAT     VRSAGGRLCFLMLGSLVAGSCSFYSFFGEP 
Q99PG6|TS1R1_MOUSE   VRSAGGRLCFLMLGSLVAGSCSLYSFFGKP 
Q7RTX1|TS1R1_HUMAN   VRSAGGRLCFLMLGSLAAGSGSLYGFFGEP 
Q9Z0R7|TS1R2_RAT     VRSAGGPMCFLMLVPLLLAFGMVPVYVGPP 
Q925I4|TS1R2_MOUSE   VRSAGGPMCFLMLVPLLLAFGMVPVYVGPP 
Q8TE23|TS1R2_HUMAN   VRSAGGPMCFLMLTLLLVAYMVVPVYVGPP 
Q7RTX0|TS1R3_HUMAN   VQASGGPLACFGLVCLGLVCLSVLLFPGQP 
Q717C1|TS1R3_GORGO   VQASGGPLACFGLVCLGLVCLSVLLFPGQP 
Q717C2|TS1R3_PANTR   VQASGGPLACFGLVCLGLVCLSVLLFPGQP 
Q923K1|TS1R3_RAT     VQASGGSLFCFGLICLGLFCLSVLLFPGRP 
Q925D8|TS1R3_MOUSE   VQASGGSQFCFGLICLGLFCLSVLLFPGRP 
P41594|MGR5_HUMAN    VKSSSRELCYIILAGICLGYLCTFCLIAKP 
Q75QW7|Q75QW7_APIME  VRASGRELTIILLAGVLVCYLNTFLLLATP 
P91685|MGR_DROME     VRASGRELSYTLLFGILVCYCNTFALIAKP 
Q8CFQ7|Q8CFQ7_MOUSE  VRASGRELSYVLLTGIFLIYAITFLMVAEP 
Q863I4|MGR6_RABIT    VRASGRELSYVLLTGIFLIYAVTFLMVAEP 
Q68ED2|MGR7_MOUSE    VRASGRELSYVLLTGIFLCYIITFLMIAKP 
P70579|MGR8_RAT      VRASGRELSYVLLTGIFLCYSITFLMIAAP 
P47743|MGR8_MOUSE    VRASGRELSYVLLTGIFLCYSITFLMIAAP 
O00222|MGR8_HUMAN    VRASGRELSYVLLTGIFLCYSITFLMIAAP 
P35400|MGR7_RAT      VRASGRELSYVLLTGIFLCYIITFLMIAKP 
Q14831|MGR7_HUMAN    VRASGRELSYVLLTGIFLCYIITFLMIAKP 
P35349|MGR6_RAT      VRASGRELSYVLLTGIFLIYAITFLMVAEP 
O15303|MGR6_HUMAN    VRASGRELSYVLLTGIFLIYAITFLMVAEP 
P31424|MGR5_RAT      VKSSSRELCYIILAGICLGYLCTFCLIAKP 
P31423|MGR4_RAT      VKASGRELSYVLLAGIFLCYATTFLMIAEP 
Q14833|MGR4_HUMAN    VKASGRELSYVLLAGIFLCYATTFLMIAEP 
P31422|MGR3_RAT      VKASGRELCYILLFGVSLSYCMTFFFIAKP 10. Appendix 
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Q9QYS2|MGR3_MOUSE    VKASGRELCYILLFGVSLSYCMTFFFIAKP 
Q14832|MGR3_HUMAN    VKASGRELCYILLFGVGLSYCMTFFFIAKP 
P31421|MGR2_RAT      VKASGRELCYILLGGVFLCYCMTFVFIAKP 
Q14416|MGR2_HUMAN    VKASGRELCYILLGGVFLCYCMTFIFIAKP 
P23385|MGR1_RAT      VKSSSRELCYIILAGIFLGYVCPFTLIAKP 
P97772|MGR1_MOUSE    VKSSSRELCYIILAGIFLGYVCPFTLIAKP 
Q13255|MGR1_HUMAN    VKSSSRELCYIILAGIFLGYVCPFTLIAKP 
Q90ZF3|Q90ZF3_ONCMA  VKSSSRELCYIILAGIFLGYICPFTLIAQP 
Q9V4U4|Q9V4U4_DROME  VRASGRELSYILLAGIFMCYGVTFALVLKP 
Q9V4U3|Q9V4U3_DROME  VRASGRELSYILLAGIFMCYGVTFALVLKP 
Q7KQS9|Q7KQS9_DROME  VRASGRELSYILLAGIFMCYGVTFALVLKP 
Q75QW6|Q75QW6_APIME  VRASGRELSYVLLSGILLCYLVTFALVLRP 
Q70GQ8|Q70GQ8_DROME  VRASGRELSYILLAGIFMCYGVTFALVLKP 
Q62916|Q62916_RAT    VKASGRELSYVLLAGIFLCYATTFLMIAEP 
 
TM3 
BW position              3.3       3.4       3.5 
                          |         |         | 
1U19.A               CNLEGFFATLGGEIALWSLVVLAIERYVVV 
P22815|BOSS_DROME    CAVRVFIMTLVYCFVFSLLLCRAVMLASIG 
Q24738|BOSS_DROVI    CGVRVFIMTLVYCFVFSLLLCRAVMLASIG 
Q24265|Q24265_DROME  CAVRVFIMTLVYCFVFSLLLCRAVMLASIG 
Q8MSJ2|Q8MSJ2_DROME  CAVRVFIMTLVYCFVFSLLLCRAVMLASIG 
Q90WL6|Q90WL6_SPAAU  CRLRQPAFGISFVLCISCILVKTNRVLLVF 
Q8JI04|Q8JI04_SQUAC  CRLRQPAFGISFVLCISCILVKTNRVLLVF 
Q6XAF1|Q6XAF1_SALSA  CRLRQPAFGISFVLCISCILVKTNRVLLVF 
Q6XAF2|Q6XAF2_SALSA  CRLRQPAFGISFVLCISCILVKTNRVLLVF 
P41180|CASR_HUMAN    CRLRQPAFGISFVLCISCILVKTNRVLLVF 
Q80ZA8|Q80ZA8_RAT    CRLRQPAFGISFVLCISCILVKTNRVLLLF 
P48442|CASR_RAT      CRLRQPAFGISFVLCISCILVKTNRVLLVF 
P35384|CASR_BOVIN    CRLRQPAFGISFVLCISCILVKTNRVLLVF 
Q9QY96|CASR_MOUSE    CRLRQPAFGISFVLCISCILVKTNRVLLVF 
Q6XAF3|Q6XAF3_SALSA  CRLRQPAFGISFVLCISCILVKTNRVLLVF 
Q5YEV6|Q5YEV6_OREMO  CRLRQPAFGVSFVLCISCILVKTNRVLLVF 
O73639|O73639_FUGRU  CMLRHTAFGITFVLCISCILGKTIVVLMAF 
O73638|O73638_FUGRU  CVLRHTAFGITFALCMSCVLAKTVAVLFAF 
O73637|O73637_FUGRU  CQLRHAAFGISFVLCVSCILVKTMVVLAVF 
O73636|O73636_FUGRU  CMLRHTAFGITFVLCISCVLGKTVVVLMAF 
O73635|O73635_FUGRU  CRLRQPAFGISFVLCISCILVKTNRVLLVF 
O75899|GABR2_HUMAN   CTVRTWILTVGYTTAFGAMFAKTWRVHAIF 
O88871|GABR2_RAT     CTVRTWILTVGYTTAFGAMFAKTWRVHAIF 
Q9BML6|Q9BML6_DROME  CTARAWILMAGFSLSFGAMFSKTWRVHSIF 
Q9Y133|Q9Y133_DROME  CTARAWILMAGFSLSFGAMFSKTWRVHSIF 
Q8IN24|Q8IN24_DROME  CTARAWILMAGFSLSFGAMFSKTWRVHSIF 
Q5TRW6|Q5TRW6_ANOGA  CTARAWLLMAGFSLAFGAMFSKTWRVHSIF 
Q9V3Q9|Q9V3Q9_DROME  CQARAWLLSTGFTLAYGAMFSKVWRVHRFT 
Q9BML7|Q9BML7_DROME  CQARAWLLSTGFTLAYGAMFSKVWRVHRFT 
Q8NHA5|Q8NHA5_HUMAN  CQARLWLLGLGFSLGYGSMFTKIWWVHTVF 
Q8IW08|Q8IW08_HUMAN  CQARLWLLGLGFSLGYGSMFTKIWWVHTVF 
Q6PGJ2|Q6PGJ2_MOUSE  CQARLWLLGLGFSLGYGSMFTKIWWVHTVF 
Q9WV18|GABR1_MOUSE   CQARLWLLGLGFSLGYGSMFTKIWWVHTVF 
Q9UBS5|GABR1_HUMAN   CQARLWLLGLGFSLGYGSMFTKIWWVHTVF 
Q8K451|GP156_RAT     IQTRLSLLCIGTTLVFGPILGKSWRLYKVF 
Q8NFN8|GP156_HUMAN   IQTRLSMLCIGTSLVFGPILGKSWRLYKVF 
Q6PCP7|GP156_MOUSE   IQTRLSLLCIGTSLVFGPILGKSWRLYKVF 
Q9VPS7|Q9VPS7_DROME  CTARVYLLSAGFSLAFGSMFAKTYRVHRIF 
Q8IPW4|Q8IPW4_DROME  CTARVYLLSAGFSLAFGSMFAKTYRVHRIF 
Q8MSP9|Q8MSP9_DROME  CTARVYLLSAGFSLAFGSMFAKTYRVHRIF 
O96954|O96954_GEOCY  CNINPWLTSLGYSLCYGTILAKTIRIWFIF 
Q8BHL4|RAI3_MOUSE    GPTRFFLFGVLFAICFSCLLAHAFNLIKLV 
Q8NFJ5|RAI3_HUMAN    GPTRFFLFGILFSICFSCLLAHAVSLTKLV 
Q9JIL6|GPC5D_MOUSE   APVRYFLFGVLFAICFSCLLAHASNLVKLV 10. Appendix 
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Q9NZD1|GPC5D_HUMAN   APVRYFLFGVLFALCFSCLLAHASNLVKLV 
Q8K3J9|GPC5C_MOUSE   CASRRFLFGVLFAICFSCLVAHVLSLNFLT 
Q9NQ84|GPC5C_HUMAN   CASRRFLFGVLFAICFSCLAAHVFALNFLA 
Q923Z0|GPC5B_MOUSE   CSIRRFLWGVLFALCFSCLLSQAWRVRRLV 
Q9NZH0|GPC5B_HUMAN   CSVRRFLWGVLFALCFSCLLSQAWRVRRLV 
Q6PA25|Q6PA25_XENLA  CPTRFFLFGVLFAICFSCLLAHASKLVRLV 
Q5T6X5|GPC6A_HUMAN   CKTRQTMFGVSFTLCISCILTKSLKILLAF 
Q5U9X3|GPC6A_BRARE   CRARQVIFGFSFTLCVSCILVKSLKILLAF 
Q8K4Z6|GPC6A_MOUSE   CKTRQTLFGVSFTLCVSCILTKSLKILLAF 
Q9PW88|GPC6A_CARAU   CRVRQVIFGLSFTLCVSCILVKSLKILLAF 
Q9Z0R8|TS1R1_RAT     CLLRQPLFSLGFAIFLSCLTIRSFQLVIIF 
Q99PG6|TS1R1_MOUSE   CLLRQPLFSLGFAIFLSCLTIRSFQLVIIF 
Q7RTX1|TS1R1_HUMAN   CLLRQALFALGFTIFLSCLTVRSFQLIIIF 
Q9Z0R7|TS1R2_RAT     CFCRQAFFTVCFSICLSCITVRSFQIVCVF 
Q925I4|TS1R2_MOUSE   CFCRQAFFTVCFSVCLSCITVRSFQIVCVF 
Q8TE23|TS1R2_HUMAN   CLCRQALFPLCFTICISCIAVRSFQIVCAF 
Q7RTX0|TS1R3_HUMAN   CLAQQPLSHLPLTGCLSTLFLQAAEIFVES 
Q717C1|TS1R3_GORGO   CLAQQPLSHLPLTGCLSTLFLQAAEIFVES 
Q717C2|TS1R3_PANTR   CLAQQPLSHLPLTGCLSTLFLQAAEIFVES 
Q923K1|TS1R3_RAT     CLAQQPMAHLPLTGCLSTLFLQAAEIFVES 
Q925D8|TS1R3_MOUSE   CLAQQPMAHLPLTGCLSTLFLQAAETFVES 
P41594|MGR5_HUMAN    CYLQRIGIGLSPAMSYSALVTKTNRIARIL 
Q75QW7|Q75QW7_APIME  CILQRFGVGVSFSAVYGALLTKTNRIARIF 
P91685|MGR_DROME     CVLQRFGIGVGFSIIYSALLTKTNRISRIF 
Q8CFQ7|Q8CFQ7_MOUSE  CASRRLLLGLGTTLSYSALLTKTNRIYRIF 
Q863I4|MGR6_RABIT    CATRRLFLGLGTTLSYSALLTKTNRIYRIF 
Q68ED2|MGR7_MOUSE    CSFRRVFLGLGMCISYAALLTKTNRIYRIF 
P70579|MGR8_RAT      CSFRRIFLGLGMCFSYAALLTKTNRIHRIF 
P47743|MGR8_MOUSE    CSFRRIFLGLGMCFSYAALLTKTNRIHRIF 
O00222|MGR8_HUMAN    CSFRRVFLGLGMCFSYAALLTKTNRIHRIF 
P35400|MGR7_RAT      CSFRRVFLGLGMCISYAALLTKTNRIYRIF 
Q14831|MGR7_HUMAN    CSFRRVFLGLGMCISYAALLTKTNRIYRIF 
P35349|MGR6_RAT      CAARRLLLGLGTTLSYSALLTKTNRIYRIF 
O15303|MGR6_HUMAN    CAARRLFLGLGTTLSYSALLTKTNRIYRIF 
P31424|MGR5_RAT      CYLQRIGIGLSPAMSYSALVTKTNRIARIL 
P31423|MGR4_RAT      CSLRRIFLGLGMSISYAALLTKTNRIYRIF 
Q14833|MGR4_HUMAN    CSLRRIFLGLGMSISYAALLTKTNRIYRIF 
P31422|MGR3_RAT      CALRRLGLGTSFAICYSALLTKTNCIARIF 
Q9QYS2|MGR3_MOUSE    CALRRLGLGTSFAICYSALLTKTNCIARIF 
Q14832|MGR3_HUMAN    CALRRLGLGSSFAICYSALLTKTNCIARIF 
P31421|MGR2_RAT      CTLRRLGLGTAFSVCYSALLTKTNRIARIF 
Q14416|MGR2_HUMAN    CTLRRLGLGTAFSVCYSALLTKTNRIARIF 
P23385|MGR1_RAT      CYLQRLLVGLSSAMCYSALVTKTNRIARIL 
P97772|MGR1_MOUSE    CYLQRLLVGLSSAMCYSALVTKTNRIARIL 
Q13255|MGR1_HUMAN    CYLQRLLVGLSSAMCYSALVTKTNRIARIL 
Q90ZF3|Q90ZF3_ONCMA  CYLQRLLVGLSATMCYSALVTKTNRIARIL 
Q9V4U4|Q9V4U4_DROME  CAIQRFGVGFCFTVVYAALLTKTNRIARIF 
Q9V4U3|Q9V4U3_DROME  CAIQRFGVGFCFTVVYAALLTKTNRIARIF 
Q7KQS9|Q7KQS9_DROME  CAIQRFGVGFCFTVVYAALLTKTNRIARIF 
Q75QW6|Q75QW6_APIME  CGIQRFAAGFCFTVVYAALLTKTNRISRIF 
Q70GQ8|Q70GQ8_DROME  CAIQRFGVGFCFTVVYAALLTKTNRIARIF 
Q62916|Q62916_RAT    CSLRRIFLGLGMSISYAALLTKTNRIYRIF 
 
TM4 
BW position                   4.4       4.5       4.6 
                               |         |         | 
1U19.A               KPMSNFRFGENHAIMGVAFTWVMALACAAPP 
P22815|BOSS_DROME    HVNGYIQAVICAFSVVAQVGMSVQLLVVMHV 
Q24738|BOSS_DROVI    HVNGYIQAIICVLSVFVQVGMSVQLLVVMHL 
Q24265|Q24265_DROME  HVNGYIQAVICAFSVVAQVGMSVQLLVVMHV 
Q8MSJ2|Q8MSJ2_DROME  HVNGYIQAVICAFSVVAQVGMSVQLLVVMHV 
Q90WL6|Q90WL6_SPAAU  WWGLNLQFLLVFLCTFVQVMICVVWLYNAPP 10. Appendix 
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Q8JI04|Q8JI04_SQUAC  WVGLNLQFLLVFLCILVQIVTCIIWLYTAPP 
Q6XAF1|Q6XAF1_SALSA  WWGLNLQFLLVFLFTFVQVMICVVWLYNAPP 
Q6XAF2|Q6XAF2_SALSA  WWGLNLQFLLVFLFTFVQVMICVVWLYNAPP 
P41180|CASR_HUMAN    WWGLNLQFLLVFLCTFMQIVICVIWLYTAPP 
Q80ZA8|Q80ZA8_RAT    WWGLNLQFLLVFLCTFMQILICIIWLYTAPP 
P48442|CASR_RAT      WWGLNLQFLLVFLCTFMQILICIIWLYTAPP 
P35384|CASR_BOVIN    WWGLNLQFLLVFLCTFMQIVICAIWLNTAPP 
Q9QY96|CASR_MOUSE    WWGLNLQFLLVFLCTFMQIVICIIWLYTAPP 
Q6XAF3|Q6XAF3_SALSA  WWGLNLQFLLVFLFTFVQVMICVVWLYNAPP 
Q5YEV6|Q5YEV6_OREMO  WWGLNLQFLLVFLCTFVQVMICVVWLYNAPP 
O73639|O73639_FUGRU  WFGPGKQKAIITFSTLVQVVICTVWLVVAPP 
O73638|O73638_FUGRU  YCSVPLQRTSVFACITLQVIICVLWLTLAPP 
O73637|O73637_FUGRU  WFGAVQQRGTVLGLTSIQAAICFAWLLSSSP 
O73636|O73636_FUGRU  WFGPPQQRMTVVTFTSIQVLICIVWLVVNPP 
O73635|O73635_FUGRU  WWGLNLQFLLVFLCTFVQVMICVVWLYNAPP 
O75899|GABR2_HUMAN   IIKDQKLLVIVGGMLLIDLCILICWQAVDPL 
O88871|GABR2_RAT     IIKDQKLLVIVGGMLLIDLCILICWQAVDPL 
Q9BML6|Q9BML6_DROME  VIKDYQLFMVVGVLLAIDIAIITTWQIADPF 
Q9Y133|Q9Y133_DROME  VIKDYQLFMVVGVLLAIDIAIITTWQIADPF 
Q8IN24|Q8IN24_DROME  VIKDYQLFMVVGVLLAIDIAIITTWQIADPF 
Q5TRW6|Q5TRW6_ANOGA  VIKDYQLFIVVGVLLAIDLAIMTTWQIADPF 
Q9V3Q9|Q9V3Q9_DROME  KVEPWKLYTMVSGLLSIDLVILLSWQIFDPL 
Q9BML7|Q9BML7_DROME  KVEPWKLYTMVSGLLSIDLVILLSWQIFDPL 
Q8NHA5|Q8NHA5_HUMAN  TLEPWKLYATVGLLVGMDVLTLAIWQIVDPL 
Q8IW08|Q8IW08_HUMAN  TLEPWKLYATVGLLVGMDVLTLAIWQIVDPL 
Q6PGJ2|Q6PGJ2_MOUSE  TLEPWKLYATVGLLVGMDILTLAIWQIVDPL 
Q9WV18|GABR1_MOUSE   TLEPWKLYATVGLLVGMDILTLAIWQIVDPL 
Q9UBS5|GABR1_HUMAN   TLEPWKLYATVGLLVGMDVLTLAIWQIVDPL 
Q8K451|GP156_RAT     IIKDLQLLGLVAALVVADVILLVTWVLTDPI 
Q8NFN8|GP156_HUMAN   IIKDLQLLGLVAALLMADVILLMTWVLTDPI 
Q6PCP7|GP156_MOUSE   IIKDLQLLGLVAALVVADVILLVTWVLTDPI 
Q9VPS7|Q9VPS7_DROME  MLQDIQLILLVGGLLLVDALLVTLWVVTDPM 
Q8IPW4|Q8IPW4_DROME  MLQDIQLILLVGGLLLVDALLVTLWVVTDPM 
Q8MSP9|Q8MSP9_DROME  MLQDIQLILLVGGLLLVDALLVTLWVVTDPM 
O96954|O96954_GEOCY  VIKDYALALFVVSLVVIDVIILGIFAIVEGL 
Q8BHL4|RAI3_MOUSE    PLSWLVILSLAVGFSLVQDVIAIEYLVLTMN 
Q8NFJ5|RAI3_HUMAN    PLSLLVILGLAVGFSLVQDVIAIEYIVLTMN 
Q9JIL6|GPC5D_MOUSE   SFCWTTILFIAIGVSLLQTIIAIEYVTLIMT 
Q9NZD1|GPC5D_HUMAN   SFSWTTILCIAIGCSLLQIIIATEYVTLIMT 
Q8K3J9|GPC5C_MOUSE   GPRGWVIFTVALLLTLVEVIINTEWLIITLV 
Q9NQ84|GPC5C_HUMAN   GPRGWVIFTVALLLTLVEVIINTEWLIITLV 
Q923Z0|GPC5B_MOUSE   SPASWQLVSLALCLMLVQVIIATEWLVLTVL 
Q9NZH0|GPC5B_HUMAN   GPAGWQLVGLALCLMLVQVIIAVEWLVLTVL 
Q6PA25|Q6PA25_XENLA  GICWWMMLLMALFLPLVQVVIAILYIVLGLV 
Q5T6X5|GPC6A_HUMAN   LKCLYRPILIIFTCTGIQVVICTLWLIFAAP 
Q5U9X3|GPC6A_BRARE   LCMLYKPYMIVSVGMGVQIIICTVWLTLYKP 
Q8K4Z6|GPC6A_MOUSE   LKCLYRPVPIVLTCTGIQVVICTLWLVLAAP 
Q9PW88|GPC6A_CARAU   LRKLYKPYVIVCMCMGLQVTICTLWLTLHRP 
Q9Z0R8|TS1R1_RAT     WAQNHGAGLFVIVSSTVHLLICLTWLVMWTP 
Q99PG6|TS1R1_MOUSE   WAQNHGAGIFVIVSSTVHLFLCLTWLAMWTP 
Q7RTX1|TS1R1_HUMAN   WVQNHGAGLFVMISSAAQLLICLTWLVVWTP 
Q9Z0R7|TS1R2_RAT     WMRYHGPYVFVAFITAIKVALVVGNMLATTI 
Q925I4|TS1R2_MOUSE   WMRYHGPYVFVAFITAVKVALVAGNMLATTI 
Q8TE23|TS1R2_HUMAN   WVRYQGPYVSMAFITVLKMVIVVIGMLATGL 
Q7RTX0|TS1R3_HUMAN   CLRGPWAWLVVLLAMLVEVALCTWYLVAFPP 
Q717C1|TS1R3_GORGO   CLRGPWAWLVVLLAMLVEVALCTWYLVAFPP 
Q717C2|TS1R3_PANTR   CLRGPWAWLVVLLAMLVEVALCTWYLVAFPP 
Q923K1|TS1R3_RAT     YLRGPWAWLVVLLATLVEAALCAWYLMAFPP 
Q925D8|TS1R3_MOUSE   YLRGLWAWLVVLLATFVEAALCAWYLIAFPP 
P41594|MGR5_HUMAN    FMSACAQLVIAFILICIQLGIIVALFIMEPP 
Q75QW7|Q75QW7_APIME  YISPASQVCIAAALIALQIVLTLVWMIIEPP 
P91685|MGR_DROME     YISPQSQVVITTSLIAIQVLITMIWMVVEPP 
Q8CFQ7|Q8CFQ7_MOUSE  FISPTSQLVITFGLTSLQVVGVIAWLGAQPP 10. Appendix 
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Q863I4|MGR6_RABIT    FISPTSQLVITFSLTSLQVVGVIAWLGAQPP 
Q68ED2|MGR7_MOUSE    LISPTSQLAITSSLISVQLLGVFIWFGVDPP 
P70579|MGR8_RAT      FISPASQLVITFSLISVQLLGVFVWFVVDPP 
P47743|MGR8_MOUSE    FISPASQLVITFSLISVQLLGVFVWFVVDPP 
O00222|MGR8_HUMAN    FISPASQLVITFSLISVQLLGVFVWFVVDPP 
P35400|MGR7_RAT      LISPTSQLAITSSLISVQLLGVFIWFGVDPP 
Q14831|MGR7_HUMAN    LISPTSQLAITSSLISVQLLGVFIWFGVDPP 
P35349|MGR6_RAT      FISPTSQLVITFGLTSLQVVGVIAWLGAQPP 
O15303|MGR6_HUMAN    FISPTSQLVITFSLTSLQVVGMIAWLGARPP 
P31424|MGR5_RAT      FMSACAQLVIAFILICIQLGIIVALFIMEPP 
P31423|MGR4_RAT      FISPASQLAITFILISLQLLGICVWFVVDPS 
Q14833|MGR4_HUMAN    FISPASQLAITFSLISLQLLGICVWFVVDPS 
P31422|MGR3_RAT      FISPSSQVFICLGLILVQIVMVSVWLILETP 
Q9QYS2|MGR3_MOUSE    FISPSSQVFICLGLILVQIVMVSVWLILETP 
Q14832|MGR3_HUMAN    FISPSSQVFICLGLILVQIVMVSVWLILEAP 
P31421|MGR2_RAT      FISPASQVAICLALISGQLLIVAAWLVVEAP 
Q14416|MGR2_HUMAN    FISPASQVAICLALISGQLLIVVAWLVVEAP 
P23385|MGR1_RAT      FMSAWAQVIIASILISVQLTLVVTLIIMEPP 
P97772|MGR1_MOUSE    FMSAWAQVIIASILISVQLTLVVTLIIMEPP 
Q13255|MGR1_HUMAN    FMSAWAQVIIASILISVQLTLVVTLIIMEPP 
Q90ZF3|Q90ZF3_ONCMA  FMSAWAQLVIAGLLVSVQLTLEVTLIILEPP 
Q9V4U4|Q9V4U4_DROME  FISPKSQLVICACLVSVQILINGVWMVIAPS 
Q9V4U3|Q9V4U3_DROME  FISPKSQLVICACLVSVQILINGVWMVIAPS 
Q7KQS9|Q7KQS9_DROME  FISPKSQLVICACLVSVQILINGVWMVIAPS 
Q75QW6|Q75QW6_APIME  FISPRSQLIICSGLVFVQILINGVWMIIDPA 
Q70GQ8|Q70GQ8_DROME  FISPKSQLVICACLVSVQILINGVWMVIAPS 
Q62916|Q62916_RAT    FISPASQLAITFILISLQLLGICVWFVVDPS 
 
TM5 
BW position                5.4       5.5       5.6 
                            |         |         | 
1U19.A               TNNESFVIYMFVVHFIIPLIVIFFCYGQLV 
P22815|BOSS_DROME    RWLWGLLAYDFALLCCVGALIPSIYRSQRN 
Q24738|BOSS_DROVI    RWLWGLLAYDFLLLCSLVSLVPFIYRSQRN 
Q24265|Q24265_DROME  RWLWGLLAYDFALLCCVGALIPSIYRSQRN 
Q8MSJ2|Q8MSJ2_DROME  RWLWGLLAYDFALLCCVGALIPSIYRSQRN 
Q90WL6|Q90WL6_SPAAU  EGSVMALGFLIGYTCLLAAICFFFAFKSRK 
Q8JI04|Q8JI04_SQUAC  EGSLMALGFLIGYTCLLAAICFFFAFKSRK 
Q6XAF1|Q6XAF1_SALSA  EGSMMALGFLIGYTCLLAAICFFFAFKSRK 
Q6XAF2|Q6XAF2_SALSA  EGSMMALGFLIGYTCLLAAICFFFAFKSRK 
P41180|CASR_HUMAN    EGSLMALGFLIGYTCLLAAICFFFAFKSRK 
Q80ZA8|Q80ZA8_RAT    EGSLMALGSLIGYTCLLAAICFFFAFKSRK 
P48442|CASR_RAT      EGSLMALGSLIGYTCLLAAICFFFAFKSRK 
P35384|CASR_BOVIN    EGSLMALGFLIGYTCLLAAICFFFAFKSRK 
Q9QY96|CASR_MOUSE    EGSLMALGSLIGYTCLLAAICFFFAFKSRK 
Q6XAF3|Q6XAF3_SALSA  EGSMMALGFLIGYTCLLAAICFFFAFKSRK 
Q5YEV6|Q5YEV6_OREMO  EGSVMALGFLIGYTCILAAICFFFAFKSRK 
O73639|O73639_FUGRU  EGSTIAFSLVLGYIGVLACMCFLLAFLARK 
O73638|O73638_FUGRU  LGSPVWFWVVLGYIGLLAVICFILAFLARK 
O73637|O73637_FUGRU  VGSTVGFAVLLSYIGLLAILSFLLAFLARN 
O73636|O73636_FUGRU  LGSSVGFWAVLGYIGLLAAVCLVLAVLARK 
O73635|O73635_FUGRU  EGSVMALGFLIGYTCLLAAICFFFAFKSRK 
O75899|GABR2_HUMAN   THMTIWLGIVYAYKGLLMLFGCFLAWETRN 
O88871|GABR2_RAT     THMTIWLGIVYAYKGLLMLFGCFLAWETRN 
Q9BML6|Q9BML6_DROME  EHMTIFVSIIYAYKGLLLVFGAFLAWETRH 
Q9Y133|Q9Y133_DROME  EHMTIFVSIIYAYKGLLLVFGAFLAWETRH 
Q8IN24|Q8IN24_DROME  EHMTIFVSIIYAYKGLLLVFGAFLAWETRH 
Q5TRW6|Q5TRW6_ANOGA  SKMTIFIGVIYAYKGLLLIFGAFLAWETRH 
Q9V3Q9|Q9V3Q9_DROME  QRNSMWLGLVYGFKGLILVFGLFLAYETRS 
Q9BML7|Q9BML7_DROME  QRNSMWLGLVYGFKGLILVFGLFLAYETRS 
Q8NHA5|Q8NHA5_HUMAN  AIRALGLCIFYGYKGLLLLLGIFLAYETKS 
Q8IW08|Q8IW08_HUMAN  RKMNTWLGIFYGYKGLLLLLGIFLAYETKS 10. Appendix 
172 
Q6PGJ2|Q6PGJ2_MOUSE  KKMNTWLGIFYGYKGLLLLLGIFLAYETKS 
Q9WV18|GABR1_MOUSE   KKMNTWLGIFYGYKGLLLLLGIFLAYETKS 
Q9UBS5|GABR1_HUMAN   RKMNTWLGIFYGYKGLLLLLGIFLAYETKS 
Q8K451|GP156_RAT     RYSDVWIALVLGCKGLLLLYGAYLAGLTNH 
Q8NFN8|GP156_HUMAN   RYSDVWIALIWGCKGLLLLYGAYLAGLTGH 
Q6PCP7|GP156_MOUSE   RYSDVWIALVLGCKGLLLLYGAYLAGLTNH 
Q9VPS7|Q9VPS7_DROME  QHTQTWLSVLYAYKGLLLVVGVYMAWETRH 
Q8IPW4|Q8IPW4_DROME  QHTQTWLSVLYAYKGLLLVVGVYMAWETRH 
Q8MSP9|Q8MSP9_DROME  QHTQTWLSVLYAYKGLLLVVGVYMAWETRH 
O96954|O96954_GEOCY  KGQVALFTVLFGYKGLLQVTALILAFNTRK 
Q8BHL4|RAI3_MOUSE    PRRNEDFVMLLIYVLVLMVLTFFTSFLVFC 
Q8NFJ5|RAI3_HUMAN    PRRNEDFVLLLTYVLFLMALTFLMSSFTFC 
Q9JIL6|GPC5D_MOUSE   YQLNVDFVCLLIYVLFLMALTFFVSKATFC 
Q9NZD1|GPC5D_HUMAN   CQLNVDFVVLLVYVLFLMALTFFVSKATFC 
Q8K3J9|GPC5C_MOUSE   AIANMDFVMALIYVMLLLLTAFLGAWPTLC 
Q9NQ84|GPC5C_HUMAN   AIANMDFVMALIYVMLLLLGAFLGAWPALC 
Q923Z0|GPC5B_MOUSE   AYEPMDFVMALIYDMVLLAITLAQSLFTLC 
Q9NZH0|GPC5B_HUMAN   AYEPMDFVMALIYDMVLLVVTLGLALFTLC 
Q6PA25|Q6PA25_XENLA  HQLNQDFVLILIYVFLLMAITFLVSLISLC 
Q5T6X5|GPC6A_HUMAN   EGSILAFGTMLGYIAILAFICFIFAFKGKY 
Q5U9X3|GPC6A_BRARE   EGFYVMFWLMLGYIALLALFCFTFAYIGRK 
Q8K4Z6|GPC6A_MOUSE   EGSALAFGTMLGYITVLAFICFVFAFKGRK 
Q9PW88|GPC6A_CARAU   EGSDLMFGLMLGYIVLLALICFTFAYKGRK 
Q9Z0R8|TS1R1_RAT     EVNSVGFLLAFTHNILLSISTFVCSYLGKE 
Q99PG6|TS1R1_MOUSE   EVNSVGFLVAFAHNILLSISTFVCSYLGKE 
Q7RTX1|TS1R1_HUMAN   ETNSLGFILAFLYNGLLSISAFACSYLGKD 
Q9Z0R7|TS1R2_RAT     PNYRNGLLFNTSMDLLLSVLGFSFAYMGKE 
Q925I4|TS1R2_MOUSE   PNYRNGLLFNTSMDLLLSVLGFSFAYVGKE 
Q8TE23|TS1R2_HUMAN   PNYRNSLLFNTSLDLLLSVVGFSFAYMGKE 
Q7RTX0|TS1R3_HUMAN   TRSWVSFGLAHATNATLAFLCFLGTFLVRS 
Q717C1|TS1R3_GORGO   TRSWVSFGLAHATNATLAFLCFLGTFLVRS 
Q717C2|TS1R3_PANTR   TRSWVSFGLAHATNATLAFLCFLGTFLVRS 
Q923K1|TS1R3_RAT     MRSWVSLGLVHITNAVLAFLCFLGTFLVQS 
Q925D8|TS1R3_MOUSE   VRSWVSLGLVHITNAMLAFLCFLGTFLVQS 
P41594|MGR5_HUMAN    NTTNLGVVTPLGYNGLLILSCTFYAFKTRN 
Q75QW7|Q75QW7_APIME  NIQDMSFLFSQLYNALLILISTVYAVKTRK 
P91685|MGR_DROME     KIQDMSFLFSQLYNMILITICTIYAIKTRK 
Q8CFQ7|Q8CFQ7_MOUSE  DMSDLSLIGCLGYSLLLMVTCTVYAIKARG 
Q863I4|MGR6_RABIT    DMSDLSLIGCLGYSLLLMVTCTVYAIKARG 
Q68ED2|MGR7_MOUSE    DITDLQIICSLGYSILLMVTCTVYAIKTRG 
P70579|MGR8_RAT      DISDLSLICSLGYSILLMVTCTVYAIKTRG 
P47743|MGR8_MOUSE    DISDLSLICSLGYSILLMVTCTVYAIKTRG 
O00222|MGR8_HUMAN    DISDLSLICSLGYSILLMVTCTVYAIKTRG 
P35400|MGR7_RAT      DITDLQIICSLGYSILLMVTCTVYAIKTRG 
Q14831|MGR7_HUMAN    DITDLQIICSLGYSILLMVTCTVYAIKTRG 
P35349|MGR6_RAT      DMSDLSLIGCLGYSLLLMVTCTVYAIKARG 
O15303|MGR6_HUMAN    DMSDLSLIGCLGYSLLLMVTCTVYAIKARG 
P31424|MGR5_RAT      NTTNLGVVTPLGYNGLLILSCTFYAFKTRN 
P31423|MGR4_RAT      DISDLSLICLLGYSMLLMVTCTVYAIKTRG 
Q14833|MGR4_HUMAN    DISDLSLICLLGYSMLLMVTCTVYAIKTRG 
P31422|MGR3_RAT      NVKDSSMLISLTYDVVLVILCTVYAFKTRK 
Q9QYS2|MGR3_MOUSE    NVKDSSMLISLTYDVVLVILCTVYAFKTRK 
Q14832|MGR3_HUMAN    NVKDSSMLISLTYDVILVILCTVYAFKTRK 
P31421|MGR2_RAT      NHRDASMLGSLAYNVLLIALCTLYAFKTRK 
Q14416|MGR2_HUMAN    NHRDASMLGSLAYNVLLIALCTLYAFKTRK 
P23385|MGR1_RAT      NTSNLGVVAPVGYNGLLIMSCTYYAFKTRN 
P97772|MGR1_MOUSE    NTSNLGVVAPVGYNGLLIMSCTYYAFKTRN 
Q13255|MGR1_HUMAN    NTSNLGVVAPLGYNGLLIMSCTYYAFKTRN 
Q90ZF3|Q90ZF3_ONCMA  NTSTVGMVAPLGYNGLLIMSCTYYAFKTRN 
Q9V4U4|Q9V4U4_DROME  SYIDASYMIAFSYPIFLIVICTVYAVLTRK 
Q9V4U3|Q9V4U3_DROME  SYIDASYMIAFSYPIFLIVICTVYAVLTRK 
Q7KQS9|Q7KQS9_DROME  SYIDASYMIAFSYPIFLIVICTVYAVLTRK 
Q75QW6|Q75QW6_APIME  SYVDASYMIAFAYPIMLIVVCTVYAVLTRK 10. Appendix 
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Q70GQ8|Q70GQ8_DROME  SYIDASYMIAFSYPIFLIVICTVYAVLTRK 
Q62916|Q62916_RAT    DISDLSLICLLGYSMLLMVTCTVYAIKTRG 
 
TM6 
BW position                 6.4       6.5 
                             |         | 
1U19.A               EVTRMVIIMVIAFLICWLPYAGVAFYI 
P22815|BOSS_DROME    REGILIVIGSVLIMVIWVAWIALSLFG 
Q24738|BOSS_DROME    REGILIVIGAVLILIIWSVWIALSMFG 
Q24265|Q24265        REGILIVIGSVLIMVIWVAWIALSLFG 
Q8MSJ2|Q8MSJ2        REGILIVIGSVLIMVIWVAWIALSLFG 
Q90WL6|Q90WL6_SPAAU  TEAKFITFSMLIFFIVWISFIPAYFST 
Q8JI04|Q8JI04_SQUAC  NEAKFITFSMLIFFIVWISFIPAYVST 
Q6XAF1|Q6XAF1_SALSA  TEAKFITFSMLIFFIVWISFIPAYFST 
Q6XAF2|Q6XAF2_SALSA  TEAKFITFSMLIFFIVWISFIPAYFST 
P41180|CASR_HUMAN    NEAKFITFSMLIFFIVWISFIPAYAST 
Q80ZA8|Q80ZA8_RAT    NEAKFITFSMLIFFIVWISFIPAYAST 
P48442|CASR_RAT      NEAKFITFSMLIFFIVWISFIPAYAST 
P35384|CASR_BOVIN    NEAKFITFSMLIFFIVWISFIPAYAST 
Q9QY96|CASR_MOUSE    NEAKFITFSMLIFFIVWISFIPAYAST 
Q6XAF3|Q6XAF3_SALSA  TEAKFITFSMLIFFIVWISFIPAYFST 
Q5YEV6|Q5YEV6_OREMO  TEAKFITFSMLIFFIVWISFIPAYFST 
O73639|O73639_FUGRU  NEARLIAFSMLIFCAVWVAFVPAYISS 
O73638|O73638_FUGRU  NEAKFITFSMLIFCAVWVTFIPAYVSS 
O73637|O73637_FUGRU  NEAKLITFSMLIFCAVWVAFVPAYINS 
O73636|O73636_FUGRU  NEAKMITFSMLIFCAVWITFIPAYVSS 
O73635|O73635_FUGRU  TEAKFITFCMLIFFIVWISFIPAYFST 
O75899|GABR2_HUMAN   NDSKYIGMSVYNVGIMCIIGAAVSFLT 
O88871|GABR2_RAT     NDSKYIGMSVYNVGIMCIIGAAVSFLT 
Q9BML6|Q9BML6_DROME  NDSKHIGFSVYNVFITCLAGAAISLVL 
Q9Y133|Q9Y133_DROME  NDSKHIGFSVYNVFITCLAGAAISLVL 
Q8IN24|Q8IN24_DROME  NDSKHIGFSVYNVFITCLAGAAISLVL 
Q5TRW6|Q5TRW6_ANOGA  NDSKHVGLSVYNCVIMCVMGAAIALVL 
Q9V3Q9|Q9V3Q9_DROME  NDSRYVGMSIYNVVVLCLITAPVGMVI 
Q9BML7|Q9BML7_DROME  NDSRYVGMSIYNVVVLCLITAPVGMVI 
Q8NHA5|Q8NHA5_HUMAN  NDHRAVGMAIYNVAVLCLITAPVTMIL 
Q8IW08|Q8IW08_HUMAN  NDHRAVGMAIYNVAVLCLITAPVTMIL 
Q6PGJ2|Q6PGJ2_MOUSE  NDHRAVGMAIYNVAVLCLITAPVTMIL 
Q9WV18|GABR1_MOUSE   NDHRAVGMAIYNVAVLCLITAPVTMIL 
Q9UBS5|GABR1_HUMAN   NDHRAVGMAIYNVAVLCLITAPVTMIL 
Q8K451|GP156_RAT     NQSLTIMVGVNLLLLTAGLLFVVTRYL 
Q8NFN8|GP156_HUMAN   NQSLTIMVGVNLLVLAAGLLFVVTRYL 
Q6PCP7|GP156_MOUSE   NQSLTIMVGVNLLLLTAGLLFVVTRYL 
Q9VPS7|Q9VPS7_DROME  NDSQYIGVSVYSVVITSAIVVVLANLI 
Q8IPW4|Q8IPW4_DROME  NDSQYIGVSVYSVVITSAIVVVLANLI 
Q8MSP9|Q8MSP9_DROME  NDSQYIGVSVYSVVITSAIVVVLANLI 
O96954|O96954_GEOCY  DDSKYIAAAIYVTSIVLAVAAISTYTL 
Q8BHL4|RAI3_MOUSE    RHGFHICFTSFLSIAIWVAWIVLLLIP 
Q8NFJ5|RAI3_HUMAN    RHGAHIYLTMLLSIAIWVAWITLLMLP 
Q9JIL6|GPC5D_MOUSE   QHGRLIFATVLVSIIIWVVWISMLLRG 
Q9NZD1|GPC5D_HUMAN   QHGRLIFITVLFSIIIWVVWISMLLRG 
Q8K3J9|GPC5C_MOUSE   KHGVFVLLTTVISIAIWVVWIVMYTYG 
Q9NQ84|GPC5C_HUMAN   KHGVFVLLTTATSVAIWVVWIVMYTYG 
Q923Z0|GPC5B_MOUSE   VNGAFILVTTFLSALIWVVWMTMYLFG 
Q9NZH0|GPC5B_HUMAN   LNGAFLLITAFLSVLIWVAWMTMYLFG 
Q6PA25|Q6PA25_XENLA  RHGAHIYVTMFFSIGIWVAWICMLLRG 
Q5T6X5|GPC6A_HUMAN   NEAKFITFGMLIYFIAWITFIPIYATT 
Q5U9X3|GPC6A_BRARE   NEAKFITFSMVICLMAWIIFIPIHVTT 
Q8K4Z6|GPC6A_MOUSE   NEAKFLTFGMLIYFIAWITFIPVYTTT 
Q9PW88|GPC6A_CARAU   NEAKFITFGMLIYLMAWVIFIPVHVTT 
Q9Z0R8|TS1R1_RAT     NEAKCVTFSLLLNFVSWIAFFTMASIY 
Q99PG6|TS1R1_MOUSE   NEAKCVTFSLLLHFVSWIAFFTMSSIY 10. Appendix 
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Q7RTX1|TS1R1_HUMAN   NEAKCVTFSLLFNFVSWIAFFTTASVY 
Q9Z0R7|TS1R2_RAT     NEAKFITLSMTFSFTSSISLCTFMSVH 
Q925I4|TS1R2_MOUSE   NEAKFITLSMTFSFTSSISLCTFMSVH 
Q8TE23|TS1R2_HUMAN   NEAKFITLSMTFYFTSSVSLCTFMSAY 
Q7RTX0|TS1R3_HUMAN   NRARGLTFAMLAYFITWVSFVPLLANV 
Q717C1|TS1R3_GORGO   NRARGLTFAMLAYFITWVSFVPLLANV 
Q717C2|TS1R3_PANTR   NRARGLTFAMLAYFITWVSFVPLLANV 
Q923K1|TS1R3_RAT     NRARGLTFAMLAYFIIWVSFVPLLANV 
Q925D8|TS1R3_MOUSE   NRARGLTFAMLAYFITWVSFVPLLANV 
P41594|MGR5_HUMAN    NEAKYIAFTMYTTCIIWLAFVPIYFG. 
Q75QW7|Q75QW7_APIME  NESKFIGFTMYTTCIIWLAFVPIYFG. 
P91685|MGR_DROME     NESKFIGFTMYTTCIIWLAFVPIYFG. 
Q8CFQ7|Q8CFQ7_MOUSE  NEAKPIGFTMYTTCIIWLAFVPIFFG. 
Q863I4|MGR6_RABIT    NEAKPIGFTMYTTCIVWLAFVPIFFG. 
Q68ED2|MGR7_MOUSE    NEAKPIGFTMYTTCIVWLAFIPIFFG. 
P70579|MGR8_RAT      NEAKPIGFTMYTTCIIWLAFIPIFFG. 
P47743|MGR8_MOUSE    NEAKPIGFTMYTTCIIWLAFIPIFFG. 
O00222|MGR8_HUMAN    NEAKPIGFTMYTTCIIWLAFIPIFFG. 
P35400|MGR7_RAT      NEAKPIGFTMYTTCIVWLAFIPIFFG. 
Q14831|MGR7_HUMAN    NEAKPIGFTMYTTCIVWLAFIPIFFG. 
P35349|MGR6_RAT      NEAKPIGFTMYTTCIIWLAFVPIFFG. 
O15303|MGR6_HUMAN    NEAKPIGFTMYTTCIIWLAFVPIFFG. 
P31424|MGR5_RAT      NEAKYIAFTMYTTCIIWLAFVPIYFG. 
P31423|MGR4_RAT      NEAKPIGFTMYTTCIVWLAFIPIFFG. 
Q14833|MGR4_HUMAN    NEAKPIGFTMYTTCIVWLAFIPIFFG. 
P31422|MGR3_RAT      NEAKFIGFTMYTTCIIWLAFLPIFYV. 
Q9QYS2|MGR3_MOUSE    NEAKFIGFTMYTTCIIWLAFLPIFYV. 
Q14832|MGR3_HUMAN    NEAKFIGFTMYTTCIIWLAFLPIFYV. 
P31421|MGR2_RAT      NEAKFIGFTMYTTCIIWLAFLPIFYV. 
Q14416|MGR2_HUMAN    NEAKFIGFTMYTTCIIWLAFLPIFYV. 
P23385|MGR1_RAT      NEAKYIAFTMYTTCIIWLAFVPIYFG. 
P97772|MGR1_MOUSE    NEAKYIAFTMYTTCIIWLAFVPIYFG. 
Q13255|MGR1_HUMAN    NEAKYIAFTMYTTCIIWLAFVPIYFG. 
Q90ZF3|Q90ZF3_ONCMA  NEAKYIAFTMYTTCIIWLAFVPIYFG. 
Q9V4U4|Q9V4U4_DROME  NESKHIGFTMYTTCVIWLAFVPLYFG. 
Q9V4U3|Q9V4U3_DROME  NESKHIGFTMYTTCVIWLAFVPLYFG. 
Q7KQS9|Q7KQS9_DROME  NESKHIGFTMYTTCVIWLAFVPLYFG. 
Q75QW6|Q75QW6_APIME  NESKHIGFTMYTTCVIWLAFVPLYFG. 
Q70GQ8|Q70GQ8_DROME  NESKHIGFTMYTTCVIWLAFVPLYFG. 
Q62916|Q62916_RAT    NEAKPIGFTMYTTCIVWLAFIPIFFG. 
 
TM7 
BW position                 7.4       7.5 
                             |         | 
1U19.A               PIFMTIPAFFAKTSAVYNPVIYIMMNKQ 
P22815|BOSS_DROME    IPLGLQASGWAVLVGILIPRTFLIVRGI 
Q24738|BOSS_DROVI    IPLGMQASGWAVLVGILIPRTFLIVRGI 
Q24265|Q24265_DROME  IPLGLQASGWAVLVGILIPRTFLIVRGI 
Q8MSJ2|Q8MSJ2_DROME  IPLGLQASGWAVLVGILIPRTFLIVRGI 
Q90WL6|Q90WL6_SPAAU  EAIAILASSFGMLACIFFNKVYIILFKP 
Q8JI04|Q8JI04_SQUAC  EVIAILASSFGLLGCIYFNKCYIILFKP 
Q6XAF1|Q6XAF1_SALSA  EVIAILASSFGLLACIFFNKVYIILFKP 
Q6XAF2|Q6XAF2_SALSA  EVIAILASSFGLLACIFFNKVYIIHQP. 
P41180|CASR_HUMAN    EVIAILAASFGLLACIFFNKIYIILFKP 
Q80ZA8|Q80ZA8_RAT    EVIAILAASFGLLACIFFNKVYIILFKP 
P48442|CASR_RAT      EVIAILAASFGLLACIFFNKVYIILFKP 
P35384|CASR_BOVIN    EVIAILAASFGLLACIFFNKVYIILFKP 
Q9QY96|CASR_MOUSE    EVIAILAASFGLLACIFFNKVYIILFKP 
Q6XAF3|Q6XAF3_SALSA  EVIAILASSFGLLACIFFNKVYIILFKP 
Q5YEV6|Q5YEV6_OREMO  EVIAILASSFGMLACIFFNKVYIILFKP 
O73639|O73639_FUGRU  EIFAILASSYGLLGCIFAPKCYIILMKS 
O73638|O73638_FUGRU  EIFAILASSFGLLFCIFAPKCYILILKP 10. Appendix 
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O73637|O73637_FUGRU  EVFAILTSSFGLLVALFGPKCYIILFRP 
O73636|O73636_FUGRU  EIFAILASSFGLILCIFAPKCFIILFKP 
O73635|O73635_FUGRU  EAIAILASSYGMLACIFFNKVYIILFKP 
O75899|GABR2_HUMAN   VALVIIFCSTITLCLVFVPKLITLRTNP 
O88871|GABR2_RAT     VALVIIFCSTITLCLVFVPKLITLRTNP 
Q9BML6|Q9BML6_DROME  LSFFIIFCTTATLCLVFVPKLVELKRNP 
Q9Y133|Q9Y133_DROME  LSFFIIFCTTATLCLVFVPKLVELKRNP 
Q8IN24|Q8IN24_DROME  LSFFIIFCTTATLCLVFVPKLVELKRNP 
Q5TRW6|Q5TRW6_ANOGA  ISVFIIFCTTATLCLVFVPKLVELKRNP 
Q9V3Q9|Q9V3Q9_DROME  VALAVIFCCFLSMLLIFVPKVIEVIRHP 
Q9BML7|Q9BML7_DROME  VALAVIFCCFLSMLLIFVPKVIEVIRHP 
Q8NHA5|Q8NHA5_HUMAN  ASLAIVFSSYITLVVLFVPKMRRLITRG 
Q8IW08|Q8IW08_HUMAN  ASLAIVFSSYITLVVLFVPKMRRLITRG 
Q6PGJ2|Q6PGJ2_MOUSE  ASLAIVFSSYITLVVLFVPKMRRLITRG 
Q9WV18|GABR1_MOUSE   ASLAIVFSSYITLVVLFVPKMRRLITRG 
Q9UBS5|GABR1_HUMAN   ASLAIVFSSYITLVVLFVPKMRRLITRG 
Q8K451|GP156_RAT     TSGGIFVCTTTVNCCVFLPQLRQRKAFE 
Q8NFN8|GP156_HUMAN   TSGGIFVCTTTINCFIFIPQLKQWKAFE 
Q6PCP7|GP156_MOUSE   TSGGIFVCTTTVNCCVFIPQLKQWKAFE 
Q9VPS7|Q9VPS7_DROME  ITALILTSTTATLCLLFIPKLHDIWARN 
Q8IPW4|Q8IPW4_DROME  ITALILTSTTATLCLLFIPKLHDIWARN 
Q8MSP9|Q8MSP9_DROME  ITALILTSTTATLLSAFHPKTP...... 
O96954|O96954_GEOCY  VGIGFLLGTTMILGLVFVPRMVGLYQDP 
Q8BHL4|RAI3_MOUSE    LSTALVANGWVFLAFYILPEFRQLPRQR 
Q8NFJ5|RAI3_HUMAN    LSSALAANGWVFLLAYVSPEFWLLTKQR 
Q9JIL6|GPC5D_MOUSE   ICIGLVTNAWVFLLIYIIPELSILYRSC 
Q9NZD1|GPC5D_HUMAN   VCIALVTNAWVFLLLYIVPELCILYRSC 
Q8K3J9|GPC5C_MOUSE   LAIALAANAWTFVLFYVIPEVSQVTKPS 
Q9NQ84|GPC5C_HUMAN   LAIALAANAWAFVLFYVIPEVSQVTKSS 
Q923Z0|GPC5B_MOUSE   LAITLAASGWVFVIFHAIPEIHYTLLPP 
Q9NZH0|GPC5B_HUMAN   LAITLAASGWVFVIFHAIPEIHCTLLPA 
Q6PA25|Q6PA25_XENLA  LSIALVANGWVFLMMYMVPELCLMTRCQ 
Q5T6X5|GPC6A_HUMAN   EIIVILISNYGILYCTFIPKCYVIICKQ 
Q5U9X3|GPC6A_BRARE   EMVVILISNYGILSCHFLPKSYIILFKK 
Q8K4Z6|GPC6A_MOUSE   EIIVILISNYGILCCIFFPKCYIILCKQ 
Q9PW88|GPC6A_CARAU   EVVVILISNYGILSCHFLPKCYIIIFKK 
Q9Z0R8|TS1R1_RAT     NVLAGLTTLSGGFSGYFLPKCYVILCRP 
Q99PG6|TS1R1_MOUSE   NVLAGLATLSGGFSGYFLPKCYVILCRP 
Q7RTX1|TS1R1_HUMAN   NMMAGLSSLSSGFGGYFLPKCYVILCRP 
Q9Z0R7|TS1R2_RAT     DLLVTVLNFLAIGLGYFGPKCYMILFYP 
Q925I4|TS1R2_MOUSE   DLLVTVLNFLAIGLGYFGPKCYMILFYP 
Q8TE23|TS1R2_HUMAN   DLLVTVLNLLAISLGYFGPKCYMILFYP 
Q7RTX0|TS1R3_HUMAN   QMGALLLCVLGILAAFHLPRCYLLMRQP 
Q717C1|TS1R3_GORGO   QMGALLLCVLGILAAFHLPRCYLLIRQP 
Q717C2|TS1R3_PANTR   QMGALLLCVLGILAAFHLPRCYLLMWQP 
Q923K1|TS1R3_RAT     QMGAILFCALGILATFHLPKCYVLLWLP 
Q925D8|TS1R3_MOUSE   QMGAILVCALGILVTFHLPKCYVLLWLP 
P41594|MGR5_HUMAN    MCFSVSLSATVALGCMFVPKVYIILAKP 
Q75QW7|Q75QW7_APIME  LCVAISLSATVTLVCLYSPKIYIILFQP 
P91685|MGR_DROME     LCISISLSASVALVCLYSPKVYILVFHP 
Q8CFQ7|Q8CFQ7_MOUSE  LTVSLSLSASVSLGMLYVPKTYVILFHP 
Q863I4|MGR6_RABIT    LTVSLSLSASVSLGMLYVPKTYVILFHP 
Q68ED2|MGR7_MOUSE    LTISMNLSASVALGMLYMPKVYIIIFHP 
P70579|MGR8_RAT      LTVSMSLSASVSLGMLYMPKVYIIIFHP 
P47743|MGR8_MOUSE    LTVSMSLSASVSLGMLYMPKVYIIIFHP 
O00222|MGR8_HUMAN    LTVSMSLSASVSLGMLYMPKVYIIIFHP 
P35400|MGR7_RAT      LTISMNLSASVALGMLYMPKVYIIIFHP 
Q14831|MGR7_HUMAN    LTISMNLSASVALGMLYMPKVYIIIFHP 
P35349|MGR6_RAT      LTVSLSLSASVSLGMLYVPKTYVILFHP 
O15303|MGR6_HUMAN    LTVSLSLSASVSLGMLYVPKTYVILFHP 
P31424|MGR5_RAT      MCFSVSLSATVALGCMFVPKVYIILAKP 
P31423|MGR4_RAT      LTVSVSLSASVSLGMLYMPKVYIILFHP 
Q14833|MGR4_HUMAN    LTVSVSLSASVSLGMLYMPKVYIILFHP 10. Appendix 
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P31422|MGR3_RAT      MCISVSLSGFVVLGCLFAPKVHIVLFQP 
Q9QYS2|MGR3_MOUSE    MCISVSLSGFVVLGCLFAPKVHIVLFQP 
Q14832|MGR3_HUMAN    MCISVSLSGFVVLGCLFAPKVHIILFQP 
P31421|MGR2_RAT      MCVSVSLSGSVVLGCLFAPKLHIILFQP 
Q14416|MGR2_HUMAN    MCVSVSLSGSVVLGCLFAPKLHIILFQP 
P23385|MGR1_RAT      TCFAVSLSVTVALGCMFTPKMYIIIAKP 
P97772|MGR1_MOUSE    TCFAVSLSVTVALGCMFTPKMYIIIAKP 
Q13255|MGR1_HUMAN    TCFAVSLSVTVALGCMFTPKMYIIIAKP 
Q90ZF3|Q90ZF3_ONCMA  TSFSVSLSVTVALGCMFSPKIYIILAKP 
Q9V4U4|Q9V4U4_DROME  MSVTISLSASVTIACLFSPKLYIILIRP 
Q9V4U3|Q9V4U3_DROME  MSVTISLSASVTIACLFSPKLYIILIRP 
Q7KQS9|Q7KQS9_DROME  MSVTISLSASVTIACLFSPKLYIILIRP 
Q75QW6|Q75QW6_APIME  MSVTISLSASVTIACLFSPKLYIILIRP 
Q70GQ8|Q70GQ8_DROME  MSVTISLSASVTIACLFSPKLYIILIRP 
Q62916|Q62916_RAT    LTVSVSLSASVSLGMLYMPKVYIILFHI 
Figure A 1: Multiple sequence alignment of 96 family C GPCRs. Positions are assigned numbering 
according to Ballesteros-Weinstein (BW) numbering scheme. Sequences are named using Swiss-Prot 
accession codes. 
10.4 Ligand data collection 
Table A 1: Ligand data collection of 1240 mGluR binding ligands. O represents the organism, the ligand 
was tested, and sel, whether the ligand is selective (+) or not selective (-) for the given receptor. If nothing 
is assigned, then data is missing.  
SMILES  ligand 
type  receptor  pIC50  O  sel 
O(C)c1cc(ccc1)C#Cc1ncc(cc1)C  partial  mGluR5  6.84  R   
Brc1cc(cnc1)C#Cc1ncc(cc1)C  partial  mGluR5  6.74  R   
O(C)c1cc(ccc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  5.89  R   
FC(F)(F)c1cc(ccc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  5.78  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1cc([N+](=O)[O-])ccc1  PAM  mGluR5  5.65  R   
O(C)c1ccc(cc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  6.38  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccc(cc1)C#N  PAM  mGluR5  5.81  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccc([N+](=O)[O-])cc1  PAM  mGluR5  6.60  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccc(cc1)C(=O)N  PAM  mGluR5  5.00  R   
Oc1ccccc1C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  5.00  R / H   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccccc1C  PAM  mGluR5  5.00  R / H   
OC(=O)c1ccc(cc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  5.00  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1cc([N+](=O)[O-
])cc([N+](=O)[O-])c1  PAM  mGluR5  7.19  R   
O(C)c1cc(ccc1OC)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  5.00  R   
O(C)c1cc(cc(OC)c1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  5.00  R  - 
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1cc(C)c(cc1)C  PAM  mGluR5  6.37  R   
Clc1cc(ccc1Cl)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  6.80  R   
Clc1ccccc1-c1nn(-c2ccccc2)c(NC(=O)c2ccccc2)c1  PAM  mGluR5  5.00  R   
Fc1ccccc1-n1nc(cc1NC(=O)c1ccccc1)-c1ccccc1  PAM  mGluR5  5.57  R   
Clc1ccccc1-n1nc(cc1NC(=O)c1ccccc1)-c1ccccc1  PAM  mGluR5  6.30  R   
Brc1ccccc1-n1nc(cc1NC(=O)c1ccccc1)-c1ccccc1  PAM  mGluR5  5.59  R   
Brc1cc(-n2nc(cc2NC(=O)c2cc(ccc2)C#N)-c2ccccc2)ccc1  PAM  mGluR5  5.00  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1cc(ccc1)C#N)c1ccccc1  PAM  mGluR5  5.00  R   
Brc1ccccc1-n1nc(cc1NC(=O)c1cc(ccc1)C#N)-c1ccccc1  PAM  mGluR5  6.64  R   
O=C(N(C(=O)c1ccc(cc1)C#N)c1n(nc(c1)-c1ccccc1)-
c1ccccc1)c1ccc(cc1)C#N  PAM  mGluR5  5.52  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccccc1[N+](=O)[O-]  PAM  mGluR5  5.00  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccc(nc1)C  PAM  mGluR5  5.46  R  - 
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccncc1  PAM  mGluR5  5.00  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)C=1CCCCC=1  PAM  mGluR5  5.35  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)C1CCCCC1  PAM  mGluR5  4.99  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)C1CCCC1  PAM  mGluR5  4.94  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)CC1CCCC1  PAM  mGluR5  5.00  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)\C=C\c1ccc([N+](=O)[O- PAM  mGluR5  5.74  R  - 10. Appendix 
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])cc1 
n1n(-c2ccccc2)c(-n2nnc(c2)-c2ccccc2)cc1-c1ccccc1  PAM  mGluR5  5.23  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)Cc1ncccc1  PAM  mGluR5  5.00  H   
Fc1ccccc1\C=N\N=C\c1ccccc1F  PAM  mGluR5  4.85  H   
N(C(c1ccccc1)c1ccccc1)CCNC(c1ccccc1)c1ccccc1  PAM  mGluR1  7.82  R   
Fc1ccccc1-n1nc(cc1NC(=O)c1ccc([N+](=O)[O-])cc1)-c1ccccc1  PAM  mGluR5  6.80  R   
Clc1ccccc1-n1nc(cc1NC(=O)c1ccc([N+](=O)[O-])cc1)-c1ccccc1  PAM  mGluR5  6.96  R   
Brc1ccccc1-n1nc(cc1NC(=O)c1ccc([N+](=O)[O-])cc1)-c1ccccc1  PAM  mGluR5  6.77  R  - 
Brc1ccccc1-n1nc(cc1NC(=O)c1cc([N+](=O)[O-])ccc1)-c1ccccc1  PAM  mGluR5  6.64  R   
Fc1ccccc1-c1nn(-c2ccccc2)c(NC(=O)c2ccc([N+](=O)[O-])cc2)c1  PAM  mGluR5  6.80  R   
O(CCCCOc1ccc(cc1)-
c1nn[nH]n1)c1ccc(C(=O)CC(C)C)c(O)c1CCC  PAM  mGluR2  6.38  H  + 
O(CCCCOc1ccc(cc1)-c1nn[nH]n1)c1ccc(C(=O)C)c(O)c1CCC  PAM  mGluR2  6.46  H  + 
O(CCCCOc1ccc(cc1)-
c1nn[nH]n1)c1ccc(C(=O)C)c(O)c1CCCCC  PAM  mGluR2  5.00  H  + 
O(CCCCOc1ccc(cc1)-c1nn[nH]n1)c1ccc(C(=O)C)c(O)c1C  PAM  mGluR2  5.47  H  + 
O(CCCCOc1ccc(cc1)-c1nn[nH]n1)c1ccc(C(=O)CC)c(O)c1C  PAM  mGluR2  6.42  H  + 
O(CCCCOc1ccc(cc1)-c1nn[nH]n1)c1ccc(C(=O)CCC)c(O)c1C  PAM  mGluR2  6.52  H  + 
O(CCCCOc1ccc(cc1)-
c1nn[nH]n1)c1ccc(C(=O)CC(C)C)c(O)c1C  PAM  mGluR2  6.64  H  + 
Clc1cc(Cl)ccc1CN[C@H]1CCN(C1)c1ncc(Cl)cn1  PAM  mGluR4  7.48  R   
o1nc(nc1C(C)(C)C)NC(=O)C1c2c(Oc3c1cccc3)cccc2  PAM  mGluR7  7.47     
O1c2c(cccc2)C(c2c1cccc2)C(=O)Nc1nn(nn1)C(C)(C)C  PAM  mGluR1  7.47  R   
O(CCC)C(=O)NC(=O)C(c1ccccc1)c1ccccc1  PAM  mGluR1  7.47  R   
O(CCCC)C(=O)NC(=O)C(c1ccccc1)c1ccccc1  PAM  mGluR1  7.47  R   
O(CCCCC)C(=O)NC(=O)C(c1ccccc1)c1ccccc1  PAM  mGluR1  7.30  R   
O(C(C)C)C(=O)NC(=O)C(c1ccccc1)c1ccccc1  PAM  mGluR1  6.03  R   
O1c2c(cccc2)C(c2c1cccc2)C(=O)NC(OCCC)=O  PAM  mGluR1  7.47  R   
O1c2c(cccc2)C(c2c1cccc2)C(=O)NC(OCCCC)=O  PAM  mGluR1  7.47  R   
S1c2c(cccc2)C(c2c1cccc2)C(=O)NC(OCC)=O  PAM  mGluR1  6.85  R   
Fc1ccc(cc1)C(=O)N1C[C@@](CCC1)(C)c1onc(n1)-c1ncccc1  PAM  mGluR5  7.41  H   
Fc1ccccc1-c1nc(on1)[C@]1(CCCN(C1)C(=O)c1ccc(F)cc1)C  PAM  mGluR5  7.41  H   
O=C(Nc1n(ncc1-c1ccccc1)-c1ccccc1)c1ccc([N+](=O)[O-])cc1  PAM  mGluR5  5.00  R  - 
O=C(N1N(\C(=N\C(=O)c2ccc(cc2)C#N)\C=C1c1ccccc1)c1ccccc
1)c1ccc(cc1)C#N  PAM  mGluR5  5.28  R   
S(=O)(=O)(N(Cc1cccnc1)c1ccc(cc1)C(=O)c1ccccc1)CC  PAM  mGluR2  5.38    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(ccc1)C(=O)c1ccccc1)CC  PAM  mGluR2  5.96    + 
S(=O)(=O)(N(Cc1cccnc1)c1ccc(cc1)C(=C)c1ccccc1)CC  PAM  mGluR2  6.11    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(ccc1)C(=C)c1ccccc1)CC  PAM  mGluR2  6.70    + 
S(=O)(=O)(N(Cc1cccnc1)c1ccc(cc1)[C@@H](C)c1ccccc1)CC  PAM  mGluR2  5.85    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(ccc1)[C@@H](C)c1ccccc1)CC  PAM  mGluR2  7.14    + 
S(=O)(=O)(N(Cc1cccnc1)c1ccc(cc1)Cc1ccccc1)CC  PAM  mGluR2  5.80    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(ccc1)Cc1ccccc1)CC  PAM  mGluR2  6.51    + 
S(=O)(=O)(N(Cc1cccnc1)c1ccc(cc1)[C@@H](F)c1ccccc1)CC  PAM  mGluR2  5.00    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(ccc1)[C@@H](F)c1ccccc1)CC  PAM  mGluR2  6.74    + 
S(=O)(=O)(N(Cc1cccnc1)c1ccc(cc1)COc1ccccc1)CC  PAM  mGluR2  5.68    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(ccc1)COc1ccccc1)CC  PAM  mGluR2  6.80    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(Oc2ccccc2)ccc1)CC  PAM  mGluR2  6.44    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OCc2ccccc2)ccc1)CC(F)(F)F  PAM  mGluR2  6.21    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OCc2ccccc2)ccc1)CC  PAM  mGluR2  6.36    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC(F)(F)F)ccc1)CC(F)(F)F  PAM  mGluR2  6.85    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC(F)(F)F)ccc1)CC  PAM  mGluR2  5.80    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC)ccc1)CC(F)(F)F  PAM  mGluR2  5.68    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OCC(F)(F)F)ccc1)CC(F)(F)F  PAM  mGluR2  7.00    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC(C)C)ccc1)CC(F)(F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OCC(C)C)ccc1)CC(F)(F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(O[C@@H](CC)C)ccc1)CC(F)(F)
F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC(CC)CC)ccc1)CC(F)(F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC[C@@H](CC)C)ccc1)CC(F)(
F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC2CCC2)ccc1)CC(F)(F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC2CCCC2)ccc1)CC(F)(F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC2CCCCC2)ccc1)CC(F)(F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OCC(OCC)=O)ccc1)CC(F)(F)F  PAM  mGluR2  6.19    + 10. Appendix 
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S(=O)(=O)(N(Cc1cccnc1)c1cc(O[C@@H](C(OCC)=O)C)ccc1)C
C(F)(F)F  PAM  mGluR2  6.64    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(OC(C(OCC)=O)(C)C)ccc1)CC(F)
(F)F  PAM  mGluR2  7.06    + 
S(=O)(=O)(N(Cc1cccnc1)c1ccc(cc1)[C@@H](O)c1ccccc1)CC  PAM  mGluR2  5.00    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(ccc1)[C@@H](O)c1ccccc1)CC  PAM  mGluR2  5.60    + 
FC(F)(F)Oc1ccc(cc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  6.58  R  + 
O(C)c1cc(ccc1)-c1nn(-c2ccccc2)c(NC(=O)c2ccccc2)c1  PAM  mGluR5  5.49  R   
O(C)c1cc(-n2nc(cc2NC(=O)c2ccccc2)-c2ccccc2)ccc1  PAM  mGluR5  5.68  R   
S(=O)(=O)(N(Cc1cccnc1)c1ccc(Oc2ccccc2)cc1)CC  PAM  mGluR2  5.82    + 
S(=O)(=O)(N(Cc1cccnc1)c1cc(O[C@@H](CCC)C)ccc1)CC(F)(
F)F  PAM  mGluR2  7.27    + 
S(=O)(=O)(N1CCC[C@@H]1c1ccc(F)cc1)c1ccc(cc1)C  PAM  mGluR1  7.22  R   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ncccc1)c1ccccc1  PAM  mGluR5  5.00  R   
Fc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ncccc2)cc1  PAM  mGluR5  5.82  H   
O(C)c1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ncccc2)cc1  PAM  mGluR5  5.85  H   
Clc1cc(CN2C(=O)c3c(cc(C)c(c3)C)C2=O)c(NC(=O)c2ncccc2)cc
1  PAM  mGluR5  5.68  H   
Clc1cc(CN2C(=O)c3c(ccc(F)c3)C2=O)c(NC(=O)c2ncccc2)cc1  PAM  mGluR5  6.48  H   
Clc1cc(CN2C(=O)c3c(ccc(OCC)c3)C2=O)c(NC(=O)c2ncccc2)c
c1  PAM  mGluR5  6.55  H   
Clc1cc2c(cc1Cl)C(=O)N(Cc1cc(Cl)ccc1NC(=O)c1ncccc1)C2=O  PAM  mGluR5  5.55  H   
Clc1cc(CN2C(=O)c3c(ccc(c3)C)C2=O)c(NC(=O)c2ncccc2)cc1  PAM  mGluR5  5.00  H   
Clc1cc(CN2C(=O)c3c(cccc3F)C2=O)c(NC(=O)c2ncccc2)cc1  PAM  mGluR5  6.21  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2cccnc2)cc1  PAM  mGluR5  4.46  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ccncc2)cc1  PAM  mGluR5  5.00  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2occc2)cc1  PAM  mGluR5  5.64  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2nsnc2)cc1  PAM  mGluR5  5.11  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2nc3SC=Cn3c2)
cc1  PAM  mGluR5  5.60  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ncccc2O)cc1  PAM  mGluR5  6.73  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ncsc2)cc1  PAM  mGluR5  5.72  H   
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2cc(OC)ccc2)cc1  PAM  mGluR5  5.82  H   
Brc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ncccc2)cc1  PAM  mGluR5  6.12  H   
O=C1N(Cc2ccccc2NC(=O)c2ncccc2)C(=O)c2c1cccc2  PAM  mGluR5  7.10  R / H   
Fc1ccc(cc1)-c1nc(on1)[C@]1(CCCN(C1)C(=O)c1ccc(F)cc1)C  PAM  mGluR5  6.37  H   
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1cc(ccc1)C#N  PAM  mGluR5  5.42  R  + 
O(CC)C(=O)NC(=O)C(c1ccccc1)c1ccccc1  PAM  mGluR1  6.77     
O1c2c(cccc2)C(c2c1cccc2)C(=O)NC(OCC)=O  PAM  mGluR1  7.47     
S(=O)(=O)(N1CCC[C@@H]1c1ccc(cc1)C)c1ccc(cc1)C  PAM  mGluR1  6.70     
o1nc(nc1C)NC(=O)C1c2c(Oc3c1cccc3)cccc2  PAM  mGluR1  7.28     
o1nc(nc1CC)NC(=O)C1c2c(Oc3c1cccc3)cccc2  PAM  mGluR1  7.47     
o1nc(nc1C(C)C)NC(=O)C1c2c(Oc3c1cccc3)cccc2  PAM  mGluR1  7.47     
o1nc(nc1CCC)NC(=O)C1c2c(Oc3c1cccc3)cccc2  PAM  mGluR1  7.47     
o1nc(nc1C1CC1)NC(=O)C1c2c(Oc3c1cccc3)cccc2  PAM  mGluR1  7.47     
o1nc(nc1CC(C)C)NC(=O)C1c2c(Oc3c1cccc3)cccc2  PAM  mGluR1  7.47     
O1c2c(cccc2)C(c2c1cccc2)C(=O)Nc1nn(nn1)C  PAM  mGluR1  6.74     
O1c2c(cccc2)C(c2c1cccc2)C(=O)Nc1nn(nn1)CC  PAM  mGluR1  7.19     
O1c2c(cccc2)C(c2c1cccc2)C(=O)Nc1nn(nn1)CCC  PAM  mGluR1  7.47     
O1c2c(cccc2)C(c2c1cccc2)C(=O)Nc1nn(nn1)C(C)C  PAM  mGluR1  7.35     
O1c2c(cccc2)C(c2c1cccc2)C(=O)Nc1nn(nn1)CC(C)C  PAM  mGluR1  7.47     
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ccccc2O)cc1  PAM  mGluR5  6.82     
Clc1cc(CN2C(=O)c3c(cccc3)C2=O)c(NC(=O)c2ncccc2)cc1  PAM  mGluR5  6.60     
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccccc1  PAM  mGluR5  5.38     
Clc1ccccc1C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  5.21     
Clc1cc(ccc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  6.39     
Clc1ccc(cc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  6.77     
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1cc(ccc1)C  PAM  mGluR5  7.00     
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1ccc(cc1)C  PAM  mGluR5  6.11     
Fc1ccccc1C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  7.00     
Fc1cc(ccc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  7.15     
Fc1ccc(cc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  7.30     
Fc1cc(ccc1F)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  7.70     
FC(F)(F)c1ccc(cc1)C(=O)Nc1n(nc(c1)-c1ccccc1)-c1ccccc1  PAM  mGluR5  6.00     
O=C(Nc1n(nc(c1)-c1ccccc1)-c1ccccc1)c1n[nH]cc1  PAM  mGluR5  8.08     10. Appendix 
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Oc1cc(ccc1)\C=N\N=C\c1cc(O)ccc1  neutral  mGluR5  5.00  H   
n1cc(ccc1C#Cc1ccccc1)C  neutral  mGluR5  6.41     
O=C(Nc1nc(ccc1)C)c1nc(ccc1CNc1cccnc1)C  NAM  mGluR5  7.44     
O(c1ccccc1-n1nc(nn1)-c1ncccc1)c1cccnc1  NAM  mGluR5  5.80     
s1cc(nc1C)C#Cc1cc(F)ccc1  NAM  mGluR5  7.64  R   
s1cc(nc1C)C#Cc1ccc(F)cc1  NAM  mGluR5  5.53  R   
s1cc(nc1C)C#Cc1cc(OC)ccc1  NAM  mGluR5  7.31  R   
s1cc(nc1C)C#Cc1ccccc1F  NAM  mGluR5  6.85  R   
s1cc(nc1C)C#Cc1ccccc1OC  NAM  mGluR5  7.44  R   
s1cc(nc1C)C#Cc1cc(ccc1)C  NAM  mGluR5  7.08  R   
Clc1cc(ccc1)C#Cc1nc(sc1)C  NAM  mGluR5  6.89  R   
s1cc(nc1C)C#Cc1cc(ccc1)C(F)(F)F  NAM  mGluR5  6.38  R   
s1cc(nc1C)C#Cc1cc(OC(F)(F)F)ccc1  NAM  mGluR5  6.58  R   
s1cc(nc1C)C#Cc1cc(ccc1)C#N  NAM  mGluR5  7.89  R   
s1cc(nc1C)C#Cc1cc(NC(=O)C)ccc1  NAM  mGluR5  5.69  R   
s1cc(nc1C)C#Cc1cc(F)cc(F)c1  NAM  mGluR5  7.60  R   
s1c(C)c(nc1C)C#Cc1cccnc1  NAM  mGluR5  6.16  R   
s1c(CC)c(nc1C)C#Cc1cccnc1  NAM  mGluR5  5.91  R   
s1cc(nc1C)C#Cc1ccc(OC)nc1  NAM  mGluR5  6.37  R   
s1cc(nc1C)C#Cc1ncc(F)cc1  NAM  mGluR5  5.96  R   
Brc1cc(cnc1)C#Cc1nc(sc1)C  NAM  mGluR5  7.22  R   
s1cc(nc1C)C#Cc1ccc(F)nc1  NAM  mGluR5  6.08  R   
s1cc(nc1C)C#Cc1cncnc1  NAM  mGluR5  6.02  R   
s1cc(nc1C)C#Cc1nccnc1  NAM  mGluR5  5.74  R   
s1cccc1C#Cc1nc(sc1)C  NAM  mGluR5  6.32  R   
s1cc(nc1C)C#Cc1ccsc1  NAM  mGluR5  6.47  R   
s1cc(nc1C)C#Cc1cc(O)ccc1  NAM  mGluR5  6.18  R   
s1cc(nc1C)C#Cc1cc(ccc1)C(=O)N  NAM  mGluR5  6.00  R   
s1cc(nc1N)C#Cc1cc(F)ccc1  NAM  mGluR5  7.10  R   
s1cc(nc1N)C#Cc1cccnc1  NAM  mGluR5  6.10  R   
s1cc(nc1NC(=O)C)C#Cc1cccnc1  NAM  mGluR5  5.72  R   
Brc1scc(n1)C#Cc1cc(F)ccc1  NAM  mGluR5  6.28  R   
s1cc(nc1C)C#Cc1cc(cnc1)-c1ccc(F)cc1  NAM  mGluR5  6.79  R   
s1cc(nc1C)C#Cc1cc(cnc1)-c1ccc(OC)cc1  NAM  mGluR5  6.65  R   
s1cc(nc1C)C#Cc1cc(cnc1)C#CCO  NAM  mGluR5  7.16  R   
s1cc(nc1C)C#Cc1cc(cnc1)C#C  NAM  mGluR5  7.72  R   
s1cc(nc1C)C#Cc1cc(cnc1)C=C  NAM  mGluR5  7.89  R   
s1cc(nc1C)C#Cc1ccc(OS(=O)(=O)C)nc1  NAM  mGluR5  5.63  R   
s1cc(nc1C)C#Cc1ccc(nc1)-c1ccc(F)cc1  NAM  mGluR5  7.89  H   
s1cc(nc1C)C#Cc1ccc(nc1)C#C  NAM  mGluR5  5.53  R   
s1cc(nc1C)C#Cc1cccnc1OC  NAM  mGluR5  6.64  R   
Clc1ncccc1C#Cc1nc(sc1)C  NAM  mGluR5  7.34  R   
s1cc(nc1C)\C=C\c1cccnc1  NAM  mGluR5  5.51  R   
Clc1ccc(Sc2nc(nc(c2)C)-c2ncccc2)cc1  NAM  mGluR5  5.90     
Clc1ccc(cc1)[C@@H](O)c1nc(ncc1)-c1ncccc1  NAM  mGluR5  5.52     
Clc1cc(Sc2nc(ncc2)-c2nc(ccc2)C)ccc1Cl  NAM  mGluR5  6.41     
Clc1cc(Sc2nc(ncc2)-c2ncc(F)cc2)ccc1Cl  NAM  mGluR5  7.10     
Clc1cc(Sc2cc(ncc2)-c2ncccc2)ccc1Cl  NAM  mGluR5  5.63     
Clc1ccc(Sc2nc(ncc2)-c2ncccc2)cc1  NAM  mGluR5  6.49     
Clc1cc(Sc2nc(ncc2)-c2ncccc2)ccc1  NAM  mGluR5  6.21     
S(c1cc(ccc1)C)c1nc(ncc1)-c1ncccc1  NAM  mGluR5  5.64     
S(c1ccc(cc1)C(F)(F)F)c1nc(ncc1)-c1ncccc1  NAM  mGluR5  6.68     
S(c1cc(F)c(F)cc1)c1nc(ncc1)-c1ncccc1  NAM  mGluR5  5.82     
Clc1cc(Sc2nc(ncc2)-c2ncccc2)ccc1Cl  NAM  mGluR5  7.05     
Brc1cc(Sc2nc(ncc2)-c2ncccc2)ccc1  NAM  mGluR5  5.54     
s1cc(nc1C)C#Cc1ccccc1C  NAM  mGluR5  7.82     
s1cc(nc1C)C#Cc1ccc(cc1)C  NAM  mGluR5  6.07     
s1cc(nc1C)C#Cc1ccccc1-c1ccccc1  NAM  mGluR5  6.37     
s1cc(nc1C)C#Cc1cc(ccc1)-c1ccccc1  NAM  mGluR5  7.39     
s1cc(nc1C)C#Cc1ccc(cc1)-c1ccccc1  NAM  mGluR5  7.66     
s1cc(nc1C)C#Cc1cc(cnc1)-c1ccccc1  NAM  mGluR5  7.89     
s1cc(nc1C)C#Cc1cc(cnc1)-c1ncccc1  NAM  mGluR5  7.66     
s1cc(nc1C)C#Cc1cc(cnc1)-c1cccnc1  NAM  mGluR5  6.23  R / H   10. Appendix 
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s1cc(nc1C)C#Cc1ccc(nc1)-c1ccccc1  NAM  mGluR5  7.89     
s1cc(nc1C)C#Cc1ccc(nc1)-c1ncccc1  NAM  mGluR5  7.80  H   
s1cc(nc1C)C#Cc1ccc(nc1)-c1cccnc1  NAM  mGluR5  7.89  H   
s1cc(nc1C)C#Cc1ccc(nc1)-c1ccncc1  NAM  mGluR5  7.54     
O(C)c1cc(NC(=O)\N=C\2/NC(=O)CN/2C)ccc1  NAM  mGluR5  5.55  H   
O=C1N\C(=N/C(=O)Nc2nccc(c2)C)\N(C1)C  NAM  mGluR5  5.51  H   
Clc1cc(NC(=O)\N=C\2/NC(=O)[C@@H](N/2C)C)ccc1  NAM  mGluR5  5.89  R / H   
Clc1cc(NC(=O)\N=C\2/NC(=O)CN/2CC)ccc1  NAM  mGluR5  6.60  R / H   
Clc1cc(NC(=O)\N=C\2/NC(=O)[C@@H](N/2CC)C)ccc1  NAM  mGluR5  6.39  R / H   
Clc1cc(NC(=O)\N=C\2/NC(=O)CN/2CCCC)ccc1  NAM  mGluR5  5.89  R / H   
Clc1cc(NC(=O)\N=C\2/NC(=O)[C@@H]3N/2CCC3)ccc1  NAM  mGluR5  5.80  R / H   
O=C1N\C(\N2[C@@H]1CCC2)=N/C(=O)Nc1ccccc1  NAM  mGluR5  5.38  H   
O=C1N\C(=N/C(=O)Nc2cc(ccc2)C#N)\N(C1)C  NAM  mGluR5  5.41  R / H   
Clc1cc(NC(=O)\N=C\2/SCCN/2C)ccc1  NAM  mGluR5  5.92  R / H   
Clc1cc(NC(=O)\N=C/2\N(CCC\2)C)ccc1  NAM  mGluR5  5.70  R / H   
O=C1N\C(=N/C(=O)Nc2cc(ccc2)C)\N(C1)C  NAM  mGluR5  6.26  H   
O=C1N\C(=N/C(=O)Nc2ccccc2)\N(C1)C  NAM  mGluR5  5.31  R / H   
Brc1cc(NC(=O)\N=C\2/NC(=O)CN/2C)ccc1  NAM  mGluR5  6.42  H   
s1cccc1NC(=O)\N=C/1\NC(=O)CN\1C  NAM  mGluR5  5.31     
O(C)c1cc(ccc1-c1ncccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  7.66     
S1C=Cn2cc(nc12)-c1cc(OC)c(cc1)-c1ncccc1  NAM  mGluR5  7.38     
S1CCn2cc(nc12)-c1cc(OC)c(cc1)-c1ncccc1  NAM  mGluR5  6.49     
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  5.53  R/H  + 
O=C(N1CCN(CC1)c1ncccc1)C#Cc1ccccc1  NAM  mGluR5  5.99    + 
O(C)c1cc(cnc1Nc1nc(ccc1)C)-c1cccnc1  NAM  mGluR5  8.07    + 
O(Cc1cc(ccc1)C#Cc1nc(ccc1)C)C  NAM  mGluR5  7.72  H   
O(C)c1cc(cnc1)C#Cc1ncccc1  NAM  mGluR5  7.80  H   
Fc1cc(cc(c1)C#N)C#Cc1ncccc1  NAM  mGluR5  7.40  H   
s1cccc1CC(=O)N1CCN(CC1)CC  NAM  mGluR5  5.00  R  - 
s1c(S(=O)(=O)N)c(nc1NC(=O)c1c2n(nc1)C(=CC(=N2)c1ccc(cc
1)C(F)(F)F)C(F)(F)F)C  NAM  mGluR2  8.07     
O(C(=O)c1c(C)c([nH]c1CNCc1ccccc1)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.00  R  + 
O(C(=O)c1c(C)c([nH]c1CN)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.00  R  + 
S(C(=O)c1[nH]c(C(OCCC)=O)c(C)c1C(OC(C)(C)C)=O)c1ccncc
1  NAM  mGluR1  5.49  R  + 
O(C(=O)c1c[nH]c(C(O)=O)c1C)C(C)(C)C  NAM  mGluR1  5.00  R  + 
O(C(=O)c1c(C)c([nH]c1CO)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.10  R  + 
O(C(=O)c1c(C)c([nH]c1COC(=O)CC)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.57  R  + 
O(C(=O)c1c(C)c([nH]c1C(O)=O)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.00  R  + 
O(C(=O)c1c(C)c([nH]c1C)C(OCC)=O)CC  NAM  mGluR1  4.80  R  + 
O(C(=O)c1c(C)c([nH]c1C)C(OCc1ccccc1)=O)Cc1ccccc1  NAM  mGluR1  5.00  R  + 
o1cccc1COC(=O)c1[nH]c(C)c(C(OC(C)(C)C)=O)c1C  NAM  mGluR1  6.70  R  + 
O(C(=O)c1c(C)c([nH]c1C)C(OCCCCCCCC)=O)C(C)(C)C  NAM  mGluR1  5.20  R  + 
O(C(=O)c1[nH]c(C)c(C(OC(C)(C)C)=O)c1C)c1ccccc1  NAM  mGluR1  5.52  R  + 
[Si](CCOC(=O)c1[nH]c(C)c(C(O)=O)c1C)(C)(C)C  NAM  mGluR1  5.00  R  + 
O(C(=O)c1[nH]c(C)c(C(O[C@@H](C(C)C)C)=O)c1C)CCC  NAM  mGluR1  7.40  R  + 
O(C(=O)c1c(C)c([nH]c1C)C(OCCC)=O)[C@H]1C[C@@H](CC1
)C  NAM  mGluR1  6.59  R  + 
O(C(=O)c1[nH]c(C)c(C(O[C@@H](C(C)(C)C)C)=O)c1C)C(C)(C
)C  NAM  mGluR1  7.30  R  + 
O(C(=O)c1c(C)c([nH]c1C)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  6.80  R  + 
O(C(=O)c1[nH]c(C)c(C(O)=O)c1C)CC  NAM  mGluR1  5.00  R  + 
O(C(=O)c1c(C)c([nH]c1C)C(O)=O)CC  NAM  mGluR1  5.00  R  + 
OC(=O)c1c(C)c([nH]c1C)C(O)=O  NAM  mGluR1  5.00  R  + 
O(C(=O)c1[nH]c(C)c(C(OC(C)(C)C)=O)c1C)Cc1ccccc1  NAM  mGluR1  5.72  R  + 
O(C(=O)c1c(C)c([nH]c1C)C(OCC=C)=O)C(C)(C)C  NAM  mGluR1  6.41  R  + 
O(C(=O)c1[nH]c(C)c(C(OCC=C)=O)c1C)Cc1ccccc1  NAM  mGluR1  5.00  R  + 
O=C(Nc1n(ncc1-c1ccccc1)-c1ccccc1)c1cc(ccc1)C#N  NAM  mGluR5  5.92  R   
O(C(C)(C)C)C(=O)N1CCC(=CC1)c1nnn(c1)-c1ccccc1  NAM  mGluR1  8.01  H  + 
O=C(N1CCC(CC1)C)Cn1cc([N+](=O)[O-])nc1  NAM  mGluR5  5.00  R  - 
O(C(=O)c1c(C)c(n(CC(=O)N(C)C)c1C)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.00  R  + 
O(C(=O)c1c(C)c(n(CC(OCC=C)=O)c1C)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  4.90  R  + 
O(C(=O)c1c(C)c(n(CN2CCCCC2)c1C)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.00  R  + 
O(C(=O)c1c(C)c(n(CC(O)=O)c1C)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.00  R  + 10. Appendix 
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O(C(=O)c1c(C)c(n(CCN2CCN(CC2)CC=C)c1C)C(OCCC)=O)C(
C)(C)C  NAM  mGluR1  5.00  R  + 
O1CCN(CC1)CCn1c(C(OCCC)=O)c(C)c(C(OC(C)(C)C)=O)c1C  NAM  mGluR1  5.00  R  + 
O(C(=O)c1c(C)c(n(C(OC(C)(C)C)=O)c1C)C(OCCC)=O)C(C)(C)
C  NAM  mGluR1  5.64  R  + 
[Si](OCCCn1c(C(OCCC)=O)c(C)c(C(OC(C)(C)C)=O)c1C)(C(C)(
C)C)(c1ccccc1)c1ccccc1  NAM  mGluR1  5.00  R  + 
[Si](OCCn1c(C(OCCC)=O)c(C)c(C(OC(C)(C)C)=O)c1C)(C(C)(C
)C)(c1ccccc1)c1ccccc1  NAM  mGluR1  5.00  R  + 
n1n(ccc1C)CCN1CCCCC1  NAM  mGluR5  5.00  R  - 
Clc1cc(NC(=O)Nc2nccn2C)ccc1  NAM  mGluR5  5.00  R / H   
Clc1ccccc1C#Cc1nc(ccc1)C  NAM  mGluR5  7.82    + 
s1cc(nc1-c1cc(F)cc(F)c1)C#Cc1cc(F)ccc1  NAM  mGluR5  5.00  R   
n1ccccc1-c1nn(nn1)-c1cc(cc(c1)C)C#N  NAM  mGluR5  7.96  R   
O(C)c1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N  NAM  mGluR5  7.96  R   
n1ccccc1-c1nn(nn1)-c1cc(cc(N)c1)C#N  NAM  mGluR5  6.51  R   
Oc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N  NAM  mGluR5  6.25  R   
O(CC1CC1)c1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N  NAM  mGluR5  6.01  R   
O(Cc1ccccc1)c1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N  NAM  mGluR5  5.00  R   
O(c1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N)c1cccnc1  NAM  mGluR5  7.80  R   
Clc1ccc(cc1-n1nc(nn1)-c1ncccc1)C#N  NAM  mGluR5  5.00  R   
Clc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N  NAM  mGluR5  7.59  R   
Clc1ccc(-n2nc(nn2)-c2ncccc2)cc1C#N  NAM  mGluR5  5.00  R   
Clc1c(-n2nc(nn2)-c2ncccc2)cccc1Cl  NAM  mGluR5  5.00  R   
n1ccccc1-c1nn(nn1)-c1cc(cc(c1)C#N)C#N  NAM  mGluR5  7.47  R   
O=[N+]([O-])c1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N  NAM  mGluR5  7.38  R   
Fc1ccc(cc1)\C=N\N=C\c1ccc(F)cc1  NAM  mGluR5  5.00  H   
s1cc(nc1C)C#Cc1cc(cnc1)C  NAM  mGluR5  7.89  H   
s1cc(nc1C)C#Cc1cc(cnc1)-c1ccncc1  NAM  mGluR5  7.74  H   
s1cc(nc1C)C#Cc1cc(cnc1)COC  NAM  mGluR5  7.89  H   
s1cc(nc1C)C#Cc1cc(cc(c1)C)C#N  NAM  mGluR5  7.89  H   
s1cc(nc1C)C#Cc1cc(cc(F)c1)C#N  NAM  mGluR5  7.89  H   
s1cc(nc1C)C#Cc1cc(OC)cnc1  NAM  mGluR5  7.89  H   
s1c(-c2ccccc2)c(nc1C)C#Cc1cccnc1  NAM  mGluR5  5.00  R   
s1cc(nc1C)C#Cc1cc2c(nc1)cccc2  NAM  mGluR5  5.00  R   
s1cc(nc1C)C#Cc1cc2nccnc2cc1  NAM  mGluR5  5.00  R   
s1cc(nc1C)C#Cc1cc2cc[nH]c2nc1  NAM  mGluR5  5.00  R   
s1cc(nc1NCc1ccccc1)C#Cc1cccnc1  NAM  mGluR5  5.00  R   
s1cc(nc1NC(=O)Nc1ccc(F)cc1F)C#Cc1cccnc1  NAM  mGluR5  5.00  R   
s1cc(nc1NC(OC)=O)C#Cc1cccnc1  NAM  mGluR5  5.00  R   
s1cc(nc1C#CCO)C#Cc1cc(F)ccc1  NAM  mGluR5  5.00  R   
s1cc(nc1C#C)C#Cc1cc(F)ccc1  NAM  mGluR5  5.53  R   
Clc1ncc(cc1)C#Cc1nc(sc1)C  NAM  mGluR5  5.00  R   
s1cc(nc1C)C#Cc1ccc(nc1)C=C  NAM  mGluR5  5.00  R   
s1cc(nc1C)C#Cc1cccnc1OS(=O)(=O)C  NAM  mGluR5  5.00  R   
s1cc(nc1C)C#Cc1cccnc1C#C  NAM  mGluR5  6.72  R   
s1cc(nc1C)\C=C\c1cc(cnc1)C  NAM  mGluR5  5.51  R   
s1cc(nc1C)C(=O)Nc1cc(F)ccc1  NAM  mGluR5  5.00  R   
s1cc(nc1C)C(=O)Nc1cc(cnc1)C  NAM  mGluR5  5.00  R   
Fc1cc(ccc1)C#Cc1nc(oc1)C  NAM  mGluR5  5.00  R   
o1cc(nc1C)C#Cc1cccnc1  NAM  mGluR5  5.00  R   
O=C1N\C(=N/C(=O)Nc2nc(ccc2)C)\N(C1)C  NAM  mGluR5  5.72  R / H   
O=C1N\C(=N/C(=O)Nc2cc(ccc2)C)\N(C)[C@@H]1c1ccccc1  NAM  mGluR5  5.00  R / H   
Clc1ccc(NC(=O)\N=C\2/NC(=O)[C@@H]3N/2CCC3)cc1  NAM  mGluR5  5.00  H   
Clc1cc(NC(=O)\N=C\2/NC(=O)[C@@H]3N/2CCC3)ccc1C  NAM  mGluR5  5.00  H   
O=C1N\C(\N2[C@@H]1CCC2)=N/C(=O)Nc1ccccc1C  NAM  mGluR5  5.00  H   
O=C1N\C(\N2[C@@H]1CCC2)=N/C(=O)Nc1cc(ccc1C)C  NAM  mGluR5  5.00  H   
O=C1N\C(\N2[C@@H]1CCC2)=N/C(=O)Nc1cccc(C)c1C  NAM  mGluR5  5.00  H   
Clc1cc(NC(=O)\N=C\2/NC(=O)CN/2C)cc(Cl)c1  NAM  mGluR5  5.00  H   
Clc1cc(NC(=O)\N=C\2/NCC(=O)N/2C)ccc1  NAM  mGluR5  5.00  R / H   
Clc1ccccc1NC(=O)\N=C\1/NC(=O)CN/1C  NAM  mGluR5  5.17    + 
Clc1ccc(NC(=O)\N=C\2/NC(=O)CN/2C)cc1  NAM  mGluR5  5.00    + 
O=C1N\C(=N/C(=O)Nc2ncccc2)\N(C1)C  NAM  mGluR5  5.96    + 
O=C1N\C(=N/C(=O)Nc2cccnc2)\N(C1)C  NAM  mGluR5  5.00    + 10. Appendix 
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O=C1N\C(=N/C(=O)Nc2ccncc2)\N(C1)C  NAM  mGluR5  5.00    + 
Clc1nc(NC(=O)\N=C\2/NC(=O)CN/2C)ccc1  NAM  mGluR5  6.78    + 
Clc1nccc(NC(=O)\N=C\2/NC(=O)CN/2C)c1  NAM  mGluR5  6.18    + 
O=C1N\C(=N/C(=O)Nc2cc(ncc2)C)\N(C1)C  NAM  mGluR5  5.57    + 
s1cc(NC(=O)\N=C\2/NC(=O)CN/2C)cc1  NAM  mGluR5  5.40    + 
Clc1cscc1NC(=O)\N=C\1/NC(=O)CN/1C  NAM  mGluR5  6.36    + 
O=C1N\C(=N/C(=O)Nc2cc(ccc2)C(OC)=O)\N(C1)C  NAM  mGluR5  5.00  H   
O=C1N\C(=N/C(=O)NCCCCCC)\N(C1)C  NAM  mGluR5  5.00  H   
s1cccc1NC(=O)\N=C\1/NC(=O)CN/1C  NAM  mGluR5  5.31  H   
Fc1ncccc1-n1nnc(C=2CCN(CC=2)C(=O)N(C(C)C)C)c1C  NAM  mGluR5  7.85  H   
Fc1ncccc1-n1nnc(C=2CCN(CC=2)C(OC(C)(C)C)=O)c1C  NAM  mGluR5  7.85  H   
S(F)(=O)(=O)CCN1C(=O)[C@@H](N(c2ccccc2)C1=O)C  NAM  mGluR5  4.39  R  - 
Fc1ccccc1OCC(=O)N1CCCC[C@H]1C  NAM  mGluR5  5.00  R  - 
O1[C@@H](CN(C(C)(C)C)C1=O)COc1ccccc1  NAM  mGluR5  4.40  R  - 
O1[C@@H](CN(CCC)C1=O)COc1ccccc1  NAM  mGluR5  5.00  R  - 
O=C(NCCNc1ccccc1[N+](=O)[O-])C#CCCCC  NAM  mGluR5  7.77  H   
O=C1N(CC)C(=NC(N2C=Cc3c(C=C2)cccc3)=C1C#N)C  NAM  mGluR1  6.89  R  + 
Clc1cccc(Cl)c1-c1nc(c(n1C)-c1ccc(Cl)cc1)-c1ccncc1  NAM  mGluR2  7.70    + 
Clc1cccc(Cl)c1-c1nc(c(n1CC)-c1ccc(cc1)C)-c1ccncc1  NAM  mGluR2  7.70     
Clc1cccc(Cl)c1-c1nc(c(n1C1CC1)-c1ccc(Cl)cc1)-c1ccncc1  NAM  mGluR2  7.68     
Clc1ccc(cc1)-c1n(CC)c(nc1-
c1ccncc1)C(O)(C1CCCCC1)C1CCCCC1  NAM  mGluR2  7.70     
O=C(N1CCN(CC1)c1ncccc1[N+](=O)[O-])C#Cc1ccccc1  NAM  mGluR5  7.66  H   
O=C1Nc2c(N=C(C1)c1cc(-n3ccnc3)ccc1)cc(cc2)C#Cc1ccccc1  NAM  mGluR2  7.66     
Ic1cc2N=C(CC(=O)Nc2cc1-n1cccc1)c1cc(ccc1)C#N  NAM  mGluR2  7.60    + 
O=C1N(CCc2ccccc2)C(C)=C(C1)C(OC)=O  NAM  mGluR5  5.00  R  - 
Fc1ccc(cc1)C#Cc1cc2N=C(CC(=O)Nc2cc1)c1cc(-n2ncnc2)ccc1  NAM  mGluR2  7.52     
Fc1c(cccc1F)-c1cc2N=C(CC(=O)Nc2cc1)c1cc(-n2nncc2)ccc1  NAM  mGluR2  7.52     
s1c2c(N=CN(C2=O)c2ccc(cc2)C)c2c3[nH]ccc3cnc12  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5c([nH]cc5)c34)C2=O)cc1  NAM  mGluR1  7.51  R / H  + 
s1c2c(N=CN(C2=O)c2ccc(OC)cc2)c2c3[nH]ccc3cnc12  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5nc[nH]c5c34)C2=O)cc1  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5ncn(c5c34)C)C2=O)cc1  NAM  mGluR1  6.99  R / H  + 
s1c2c(N=CN(C2=O)c2ccc(cc2)C)c2c3[nH]ncc3cnc12  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5c([nH]nc5)c34)C2=O)cc1  NAM  mGluR1  7.42  R / H  + 
S1c2c(NC1=S)c1c3N=CN(C(=O)c3sc1nc2)c1ccc(cc1)C  NAM  mGluR1  6.00  R / H  + 
s1c2c(nc1SC)c1c3N=CN(C(=O)c3sc1nc2)c1ccc(cc1)C  NAM  mGluR1  6.10  R / H  + 
S1c2c(NC1=O)c1c3N=CN(C(=O)c3sc1nc2)c1ccc(cc1)C  NAM  mGluR1  6.00  R / H  + 
s1c2c(N=CN(C2=O)c2ccc(cc2)C)c2c3NCCOc3cnc12  NAM  mGluR1  6.15  R / H   
s1c2c(N=CN(C2=O)c2ccc(cc2)C)c2c3NC[C@H](Oc3cnc12)C  NAM  mGluR1  6.22  R / H   
s1c2c(N=CN(C2=O)c2ccc(OC)cc2)c2c3NCCOc3cnc12  NAM  mGluR1  7.51  R / H  + 
s1c2c(N=CN(C2=O)c2ccc(OC)cc2)c2c3NC[C@H](Oc3cnc12)C  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5OCCNc5c34)C2=O)cc1  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5OC[C@@H](Nc5c34)C)C2=O)cc1  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5OC[C@@H](Nc5c34)C)C2=O)cc1  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5O[C@@H](CNc5c34)C)C2=O)cc1  NAM  mGluR1  7.51  R / H  + 
Clc1ccc(N2C=Nc3c(sc4ncc5O[C@@H](CNc5c34)C)C2=O)cc1  NAM  mGluR1  7.51  R / H  + 
O1C[C@H]2CC(C[C@@]2(Cc2cc3c(cc2)cccc3)C1=O)=C  NAM  mGluR1  6.80  R  + 
O(C)c1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.03  R / H  + 
Ic1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  6.79  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C#N  NAM  mGluR1  6.76  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)N  NAM  mGluR1  7.49  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(O)nc2cc1  NAM  mGluR1  7.07  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc3N(CCCc3c2)C)cc1  NAM  mGluR1  7.49  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc3CCCc3c2)cc1  NAM  mGluR1  7.07  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc(cc2)CCC)cc1  NAM  mGluR1  7.49  R / H   
S1CCc2cc3cc(ccc3nc12)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CCC)c(nc2cc1)C  NAM  mGluR1  7.49  R / H   
O1CCCc2cc3cc(ccc3nc12)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R / H  + 
O(C)c1cc(ccc1OC)CC(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  5.00  R  + 
O(C)C1CCC(CC1)C(=O)c1cc2cc(cnc2cc1)CC  NAM  mGluR1  7.29  R / H   
O(C(C)(C)C)C(=O)N1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  5.00  R   
s1cc(cc1)CC(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.13  R / H   10. Appendix 
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O1CCCc2cc3cc(ccc3nc12)C(=O)Cc1ccc(cc1)C  NAM  mGluR1  6.80  R / H   
Fc1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  5.08  R   
Clc1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R / H   
s1cc(cc1)-c1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C(OC(C)C)=O  NAM  mGluR1  6.79  R / H   
OC1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.49  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)NCCOC  NAM  mGluR1  6.98  H   
s1ccnc1-c1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  5.00  R   
s1cccc1-c1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  5.48  R   
Oc1nc2c(cc1CC)cc(cc2)C(=O)Cc1ccccc1  NAM  mGluR1  7.07  R / H   
O(C)c1nc2c(cc1CC)cc(cc2)/C(=N\O)/C1CCC(OC)CC1  NAM  mGluR1  7.10  R / H   
O(C)c1nc2c(cc1CC)cc(cc2)/C(=N\O)/C1CCC(OC)CC1  NAM  mGluR1  5.00  R   
O(C)c1nc2c(cc1CC)cc(cc2)/C(=N\N)/C1CCC(OC)CC1  NAM  mGluR1  5.30  R   
O(C)c1nc2c(cc1CC)cc(cc2)C(=C)C1CCC(OC)CC1  NAM  mGluR1  5.36  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc3CCCCCc3c2)cc1  NAM  mGluR1  7.49  R / H   
O(C)C1CCC(CC1)C(=O)c1cc2C=C(CCC)[C@@H](Nc2cc1)C  NAM  mGluR1  7.49  R / H   
O=C(C1CCC(CC1)C)c1cc2c(nc3CCCCCc3c2)cc1  NAM  mGluR1  6.35  R / H   
O(C)c1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  H   
Clc1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  5.63  R   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.84  R   
O1CCCc2cc3c(nc12)cc(cc3)C(=O)Cc1ccccc1  NAM  mGluR1  7.19  R   
Clc1cc(Cl)ccc1C(OC[C@H]1[C@@H]2N(CCC1)CCCC2)=O  NAM  mGluR5  5.00  R  - 
O1C2=C(C=C([C@@H]1N(C)C)c1ccccc1)C(=O)CC(C2)(C)C  NAM  mGluR5  4.42  R  - 
Fc1ccc(cc1)-c1cc2N=C(CC(=O)Nc2cc1)c1cc(-n2cc(nc2)C)ccc1  NAM  mGluR2  7.44     
s1cc(nc1-c1cc(ccc1)C1=Nc2cc(ccc2NC(=O)C1)-c1ccccc1F)CC  NAM  mGluR2  7.41     
Fc1cc(cc(-n2cc(cc2)-c2ncccc2)c1)C#N  NAM  mGluR5  7.40  R   
O=C(Nc1n(ncc1-c1ccccc1)-c1ccccc1)c1ccccc1  NAM  mGluR5  5.93  R   
n1c(cn(c1C)-c1nc(ccc1)C1CC1)C#Cc1cc(ncc1)C  NAM  mGluR5  7.37     
s1c2c(N=CN(C2=O)c2ccc(OC)cc2)c2c1nccc2N(C)C  NAM  mGluR1  7.35  R / H  + 
O(C(=O)c1[nH]c(C)c(C(O[C@@H](C(C)(C)C)C)=O)c1C)CCC  NAM  mGluR1  7.32  R  + 
S(C(=O)c1[nH]cc(C(OC(C)(C)C)=O)c1C)c1ccncc1  NAM  mGluR1  5.52  R  + 
O(C(=O)c1[nH]c(C)c(C(O[C@H](C(C)(C)C)C)=O)c1C)CCC  NAM  mGluR1  7.32  R  + 
O(C(=O)c1[nH]c(C)c(C(O[C@@H](C(C)(C)C)C)=O)c1C)CCC  NAM  mGluR1  7.32  R  + 
o1cccc1C(OC1C[C@@H]2N([C@H](C1)CC2)C)=O  NAM  mGluR5  5.00  R  - 
O=C1c2c(-c3c1n(Cc1ccccc1)c(C)c3CN(C)C)cccc2  NAM  mGluR5  4.20  R  - 
Clc1sc(S(=O)(=O)N)cc1NC(=O)c1c2n(nc1)C(=CC(=N2)c1ccc(c
c1)C(F)(F)F)C(F)(F)F  NAM  mGluR2  7.28     
O=C(Nc1n2c(nc1-c1ccccc1)C=CC=C2)c1ccccc1  NAM  mGluR5  5.41  R   
O=C(Nc1n2c(nc1-c1ccccc1)C=CC=C2)c1cc(ccc1)C#N  NAM  mGluR5  5.70  R   
Fc1ccccc1-c1cc2N=C(CC(=O)Nc2cc1)c1cc(-n2nncc2)ccc1  NAM  mGluR2  7.27     
s1cc(nc1-c1cc(ccc1)C1=Nc2cc(ccc2NC(=O)C1)-
c1ccccc1F)C(O)=O  NAM  mGluR2  7.27     
O(C(=O)[C@@]12[C@@H](C1)\C(=N\O)\c1c(C2)cccc1)CC  NAM  mGluR1  5.82  H  + 
O1c2c(cccc2)/C(=N\O)/[C@@H]2C[C@]12C(=O)Nc1ccccc1  NAM  mGluR3  7.11    77 
o1cccc1C(=O)N1CCN(CC1)C1CCC(CC1)c1ccccc1  NAM  mGluR5  5.00  R  - 
Fc1cc(F)ccc1-c1cc2N=C(CC(=O)Nc2cc1)c1cc(-n2nncc2)ccc1  NAM  mGluR2  7.23     
o1c2c(cc1CN1CCCCC1)cccc2  NAM  mGluR5  5.00  R  - 
n12c(ccc1)C(=NC(=C2)C)C#Cc1ccccc1  NAM  mGluR5  8.07  H  + 
n12c(ccc1)C(=NC(=C2)C)C#Cc1cc(ccc1)C  NAM  mGluR5  8.03  H  + 
Fc1ccc(cc1)C#CC1=NC(=Cn2c1ccc2)C  NAM  mGluR5  7.80  H  + 
Clc1ccc(cc1)C#CC1=NC(=Cn2c1ccc2)C  NAM  mGluR5  6.20  H  + 
Brc1ccc(cc1)C#CC1=NC(=Cn2c1ccc2)C  NAM  mGluR5  0.01  H  + 
Oc1cc(ccc1)C#CC1=NC(=Cn2c1ccc2)C  NAM  mGluR5  6.50  H  + 
n12c(ccc1)C(=NC(=C2)C)C#C[C@@H]1NC=CC=N1  NAM  mGluR5  5.70  H  + 
n12c(ccc1)C(=NC(=C2)C)C#C[C@H]1NC=Cc2c1cccc2  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(c1)C=CN=C2C#Cc1ccccc1  NAM  mGluR5  6.80  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1  NAM  mGluR5  7.40  H  + 
n12c(cc(c1)C#N)C(=NC(=C2)C)C#Cc1ccccc1  NAM  mGluR5  8.05  H  + 
O=C(N1CCN(CC1)C)c1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1  NAM  mGluR5  7.00  H  + 
O=C(N1CCCC1)c1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1  NAM  mGluR5  7.10  H  + 
O1CCN(CC1)C(=O)c1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1  NAM  mGluR5  7.80  H  + 
n12c(cc(c1)C)C(=NC(=C2)C)C#Cc1ccccc1  NAM  mGluR5  7.30  H  + 
O(C(=O)c1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1)CC  NAM  mGluR5  8.00  H  + 
o1nc(nc1-c1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1)C  NAM  mGluR5  8.09  H  + 10. Appendix 
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O=C(NC)c1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1  NAM  mGluR5  6.90  H  + 
n12c(cc(c1)CN1CCCCC1)C(=NC(=C2)C)C#Cc1ccccc1  NAM  mGluR5  6.80  H  + 
n12c(cc(c1)CN1CCN(CC1)C)C(=NC(=C2)C)C#Cc1ccccc1  NAM  mGluR5  6.30  H  + 
O=C(N1CCN(CC1)Cc1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1)C  NAM  mGluR5  6.50  H  + 
O=C1NCCN(C1)Cc1cc2n(C=C(N=C2C#Cc2ccccc2)C)c1  NAM  mGluR5  6.70  H  + 
FC(F)(F)c1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C)C  NAM  mGluR5  0.01  H  + 
Clc1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C)C  NAM  mGluR5  0.01  H  + 
Fc1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C)C  NAM  mGluR5  6.40  H  + 
n12c(cc(c1)C)C(=NC(=C2)C)C#Cc1ccc(cc1)C#N  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C)C  NAM  mGluR5  6.80  H  + 
n12c(cc(c1)C)C(=NC(=C2)C)C#Cc1cc(ccc1)[C@@H]1NC=CC=
C1  NAM  mGluR5  5.70  H  + 
s1cc(cc1)-c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C)C  NAM  mGluR5  7.20  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2cc(OC)ccc2)C)c1  NAM  mGluR5  7.10  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  6.50  H  + 
Fc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  7.80  H  + 
Clc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  7.00  H  + 
Brc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  7.60  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2cc(ccc2)C#N)C)c1  NAM  mGluR5  7.90  H  + 
S(=O)(=O)(Nc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C)C  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2cc(NC(=O)C)ccc2)C)c1  NAM  mGluR5  6.10  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2cc(ccc2)C(O)=O)C)c1  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2cc(ccc2)C(OC(C)(C)C)=O)C)
c1  NAM  mGluR5  0.01  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  6.90  H  + 
Clc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  5.30  H  + 
FC(F)(F)c1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  0.01  H  + 
Fc1cc(F)ccc1C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  0.01  H  + 
Fc1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  7.00  H  + 
Clc1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  5.70  H  + 
FC(F)(F)c1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2ccc(cc2)C#N)C)c1  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2ccc(N(C)C)cc2)C)c1  NAM  mGluR5  0.01  H  + 
S(=O)(=O)(Nc1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C)C  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#CC=2C=CNCC=2)C)c1  NAM  mGluR5  7.10  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#C[C@@H]2NC=CC=C2)C)c1  NAM  mGluR5  7.30  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#CC=2CNC=CC=2)C)c1  NAM  mGluR5  6.30  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2n(cnc2)C)C)c1  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#Cc2ccoc2)C)c1  NAM  mGluR5  7.30  H  + 
s1cccc1C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  7.20  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(F)(F)F)C  NAM  mGluR5  8.00  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#C[C@H]2C=C(C=CC2)c2cn[nH]c
2)C)c1  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#C[C@H]2C=C(C=CC2)c2cnoc2)
C)c1  NAM  mGluR5  6.10  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#C[C@H]2C=C(C=CC2)c2cn(nc2)
C)C)c1  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#C[C@H]2C=C(C=CC2)c2c(noc2
C)C)C)c1  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1cc2n(C=C(N=C2C#C[C@H]2C=C(C=CC2)c2ccoc2)
C)c1  NAM  mGluR5  5.00  H  + 
s1cc(cc1)C=1C=CC[C@@H](C=1)C#CC1=NC(=Cn2c1cc(c2)C(
F)(F)F)C  NAM  mGluR5  5.30  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C#N)C  NAM  mGluR5  8.07  H  + 
Fc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C#N)C  NAM  mGluR5  8.04  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C#N)C  NAM  mGluR5  7.80  H  + 
s1cc(cc1)-c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C#N)C  NAM  mGluR5  8.03  H  + 
Clc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(OCC)=O)C  NAM  mGluR5  7.70  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(OCC)=O)C  NAM  mGluR5  6.70  H  + 
O(C(=O)c1cc2n(C=C(N=C2C#Cc2cc(ccc2)C#N)C)c1)CC  NAM  mGluR5  8.07  H  + 
O(C(=O)c1cc2n(C=C(N=C2C#Cc2ccc(cc2)C#N)C)c1)CC  NAM  mGluR5  0.01  H  + 
FC(F)(F)c1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(OCC)=O)C  NAM  mGluR5  0.01  H  + 
Clc1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(OCC)=O)C  NAM  mGluR5  0.01  H  + 
Fc1ccc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(OCC)=O)C  NAM  mGluR5  6.40  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(OCC)=O)C  NAM  mGluR5  6.50  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(OCC)=O)C  NAM  mGluR5  8.09  H  + 10. Appendix 
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O(C(=O)c1cc2n(C=C(N=C2C#C[C@@H]2NC=CC=C2)C)c1)CC  NAM  mGluR5  5.80  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(=O)N)C  NAM  mGluR5  6.30  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N)C  NAM  mGluR5  7.10  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N)C  NAM  mGluR5  7.30  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(=O)NC)C  NAM  mGluR5  5.80  H  + 
Fc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)NC)C  NAM  mGluR5  7.00  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)NC)C  NAM  mGluR5  7.30  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCCC1)C  NAM  mGluR5  6.60  H  + 
Fc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCCC1)C  NAM  mGluR5  7.70  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCCC1)
C  NAM  mGluR5  6.80  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCCC1)C  NAM  mGluR5  7.70  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCOCC1)C  NAM  mGluR5  6.90  H  + 
Fc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCOCC1)C  NAM  mGluR5  7.70  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCOCC
1)C  NAM  mGluR5  7.90  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCOCC1)C  NAM  mGluR5  8.00  H  + 
Fc1ccccc1C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCN(CC1)C)C  NAM  mGluR5  5.90  H  + 
Fc1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCN(CC1)C)C  NAM  mGluR5  6.70  H  + 
FC(F)(F)c1cc(ccc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCN(C
C1)C)C  NAM  mGluR5  6.60  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCN(CC1)C)C  NAM  mGluR5  6.80  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCCC1(C)C)C  NAM  mGluR5  5.90  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CC(F)(F)CC1)C  NAM  mGluR5  6.90  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1[C@@H](CC[C@
H]1C)C)C  NAM  mGluR5  6.40  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1C[C@H](O[C@@
H](C1)C)C)C  NAM  mGluR5  6.50  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCC[C@H]1C)C  NAM  mGluR5  7.40  H  + 
s1cc(cc1)C#CC1=NC(=Cn2c1cc(c2)C(=O)N1CCCC[C@H]1C)C  NAM  mGluR5  7.00  H  + 
O(C(=O)CCc1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.05    + 
Ic1cc(ccc1)C(Oc1cc(ccc1)C#Cc1nc(ccc1)C)=O  NAM  mGluR5  5.96     
O(C(=O)CCCc1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.93     
S(Oc1cc(ccc1)C#Cc1nc(ccc1)C)(=O)(=O)C  NAM  mGluR5  6.74     
O(CCc1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.80     
Fc1ccc(cc1)CCOc1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.69     
O(CCCc1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.92     
O(CCCCc1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.94     
O(CC1CC1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.38     
O(Cc1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.74     
Ic1cc(ccc1)COc1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.70     
O(Cc1cc(OC)ccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.89     
O(CC(OC)=O)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.62     
n1c(cccc1C)C#Cc1cc(ccc1)-c1ccccc1  NAM  mGluR5  6.00     
O(C)c1cc(ccc1)-c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.63     
o1cccc1-c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.43     
s1cccc1-c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.18     
n1c(cccc1C)C#Cc1cc(cnc1)-c1ccccc1  NAM  mGluR5  7.70     
O(C)c1cc(ccc1)-c1cc(cnc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.55     
o1cccc1-c1cc(cnc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.69     
s1cccc1-c1cc(cnc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.57     
n1c(cccc1C)-c1cc(cnc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.59     
n1c(cccc1C)C#Cc1cc(N)ccc1  NAM  mGluR5  6.73     
O(C(=O)c1cc(ccc1)C#Cc1nc(ccc1)C)C  NAM  mGluR5  6.68     
O=C(C)c1cc(cnc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.84     
O(C(=O)c1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.82     
BrCCCC(Oc1cc(ccc1)C#Cc1nc(ccc1)C)=O  NAM  mGluR5  5.47     
O(C(=O)c1cc(OC)ccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  5.76     
o1cccc1C(Oc1cc(ccc1)C#Cc1nc(ccc1)C)=O  NAM  mGluR5  6.00     
O(C(=O)Cc1ccccc1)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.13     
Clc1cc(ccc1)-c1onc(n1)C[C@H]1CCn2c1nnc2-c1ccncc1  NAM  mGluR5  7.31  H   
Fc1cc(cc(-n2nc(nn2)-c2ncc(cc2)C#N)c1)C#N  NAM  mGluR5  7.96  H   
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)C#N  NAM  mGluR5  7.85     
Clc1ccc(nc1)-c1nn(nn1)-c1cc(cc(F)c1)C#N  NAM  mGluR5  7.74  H   
Brc1ccc(nc1)-c1nn(nn1)-c1cc(cc(F)c1)C#N  NAM  mGluR5  7.21  H   10. Appendix 
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Clc1cc(ccc1)-c1onc(n1)CCN1CCCCn2c1nnc2-c1ccncc1  NAM  mGluR5  7.09  H   
Clc1cc(ccc1)-c1nc(on1)[C@@H]1N(CCOC1)c1nnc(n1C)-
c1ccc(OC(F)F)cc1  NAM  mGluR5  6.70  H   
Clc1cc(-n2nc(cn2)[C@H](Oc2nnc(n2C)-c2ccncc2)C)ccc1  NAM  mGluR5  7.39  H   
Clc1cc(-n2nnc(c2)CSc2nnc(n2C2CC2)-c2ccncc2)ccc1  NAM  mGluR5  6.58  H   
Clc1cc(-n2nc(nn2)[C@H](Sc2nnc(n2C)-c2ccncc2)C)ccc1  NAM  mGluR5  7.26  H   
Clc1cc(-n2nc(nn2)[C@@H](N2CCN(CC2)C(OCC)=O)C)ccc1  NAM  mGluR5  6.88  H   
Fc1cc(cc(-n2nc(nn2)-c2ncc(F)cc2)c1)C#N  NAM  mGluR5  7.96  H   
Clc1nc(C(=O)Nc2ncccc2)c(nc1N(C)C)N  NAM  mGluR5  6.87     
Clc1nc(cnc1N(C)C)C(=O)Nc1ncccc1  NAM  mGluR5  6.80     
Clc1nc(C(=O)Nc2ncccc2)c(nc1N1CCCCC1)N  NAM  mGluR5  6.99     
Clc1nc(C(=O)Nc2ncccc2)c(nc1NC(C)C)N  NAM  mGluR5  7.44     
Clc1nc(C(=O)Nc2ncccc2)c(nc1N)N  NAM  mGluR5  5.42     
Clc1nc(C(=O)Nc2ncccc2)c(nc1)N  NAM  mGluR5  7.44     
Clc1nc(cnc1)C(=O)Nc1ncccc1  NAM  mGluR5  6.60     
O=C(Nc1ncccc1)c1nc(cnc1)C  NAM  mGluR5  6.78     
O=C(Nc1ncccc1)c1nccnc1N  NAM  mGluR5  5.45     
Brc1nc(C(=O)Nc2ncccc2)c(nc1)N  NAM  mGluR5  7.44     
O=C(Nc1ncccc1)c1nc(cnc1N)C  NAM  mGluR5  7.55     
Clc1nc(C(=O)Nc2ncccc2)c(nc1)NC  NAM  mGluR5  6.84     
Clc1nc(C(=O)Nc2nc(ccc2)C)c(nc1)N  NAM  mGluR5  7.44     
O=C(Nc1nc(ccc1)C)c1nc(cnc1N)C  NAM  mGluR5  7.44     
O=C(Nc1nc(ccc1)C)c1nc(ccc1)C  NAM  mGluR5  7.44     
Oc1ccc(nc1C(=O)Nc1nc(ccc1)C)C  NAM  mGluR5  7.44     
Brc1nc(ccc1)C(=O)Nc1nc(ccc1)C  NAM  mGluR5  7.44     
O=C(Nc1ncccc1)c1ncc(nc1N)N(C)C  NAM  mGluR5  5.29     
O=C(Nc1nc(ccc1)C)c1nc(ccc1N)C  NAM  mGluR5  7.44     
n1c(cccc1C)C#Cc1ccccc1  NAM  mGluR5  7.52  R/H   
s1ccnc1C#Cc1ccccc1  NAM  mGluR5  7.09     
s1cc(nc1)C#Cc1ccccc1  NAM  mGluR5  7.01     
s1cc(nc1C#Cc1ccccc1)C  NAM  mGluR5  7.89     
s1cc(nc1C)C#Cc1ccccc1  NAM  mGluR5  7.01  R/H  + 
s1cc(nc1C)C#Cc1ncccc1  NAM  mGluR5  7.28    + 
s1cc(nc1C)C#Cc1cccnc1  NAM  mGluR5  7.61  R/H  + 
s1cc(nc1C)C#Cc1ccncc1  NAM  mGluR5  6.91     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1ccccc1  NAM  mGluR5  6.48     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1ccccc1C  NAM  mGluR5  6.95     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)C#N  NAM  mGluR5  6.72     
O(c1cc(-n2nc(nn2)-c2ncccc2)ccc1)c1ccccc1  NAM  mGluR5  5.84     
O(c1cc(-n2nc(nn2)-c2ncccc2)ccc1)c1ncccc1  NAM  mGluR5  5.54     
O(c1cc(-n2nc(nn2)-c2ncccc2)ccc1)c1cccnc1  NAM  mGluR5  7.23     
O(c1ccc(-n2nc(nn2)-c2ncccc2)cc1)c1cccnc1  NAM  mGluR5  6.13     
Fc1cc(-n2nc(nn2)-c2ncccc2)cc(Oc2cccnc2)c1  NAM  mGluR5  7.92     
S(c1cc(-n2nc(nn2)-c2ncccc2)cc(F)c1)c1cccnc1  NAM  mGluR5  7.80     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)Cc1cccnc1  NAM  mGluR5  7.42     
Fc1cc(Nc2cccnc2)cc(-n2nc(nn2)-c2ncccc2)c1  NAM  mGluR5  6.91     
Fc1cc(N(C)c2cccnc2)cc(-n2nc(nn2)-c2ncccc2)c1  NAM  mGluR5  7.52     
Fc1cc(-n2c3c(cc2)ccnc3)cc(-n2nc(nn2)-c2ncccc2)c1  NAM  mGluR5  7.60     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1  NAM  mGluR5  6.61     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1C  NAM  mGluR5  6.92     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cc(ccc1)C  NAM  mGluR5  5.83     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1C#N  NAM  mGluR5  7.96     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1N  NAM  mGluR5  7.96     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ncccc1  NAM  mGluR5  7.02     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cccnc1  NAM  mGluR5  7.43     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ncccc1C  NAM  mGluR5  7.51     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccncc1C  NAM  mGluR5  7.20     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cccnc1C  NAM  mGluR5  7.35     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cnccc1C  NAM  mGluR5  7.96     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccc(nc1)C  NAM  mGluR5  7.24     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cc(cnc1)C  NAM  mGluR5  6.30     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cnccc1N  NAM  mGluR5  6.97     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ncccc1N  NAM  mGluR5  7.51     10. Appendix 
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Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccncc1  NAM  mGluR5  6.02     
n1ccccc1-c1ccn(c1)-c1cc(ccc1)C#N  NAM  mGluR5  5.00     
n1ccccc1-n1nc(cc1)-c1cc(ccc1)C#N  NAM  mGluR5  5.00     
n1ccccc1-c1nn(cc1)-c1cc(ccc1)C#N  NAM  mGluR5  6.28     
n1ccccc1-n1ncc(c1)-c1cc(ccc1)C#N  NAM  mGluR5  5.00     
n1ccccc1-c1cn(nc1)-c1cc(ccc1)C#N  NAM  mGluR5  6.60     
n1ccccc1-c1ncn(c1)-c1cc(ccc1)C#N  NAM  mGluR5  5.94     
n1ccccc1-n1nc(cn1)-c1cc(ccc1)C#N  NAM  mGluR5  6.68     
n1ccccc1-c1nnn(c1)-c1cc(ccc1)C#N  NAM  mGluR5  5.00     
n1ccccc1-c1nn(nc1)-c1cc(ccc1)C#N  NAM  mGluR5  6.52     
n1cn(nc1-c1cc(ccc1)C#N)-c1ncccc1  NAM  mGluR5  5.00     
n1ccccc1-c1ncn(n1)-c1cc(ccc1)C#N  NAM  mGluR5  5.00     
n1ccccc1-n1nc(nn1)-c1cc(ccc1)C#N  NAM  mGluR5  6.35     
o1nc(nc1-c1cc(ccc1)C#N)-c1ncccc1  NAM  mGluR5  6.31     
n1ccccc1-n1cc(cc1)-c1cc(ccc1)C#N  NAM  mGluR5  5.00     
Fc1cc(cc(-n2nc(nn2)-c2[nH]c(cn2)C)c1)C#N  NAM  mGluR5  7.11     
Fc1cc(-n2nc(nn2)-c2[nH]ccn2)cc(Oc2cccnc2)c1  NAM  mGluR5  7.96     
Fc1cc(cc(-n2nc(nn2)-c2[nH]ccn2)c1)-c1cnccc1C  NAM  mGluR5  7.70     
s1ccnc1-c1nn(nn1)-c1cc(ccc1)C#N  NAM  mGluR5  6.74     
s1cc(nc1)-c1nn(nn1)-c1cc(ccc1)C#N  NAM  mGluR5  6.80     
[nH]1ccnc1-c1nn(nn1)-c1cc(ccc1)C#N  NAM  mGluR5  7.11     
Fc1cc(cc(-n2nc(nn2)-c2[nH]ccn2)c1)C#N  NAM  mGluR5  7.33     
Clc1cc(NC(=O)\N=C\2/NC(=O)CN/2C)ccc1  NAM  mGluR5  6.48     
Clc1cc(ccc1CC#N)-c1oc2c(n1)cccc2  NAM  mGluR5  7.52     
o1c2c(nc1-c1cc(OC)c(cc1)CC#N)cccc2  NAM  mGluR5  7.38     
o1c2c(nc1-c1cc(OC)c(cc1)-c1cccnc1)cccc2  NAM  mGluR5  6.38     
O(C)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  8.26  R/H   
n1c(cccc1C)C#Cc1cc(ccc1)C#N  NAM  mGluR5  8.52  R/H   
n1c(cccc1C)C#Cc1cccnc1  NAM  mGluR5  7.30  R  + 
o1c2c(nc1-c1cc(OC)c(cc1)-c1ncccc1)cccc2  NAM  mGluR5  6.80  R/H   
s1c2c(N=CN(N3CCCCCC3)C2=O)c2c1nccc2N(C)C  NAM  mGluR1  5.97  H  - 
n1c(cccc1Nc1ncc(c2c1nccc2)-c1cccnc1)C  NAM  mGluR5  6.91  R/H   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.49  R   
O(C)c1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49     
O(C)C1CCC(CC1)C(=O)c1cc2cc(cnc2cc1)CC  NAM  mGluR1  7.49  R   
Clc1nc2cc(C)c(cc2cc1CC)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)N(C)C  NAM  mGluR1  7.49     
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)COC(=O)C  NAM  mGluR1  7.04     
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(O)nc2cc1  NAM  mGluR1  7.49     
O=C(Cc1ccccc1)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.49  R   
O=C([C@H]1[C@H]2CC[C@@H](C1)C2)c1cc2cc(CC)c(nc2cc1
)C  NAM  mGluR6  7.49  R   
O(C)C1CCC(CC1)CC(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.49     
O=C(C1CCC(CC1)C)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.49     
FC1(CCC(OC)CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.49     
O=C(C1Cc2c(C1)cccc2)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.25     
O=C(C[C@@H]1[C@@H]2CC[C@H](C1)C2)c1cc2cc(CC)c(nc
2cc1)C  NAM  mGluR1  7.22     
O(C)c1ccccc1CC(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  7.17     
O1c2c(OC[C@@H]1C(=O)c1cc3cc(CC)c(nc3cc1)C)cccc2  NAM  mGluR1  7.08     
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)C#N  NAM  mGluR1  7.49     
S1CCc2cc3cc(ccc3nc12)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc3N(CCCc3c2)C)cc1  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2C=C(CC)C(=O)Nc2cc1  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2nc(C)c(nc2cc1)C  NAM  mGluR1  7.44     
O(C)C1CCC(CC1)C(=O)c1cc2C=C(c3n(nnn3)-c2cc1)CC  NAM  mGluR1  7.36     
s1cc(cc1)C(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.49     
Brc1ccc(cc1)C(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.49     
Fc1ccc(cc1)C(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.49     
Fc1c(cccc1F)C(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.13     
O1CCCc2cc3cc(ccc3nc12)Cc1ccccc1  NAM  mGluR1  7.07     
Fc1ccccc1C(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.38     
O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@@]12C(OCC)=O  NAM  mGluR1  5.47     
O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@]12C(OCC)=O  NAM  mGluR1  5.52     10. Appendix 
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O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@@]12C(OCC)=O  NAM  mGluR1  5.82     
O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@@]12C(=O)N[C@H](Cc1c
cccc1)C(OC)=O  NAM  mGluR1  6.37     
O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@@]12C(=O)N[C@@H](Cc
1ccccc1)C(OC)=O  NAM  mGluR1  5.85     
O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@@]12C(=O)N[C@@H](Cc
1ccccc1)C(OC)=O  NAM  mGluR1  6.03     
O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@@]12C(=O)N[C@H](Cc1c
cccc1)C(OC)=O  NAM  mGluR1  5.85     
S(CCO)c1nc(Nc2ccc(OC)cc2)c2cc(OC)ccc2n1  NAM  mGluR1  7.33     
Clc1cccc(Cl)c1CSCCNc1nc(nc2c1CCCC2)C  NAM  mGluR1  7.57     
Clc1cc2c(nc(SCCO)nc2NC2C3CCC2CC3)cc1  NAM  mGluR1  7.36     
Clc1cccc(Cl)c1CSCCNc1ncnc2c1cccc2  NAM  mGluR1  7.34     
O(C)c1ccc(Nc2ncnc3c2cc(OC)cc3)cc1  NAM  mGluR1  7.02     
Clc1cc2c(ncnc2NC2C3CCC2CC3)cc1  NAM  mGluR1  6.40     
Clc1c2ncnc(NC3C4CCC3CC4)c2ccc1  NAM  mGluR1  5.72     
O(CCOC)c1nc(N2CCc3c(CC2)cccc3)c(nn1)C#N  NAM  mGluR1  5.52     
n1c(N2CCc3c(CC2)cccc3)c(nnc1N)C#N  NAM  mGluR1  7.28     
n1c(N2CCc3c(CC2)cccc3)c(nnc1N(C)C)C#N  NAM  mGluR1  5.86     
n1c(N2CCc3c(CC2)cccc3)c(nnc1NCC1CC1)C#N  NAM  mGluR1  7.28     
OCCNc1nc(N2CCc3c(CC2)cccc3)c(nn1)C#N  NAM  mGluR1  7.28     
O[C@@H](CNc1nc(N2CCc3c(CC2)cccc3)c(nn1)C#N)C  NAM  mGluR1  7.28     
n1c(N2CCc3c(CC2)cccc3)c(nnc1NN)C#N  NAM  mGluR1  6.43     
O(C(C)(C)C)C(=O)NCCNc1nc(N2CCc3c(CC2)cccc3)c(nn1)C#N  NAM  mGluR1  7.28     
n1c(N2CCc3c(CC2)cccc3)c(nnc1NCCc1cccnc1)C#N  NAM  mGluR1  7.28     
n1c(CC)c(nc(N2CCc3c(CC2)cccc3)c1C#N)C  NAM  mGluR1  7.28     
n1c(C)c(nc(N2CCc3c(CC2)cccc3)c1C#N)CC  NAM  mGluR1  6.99     
n1ccnc(N2CCc3c(CC2)cccc3)c1C#N  NAM  mGluR1  6.33     
n1c(-c2ccccc2)c(nc(N2CCc3c(CC2)cccc3)c1C#N)C  NAM  mGluR1  7.28     
OCCNc1nc(N2CCc3c(CC2)cccc3)c(nc1)C#N  NAM  mGluR1  6.30     
s1c2CCN(CCc2nc1C)C=1N=C(NC(=O)C=1[N+](=O)[O-])C  NAM  mGluR1  4.52     
s1c2CCN(CCc2nc1C)c1nc(nc(OCC)c1[N+](=O)[O-])C  NAM  mGluR1  5.38     
s1c2CCN(CCc2nc1C)C=1N=C(N(CC)C(=O)C=1[N+](=O)[O-])C  NAM  mGluR1  5.68     
s1c2CCN(CCc2nc1N)C=1N=C(NC(=O)C=1[N+](=O)[O-])C  NAM  mGluR1  4.31     
s1c2CCN(CCc2nc1N)C=1N=C(N(CC)C(=O)C=1[N+](=O)[O-])C  NAM  mGluR1  5.22     
s1c2CCN(CCc2nc1)C=1N=C(NC(=O)C=1[N+](=O)[O-])C  NAM  mGluR1  4.37     
s1c2CCN(CCc2cc1)C=1N=C(NC(=O)C=1[N+](=O)[O-])C  NAM  mGluR1  5.72     
s1c2CCN(CCc2cc1)c1nc(nc(OCC)c1[N+](=O)[O-])C  NAM  mGluR1  6.36     
s1c2CCN(CCc2cc1)C=1N=C(N(CC)C(=O)C=1[N+](=O)[O-])C  NAM  mGluR1  7.16     
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)N1CCCCC1  NAM  mGluR1  5.44     
o1cccc1-c1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  6.59     
O(C)C1CCC(CC1)C(=O)Nc1cc2cc(CC)c(O)nc2cc1  NAM  mGluR1  5.00     
O1c2c(cccc2)/C(=N/O)/[C@H]2C[C@@]12C(=O)N(C)c1ccccc1  NAM  mGluR1  5.70     
O1CCCc2cc3c(nc12)cc(cc3)C(=O)c1ccccc1  NAM  mGluR1  5.08     
O(C)C1CCC(CC1)C(=O)c1ccc(NC(=O)C)cc1  NAM  mGluR1  5.12     
O(C)C1CCC(CC1)C(=O)c1cc2[nH]c(nc2cc1)C  NAM  mGluR1  6.24     
O=C(CCc1ccccc1)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.64     
O=C(Cc1ccc(N(C)C)cc1)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.19     
O=C([C@@H]1CCc2c1cccc2)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.61     
O=C(C1CCNCC1)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  5.00     
O=C(C1CCC(N(C)C)CC1)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  5.00     
O(C)c1cc(ccc1OC)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  5.00     
O1C[C@@H](Cc2c1cccc2)C(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.94     
O=C(C12CC3CC(C1)CC(C2)C3)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.90     
O=C(CC(C)C)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.79     
O(C)c1cc(ccc1)CC(=O)c1cc2cc(CC)c(nc2cc1)C  NAM  mGluR1  6.87     
O(C)C1CCC(NC(=O)c2cc3cc(CC)c(O)nc3cc2)CC1  NAM  mGluR1  5.00     
O(C)C1CCC(CC1)\C(=N\O)\c1cc2cc(CC)c(O)nc2cc1  NAM  mGluR1  5.00     
Fc1cc(ccc1)C(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.32     
n1c(cccc1C)C#Cc1ccc(cc1)C#N  NAM  mGluR5  6.00     
Oc1ccccc1C#Cc1nc(ccc1)C  NAM  mGluR5  8.06     
n1c(cccc1C)C#Cc1ccccc1C  NAM  mGluR5  8.70     
n1c(cccc1C)C#Cc1cc(ccc1)C  NAM  mGluR5  7.48     
O=C(Nc1ccccc1)c1nc(ccc1)C  NAM  mGluR5  7.44     10. Appendix 
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Oc1ccc(cc1)C#Cc1nc(ccc1)C  NAM  mGluR5  8.70     
O(C)c1ccccc1C#Cc1nc(ccc1)C  NAM  mGluR5  8.70     
n1c(cccc1C)C#Cc1ccc(cc1)C  NAM  mGluR5  8.70     
O(C(=O)c1c(C)c([nH]c1C)C(OCCCC)=O)C(C)(C)C  NAM  mGluR1  6.80     
O1CCCc2cc3cc(ccc3nc12)C(=O)c1ccccc1  NAM  mGluR1  7.49     
O1CCCc2cc3cc(ccc3nc12)C(=O)Cc1ccccc1  NAM  mGluR1  7.49  R   
Brc1cc2SC3=C(CCC(C3)(C)C)C(=O)c2cc1  NAM  mGluR1  8.05     
S1C2=C(CCC(C2)(C)C)C(=O)c2c1cc(cc2)-c1cccnc1  NAM  mGluR1  7.51     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2c1cc(cc2)-
c1cc(ccc1)C#N  NAM  mGluR1  7.64     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2c1cc(N1CCCCC1)cc2  NAM  mGluR1  7.89     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2cc(F)c(N3CCCCC3)cc12  NAM  mGluR5  7.55     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2c1cc(N(COCC)C)cc2  NAM  mGluR1  7.66     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2c1cc(cc2)-c1cncnc1  NAM  mGluR1  7.46     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2c1cc(cc2)C=1NC(ON=1)
=O  NAM  mGluR1  7.09     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2c1cc(NS(=O)(=O)C1CC1
)cc2  NAM  mGluR1  7.60     
o1cc(nc1-c1cc(ccc1)C#N)-c1ncccc1  NAM  mGluR5  7.35     
S(CC(OCC)=O)c1nc(N)c(cn1)Cc1ccccc1  NAM  mGluR5  6.85     
Brc1ccc(cc1)Cc1cnc(SCC(OCC)=O)nc1N  NAM  mGluR5  6.74     
s1cc(cc1)Cc1cnc(SCC(OCC)=O)nc1N  NAM  mGluR5  6.74     
S(CC(OCC)=O)c1nc(N)c(cn1)Cc1ccoc1  NAM  mGluR5  6.80     
S(CC(OCC=C)=O)c1nc(N)c(cn1)Cc1ccccc1  NAM  mGluR5  6.92     
s1cccc1Cc1cnc(SCC(OCC)=O)nc1NCC(C)C  NAM  mGluR5  6.80     
S1C2=C(CC[C@@H](C2)CC)C(=O)c2c1cc(cc2)-c1[nH]nnn1  NAM  mGluR1  8.05     
FC(F)(F)COc1nc(nc(N2CCC(CC2)c2ccccc2)c1C#N)NCCO  NAM  mGluR1  7.44     
Clc1nc(nc(N2CCN(CC2)c2ccccc2)c1C#N)NCC1CC1  NAM  mGluR1  7.60     
Fc1ccc(N2CCN(CC2)C=2N=C(N(CCO)C(=O)C=2[N+](=O)[O-
])C)cc1  NAM  mGluR1  7.38     
Fc1ccc(N2CCN(CC2)c2nc(nc(OCCO)c2[N+](=O)[O-])C)cc1  NAM  mGluR1  7.24     
Fc1ccc(N2CCN(CC2)C=2N=C(N(CC)C(=O)C=2[N+](=O)[O-
])C)cc1  NAM  mGluR1  7.31     
n1c(N2CCN(CC2)c2ccccc2)c(C#N)c(nc1NC1CC1)NC1CC1  NAM  mGluR1  7.19     
OCCNc1nc(nc(N2CCN(CC2)c2ccccc2)c1C#N)NC1CC1  NAM  mGluR1  7.48     
OCCNc1nc(nc(N2CCC(CC2)c2ccccc2)c1C#N)NCc1cccnc1  NAM  mGluR1  7.52     
ClC=1C=Cn2cc(nc2C=1)-c1cc(C)c(cc1)C  NAM  mGluR5  8.09     
O(C)C=1C=Cn2cc(nc2C=1)-c1cc(C)c(cc1)C  NAM  mGluR5  8.10     
n1c2n(cc1-c1cc(C)c(cc1)C)C=CC=C2  NAM  mGluR5  8.10     
n1c2n(cc1-c1cc(C)c(cc1)C)C=CC(=C2)C  NAM  mGluR5  8.10     
Brc1cc(ccc1F)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.10     
s1c(C)c(cc1C)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.10     
O(C(=O)c1[nH]cc(c1)C(O[C@@H](C(C)(C)C)C)=O)CCC  NAM  mGluR1  7.32     
Oc1ccc(nc1N=Nc1ccccc1)C  NAM  mGluR5  5.43     
O(C)c1cc(ccc1OC)-c1nc2n(c1)C=CC(=C2)C  NAM  mGluR5  8.06     
O(C)c1cc(ccc1OC)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
O(C)c1cc(ccc1OC)-c1nc2n(c1)C=CC(OC)=C2  NAM  mGluR5  8.06     
O(Cc1ccccc1)c1ccc(cc1OC)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
Brc1cc(ccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
Ic1cc(ccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
Clc1cc(ccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
n1c2n(cc1-c1cc(ccc1)C)C=CC=C2  NAM  mGluR5  8.06     
FC(F)(F)c1cc(ccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
Fc1cc(ccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
n1c2n(cc1-c1cc(C)c(cc1)C)C=CC(=C2)CC  NAM  mGluR5  8.06     
s1c(ccc1C)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
n1c2n(cc1-c1ccccc1)C=CC(=C2)C  NAM  mGluR5  8.09     
n1c2n(cc1-c1ccc(cc1)C)C=CC=C2  NAM  mGluR5  8.06     
O(C)c1cc(ccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
O(C)c1cc(ccc1OC)-c1nc2n(C=C(C=C2)C)c1  NAM  mGluR5  8.06     
O1c2c(OC[C@H]1c1nc3n(c1)C=CC=C3)cccc2  NAM  mGluR5  8.06     
n1c2n(C=C(C=C2)C)cc1-c1ccc(cc1)C  NAM  mGluR5  8.09     
n1c2n(cc1-c1cc3CCCc3cc1)C=CC=C2  NAM  mGluR5  8.06     
o1c2c(cc1-c1nc3n(c1)C=CC=C3)cccc2  NAM  mGluR5  8.06     
s1cc(c2c1cccc2)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     10. Appendix 
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O1CCc2cc(ccc12)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
S(CC(OCC)=O)c1nc(N)c(cn1)Cc1n(ccc1)C  NAM  mGluR5  6.42     
Clc1cc(Cl)ccc1-c1cnc(SCC(OCC)=O)nc1N  NAM  mGluR5  5.41     
S(CC(OCC)=O)c1nc(N)c(cn1)C(OCC)=O  NAM  mGluR5  6.57     
s1cccc1Cc1cnc(SCC(OCC)=O)nc1NCC  NAM  mGluR5  6.22     
s1cccc1Cc1cnc(SCC#C)nc1N  NAM  mGluR5  5.86     
S(CC(OC[C@@H]1C[C@H]1C)=O)c1nc(N)c(cn1)Cc1ccccc1  NAM  mGluR5  6.20     
S(CC(OCC1CCC1)=O)c1nc(N)c(cn1)Cc1ccccc1  NAM  mGluR5  5.84     
S(CC(OCC1CC1)=O)c1nc(N)c(cn1)Cc1ccccc1  NAM  mGluR5  6.70     
S(Cc1onc(n1)C1CC1)c1nc(N)c(cn1)Cc1ccccc1  NAM  mGluR5  6.35     
s1cccc1Cc1cnc(SCC=C)nc1N  NAM  mGluR5  5.55     
s1cccc1Cc1cnc(SCc2ncon2)nc1N  NAM  mGluR5  6.40     
Fc1ccc(N2CCN(CC2)c2nc(nc(OCC)c2[N+](=O)[O-])C)cc1  NAM  mGluR1  6.74     
O=C1NC(=NC(N2CCC(CC2)c2ccccc2)=C1[N+](=O)[O-])C  NAM  mGluR1  7.20     
Fc1ccc(N2CCN(CC2)C=2N=C(NC(=O)C=2[N+](=O)[O-])C)cc1  NAM  mGluR1  6.09     
S(C)c1ccccc1N1CCN(CC1)c1nc(nc(NCCO)c1C#N)NCCO  NAM  mGluR1  6.46     
Fc1ccc(cc1)C1CCN(CC1)C=1N=C(N(CCCCO)C(=O)C=1[N+](=
O)[O-])C  NAM  mGluR1  6.55     
Fc1ccccc1N1CCN(CC1)c1nc(nc(NCCO)c1C#N)NCCO  NAM  mGluR1  6.54     
OCCNc1nc(nc(N2CCN(CC2)c2ccccc2[N+](=O)[O-
])c1C#N)NCCO  NAM  mGluR1  6.12     
Fc1ccc(cc1)C1CCN(CC1)c1nc(nc(NCCO)c1C#N)NCCO  NAM  mGluR1  6.15     
Fc1ccc(cc1)C=1CCN(CC=1)c1nc(nc(NCCO)c1C#N)NCCO  NAM  mGluR1  6.41     
OCCNc1nc(nc(N2CCC(CC2)c2ccc(cc2)C#N)c1C#N)NCCO  NAM  mGluR1  5.74     
n1c(N2CCC(CC2)c2ccccc2)c(C#N)c(nc1NCc1ncccc1)NCc1ncc
cc1  NAM  mGluR1  5.82     
OCCNc1nc(nc(N2CCN(CC2)c2ccccc2)c1C#N)NCc1cccnc1  NAM  mGluR1  6.82     
Clc1nc(nc(N2CCC(CC2)c2ccc(F)cc2)c1C#N)NCCO  NAM  mGluR1  6.85     
S(C)c1nc(nc(N2CCN(CC2)c2ccc(F)cc2)c1C#N)N  NAM  mGluR1  6.68     
S(C)c1nc(nc(N2CCC(CC2)c2ccc(F)cc2)c1C#N)N  NAM  mGluR1  6.80     
n1c(CC)c(nc(N2CCN(CC2)c2ccccc2)c1C#N)C  NAM  mGluR1  7.28     
n1c(C)c(nc(N2CCN(CC2)c2ccccc2)c1C#N)CC  NAM  mGluR1  7.28     
Fc1ccc(N2CCN(CC2)c2nc(NCCO)cnc2C#N)cc1  NAM  mGluR1  6.00     
OCCNc1nc(N2CCC(=CC2)c2ccccc2)c(nn1)C#N  NAM  mGluR1  6.18     
Fc1ccc(N2CCN(CC2)c2nc(C)c([n+]([O-])c2C#N)CC)cc1  NAM  mGluR1  7.48     
O(C(=O)c1n(C)c(nc1C)C#Cc1ccccc1)CC  NAM  mGluR5  8.00     
O(C(=O)c1[nH]c(nc1C)C#Cc1ccccc1)CC  NAM  mGluR5  7.66     
O(C)c1cc(ccc1)C#Cc1nc(C)c(n1C)C(OCC)=O  NAM  mGluR5  7.25     
n1ccn(C)c1C#Cc1ccccc1  NAM  mGluR5  8.00     
[nH]1ccnc1C#Cc1ccccc1  NAM  mGluR5  7.66     
OCCn1c(ncc1[N+](=O)[O-])C#Cc1ccccc1  NAM  mGluR5  7.66     
Clc1cccc(Cl)c1C#Cc1nc(C)c(n1C)C(OCC)=O  NAM  mGluR5  8.00     
O(C(=O)c1nc(n(c1C)-c1ccccc1)C#Cc1ccccc1)CC  NAM  mGluR5  7.66     
O(C(=O)c1n(C)c(nc1C)C#Cc1cc(ccc1)C)CC  NAM  mGluR5  8.00     
O(C(=O)c1n(C)c(nc1C)C#Cc1cc(NC(=O)C)ccc1)CC  NAM  mGluR5  7.57     
O(C(=O)c1n(C)c(nc1C)C#Cc1cc(-n2c(ccc2C)C)ccc1)CC  NAM  mGluR5  7.66     
o1nc(nc1-c1n(C)c(nc1C)C#Cc1ccccc1)C  NAM  mGluR5  7.66     
Clc1ccc(cc1)C#Cc1nc(C)c(n1C)C(OCC)=O  NAM  mGluR5  8.00     
Fc1ccc(cc1)C#Cc1nc(C)c(n1C)C(OCC)=O  NAM  mGluR5  8.00     
O(C(=O)c1n(C)c(nc1C)C#Cc1ccc(cc1)-c1ccccc1)CC  NAM  mGluR5  8.00     
Fc1ccccc1C#Cc1nc(C)c(n1C)C(OCC)=O  NAM  mGluR5  8.00     
Fc1ccccc1C#Cc1nccn1C  NAM  mGluR5  8.00     
O(C(=O)c1n(C)c(nc1C)C#Cc1ccc(N)cc1)CC  NAM  mGluR5  7.89     
Clc1ccccc1C#Cc1nccn1C  NAM  mGluR5  8.00     
Clc1n(CC(OCC)=O)c(nc1Cl)C#Cc1ccccc1  NAM  mGluR5  8.00     
n1cc(n(c1)C)C#Cc1ccccc1  NAM  mGluR5  7.66     
O(C)c1cc2c([nH]c(C#Cc3ccccc3)c2CCNC(=O)C)cc1  NAM  mGluR5  7.47     
S1Cc2n(-c3cccnc13)cnc2C#Cc1ccccc1  NAM  mGluR5  7.66     
O1Cc2n(-c3c1cccc3)cnc2C#Cc1ccccc1  NAM  mGluR5  7.66     
ClC[C@@H](O)Cn1c([N+](=O)[O-])c(nc1C)C#Cc1ccccc1  NAM  mGluR5  7.66     
O=Cc1n(cnc1C#Cc1ccccc1)C  NAM  mGluR5  7.66     
[nH]1cc(nc1)C#Cc1ccccc1  NAM  mGluR5  7.66     
n1cn(cc1C#Cc1ccccc1)C  NAM  mGluR5  7.66     
O=[N+]([O-])c1n(C)c(nc1C#Cc1ccccc1)C  NAM  mGluR5  7.25     10. Appendix 
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n1n(C)c(cc1C)C#Cc1ccccc1  NAM  mGluR5  7.66     
n1c(C(C)C)c(n(C)c1\C=C\c1ccccc1)C(C)C  NAM  mGluR5  7.25     
Fc1ccc(cc1)\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
Clc1ccc(cc1)\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
O(CCCC)c1ccc(cc1)\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
O(C)c1cc(C)c(\C=C\c2nc(C(C)C)c(n2C)C(C)C)c(C)c1C  NAM  mGluR5  7.25     
O(C)c1ccc(cc1)\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
Clc1ccc(cc1F)\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
O(CC)c1ccc(cc1)\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
O(C)c1c(OC)c(OC)ccc1\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
Clc1cc(Cl)ccc1\C=C\c1nc(C(C)C)c(n1C)C(C)C  NAM  mGluR5  7.25     
Brc1ncn(C)c1\C=C\c1ccccc1  NAM  mGluR5  8.00     
n1cc(n(c1)C)\C=C\c1ccccc1  NAM  mGluR5  7.28     
O=C1CC(=C2N=CC(N(C)C)=C(N=C2C1)C#Cc1ccccc1)c1cc(cc
c1)C#N  NAM  mGluR2  7.52     
Fc1ccccc1C1=CNC2=C(N=C1OCC(F)(F)F)C=C(CC2=O)c1cc(c
cc1)-c1onc(c1)C  NAM  mGluR2  7.52     
FC(F)(F)C1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(ccc1)-
c1onc(c1)CN1CCOCC1  NAM  mGluR2  6.90     
FC(F)(F)C=1N=C2CC(=O)CC(=C2N=CC=1N(C)C1CC1)c1cc(n
cc1)C#N  NAM  mGluR2  7.60     
FC(F)(F)C=1N=C2CC(=O)CC(=C2N=CC=1OCC(F)(F)F)c1cc(n
cc1)C#N  NAM  mGluR2  7.60     
O=C1CC(=C2N=CC(N(CCC)C)=C(N=C2C1)C)c1cc(ccc1)C#N  NAM  mGluR2  7.60     
o1nc(cc1-
c1cc(ccc1)C=1CC(=O)CC2=NC(C#N)=C(N(CC)CC)C=NC=12)
C 
NAM  mGluR2  7.77     
O1CCCc2cc3cc(ccc3nc12)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
Clc1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
Fc1nc2c(cc1CC)cc(cc2)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
O1CCc2cc3cc(ccc3nc12)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
S1CCCc2cc3cc(C(=O)Cc4ccccc4)c(cc3nc12)C  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc3CCCc3c2)cc1  NAM  mGluR1  7.49  R   
S1CCCc2cc3cc(ccc3nc12)C(=O)C1CCC(OC)CC1  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc(cc2)CCC)cc1  NAM  mGluR1  7.49  R   
FC1(CCC(OC)CC1)C(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.49  R   
O1CCCc2cc3cc(C(=O)Cc4ccccc4)c(cc3nc12)C  NAM  mGluR1  7.49  R   
Fc1ccccc1CC(=O)c1cc2c(nc3OCCCc3c2)cc1  NAM  mGluR1  7.49  R   
S1CCCc2cc3cc(ccc3nc12)C(=O)Cc1ccccc1  NAM  mGluR1  7.49  R   
O1CCCc2cc3cc(ccc3nc12)C(=O)C[C@@H]1[C@@H]2CC[C@
H](C1)C2  NAM  mGluR1  7.49  R   
S1CCCc2cc3cc(ccc3nc12)C(=O)Cc1ccccc1F  NAM  mGluR1  7.49  R   
s1cc(cc1)CC(=O)c1cc2c(cc1)cc1OCCCc1c2  NAM  mGluR1  7.49  R   
O1c2nc3c(cc(cc3)C(=O)Cc3ccccc3)cc2C[C@H]1C  NAM  mGluR1  7.49  R   
S1CCc2cc3cc(ccc3nc12)C(=O)C1CCCCC1  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1)N  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CCC)c(nc2cc1)C  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2cc(CC)c(nc2cc1C)C  NAM  mGluR1  7.49  R   
O(C)C1CCC(CC1)C(=O)c1cc2c(nc3CCCCc3c2)cc1  NAM  mGluR1  7.49  R   
FC(F)(F)C=1N=C2CC(=O)CC(=C2N=CC=1N1CCOCC1)c1cc(n
cc1)C#N  NAM  mGluR2  7.60     
O=C1CC(=C2N=CC=C(n3cccc3)N=C2C1)c1cc(ccc1)C#N  NAM  mGluR2  7.46     
IC=1C=NC=2C(=NC=1n1cccc1)CC(=O)CC=2c1cc(ncc1)C#N  NAM  mGluR2  7.12     
O=C1CC(=C2N=CC=C(n3cc(cc3)-
c3ccccc3)N=C2C1)c1cc(ccc1)C#N  NAM  mGluR2  7.12     
O(C)C=1C=NC=2C(=NC=1n1cccc1)CC(=O)CC=2c1cc(ccc1)C#
N  NAM  mGluR2  7.36     
O(C)C=1C=NC=2C(=NC=1n1cccc1C(C)(C)C)CC(=O)CC=2c1c
c(ccc1)C#N  NAM  mGluR2  7.10     
o1cnc(C(OCC)=O)c1-
c1cc(ccc1)C=1CC(=O)CC2=NC(n3cccc3)=CC=NC=12  NAM  mGluR2  7.54     
o1cc(nc1-
c1cc(ccc1)C=1CC(=O)CC2=NC(n3cccc3)=CC=NC=12)C(=O)N  NAM  mGluR2  7.21     
o1cc(nc1-
c1cc(ccc1)C=1CC(=O)CC2=NC(n3cccc3)=CC=NC=12)C(=O)N
CCO 
NAM  mGluR2  7.04     
FC(F)(F)C=1N=C2CC(=O)CC(=C2N=CC=1OCC)c1cc(ncc1)C#
N  NAM  mGluR2  7.60     
FC(F)(F)C=1N=C2CC(=O)CC(=C2N=CC=1C)c1cc(ncc1)C#N  NAM  mGluR2  7.60     10. Appendix 
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o1nc(cc1-
c1ccc(cc1)C=1CC(=O)CC2=NC(C#N)=C(N3CCOCC3)C=NC=1
2)C 
NAM  mGluR2  7.49     
O[C@@]1([C@@H]2[C@H](N(CC2)C(OC)=O)CCC1)C#Cc1cc(
ccc1)C  NAM  mGluR5  7.60     
O(C)c1cc2c(ncnc2N[C@H]2[C@@H]3CC[C@H](C2)C3)cc1  NAM  mGluR1  5.61     
O(C)c1cc2c(ncnc2NC2CCCCC2)cc1  NAM  mGluR1  6.48     
Clc1nc(NC2Cc3c(C2)cccc3)c2cc(OC)ccc2n1  NAM  mGluR1  7.33     
Clc1ccccc1CCNc1ncnc2c1cc(OC)cc2  NAM  mGluR1  6.52     
Clc1nc(Nc2ccc(OC)cc2)c2cc(OC)ccc2n1  NAM  mGluR1  7.33     
Clc1cc2c(nc(Cl)nc2NC2Cc3c(C2)cccc3)cc1  NAM  mGluR1  7.52     
Clc1ccccc1CCNc1nc(Cl)nc2c1cc(OC)cc2  NAM  mGluR1  7.33     
Clc1cc2c(ncnc2N[C@H]2[C@H]3CC[C@@H](C2)C3)cc1  NAM  mGluR1  5.95     
S(CC)c1nc(NC[C@H](F)c2ccccc2)c2CCCCc2n1  NAM  mGluR1  7.57     
S(CC)c1nc(NOC)c2CCCCc2n1  NAM  mGluR1  7.49     
Clc1ccccc1[C@@H](O)CNc1nc(SCC)nc2c1CCCC2  NAM  mGluR1  7.57     
S(CC)c1nc(NCC(F)(F)c2ccccc2)c2CCCCc2n1  NAM  mGluR1  7.57     
Clc1ccccc1CCNc1nc(SCC)nc2c1CCCC2  NAM  mGluR1  7.57     
S(CC)c1nc(Nc2ccc(F)cc2)c2CCCCc2n1  NAM  mGluR1  7.49     
S(CC)c1nc(NC2Cc3c(C2)cccc3)c2CCCCc2n1  NAM  mGluR1  7.41     
Clc1cccc(Cl)c1CSCCNc1nc(SCC)nc2c1CCCC2  NAM  mGluR1  6.61     
S(CC)c1nc(NN2Cc3c(C2)cccc3)c2CCCCc2n1  NAM  mGluR1  6.26     
Clc1ccccc1[C@@H](OC)CNc1nc(SCC)nc2c1CCCC2  NAM  mGluR1  6.21     
Clc1ccccc1OCCNc1nc(SCC)nc2c1CCCC2  NAM  mGluR1  6.00     
S(CC)c1nc(N[C@H]2[C@H]3CC[C@@H](C2)C3)c2CCCCc2n1  NAM  mGluR1  6.49     
O(C(=O)c1c[nH]c(C(OCC)=O)c1C)C(C)(C)C  NAM  mGluR1  6.47    + 
O(C(=O)c1c[nH]c(C(OCCC)=O)c1C)C(C)(C)C  NAM  mGluR1  7.32    + 
O(C(=O)c1c(C)c([nH]c1COC(=O)C)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  8.30    + 
O(C(=O)c1c(C)c([nH]c1C=O)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  5.70    + 
O(C(=O)c1c(C)c([nH]c1C(OC)=O)C(OCCC)=O)C(C)(C)C  NAM  mGluR1    R  + 
O(C(=O)c1c(C)c([nH]c1C(=O)NCC1CC1)C(OCCC)=O)C(C)(C)
C  NAM  mGluR1  5.60    + 
O(C(=O)c1c[nH]c(C(OC(C)(C)C)=O)c1C)C(C)(C)C  NAM  mGluR1  7.00    + 
o1cccc1COC(=O)c1[nH]cc(C(OC(C)(C)C)=O)c1C  NAM  mGluR1  5.92    + 
O(C(=O)c1[nH]cc(C(OC(C)(C)C)=O)c1C)CC1CC1  NAM  mGluR1  7.32    + 
O(C(=O)c1[nH]cc(C(O[C@@H](C(C)(C)C)C)=O)c1C)CCC  NAM  mGluR1  7.32    + 
O(C(=O)c1[nH]cc(C(O[C@@H](C(C)(C)C)C)=O)c1C)C(C)(C)C  NAM  mGluR1  7.32    + 
Fc1c(OC(=O)c2[nH]cc(C(O[C@@H](C(C)(C)C)C)=O)c2C)c(F)c
(F)c(F)c1F  NAM  mGluR1  6.80    + 
O([C@@H](C(C)(C)C)C)C(=O)c1c[nH]c(C(O[C@@H](CN(C)C)
C)=O)c1C  NAM  mGluR1  6.41    + 
Clc1[nH]c(C(OCCC)=O)c(C)c1C(O[C@@H](C(C)(C)C)C)=O  NAM  mGluR1  6.80    + 
O(C(=O)c1[nH]cc(C(O[C@@H](C(C)(C)C)C)=O)c1C)c1cccnc1  NAM  mGluR1  6.14    + 
O(C(=O)c1[nH]cc(C(O[C@@H](C(C)(C)C)C)=O)c1C)[C@@H]1
CCN(C1)CC  NAM  mGluR1  6.59    + 
O(C(=O)c1[nH]cc(C(O[C@@H](C(C)(C)C)C)=O)c1C)c1ncncc1  NAM  mGluR1  5.84    + 
O(C(=O)c1c(C)c(n(C)c1C)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  8.05    + 
O(C(=O)c1n(CCCO)c(C)c(C(O[C@@H](C(C)(C)C)C)=O)c1C)C
CC  NAM  mGluR1  8.05    + 
O(C(=O)c1n(nc(c1)C(O[C@@H](C(C)(C)C)C)=O)C)CCC  NAM  mGluR1  7.59     
O(C(=O)c1nn(C)c(c1)C(O[C@@H](C(C)(C)C)C)=O)CCC  NAM  mGluR1  7.59     
O([C@@H](C(C)(C)C)C)C(=O)c1n(nc(c1)C(O[C@@H](C(C)(C)
C)C)=O)C  NAM  mGluR1  7.59     
O(C(=O)c1n(nc(c1)C(O[C@@H](C(C)(C)C)C)=O)C)CC  NAM  mGluR1  7.59     
O(C(=O)c1n[nH]c(c1)C(O[C@@H](C(C)(C)C)C)=O)CCCC  NAM  mGluR1  7.59     
O(C(=O)c1n[nH]c(c1)C(O[C@@H](C(C)(C)C)C)=O)CCC  NAM  mGluR1  7.59     
s1c(C(OC)=O)c(C)c(C(OCC)=O)c1N  NAM  mGluR1  7.29     
s1c(C)c(C(OCC)=O)c(N)c1C(OCC)=O  NAM  mGluR1  7.29     
s1cc(C(OCC)=O)c(C)c1C(OCC)=O  NAM  mGluR1  7.29     
s1cc(C(OC(C)(C)C)=O)c(C)c1C(OCCC)=O  NAM  mGluR1  7.29     
s1cc(C(O[C@@H](C(C)(C)C)C)=O)c(C)c1C(OCCC)=O  NAM  mGluR1  7.29     
s1c(C(OCCC)=O)c(C)c(C(O[C@@H](C(C)(C)C)C)=O)c1N  NAM  mGluR1  7.32     
O(C(=O)c1ccc(cc1)C(OCCC)=O)CCC  NAM  mGluR1  7.59     
O(C(=O)c1ccc(cc1)C(OCCC)=O)C(C)(C)C  NAM  mGluR1  7.59     
O(C(=O)c1ccc(cc1)C(O[C@@H](C(C)(C)C)C)=O)CCC  NAM  mGluR1  7.59     
O(C(=O)c1ccc(cc1)C(O[C@@H](C(C)(C)C)C)=O)CC1CC1  NAM  mGluR1  7.59     10. Appendix 
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O(C)c1cc(ccc1-c1cccnc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  7.04     
S1C=Cn2cc(nc12)-c1cc(OC)c(cc1)-c1cccnc1  NAM  mGluR5  7.03     
S1CCn2cc(nc12)-c1cc(OC)c(cc1)-c1cccnc1  NAM  mGluR5  6.49     
Clc1cc2C3=C(CCCC3)C(Oc2cc1OC(C)C)=O  NAM  mGluR1  9.00     
Fc1cc(-n2c(C)c(cc2C)C=C2C(=O)c3c(cccc3)C2=O)ccc1  NAM  mGluR1  7.40     
S\1c2c(cccc2)C(=O)/C/1=C/c1ccc(OC)c(CC)c1OC  NAM  mGluR1  7.24     
OC=1n2nc(cc2N=C(C=1)c1ccccc1)-c1cc(ccc1)C  NAM  mGluR1  7.28     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccc(cc1)C  NAM  mGluR5  7.96     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cc(ccc1)C#N  NAM  mGluR5  7.92     
O(c1ccccc1-n1nc(nn1)-c1ncccc1)c1ncccc1  NAM  mGluR5  7.96     
[nH]1cc(nc1)-c1nn(nn1)-c1cc(ccc1)C#N  NAM  mGluR5  5.70     
[nH]1nccc1-c1nn(nn1)-c1cc(ccc1)C#N  NAM  mGluR5  5.70     
O=[N+]([O-])c1cc(ccc1)-c1nc2n(c1)C=CC=C2  NAM  mGluR5  8.06     
n1cn(cc1-c1cc(ccc1)C#N)-c1ncccc1  NAM  mGluR5  5.00     
n1ccccc1-n1nnc(c1)-c1cc(ccc1)C#N  NAM  mGluR5  5.00     
Clc1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.82     
Fc1cccc(F)c1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.82     
O(C(=O)c1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1)C  NAM  mGluR5  6.65     
FC(F)(F)c1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.64     
Oc1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.54     
O(C)c1ccc(cc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1)C  NAM  mGluR5  6.51     
O(CC)c1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.50     
Fc1ccc(F)cc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.47     
FC(F)(F)Oc1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.42     
O=C(C)c1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.38     
O(c1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1)c1ccccc1  NAM  mGluR5  6.35     
O(Cc1ccccc1)c1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.35     
O(C)c1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.34     
O=Cc1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.30     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1ccccc1CC  NAM  mGluR5  6.18     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1c(cccc1C)C  NAM  mGluR5  6.02     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1ccccc1-c1ccccc1  NAM  mGluR5  6.01     
O(C(=O)c1cc(ccc1)-c1cc(-n2nc(nn2)-c2ncccc2)ccc1)C  NAM  mGluR5  6.47     
Clc1cc(ccc1)-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.02     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1cc(ccc1)C  NAM  mGluR5  5.93     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1ccc(cc1)C  NAM  mGluR5  5.81     
Clc1ccc(cc1)-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  5.52     
Clc1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)cc(F)c1  NAM  mGluR5  6.97     
Fc1cccc(F)c1-c1cc(-n2nc(nn2)-c2ncccc2)cc(F)c1  NAM  mGluR5  6.97     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1O  NAM  mGluR5  6.70     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1OC  NAM  mGluR5  6.57     
Fc1ccccc1-c1cc(-n2nc(nn2)-c2ncccc2)cc(F)c1  NAM  mGluR5  6.54     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1[N+](=O)[O-]  NAM  mGluR5  6.51     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1OC(F)(F)F  NAM  mGluR5  6.50     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1C=O  NAM  mGluR5  6.44     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1C(=O)N  NAM  mGluR5  6.41     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1Oc1ccccc1  NAM  mGluR5  6.38     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1OCC  NAM  mGluR5  6.35     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1c(cccc1C)C  NAM  mGluR5  6.06     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1-c1ccccc1  NAM  mGluR5  6.00     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccccc1CC  NAM  mGluR5  5.52     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cc(F)ccc1  NAM  mGluR5  6.66     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cc(ccc1)C(OC)=O  NAM  mGluR5  6.50     
Clc1cc(ccc1)-c1cc(-n2nc(nn2)-c2ncccc2)cc(F)c1  NAM  mGluR5  6.08     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1ccc(F)cc1  NAM  mGluR5  6.47     
Clc1ccc(cc1)-c1cc(-n2nc(nn2)-c2ncccc2)cc(F)c1  NAM  mGluR5  5.69     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1cccnc1  NAM  mGluR5  7.16     
o1nc(C)c(-c2cc(-n3nc(nn3)-c3ncccc3)ccc2)c1C  NAM  mGluR5  6.60     
O(C)c1ncc(cn1)-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  6.51     
o1nc(cc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1)-c1ccccc1  NAM  mGluR5  6.05     
o1cccc1-c1cc(-n2nc(nn2)-c2ncccc2)ccc1  NAM  mGluR5  5.52     
n1ccccc1-c1nn(nn1)-c1cc(ccc1)-c1ccncc1  NAM  mGluR5  5.68     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1c(noc1C)C  NAM  mGluR5  7.55     10. Appendix 
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Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1onc(c1)-c1ccccc1  NAM  mGluR5  7.12     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cnc(OC)nc1  NAM  mGluR5  7.03     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1cncnc1  NAM  mGluR5  6.70     
Fc1cc(cc(-n2nc(nn2)-c2ncccc2)c1)-c1occc1  NAM  mGluR5  6.24     
c1c(cccc1C)C#Cc1ccccc1  NAM  mGluR5  5.96     
n1ccccc1C#Cc1ccccc1  NAM  mGluR5  7.04     
n1cccc(C)c1C#Cc1ccccc1  NAM  mGluR5  7.20     
n1c(cc(cc1C)C)C#Cc1ccccc1  NaM  mGluR5  7.21     
Brc1nc(ccc1)C#Cc1ccccc1  NAM  mGluR5  6.18     
S(C)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.68     
O(CC=C)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.53     
n1c(cccc1C)C#Cc1ncccc1  NAM  mGluR5  6.74    + 
n1c(cccc1C)C#Cc1ccncc1  NAM  mGluR5  7.03    + 
O(C)c1cc(cnc1)C#Cc1nc(ccc1)C  NAM  mGluR5  7.66     
Brc1cc(cnc1)C#Cc1nc(ccc1)C  NAM  mGluR5  7.92     
O(C)c1nc(ccc1)C#Cc1ccccc1  NAM  mGluR5  5.71     
O(C)c1cc(OC)ccc1C#Cc1nc(ccc1)C  NAM  mGluR5  6.56     
O(C)c1ccc(OC)cc1C#Cc1nc(ccc1)C  NAM  mGluR5  7.09     
O(C)c1cc(ccc1OC)C#Cc1nc(ccc1)C  NAM  mGluR5  6.09     
O1c2cc(ccc2OC1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.20     
O=[N+]([O-])c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  7.87     
FC(F)(F)c1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.45     
Fc1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.45     
OCc1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  6.62     
n1c(cccc1C)C#Cc1cc2c(nc1)cccc2  NAM  mGluR5  6.63     
n1c(cccc1C)C#Cc1c2c(cccc2)cnc1  NAM  mGluR5  7.68     
n1c(cccc1C)C#Cc1cc2n(ccc2cc1)C  NAM  mGluR5  5.74     
n1c(cccc1C)C#Cc1cc2c(n(cc2)C)cc1  NAM  mGluR5  6.26     
n1c(cccc1C)C#Cc1cncnc1  NAM  mGluR5  6.76     
s1cc(nc1C#Cc1cc(OC)ccc1)C  NAM  mGluR5  7.25     
s1cc(nc1C)C#Cc1cc(ccc1)CO  NAM  mGluR5  6.37     
s1cc(nc1C)C#Cc1c2c(cccc2)cnc1  NAM  mGluR5  7.70     
s1cc(nc1C)C#Cc1cc([N+](=O)[O-])ccc1  NAM  mGluR5  7.82     
Brc1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  8.70     
Clc1c(cc(Cl)cc1Cl)\C=C\c1nc(ccc1)C  NAM  mGluR5  8.06     
O(C)c1ccc(nc1C#Cc1cc(ccc1)C)C  NAM  mGluR5  7.66     
Clc1c(cc(Cl)cc1Cl)C#Cc1nc(ccc1)C  NAM  mGluR5  8.06     
Clc1cc(cc(Cl)c1)C#Cc1nc(ccc1)C  NAM  mGluR5  8.70     
FC(F)(F)Oc1cc(ccc1)C#Cc1nc(ccc1)C  NAM  mGluR5  8.06     
Fc1cc(ccc1)C#Cc1nc(cc(c1)C)C  NAM  mGluR5  8.00     
n1c(cccc1C)C#Cc1cc(ccc1)C#C  NAM  mGluR5  8.70     
Fc1ccc(-n2cc(nc2C)C#Cc2cc(F)ncc2)cc1  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1nc(ccc1)C(F)(F)F)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1cc(F)cnc1)C  NAM  mGluR5  7.20     
Fc1ccc(-n2cc(nc2C)C#Cc2cc(ncc2)C#N)cc1  NAM  mGluR5  7.36     
Clc1cc(-n2cc(nc2C)C#Cc2cc(Cl)ncc2)ccc1Cl  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1cc(C)c(F)cc1)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1ccc(cc1)C)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1ccc(OC)cc1)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1nc(ccn1)C)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1nc(OC)ccn1)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1nc(ncc1)C(F)(F)F)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1ncc(cc1)C)C  NAM  mGluR5  7.37     
Clc1ncc(-n2cc(nc2C)C#Cc2cc(ncc2)C#N)cc1  NAM  mGluR5  7.16     
Clc1nccc(c1)C#Cc1nc(n(c1)-c1ccc(nc1)C1CC1)C  NAM  mGluR5  7.37     
Clc1nccc(c1)C#Cc1nc(n(c1C)-c1ccc(F)cc1)C  NAM  mGluR5  7.37     
o1c2c(nc1-c1cc(OC)c(cc1)-c1ccncc1)cccc2  NAM  mGluR5  7.38     
O=C(Nc1ncccc1)c1nccnc1  NAM  mGluR5  7.44     
O=C(Nc1nc(ccc1)C)c1nc(ccc1Nc1cccnc1)C  NAM  mGluR5  7.44     
Brc1cc(cnc1)C(=O)Nc1ncccc1  NAM  mGluR5  7.44     
Brc1cc(ccc1)C(=O)Nc1ncccc1  NAM  mGluR5  7.27     
S(Oc1cc(ccc1)C#Cc1nc(ccc1)C)(=O)(=O)c1ccc(cc1)C  NAM  mGluR5  8.70     
O=C1N(c2ccc(cc2)C(OCC(=O)c2ccc(cc2)C)=O)C(=O)[C@H]2[ NAM  mGlur5  5.02     10. Appendix 
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C@H]1CC=CC2 
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc(C)c(cc2)C)=O)C(=O)[C@H
]2[C@H]1CC=CC2  NAM  mGlur5  6.76     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc3CCCc3cc2)=O)C(=O)[C@
H]2[C@H]1CC=CC2  NAM  mGlur5  6.40     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc3CCCCc3cc2)=O)C(=O)[C
@H]2[C@H]1CC=CC2  NAM  mGlur5  6.77     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc3c(cc2)cccc3)=O)C(=O)[C
@H]2[C@H]1CC=CC2  NAM  mGlur5  6.52     
O=C1N(c2ccc(cc2)C(OCC(=O)c2ccc(cc2)C2CCCCC2)=O)C(=O
)[C@H]2[C@H]1CC=CC2  NAM  mGlur5  4.74     
O(C)c1cc(ccc1OC)C(=O)COC(=O)c1ccc(N2C(=O)[C@H]3[C@
@H](CC=CC3)C2=O)cc1  NAM  mGlur5  5.79     
O1CCOc2c1cc(cc2)C(=O)COC(=O)c1ccc(N2C(=O)[C@H]3[C@
@H](CC=CC3)C2=O)cc1  NAM  mGlur5  5.69     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc([N+](=O)[O-
])c(cc2)C)=O)C(=O)[C@H]2[C@H]1CC=CC2  NAM  mGlur5  5.42     
O(C)c1ccc(cc1[N+](=O)[O-
])C(=O)COC(=O)c1ccc(N2C(=O)[C@H]3[C@@H](CC=CC3)C2
=O)cc1 
NAM  mGlur5  5.77     
O=C1N(c2ccc(cc2)C(OCC(=O)c2ccc(N3CCCC3)cc2)=O)C(=O)[
C@H]2[C@H]1CC=CC2  NAM  mGlur5  5.96     
O1CCN(CC1)c1ccc(cc1)C(=O)COC(=O)c1ccc(N2C(=O)[C@H]3
[C@@H](CC=CC3)C2=O)cc1  NAM  mGlur5  5.47     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc(C)c(cc2)C)=O)C(=O)[C@
@H]2[C@H]1CCCC2  NAM  mGlur5  6.72     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc(C)c(cc2)C)=O)C(=O)[C@H
]2[C@H]1CCCC2  NAM  mGlur5  6.82     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc(C)c(cc2)C)=O)C(=O)[C@H
]2[C@H]1C[C@@H](CC2)C  NAM  mGlur5  6.95     
Br[C@@H]1C[C@@H]2[C@@H](C[C@H]1Br)C(=O)N(c1ccc(c
c1)C(OCC(=O)c1cc(C)c(cc1)C)=O)C2=O  NAM  mGlur5  7.01     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc(C)c(cc2)C)=O)C(=O)[C@H
]2[C@H]1CC(=CC2)C  NAM  mGlur5  6.67     
O=C1N(c2ccc(cc2)C(OCC(=O)c2cc(C)c(cc2)C)=O)C(=O)[C@
@H]2[C@H]1[C@H]1C=C[C@@H]2C1  NAM  mGlur5  5.99     
O=C1N(C(=O)CC1)c1ccc(cc1)C(OCC(=O)c1cc(C)c(cc1)C)=O  NAM  mGlur5  6.30     
O=C1N(C(=O)C[C@H]1C)c1ccc(cc1)C(OCC(=O)c1cc(C)c(cc1)
C)=O  NAM  mGlur5  6.39     
O=C1N(C(=O)C=C1C)c1ccc(cc1)C(OCC(=O)c1cc(C)c(cc1)C)=
O  NAM  mGlur5  5.32     
O=C1N(C(=O)C(C)=C1C)c1ccc(cc1)C(OCC(=O)c1cc(C)c(cc1)C
)=O  NAM  mGlur5  5.19     
O=C1N(C(=O)CCC1)c1ccc(cc1)C(OCC(=O)c1cc(C)c(cc1)C)=O  NAM  mGlur5  5.49     
O=C1N(C(=O)CC(C1)C)c1ccc(cc1)C(OCC(=O)c1cc(C)c(cc1)C)
=O  NAM  mGlur5  5.74     
Clc1cc(-n2nc(nn2)[C@@H]2N(CCCC2)c2nnc(n2C)-
c2ccncc2)ccc1  NAM  mGluR5  7.39  H   
s1c2c(N=CN(C2=O)c2ccccc2)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)C)c2c1nccc2N(C)C  NAM  mGluR5  6.05     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2N(C)C  NAM  mGluR5  6.35     
s1c2c(N=CN(C2=O)c2ccc(cc2)CCC)c2c1nccc2N(C)C  NAM  mGluR5  5.69     
s1c2c(N=CN(C2=O)c2ccc(cc2)C(C)C)c2c1nccc2N(C)C  NAM  mGluR5  5.45     
s1c2c(N=CN(C2=O)c2ccc(cc2)C(C)(C)C)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)C2CC2)c2c1nccc2N(C)C  NAM  mGluR5  5.34     
s1c2c(N=CN(C2=O)c2ccc(cc2)C2CCCCC2)c2c1nccc2N(C)C  NAM  mGluR5  3.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)C2CCC2)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)C2CCCC2)c2c1nccc2N(C)C  NAM  mGluR5  5.94     
s1c2c(N=CN(C3CCCCC3)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  6.19     
s1c2c(N=CN([C@@H]3CCCC[C@H]3C)C2=O)c2c1nccc2N(C)
C  NAM  mGluR5  5.00     
s1c2c(N=CN([C@H]3C[C@@H](CCC3)C)C2=O)c2c1nccc2N(C
)C  NAM  mGluR5  5.67     
s1c2c(N=CN(C3CCC(CC3)C)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  6.23     
s1c2c(N=CN(C3CCCCCC3)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  6.83     
s1c2c(N=CN(C34CC5CC(C3)CC(C4)C5)C2=O)c2c1nccc2N(C)
C  NAM  mGluR5  6.81     
s1c2c(N=CN(C(CC)CC)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(CC3CCCC3)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(CC3CCCCC3)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(C3CC3)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=C(N(C2=O)c2ccc(cc2)CC)C)c2c1nccc2N(C)C  NAM  mGluR5  6.35     10. Appendix 
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s1c2c(N=C(N(C2=O)c2ccc(cc2)CC)CC)c2c1nccc2N(C)C  NAM  mGluR5  5.34     
s1c2c(N=C(N(C2=O)c2ccc(cc2)CC)CCCC)c2c1nccc2N(C)C  NAM  mGluR5  6.05     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1cccc2N(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1cncc2N(C)C  NAM  mGluR5  5.67     
s1c2c(N=CN(C2=O)c2ccc(cc2)C)c2c1cncc2N(C)C  NAM  mGluR5  5.39     
s1c2c(N=CN(C2=O)c2ccc(cc2)C)c2c1nccc2N(CC)C  NAM  mGluR5  5.59     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2N(CCOC)C  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2N1CCCC1  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2NC1CC1  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2NCC#N  NAM  mGluR5  5.68     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2NCC(F)(F)F  NAM  mGluR5  5.00     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2NC  NAM  mGluR5  5.22     
s1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2[N+]([O-])(C)C  NAM  mGluR5  5.00     
s1c2c(N=CN(N3CCCCCC3)C2=O)c2c1nccc2[N+]([O-])(C)C  NAM  mGluR5  5.00     
o1c2c(N=CN(C2=O)c2ccc(cc2)CC)c2c1nccc2N(C)C  NAM  mGluR5  5.00     
o1c2c(N=CN(C3CCC(CC3)C)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  6.05     
s1c2c(N=NN(C3CCCCCC3)C2=O)c2c1nccc2N(C)C  NAM  mGluR5  6.09     
s1ccnc1N1CCN(CC1)C(=O)C#Cc1ccccc1  NAM  mGluR5  7.52    + 
O=C1N(CNc2cc(ccc2)C)C(=O)[C@@H]2[C@H]1[C@H]1C=C[
C@@H]2C1  NAM  mGluR5  7.72     
O1c2c(C[C@@H]1CN(C(OC)=O)C)cccc2  NAM  mGluR5  5.00  R  - 
O1CCN(CC1)C(=O)CCCOc1ccc(cc1)C  NAM  mGluR5  5.46  R  - 
O1CCN(CC1)C(=O)Cc1ccc(OCCCC)cc1  NAM  mGluR5  5.00  R  - 
O=C(N1CCCC1)\C=C\c1ccccc1  NAM  mGluR5  5.00  R  - 
Clc1ccc(cc1)\C=C\C(=O)N1CCCC1  NAM  mGluR5  5.00  R  - 
O=C1N(CCC1)CC(=O)N(Cc1ccccc1)C  NAM  mGluR5  5.00  R  - 
O1c2cc(ccc2OC1)\C=C\C(=O)N1CCC(CC1)C  NAM  mGluR5  4.48  R  - 
S\1c2c(N(C)/C/1=C/C(=O)C(C)C)cccc2  NAM  mGluR5  4.62  R  - 
S\1c2c(N(C)/C/1=C\C(=O)C1CCC1)cccc2  NAM  mGluR5  5.00  R  - 
O1c2c(C[C@@H]1C(=O)N1CCCCC1)cccc2  NAM  mGluR5  5.00  R  - 
O=C1N(C)C(=O)N(c2c1cn(c2)-c1cc(ccc1)C)C  NAM  mGluR5  5.00  R  - 
O=C(\C=C\c1ccccc1)c1nc(ccc1)C  NAM  mGluR5  7.55     
n1c(C(C)C)c(n(C)c1\C=C\c1ccc(cc1)C)C(C)C  NAM  mGluR5  7.25     
Fc1c(cccc1F)C1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(-
n2nncc2)ccc1  NAM  mGluR2  7.15     
ClC1=CNC2=C(N=C1N(CCOC)C)C=C(CC2=O)c1cc(ccc1)-
c1onc(c1)C  NAM  mGluR2  7.60     
ClC1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(ccc1)-
c1n(ncc1)C  NAM  mGluR2  7.64     
ClC1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(ccc1)-
c1scc(n1)CO  NAM  mGluR2  7.52     
ClC1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(ccc1)-
c1occ(n1)CO  NAM  mGluR2  7.41     
ClC1=CNC2=C(N=C1N(CCC)C)C=C(CC2=O)c1cc(-
n2nncc2CO)ccc1  NAM  mGluR2  7.52     
ClC1=CNC2=C(N=C1N(CC)CC)C=C(CC2=O)c1cc(-
n2nncc2CO)ccc1  NAM  mGluR2  7.36     
ClC1=CNC2=C(N=C1N1CCCC1)C=C(CC2=O)c1cc(-
n2nncc2CO)ccc1  NAM  mGluR2  7.72     
ClC1=CNC2=C(N=C1N(C)C1CC1)C=C(CC2=O)c1cc(-
n2nncc2CO)ccc1  NAM  mGluR2  6.80     
ClC1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(-n2nccc2)ccc1  NAM  mGluR2  6.96     
S(C)c1nccn1-c1noc(c1)-
c1cc(ccc1)C=1CC(=O)C=2NC=C(C(F)(F)F)C(=NC=2C=1)N(C)
C 
NAM  mGluR2  7.72     
FC(F)(F)C1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(-
n2nncc2CNC2CC2)ccc1  NAM  mGluR2  7.31     
ClC1=CNC2=C(N=C1N([C@@H](CC)C)C)C=C(CC2=O)c1cc(-
n2nncc2CO)ccc1  NAM  mGluR2  7.70     
ClC1=CNC2=C(N=C1N(CCC)C)C=C(CC2=O)c1cc(-
n2nncc2CN2CCC2)ccc1  NAM  mGluR2  7.77     
ClC1=CNC2=C(N=C1N([C@@H](CC)C)C)C=C(CC2=O)c1cc(-
n2ncnc2CO)ccc1  NAM  mGluR2  7.05     
FC(F)(F)C1=CNC2=C(N=C1N(CCC)C)C=C(CC2=O)c1cc(-
n2ncnc2)ccc1  NAM  mGluR2  7.57     
FC(F)(F)C1=CNC2=C(N=C1N([C@@H](CC)C)C)C=C(CC2=O)
c1cc(-n2ncnc2)ccc1  NAM  mGluR2  7.77     
ClC1=CNC2=C(N=C1N([C@@H](CC)C)C)C=C(CC2=O)c1cc(c
cc1)-c1scc(n1)CO  NAM  mGluR2  7.77     
ClC1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(ccc1)- NAM  mGluR2  6.32     10. Appendix 
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c1nc(sc1)NCC 
s1c(nnc1CO)-
c1cc(ccc1)C=1CC(=O)C=2NC=C(C(F)(F)F)C(=NC=2C=1)N(C)
C 
NAM  mGluR2  7.77     
FC(F)(F)C1=CNC2=C(N=C1N(C)C)C=C(CC2=O)c1cc(ccc1)-
c1nc(oc1CCC)C  NAM  mGluR2  7.34     
s1c(nnc1CO)-
c1cc(ccc1)C=1CC(=O)C=2NC=C(C(F)(F)F)C(=NC=2C=1)N(CC
C)C 
NAM  mGluR2  7.77     
FC(F)(F)C1=CNC2=C(N=C1N1CCOCC1)C=C(CC2=O)c1cc(-
n2nncc2CO)ccc1  NAM  mGluR2  7.13     
O=C1CC(=CC=2N=CC(n3cccc3)=CNC1=2)c1cc(-n2ccnc2)ccc1  NAM  mGluR2  7.60     
s1cc(nc1-
c1cc(ccc1)C=1CC(=O)C=2NC=C(n3cccc3)C=NC=2C=1)CO  NAM  mGluR2  7.55     
O=C1CC(=CC=2N=CC(n3cccc3)=CNC1=2)c1cc(-n2nncc2)ccc1  NAM  mGluR2  7.77     
o1ccnc1-
c1cc(ccc1)C=1CC(=O)C=2NC=C(n3cccc3)C=NC=2C=1  NAM  mGluR2  7.64     
O1CCN(CC1)C1=NC2=C(NC=C1)C(=O)CC(=C2)c1cc(ccc1)-
c1n(ncc1)C  NAM  mGluR2  7.77     
FC(F)(F)C1=CNC2=C(N=C1OCC)C=C(CC2=O)c1cc(-
n2nncc2CO)ccc1  NAM  mGluR2  7.08     
ClC1=NC2=C(NC=C1C(F)(F)F)C(=O)CC(=C2)c1cc(-
n2nncc2CNC2CC2)ccc1  NAM  mGluR2  7.77     
FC(F)(F)C1=CNC2=C(N=C1C)C=C(CC2=O)c1cc(-
n2nncc2CNC2CC2)ccc1  NAM  mGluR2  7.59     
s1cc(nc1CO)-
c1cc(ccc1)C=1CC(=O)C=2NC=C(C(F)(F)F)C(=NC=2C=1)C  NAM  mGluR2  7.77     
FC(F)(F)C1=CNC2=C(N=C1C)C=C(CC2=O)c1cc(-
n2nccc2)ccc1  NAM  mGluR2  7.15     
Clc1cc(Cl)ccc1/C(/OC(C)C)=C\n1ncnc1  NAM  mGluR2  6.19     
Brc1ccc(cc1)/C(/OCCCC)=C\n1ncnc1  NAM  mGluR2  6.18     
Clc1ccc(cc1)/C(/OCCCC)=C\n1ncnc1  NAM  mGluR2  6.22     
Clc1cccc(Cl)c1/C(/OCCCC)=C\n1ncnc1  NAM  mGluR2  6.22     
Clc1cc(Cl)ccc1/C(/OCc1ccccc1)=C\n1ncnc1  NAM  mGluR2  6.37     
Clc1cc(Cl)ccc1/C(/OC1CCCCC1)=C\n1ncnc1  NAM  mGluR2  7.00     
Clc1cc(Cl)ccc1/C(/OCc1ccccc1)=C\n1nnnc1  NAM  mGluR2  6.57     
Clc1cc(Cl)ccc1/C(/OCc1ccc(OC)cc1)=C\n1ncnn1  NAM  mGluR2  6.00     
Clc1cc(Cl)ccc1[C@@H](OC(=O)c1ccccc1)Cn1nnnc1  NAM  mGluR2  6.05     
O\1\C(=C\2/N(c3c(cc(cc3)C)C=C/2)CC)\C(=O)N(CC)/C/1=N/c1c
cc(Oc2ccccc2)cc1  NAM  mGluR1?  7.34     
S(=O)(=O)(CCc1oc(cc1)\C=C\1/C(C(OC)=O)=C(N(C/1=O)c1ccc
cc1)C)c1ccc(cc1)C  NAM  mGluR1?  7.49     
O(C)c1ccc(cc1)\C=C\C(=O)N1CCCCCC1  NAM  mGluR5  5.92    - 
Oc1ccc(cc1C(=O)Nc1nc(ccc1)C)C  NAM  mGluR5  7.44     
O=C(N(C)c1nc(ccc1)C)c1nc(cnc1N)C  NAM  mGluR5  7.44     
 
10.5 Vendor Ligand Data Bases 
Table A 2: Vendor ligand data collections sources and versions. 
   
Data source URL  Version 
   
www.acbblocks.com  2007.3 
www.acros.com  2006.4 
www.akosgmbh.de  2008.7 
www.alfa.com  2008.2 
www.amriglobal.com  2007.9 
www.analyticon.com  2007.2 
www.apolloscientific.co.uk  2006.6 
www.asinex.com  2006.11 
www.bachem.com  2005.6 
www.biofocus.com  2007.4 
www.chemdiv.com  2007.8 10. Appendix 
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www.chemblock.com  2007.3 
www.chemstar.ru  2008 
www.combi-blocks.com  2007.4 
www.enamine.net  2008.1 
www.frinton.com  2006.12 
www.ibscreen.com  2008.2 
www.keyorganics.ltd.uk  2008.2 
www.lifechemicals.com  2008.8 
www.maybridge.com  2008.5 
www.mdpi.org  2005.6 
www.msdiscovery.com  2008.1 
http://mlsmr.glpg.com/MLSMR_HomePage/  2005.9 
www.nanosyn.com  2008.1 
www.nchlab.com  2008.4 
www.oakwoodchemical.com  2007.4 
www.otavachemicals.com  2007.12 
www.peakdale.com  2006 
www.pharmeks.com  2007.4 
www.prestwickchemical.fr  2008.1 
http://pubchem.ncbi.nlm.nih.gov/  2003.11 
www.sigmaaldrich.com  2006.5 
www.specs.net  2008.1 
www.synphabase.ch  2006.12 
www.timtec.net  2008.1 
www.ubichem.com  2008.1 
www.toslab.com  2008.1 
www.vitasmlab.com  2008.2 
   
10.6 PyMol script for mutation highlighting 
Load mGluR5_structure.pdb 
color gray 
show cartoon 
hide lines 
cmd.hide("(mGluR5_structure and hydro)") 
hide all 
 
select rest, resi 607-609+640-644+674-686+718-733+764-769+796-801+830-
850 
color gray, rest 
show cartoon, rest 
 
select ec2, resi 674-686 
#color yellow, ec2 
 
select TM_region, resi 577-606+610-639+644-673+687-717+734-763+769-
795+802-829 
cmd.spectrum("b",selection=("TM_region"),quiet=0) 
show cartoon, TM_region 
#r = cmd.create ( "entropy", "TM_region") 
#show cartoon,"entropy" 
#cmd.spectrum("b",selection=("entropy"),quiet=0) 
 
######family C mutations from literature translated using WS numbering 
on proposed alignment###### 
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select lit_mutations, resid 
635+646+647+648+651+652+655+656+658+659+702+703+740+743+744+745+747+78
1+785+786+787+788+789+790+791+792+802+803+805+806+807+810+813 
 
##################negative modulators################################# 
#CPCCOEt human mGluR1 antagonist T815+A818 
select CPCCOET, resi 802+805 
 
#EM_TBPC rat mGluR1 antagonist Y672+V757+798+F801+Y805+T815 
select EM_TBPC, resi 659+744+788+785+792+802 
 
#M-MPEP human mGluR5 antagonist P655+S658+A810 
select M_MPEP, resi 655+658+810 
 
#MPEP rat mGluR5 antagonist P654+Y658+L743+T780+W784+F787+Y791+A809 
select MPEP_rat, resi 655+659+744+781+785+788+792+810 
 
#MPEP human mGluR5 antagonist P655+S658+A810 
select MPEP_human, resi 655+658+810 
 
#NPS_2143 Antagonist of CaSR resi F668+F684+R680+688+E837+I841 
#on mGluR5 full length select NPS_2143, resi 635+651+646+655+803+807 
select NPS_2143, resi 635+651+646+655+803+807 
 
#Calhex_231 CaSR antagonist F684+F688+E837+I841 
#on mGluR5 full length select Calhex_231, resi 651+655+803+807 
select Calhex_231, resi 651+655+803+807 
 
#Fenobam rmGR5 NAM resi 
R647A+P654S+S657C+Y658V+L743V+T780A+W784+F787A+V788M+Y791A+809 
#on mGluR5 full length select 648+655+658+659+744+781+785+788+792+810 
select fenobam, resid 648+655+658+659+744+781+785+788+792+810 
 
#Lactisole Nam for hT1R3 
640(3.32)+641(3.33)+733(5.42)+735(5.39)+738(5.42)+739(5.43)+778+782+79
8 
#on mGluR5 full length select 649+650+740+743+745+748+749+788+792+806 
select lactisole, resid 649+650+740+743+745+748+749+788+792+806 
 
select NAM_mGR1,resi 659+744+788+785+792+802+805 
select NAM_mGR5,resi 648+655+658+659+744+781+785+788+792+810 
select NAM_HUM_mGR5, resi 655+658+810 
select NAM_HUM_mGR1, resi 802+805 
select NAM_RAT_mGR5,resi 648+655+658+659+744+781+785+788+792+810 
select NAM_RAT_mGR1,resi 659+744+788+785+792+802 
select NAM_CASR,resi 635+651+646+803+655+807 
select NAM_T1R3, resi 649+650+740+743+745+748+749+788+792+806 
select mGR_NAM,resi 659+744+788+785+792+802+805+648+655+658+781+810 
select NAM, resi 
635+646+648+651+655+658+659+744+781+785+788+792+802+803+805+806+807+81
0 
 
##################positive modulators################################# 
#DFB agonist of rat mGluR5 S657+L743+T780+W784+F787+M801 
#on mGluR5 human full length DFB S658+L744+T781+W785+F788+M802 
select DFB, resi 658+744+781+785+788+802 
 
#LY 487379 PAM for hmGluR2 S688L+G689V+N735D+A733T 
#on mGluR5 full length select 702+703+747+745 
select ly_487379, resid 702+703+747+745 
 
#Ro67_7476 rat mGluR1 agonist S668+C671+V757 
select RO67_7476, resi 655+658+792 10. Appendix 
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#cyclamate HT1R3 pam Q636+F730+L782+S640 
#on mGluR5 human full length 647+740+788+651 
select cyclamate, resi 647+740+788+651 
 
#d-tryptophan orthosteric agonist on hT1R3 L644+T645+Y771+Q794+I805 
#on mGluR5 human full length 655+656+745+802+813 
#select d_tryptophan, resid 655+656+745+802+813 
 
select PAM, DFB or ly_487379 or RO67_7476 or cyclamate or d-tryptophan 
select mGR_PAM, DFB + ly_487379 + RO67_7476 
select T1R3_PAM, cyclamate or d-tryptophan 
 
select mGR_PAM_NAM, (NAM_mGR1+NAM_mGR5) and (mGR_PAM) 
select both_NAM_PAM, NAM and PAM 
 
###########positions_of_mutation_with_no_effect############# 
 
#3.32+6.52+6.55+5.43+45.53+5.39+5.44+5.48+7.38+7.4+7.45+7.46+6.48+6.51
+3.27+3.36+5.42 
select no_effect, resi 
651+789+792+744+734+740+745+749+808+810+815+817+785+788+646+655+743 
 
10.7 PyMol script for structural features and comparison 
load mGluR5_structure.pdb 
color gray 
show cartoon 
hide lines 
cmd.hide("(mGluR5_structure and hydro)") 
hide all 
 
select rest, resi 607-609+640-644+674-686+718-733+764-769+796-801+830-
850 
color gray, rest 
show cartoon, rest 
 
select ec2, resi 674-686 
#color yellow, ec2 
 
select TM_region, resi 577-606+610-639+644-673+687-717+734-763+769-
795+802-829 
cmd.spectrum("b",selection=("TM_region"),quiet=0) 
show cartoon, TM_region 
#r = cmd.create ( "entropy", "TM_region") 
#show cartoon,"entropy" 
#cmd.spectrum("b",selection=("entropy"),quiet=0) 
 
########positions_with_identical_property_in familyC_GPCRs######### 
 
select ident_prop_to_famC, resi 
580+583+586+588+590+593+598+599+600+602+603+604+605+610+617+618+622+62
3+626+629+630+632+637+644+645+646+649+650+653+654+657+661+662+666+672+
700+701+703+708+709+716+717+737+740+741+743+749+750+752+756+757+759+77
1+772+774+778+780+783+785+786+788+795+804+805+807+809+811+817+818+820+
822+823+824+826+828 
 
###########positions_with_low_H_using_9function_coding############# 
select selow_9f, resi 
590+594+620+622+644+662+665+666+669+703+705+750+758+774+777+778+786+80
6+820+825 10. Appendix 
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###########positions_with_high_H_using_9function_coding############# 
select se_high_9f, resi 
606+616+645+689+690+691+692+734+735+737+739+747+763+773+794 
 
##################dimerization################################# 
select dimeFromFamA, resi 
584+588+591+598+634+638+698+701+704+705+708+712+715+717+735+737+738+74
2+779+705+712+715 
select expDimFromFamA, resi 584+588+591+634+638+704+717+779 
 
##################g-protein coupling################################# 
select gprotein, resi 
670+672+673+759+762+773+774+823+827+610+611+616+668+669+670+672 
select gproteinProp, resi 606+687+690+693+694+770+829 
 
#################helix helix contacts################################ 
# weistein positions 
1.5+2.45+2.5+3.35+3.37+3.42+4.49+4.50+4.52+5.46+6.44+6.47+7.46+7.48 
select hhcontacts, resi 
594+616+621+654+656+661+706+707+709+747+781+784+816+818 
 
##################DRY motiv################################# 
select DRYmotiv, resi 668+669+670 
 
##################NPXXY motiv################################# 
select NPXXYmotiv, resi 819+820+821+822+823 
 
##################FXXXW motiv################################# 
select FXXXWmotiv, resi 781+782+783+784+785 
 
##################FamA ligand binding################################# 
select FamA_BP, resi 
623+624+625+629+644+652+654+655+665+666+740+751+785+822+647+813 
 
##################constantly active################################# 
select CA, resi 
594+614+616+624+644+654+662+665+666+668+669+740+758+774+777+787 
 
##################carazolol binding 
pocket################################# 
select carazolol_bp, resi 
647+651+652+655+656+739+743+747+785+788+789+792+805+809+813 
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10.8 Mutation data collection 
Table A 3: Mutation data collection 
Receptor  Mutation  BW pos 
TM 
or 
loop 
Modulator  Effect  Reference 
hCasR  F668A  2.64  2  NPS R-568  reduced NPS R-568 binding  Miedlich et al. 2004 
hCasR  F668A  2.64  2  NSP 2143  Reduced NSP 2143 binding and expression on cell 
membrane  Miedlich et al. 2004 
hCasR  R680A  3.27  3  NPS 2143, Calhex 233  decreased inhibition  Petrel et al. 2004 
hCasR  R680A  3.27  3  NPS R-568, Calindol  no effect on Ca2+ response or PAM effects  Petrel et al. 2004 
hCasR  R680A  3.27  3  NSP 2143  Reduced NSP 2143 binding  Miedlich et al. 2004 
hT1R3  Q636  3.28  3  Cyclamate  reduced sensitivity to Cyclamate  Jiang et al. 2005 b 
rmGluR5  R647A  3.29  3  Fenobam  Decreased binding  Malherbe et al. 2006 
hCasR  F684A  3.32  3  Calhex 231  No binding of Calhex 231  Petrel et al. 2003 
hCasR  F684A  3.32  3  NPS 2143, Calhex 231  no block of Ca2+  Petrel et al. 2004 
hCasR  F684A  3.32  3  NPS R-568, Calindol  reduced Ca2+ potentiation, no effect on PAM  Petrel et al. 2004 
hT1R3  S640A  3.32  3  Lactisole  Increased sensitivity to lactisole  Jiang et al. 2005 a 
hT1R3  S640A  3.32  3  Cyclamate, D-Tryptophan  no effect on ligand effect  Jiang et al. 2005 b 
hCasR  F684A  3.32  3  NPS R-568  reduced NPS R-568 binding  Miedlich et al. 2004 
hCasR  F684A  3.32  3  NSP 2143  Reduced NSP 2143 binding  Miedlich et al. 2004 
hT1R3  H641A  3.33  3  Lactisole  No lactisole binding  Jiang et al. 2005 a 
hCasR  F688A  3.36  3  Calhex 231  Reduced binding of Calhex 231  Petrel et al. 2003 
hCasR  F688A  3.36  3  NPS 2143, Calhex 231  no block of Ca2+  Petrel et al. 2004 10. Appendix 
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hCasR  F688A  3.36  3  NPS R-568, Calindol  reduced Ca2+ potentiation, no effect on PAM  Petrel et al. 2004 
rmGluR1a  S668P  3.36  3  RO 67-7476  loss of PAM effect  Knoflach et al 2001 
rmGluR5  P654S  3.36  3  Fenobam  no binding  Malherbe et al. 2006 
hT1R3  L644A  3.36  3  D-Tryptophan  No binding  Jiang et al. 2005 a 
hT1R3  L644A  3.36  3  Cyclamate, D-Tryptophan  no respose to cyclamate or d-tryptophan  Jiang et al. 2005 b 
rmGluR5a  P654S  3.36  3  [H3]MPEP  Decrease in MPEP binding affinity  Malherbe et al. 2003 b 
hmGluR5a  P655S  3.36  3  [H3]M-MPEP  Decrease in M-MPEP binding affinity  Pagano et al. 2000 
hT1R3  T645A  3.37  3  D-Tryptophan  No binding  Jiang et al. 2005 a 
hT1R3  T645A  3.37  3  Cyclamate, D-Tryptophan  no respose to cyclamate or d-tryptophan  Jiang et al. 2005 b 
rmGluR5a  S657C  3.39  3  DFB  Abolished DFB enhancement  Mühlemann et al. 2006 
rmGluR5  S657C  3.39  3  Fenobam  no binding  Malherbe et al. 2006 
hmGluR5a  S658C  3.39  3  [H3]M-MPEP  Decrease in M-MPEP binding affinity  Pagano et al. 2000 
rmGluR1a  Y672V  3.4  3  EM-TBPC  Decrease of EM-TBPC-binding  Malherbe et al. 2003 a 
rmGluR5  Y658V  3.4  3  Fenobam  no binding  Malherbe et al. 2006 
rmGluR5  Y658F  3.4  3  Fenobam  slightly increased binding  Malherbe et al. 2006 
rmGluR5a  Y658V  3.4  3  [H3]MPEP  Complete loss of MPEP binding and inhibition  Malherbe et al. 2003 b 
hT1R3  F730A  5.39  5  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 
hT1R3  F730A  5.39  5  Cyclamate  Diminished response to cyclamate  Jiang et al. 2005 b 
hT1R3  F730Y  5.39  5  Cyclamate  slightly enhanced cyclamate activity  Jiang et al. 2005 b 
rT1R3  L735F  5.39  5  lactisole  gain of function, lactisole activity like in humans  Winning et al. 2005 
hCasR  L776A  5.42  5  Calhex 231  Increased affinity for Calhex 231  Petrel et al. 2003 10. Appendix 
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hCasR  L776A  5.42  5  NPS 2143, Calhex 231  decreased inhibition for Calhex, no effect on NAM 
activity for NPS  Petrel et al. 2004 
hCasR  L776A  5.42  5  NPS R-568, Calindol  reduced Ca2+ potentiation, no effect on PAM  Petrel et al. 2004 
rT1R3  V738A  5.42  5  lactisole  increased lactisole sensitivity to half of hTasIr3 level  Winning et al. 2005 
hT1R3  A733V  5.42  5  Lactisole  Decreased sensitivity to lactisole  Jiang et al. 2005 a 
mT1R3  V738A  5.42  5  Lactisole  Increased sensitivity to lactisole  Jiang et al. 2005 a 
rT1R3  V738A  5.42  5  lactisole  gain of function, lactisole activity like in humans  Winning et al. 2005 
rmGluR5a  L743A  5.43  5  DFB  Increased DFB enhancement  Mühlemann et al. 2006 
rmGluR5a  L743V  5.43  5  DFB  Increased DFB enhancemen  Mühlemann et al. 2006 
rmGluR1a  V757L  5.43  5  RO 67-7476  Critical for RO-67-7476 and EM-TBPC-binding  Knoflach et al 2001 
hmGluR1a  L757V  5.43  5  EM-TBPC  Mutation converts to rmGluR1a, high binding affinity 
to EM-TBPC  Malherbe et al. 2003 a 
rmGluR1a  V757L  5.43  5  EM-TBPC  Mutation converts to hmGluR1a, reduction of EM-
TBPC binding  Malherbe et al. 2003 a 
rmGluR1a  V757A  5.43  5  EM-TBPC  reduction of EM-TBPC binding  Malherbe et al. 2003 a 
rmGluR5  L743V  5.43  5  Fenobam  no effect on binding  Malherbe et al. 2006 
rmGluR5  L743A  5.43  5  Fenobam  slightly increased binding  Malherbe et al. 2006 
rmGluR5a  L743A  5.43  5  [H3]MPEP  Decrease in MPEP binding affinity  Malherbe et al. 2003 b 
hT1R3  A735I  5.44  5  Lactisole  no change on Lactisole effect  Jiang et al. 2005 a 
hGluR2  N735D  5.46  5  LY 487379  Reduced LY 487379 binding  Schaffhauser et al. 2003 10. Appendix 
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hT1R3  T739M  5.48  5  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 
rmGluR5a  T780A  6.44  6  DFB  Abolished DFB enhancement  Mühlemann et al. 2006 
rmGluR5  T780A  6.44  6  Fenobam  no binding  Malherbe et al. 2006 
hT1R3  Y771A  6.44  6  D-Tryptophan  No binding  Jiang et al. 2005 a 
hT1R3  Y771A  6.44  6  Cyclamate, D-Tryptophan  no respose to cyclamate or d-tryptophan  Jiang et al. 2005 b 
rmGluR5a  T780A  6.44  6  [H3]MPEP  Decrease in MPEP binding affinity  Malherbe et al. 2003 b 
rmGluR5a  W784A  6.48  6  DFB  Increased DFB enhancemen  Mühlemann et al. 2006 
rmGluR5a  W784F  6.48  6  DFB  Increased DFB enhancemen  Mühlemann et al. 2006 
hCasR  W818A  6.48  6  Calhex 231  Reduced binding of Calhex 231  Petrel et al. 2003 
hCasR  W818A  6.48  6  NPS 2143, Calhex 231  no effect on NAM effect  Petrel et al. 2004 
hCasR  W818A  6.48  6  NPS R-568, Calindol  left-shift (stronger for NPS), Emax increase  Petrel et al. 2004 
rmGluR1a  W798F  6.48  6  EM-TBPC  Increased binding affinity to EM-TBPC  Malherbe et al. 2003 a 
rmGluR5  W784F  6.48  6  Fenobam  Decreased binding  Malherbe et al. 2006 
rmGluR5  W784A  6.48  6  Fenobam  no binding  Malherbe et al. 2006 
rmGluR5a  W784A  6.48  6  [H3]MPEP  Complete loss of MPEP binding and inhibition  Malherbe et al. 2003 b 
hCasR  I819A  6.49  6  Ca  Increased Ca-sensitivity  Hu et al. 2005 
hCasR  S820F  6.5  6  Ca  Naturaly occuring mutation,Increased Ca-sensitivity  Hu et al. 2005 
rmGluR5a  F787A  6.51  6  DFB  Converts DFB into a partial antagonist  Mühlemann et al. 2006 
hCasR  F821A  6.51  6  Calhex 231  Increased affinity for Calhex 231  Petrel et al. 2003 
hCasR  F821A  6.51  6  NPS 2143, Calhex 231  no effect on NAM effect  Petrel et al. 2004 10. Appendix 
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hCasR  F821A  6.51  6  NPS R-568, Calindol  small left-shift, no Emax effect  Petrel et al. 2004 
hCasR  F821L  6.51  6  Ca  Naturaly occuring mutation,Increased Ca-sensitivity  Hu et al. 2005 
rmGluR1a  F801A  6.51  6  EM-TBPC  Complete loss of EM-TBPC-binding  Malherbe et al. 2003 a 
rmGluR5  F787A  6.51  6  Fenobam  no binding  Malherbe et al. 2006 
hT1R3  F778A  6.51  5  Lactisole  Decreased sensitivity to lactisole  Jiang et al. 2005 a 
hT1R3  L782A  6.51  6  Cyclamate  reduced sensitivity to Cyclomate  Jiang et al. 2005 b 
rmGluR5a  F787A  6.51  6  [H3]MPEP  Complete loss of MPEP binding and inhibition  Malherbe et al. 2003 b 
hCasR  I822A  6.52  6  Ca  Increased Ca-sensitivity  Hu et al. 2005 
rmGluR5  V788M  6.52  6  Fenobam  no effect on binding  Malherbe et al. 2006 
hT1R3  V776A  6.52  6  Cyclamate, D-Tryptophan  no effect on ligand effect  Jiang et al. 2005 b 
hCasR  P823A  6.53  6  Ca  Reduction of Ca response, slitly increased with NPS 
R-568  Hu et al. 2005 
hCasR  A824S  6.54  6  Ca  Naturaly occuring mutation,Increased Ca-sensitivity  Hu et al. 2005 
hCasR  Y825A  6.55  6  Ca  Increased Ca-sensitivity  Hu et al. 2005 
rmGluR1a  Y805A  6.55  6  EM-TBPC  Complete loss of EM-TBPC-binding  Malherbe et al. 2003 a 
rmGluR5  Y791A  6.55  6  Fenobam  Decreased binding  Malherbe et al. 2006 
hT1R3  L782A  6.55  6  Lactisole  Increased sensitivity to lactisole  Jiang et al. 2005 a 
hT1R3  V779A  6.55  6  Cyclamate, D-Tryptophan  no effect on ligand effect  Jiang et al. 2005 b 
rmGluR5a  Y791A  6.55  6  [H3]MPEP  Increased MPEP-potency but not binding affinity  Malherbe et al. 2003 b 
hCasR  V836L  7.31  7  Ca  Increased Ca-sensitivity  Hu et al. 2005 10. Appendix 
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hCasR  V836L  7.31  7  Ca  Naturaly occuring mutation,Increased Ca-sensitivity  Hu et al. 2005 
rmGluR5a  M801T  7.32  7  DFB  Abolished DFB enhancement  Mühlemann et al. 2006 
hCasR  E837D  7.32  7  Ca  Increased Ca-sensitivity  Hu et al. 2005 
hCasR  E837K  7.32  7  Ca  Increased Ca-sensitivity  Hu et al. 2005 
hCasR  E837  7.32  7  Ca  Crutial salt bridge to NPS R-568 and NPS 2143  Hu et al. 2005 
hmGluR1b  T815  7.32  7  (-)-CPCCOEt  Critical for CPCCOEt-binding  Litching et al. 1999 
rmGluR1a  T815M  7.32  7  EM-TBPC  Complete loss of EM-TBPC-binding  Malherbe et al. 2003 a 
hT1R3  Q794A  7.32  7  D-Tryptophan  No binding  Jiang et al. 2005 a 
hT1R3  Q794A  7.32  7  Cyclamate, D-Tryptophan  no respose to cyclamate or d-tryptophan  Jiang et al. 2005 b 
hCasR  E837A  7.33  7  Calhex 231  No binding of Calhex 231  Petrel et al. 2003 
hCasR  E837A  7.33  7  NPS 2143, Calhex 233  no block of Ca2+  Petrel et al. 2004 
hCasR  E837A  7.33  7  NPS R-568, Calindol  no left-shift, Emax decrease only for Calindol  Petrel et al. 2004 
hCasR  E837A  7.33  EC3  NPS R-568  Critical for NPS R-568 binding  Hu et al. 2002 
hCasR  E837I  7.33  7  NPS R-568  reduced NPS R-568 binding  Miedlich et al. 2004 
hCasR  E837I  7.33  7  NSP 2143  Reduced NSP 2143 binding  Miedlich et al. 2004 
hmGluR1b  A818S  7.35  7  (-)-CPCCOEt  Critical for CPCCOEt-binding  Litching et al. 1999 
hT1R3  L798I  7.36  7  Lactisole  Decreased sensitivity to lactisole  Jiang et al. 2005 a 
hCasR  I841A  7.37  7  Calhex 231  Reduced binding of Calhex 231  Petrel et al. 2003 
hCasR  I841A  7.37  7  NPS 2143, Calhex 233  decreased inhibition  Petrel et al. 2004 
hCasR  I841A  7.37  7  NPS R-568, Calindol  no left-shift, Emax decrease  Petrel et al. 2004 
hT1R3  L800V  7.38  7  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 10. Appendix 
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rmGluR5  A809V  7.4  7  Fenobam  no binding  Malherbe et al. 2006 
hT1R3  V802A  7.4  7  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 
rmGluR5a  A809V  7.4  7  [H3]MPEP  Complete loss of MPEP binding and inhibition  Malherbe et al. 2003 b 
hmGluR5a  A810V  7.4  7  [H3]M-MPEP  Loss of M-MPEP binding affinity  Pagano et al. 2000 
hmGluR5a  A810G  7.4  7  [H3]M-MPEP  Loss of M-MPEP binding affinity  Pagano et al. 2000 
hT1R3  I805A  7.43  7  D-Tryptophan  No binding  Jiang et al. 2005 a 
hT1R3  I805A  7.43  7  Cyclamate, D-Tryptophan  no respose to cyclamate or d-tryptophan  Jiang et al. 2005 b 
hT1R3  A807V  7.45  7  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 
hT1R3  A808T  7.46  7  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 
rmGluR1a  N747A  45.53  EC2  EM-TBPC  Complete loss of EM-TBPC-binding  Malherbe et al. 2003 a 
rmGluR5  N733A  45.53  EC2  Fenobam  no effect on binding  Malherbe et al. 2006 
rmGluR5  P654S/ 
S657C 
3.36, 
3.39  3  Fenobam  no binding  Malherbe et al. 2006 
hmGluR5a  P655S/S658C  3.36 / 
3.39  3  [H3]M-MPEP  Loss of M-MPEP binding affinity  Pagano et al. 2000 
hGluR2  S688L, 
G689V 
4.45, 
4.46  4  LY 487379  Reduced LY 487379 binding  Schaffhauser et al. 2003 
hGluR2  S688L, 
N735D 
4.45, 
5.46  4.5  LY 487379  Strongly reduced LY 487379 binding  Schaffhauser et al. 2003 
hGluR2  G689V, 
N735D 
4.46, 
5.46  4.5  LY 487379  Strongly reduced LY 487379 binding  Schaffhauser et al. 2003 
rT1R3  V738A, 
L735F 
5.39, 
5.42  5  lactisole  Increased lactisole sensitivity to hTasIr3 level  Winnig et al. 2005 
hGluR2  A733T, 
N735D 
5.44, 
5.46  5  LY 487379  Strongly reduced LY487379 binding  Schaffhauser et al. 2003 
hCasR  K831A  7.26 / 
EC3  7  Ca  Increased Ca-sensitivity  Hu et al. 2005 10. Appendix 
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hCasR  F832S  7.27 / 
EC3  7  Ca  Naturaly occuring mutation,Increased Ca-sensitivity  Hu et al. 2005 
hCasR  A835T  7.30, 
EC3  7  Ca  Naturaly occuring mutation,Increased Ca-sensitivity  Hu et al. 2005 
hCasR  T764A    EC2  Calhex231  no effect  Petrel et al. 2003 
hCasR  H766A    EC2  Calhex231  no effect  Petrel et al. 2003 
hCasR  T764A    EC2  NPS 2143, Calhex 231  no effect on NAM effect  Petrel et al. 2004 
hCasR  H766A    EC2  NPS 2143, Calhex 231  no effect on NAM effect  Petrel et al. 2004 
hT1R2  S144A    EC      Xu et al. 2004 
hT1R2  Y218A    EC    Abolished response to sweeteners, possibly not 
expressed on cell surface  Xu et al. 2004 
hT1R2  E302A    EC    Selectively affected response to diff. sweeteners  Xu et al. 2004 
hCasR  D758A    EC2  Ca  Conserved in all CaSR, increased Ca-sensitivity  Hu et al. 2002 
hCasR  E759A    EC2  Ca  Conserved in all CaSR, increased Ca-sensitivity  Hu et al. 2002 
hCasR  E767A    EC2  Ca  Conserved in all CaSR, increased Ca-sensitivity  Hu et al. 2002 
hCasR  F788C    EC2  Ca  Impaired Ca-sesitivity  Hu et al. 2002 
hCasR 
E755A, 
E757A, 
D758A, 
E759A, 
E767A 
  EC2  Ca  Incorrect fold, poorly expressed at cell surface  Hu et al. 2002 
hCasR  G830A    EC3  Ca  Increased Ca-sensitivity  Hu et al. 2005 
hT1R3  A537T    CRD  Brazzein  Diminished response to brazzein  Jiang et al. 2004 
hT1R3  F540P    CRD  Brazzein  Diminished response to brazzein  Jiang et al. 2004 10. Appendix 
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mT1R3  T542A    CRD  Brazzein  Increased response to brazzein  Jiang et al. 2004 
hT1R3  R790Q    EC3, 
H7  Lactisole  Decreased sensitivity to lactisole  Jiang et al. 2005 a 
hT1R3  V788A    EC3  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 
hT1R3  L789Y    EC3  Lactisole  no effect on Lactisole effect  Jiang et al. 2005 a 
hT1R3  R790    EC3  Cyclamate  Diminished response to cyclamate  Jiang et al. 2005 b 
hT1R3  H721    EC2  Cyclamate  reduced sensitivity to Cyclamate  Jiang et al. 2005 b 
hT1R3  R723    EC2  Cyclamate  reduced sensitivity to Cyclamate  Jiang et al. 2005 b 
hT1R3  R790H    EC3  Cyclamate  no response to both, nonfunctional?  Jiang et al. 2005 b Curriculum Vitae 
      211 
Curriculum Vitae 
 
Swetlana Derksen 
Dipl. Bioinformatician 
 
Personal Details 
 
Born on 28 September 1980 in Orsk, Russia 
Nationality: German and Russian 
 
Current Position 
 
Since 01.12.2009   Molecular Modeler at BASF Aktiengesellschaft,  
Computational Chemistry & Biology,  
Carl-Bosch-Straße, 67056 Ludwigshafen/Rhein, Germany. 
 
Former positions 
 
01.2006-11.2008  Ph.D. student in the group of Prof. Dr. G. Schneider (Johann-
Wolfgang von Goethe University, Frankfurt am Main) 
 
Scholarship holder of Merz Pharmaceuticals  
GmbH & Co. KGaA, Eckenheimer Landstraße 100, 
60318 Frankfurt am Main  
 
Education 
 
June 2000  High  school  graduation  (German  Abitur)  from  Goethe-
Gymnasium in Kassel, Germany 
October 2000  studies in Bioinformatics at Goethe-University in Frankfurt am 
Main, Germany 
September 2005  Diploma examination; overall grade: very good 
Diploma thesis, “De novo design using combinatorial molecule 
libraries”  advisor  Prof.  Dr.  G.  Schneider  (University  of 
Frankfurt) 
01.2006 - 08.2009  Postgraduate  studies  at  group  of  Prof.  Dr.  G.  Schneider 
(University of Frankfurt) 
  “Investigation of Structure and Allosteric Modulation of Family 
C  GPCRs  by  Sequence-,  Structure-  and  Ligand-based 
Approaches” 
 
Internship 
 
11.2005-12.2005  at Merz Pharmaceuticals, Medicinal Chemistry group (Dr. Tanja 
Weil), Task: Programming a tool for fingerprint calculation and 
clustering  of  ligand  binding  poses  based  on  molecular 
interactions in Java Curriculum vitae 
212 
 
Scholarship 
 
Scholarship from Merz Pharmaceuticals granted for 2006-2007, extended for 2008. 
 
Publications 
 
Journal Articles 
 
Renner  S.,  Derksen  S.,  Radestock  S.  and  Mörchen  F.  (2008)  Maximum  common 
binding  modes  (MCBM):  consensus  docking  scoring  using  multiple  ligand 
information and interaction fingerprints. J. Chem. Inf. Model. 48, 319-332. 
 
Proschak E., Rupp M., Derksen S. and Schneider G. (2007) Shapelets: Possibilities 
and limitations of shape-based virtual screening. J. Comp. Chem. 29, 108-114. 
 
Derksen S., Rau O., Schneider P., Schubert-Zsilavecz M. and Schneider G. (2006) 
Virtual  screening  for  PPAR  modulators  using  a  probabilistic  neural  network, 
ChemMedChem, 1, 1346-1350. 
 
Boecker  A.,  Derksen  S.,  Schmidt  E.,  Teckentrup  A.  and  Schneider  G.  (2005)  A 
Hierarchical  Clustering  Approach  for  Large  Compound  Libraries,  J.  Chem.  Inf. 
Model, 45, 807-815. 
Download at http://gecco.org.chemie.uni-frankfurt.de/hkmeans/index.html 
 
Conference Posters 
 
Derksen S., Weil T. and Schneider G., (2007) Improving Models of Transmembrane 
Domains of Class C GPCR using Property Conservation Analysis, 4th Joint Sheffield 
Conference on Chemoinformatics. 
 
2. German Conference on Chemoinformatics Goslar, Germany (2006) 
I) Noeske T., Derksen S., Weil T. and Schneider G., “Selectivity Profiles for Ligands 
of Family C GPCRs” 
II) Derksen S., Rupp M., Proschak E., Schneider G., “Kernel based classifier in virtual 
screening” 
 
Derksen S., Rau O., Syha Y., Popescu L., Schubert-Zsilavecz M., Schneider G. (2006) 
Quest for Novel Ligands of Peroxisome Proliferator-Activated Receptors (PPAR) 
Using Probabilistic Neural Networks, Annual Meeting "Frontiers in Medicinal 
Chemistry", Frankfurt am Main. 
 
Jimenez T., Derksen S., Schmidt E., Gohlke H. (2005) Binding pocket comparison 
based on knowledge-based potential fields, 19. Darmstädter Molecular Modelling 
Workshop, Erlangen 